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Erectile dysfunction is a widespread problem, affecting many men across all age 
groups and it is more than a serious quality of life problem for sexually active men. 
This book contains chapters written by widely acknowledged experts, each of which 
provides a unique synthesis of information on emergent aspects of ED. All chapters 
take into account not only the new perspectives on ED but also recent extensions of 
basic knowledge that presage directions for further research. The approach in this book 
has been to not only describe recent popular aspects of ED, such as basic mechanism 
updates, etiologic factors and pharmacotherapy, but also disease-associated ED and 
some future perspectives in this field.
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I am delighted to bring you the Erectile Dysfunction (ED) book. Organizing this book 
was an enlightening experience and an amazing adventure in science. Considering the 
breadth and depth of information available in the continuously expanding field of ED, 
this book provides information ranging from the basic mechanism of erectile function 
and dysfunction to updates regarding most discussed topics in ED nowadays, such as 
association between ED and cardiovascular diseases. Although ED disorder has been 
described for more than 1,000 years, the molecular basis and mechanisms of ED have 
yet to be completely understood. Over the last four decades, elucidation of the 
macroscopic structures of the erectile system ushered in a new era of therapeutic 
options for erectile disorders. Later, new insights into erectile neurotransmission, 
essentially the nitric oxide (NO) pathway, resulted in rational alternatives as a 
treatment. Nowadays, advances in gene discovery and intensive research regarding 
different mechanisms that could lead to ED have increased the working knowledge of 
the pathways involved in this condition. However, many questions still need to be 
elucidated.  
This book contains chapters written by widely acknowledged experts, each of which 
provides a unique synthesis of information on emergent aspects of ED. All chapters 
take into account not only new perspectives on ED but also recent extensions of basic 
knowledge that presage directions for further research. The approach in this book has 
been to not only describe the recent popular aspects of ED, such as basic mechanism 
updates, etiologic factors and pharmacotherapy, but also disease-associated ED and 
some future perspectives in this field.   
ED is a widespread problem affecting many men across all age groups and it is more 
than a serious quality of life problem for sexually active men. The prevalence of ED is 
very high and is expected to rise considerably over the next 25 years, affecting more than 
300 million men by 2025. ED is a multifactorial pathology and has recently been 
observed as a condition that may predict cardiovascular disease, making the knowledge 
in this area extremely important to prevent future diseases. Finally, to you, our readers, 
even though this book is a small overview of ED field, I hope that it provides enough 
useful and updated information that you will consider joining us in studying this 
condition. In addition, for readers who are not physicians, I wish that basic information 
as well as a scientific overview about research in ED can be acquired from this work. 
X Preface 
 
I would like to thank Dr R. Clinton Webb, Professor and Chairperson of the 
Physiology Department at Georgia Health Sciences University, for his help and advice 
in the preparation of this edition. Many thanks are also due to Dr Maria Elena De Lima 
and Dr Romulo Leite for introducing me to the scientific research world. Special 
thanks to my co-workers, as well as to my parents, Feliciano (in memoriam) and 
Conceição, who have always been behind the scenes supporting me. It would not be 
fitting for me to conclude this preface without a major acknowledgment to my beloved 
husband, Russell Bruhn. My husband’s journalistic experience in reading and revising 
many parts of this book was an indispensable aid in accomplishing this work.   
As it is inevitable when preparing a text, in addition to my own experience, I have 
called upon the help and advice of many others as I have in ten years or since I started 
research in this field. Thus, I’m deeply grateful to all the people who made this book 
possible.  
Comments on this edition will be welcome. 
Kenia Pedrosa Nunes  
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 Mechanisms in Erectile Function and 
Dysfunction: An Overview  
Kenia Pedrosa Nunes and R. Clinton Webb 
Georgia Health Sciences University, Augusta, Georgia 
USA 
1. Introduction 
Erectile dysfunction (ED) is a widespread problem affecting many men across all age groups 
and it is more than a serious quality of life problem for sexually active men. Over 30 million 
men suffer from ED in the U.S. 1 and it is becoming a public health issue. The prevalence of 
ED is very high and is expected to raise considerably over the next 25 years, impacting more 
than 300 million men by 2025 2. ED is defined as the persistent inability to maintain or 
achieve a penile erection sufficient for satisfactory sexual performance. Its etiology is 
multifactorial. Various aspects affect the expression/degree of ED and risk factors include 
age, diabetes mellitus, neurologic diseases, smoking and cardiovascular diseases (CVD), 
among others 3. Although the disorder has been described for more than 1000 years, the 
molecular basis and mechanisms of ED have yet to be completely understood. In the last 4 
decades, elucidation of the macroscopic structures of the erectile system 4-5 ushered in a new 
era of therapeutic options for erectile disorders. Later, new insights into erectile 
neurotransmission, 6 essentially the nitric oxide (NO) pathway, 7  resulted in rational 
alternatives as a treatment 8. Nowadays, advances in gene discovery and intensive research 
regarding different mechanisms which could lead to ED have increased the working 
knowledge of the pathways involved in this condition. This chapter will describe the basic 
penile physiology and the emergent mechanisms associated to pathophisiology of 
vasculogenic ED. Penile anatomy and physiology will be summarized in order to review the 
new insights regarding pathways and critical modifications observed in ED condition.  
2. Penile anatomy  
The penis is composed of three bodies of erectile tissue running in paralel; the corpus 
spongiosum, encompassing the urethra and terminating in the glans penis; and the two 
corpora cavernosa (CC) which function as blood-filled capacitors providing structure to the 
erect organ 9. The penile CC are highly specialized vascular structures that are 
morphologically adapted to their function of becoming engorged during sexual arousal. The 
trabecular smooth muscle constitutes approximately 40-50% of tissue cross-sectional area, as 
assessed by histomorphometric analysis 10. There are three main arteries in the penis: 
cavernosal, dorsal, and bulbourethral. All three arise from a shared branch of the internal 
pudendal artery and provide an extensive anastomotic network 11. Nowadays, there is a 
tendency to perform in vitro experiments using the pudendal artery instead of cavernosal 
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tissue to investigate patophysiological aspects of ED since this artery is the major resistance 
to penile engogerment during sexual stimulation. Novel findings suggest that the pudendal 
artery contributes 70% of the total penile vascular resistence 12. The arterial blood supply in 
the CC is mainly fed from the deep penile cavernosal artery 9, which causes corporal 
enlargement  during erection, whereas the deep dorsal artery causes glans enlargement. 
Venous drainage is not similar to arterial supply; there exists only one deep dorsal vein that 
runs alongside the dorsal arteries and nerves in Buck’s fascia above the tunica albuginea, 
which is a multilayered structure where emissary veins pass. The human penile venous 
system is generally described as a single deep dorsal vein accompanied by a pair of dorsal 
arteries positioned between the tunica albuginea and Buck’s fascia for the venous drainage 
13. The corpus spongiosum is erectile tissue analogous to CC, but with a thinner tunica 
albuginea. The urethra lies within the spongiosum. The innervations of the penis is both 
autonomic (sympathetic and parasympathetic) and somatic (sensory and motor). From the 
neurons in the spinal cord and peripheral ganglia, the sympathetic and parasympathetic 
nerves merge to form the cavernous nerves, which enter in the CC and corpus spongiosum 
to affect the neurovascular events during tumescence and detumescence 14.  
 
Fig. 1. Penile anatomy. Adapted from Fazio and Brock , 2004.15     
3. Physiology of Penile Erection 
Penile erection (PE) involves central and peripheral pathways. Tumescence is initiated after 
central processing and integration of tactile, visual, olfactory and imaginative stimuli. Upon 
sexual stimulation, signals are generated to the peripheral tissues involved. Thus, final 
response is mediated by coordinated spinal activity in the autonomic pathways to the penis, 
and also in the somatic pathways to the perineal striated muscles. Both central and 
peripheral regulation of PE involves several neurotransmitters and systems, of which details 
are still not completely known. Spinally, there seems to be a network consisting of primary 
afferents from the genitals, spinal interneurons, sympathetic, parasympathetic and somatic 
nuclei, which is capable of integrating all information. Peripherally, the balance between 
substances that control the degree of contraction of the cavernosal smooth muscle 
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determines the functional state of the penis 16. The dynamic interplay of vasoconstrictors 
and vasodilators in the penis establish the erect or flaccid state.  
PE is determined by pressure changes in the cavernosal arterioles and sinuses. The 
vasculature of the erectile mechanism differs from most vascular beds as it is composed of 
arterioles and hallow blood-filled sinuses, both which are lined with smooth muscle and 
endothelial cells 14 as previously described. In the flaccid state, this tissue is tonically 
contracted, allowing only a small amount of arterial flow for nutritional purposes. The 
partial pressure of oxygen (PO2) in the blood is around 35mmHg 17. On the other hand, 
dilation of the penile arteries is the first event in the development of erection. Its 
consequence is the increase of blood flow and pressure into the lacunar space. Then, the 
expansion of sinusoids blocks the incoming blood. Also, venous outflow is reduced by 
compression of venular spaces between the tunica albuginea and peripheral sinusoids. This 
stretches the tunica to its capacity and decreases the venous outflow to a minimum, leading 
to an increase in intracavernosal pressure, which is maintained at approximately 100mmHg 
(2). Thus, erection includes sinusoidal relaxation, arterial dilation and venous compression (3).  
3.1 Mechanisms mediating erection and penile relaxation 
In general, mechanisms leading to normal erectile function imply inter-connections among 
neurons, striated perineal muscles and androgens which are responsible for maintaining 
sexual behavior in adults. Locally, the stage of penile erection requires relaxation of 
cavernosal smooth muscle. It is triggered by release of substances from parasympathetic and 
non-adrenergic non-cholinergic nerves (NANC), which in turn promotes vascular and 
cavernosal relaxation, leading to an increase in blood flow and intracavernosal pressure 
resulting in erection (Figure 1). Although several vasodilators have been implicated in this 
process, nitric oxide (NO) still is the main vasodilator involved 18-19. In the penis, stimulation 
of parasympathetic nerves inhibits noradrenalin release and evokes acetylcholine (Ach) 
release, which binding to muscarinic receptors in endothelial cells promoting eNOS 
activation and consequently NO production. Cholinergic nerves have been demonstrated 
within the human cavernous smooth muscle and surrounding penile arteries and 
ultrastructural examination has also identified terminals containing cholinergic vesicules in 
the same area 20. Two decades ago, it was suggested that NO released from NANC increases 
the production of 3’,5’-cyclic guanosine monophosphate (cGMP), which in turn relaxes the 
cavernosal smooth muscle 7, 21. Nowadays, it is well known that NO plays a critical role in 
erectile function. NO is formed from the precursor amino acid, L-arginine, by enzymatic 
action of NOS, which exists as three main isoforms: neuronal NOS (nNOS), inducible 
(iNOS), and endothelial NOS (eNOS). All three isoforms have been detected in the penis, 
although nNOS and eNOS are the main constitutively active NOS enzymes expressed in 
penile tissues 22, it is activated by calcium entry into the cell, binding to calmodulin 
associated with enzymes 23.  
There are two main intracellular mechanisms for relaxing the cavernosal smooth muscle: the 
guanylate cyclase (GS)/cGMP and adenylate cyclase/cAMP pathways (Figure 3). NO is 
associated with GS/cGMP signaling, called NO/cGMP pathway. Upon its release, NO 
diffuses locally into adjacent smooth muscle cells of the corpus cavernosum and binds to 
soluble guanylyl cyclase (GC), which catalyzes the conversion of guanosine trisphosphate 
(GTP) to cGMP. This cyclic nucleotide then activates protein kinase G, also known as  
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Fig. 2. Sequence of events required for penile erection. Upon sexual stimulation, substances 
such as Ach and NO are released from endothelial cells, parasympathetic and NANC 
neuronal endings evoking vascular relaxation and consequently increase in blood flow. 
Thus, there is an increase in intracavernosal pressure resulting in penile erection.  
cGMP-dependent protein kinase I (cGKI), which decreases cytosolic Ca2+ by various 
mechanisms. cGMP also blocks RhoA migration avoiding Rho-kinase pathway activation, 
which is a step very important to penile relaxation. The decay in cytosolic Ca2+ 
concentration induces relaxation of the vascular and cavernosal smooth muscle cells, 
leading to dilation of arterial vessels, increased blood flow into the corpora cavernosa, and 
penile erection (Figure 3). Contributing to penile relaxation, substances such as 
prostaglandin E1 (PGE1) can bind to G protein coupled receptors and activate the enzyme 
adenylate cyclase, which catalyzes the conversion of adenosine monophosphate (AMP) to 
cyclic AMP (cAMP). This cyclic nucleotide activates protein kinase A (PKA), which also 
decreases the intracellular Ca2+. PGE1, injected intracavernosally, alone or in combination, is 
today the second-line treatment for ED 24. These second messengers, cGMP and cAMP 
activate protein kinase (PKG and PKA respectively), which in turn phosphorylate certain 
proteins and ion channels, resulting in opening of the potassium channels and 
hyperpolarization, sequestration of intracellular Ca+2 by the endoplasmatic reticulum, and 
inhibition of voltage-dependent Ca+2 channels, blocking the Ca+2 influx 25. Both, cGMP and 
cAMP levels are modulated by phosphodiesterase (PDE) enzymes, which cleave these 
signaling molecules to 5’GMP and 5’AMP, respectively (Figure 3). Phosphodisterase-5 
(PDE-5) is a key enzyme in the NO/cGMP signal transduction pathway and functions to 
restrain smooth muscle cells relaxation and erectile process 18. Predominantly expressed in 
CC, PDE-5 catalyzes the hydrolysis cGMP to the inactive metabolite 5’GMP. Nowadays, the 
PDE5 inhibitors are the first-line treatment for ED 26. 
Another mechanism which has been demonstrated to be involved in maintenance of the 
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blood flow and endothelial shear stress lead to sustained NO production and maximal 
erection 27.  
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concentration, which is due to activation of PKA and PKG, leading consequently to erection. 
In addition, PKA and PKG cause inhibition of calcium channels and activation of potassium 
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3.2 Flaccidity and detumescense 
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appears to be predominantly mediated by ETA receptor. In the penis, ET-1/ETA receptor-
mediated biological effects involve activation of the inositol trisphosphate (IP3)/calcium 
(Ca2+) and RhoA/Rho-kinase signaling pathways 30. However, both ETA and ETB receptors 
have been found in human CC smooth muscle membranes, and it cannot be excluded that 
both receptor subtypes are functional 28. The role of ETB receptors in the CC has not been 
clarified. This receptor activation is known to possibly induce a NO-mediated decrease in 
penile vascular tone 31.  
The intracellular mechanism in the absence of arousal stimuli, initiates with activation of G 
proteins following ligand binding to membrane receptors in order to keep cavernosal 
arterioles and sinuses constricted, maintaining the penis in the non-erect state. Subsequently 
to G protein activation, two signaling pathways are brought into play to cause smooth 
muscle contraction in the arterioles and cavernosum: the well characterized Ca+2 dependent 
pathway (phopholipase C) and the recently identified RhoA/Rho-kinase pathway know as 
Ca+2 sensitization. The Rho-kinase pathway is intrinsically involved with the process of 
smooth muscle contraction. The Ca2+ sensitivity of smooth muscle reflects the ratio of 
activities of MLCP to myosin light-chain kinase (MLCK), resulting in contraction or 
relaxation. Activation of G-protein coupled receptors by several agonists such as endothelin, 
angiotensin II, and noradrenalin, leads to the exchange of GDP for GTP on the small 
monomeric GTPase RhoA. This event actives RhoA and is catalyzed by the guanine 
nucleotide exchange factors, which causes dissociation of RhoA from its biding partner, 
Rho-guanine dissociation inhibitor. As a result, RhoA translocates from the cytosol to the 
membrane, allowing the downstream activation of several effectors such as Rho-kinase. 
Phophorylation of the regulatory subunit of MLC phophatase by Rho kinase causes 
inhibition phosphatase activity, which increases the contractile response at a constant 
intracellular calcium concentration 32. It is now widely accepted that MLCK and the 
RhoA/Rho-kinase pathway are two major cellular targets for regulating Ca2+ sensitivity of 
myosin light chain, and they generally operate in parallel. RhoA/Rho-kinase activity is a 
fundamental component to keep the penis in the non-erect state, and this pathway is 
upregulated in ED. Also, the essential balance between contraction and relaxation in the 
penis, which is maintained by the RhoA/Rho-kinase and NO/cyclicGMP pathways, is 
modified in this pathology 33-34. It has been demonstrated that Rho-kinase antagonism 
stimulated rat penile erection independently of NO suggesting that this principle could be a 
potential alternative for ED treatment 35-36. Many studies have suggested that NO inhibits 
RhoA/Rho-kinase activity 37-38. Increased of RhoA/Rho-kinase activity may lead to 
abnormal contractility of the CC and has been suggested to be involved not only in ED, but 
in several diseases which are risk factors for ED such as hypertension and diabetes 39.  
Another mechanism involved in penile vasoconstriction in absence of arousal stimuli, is the 
phospholipase C  (PLC) pathway. The stimulation of PLC occurs through the binding of 
vasoconstrictors agonists, such as norepinephrine (NE), angiotensin II (Ang II), endothelin-1 
(ET-1) and others, to their respective receptors. PLC hydrolyzes phosphatidylinositol 4,5-
biphosphate (PIP2) to release IP3 (inositol 1,4,5-trisphosphate) and DAG (1,2-diacylglycerol). 
IP3 binds to specific receptors (IP3R) on the endoplasmatic reticulum (ER) to stimulate the 
release of Ca+2 from the intracellular stores. DAG directly stimulates protein kinase C 
(PKC), which can regulate smooth muscle tone by controlling ion channels, allowing Ca+2 
influx. PKC also phosphorylates multiple substrates to facilitate contraction (figure 4).  
 




Fig. 4. Regulation of cavernosal smooth muscle contraction leading to penile flaccidity. 
Pathways mediating the contraction of smooth muscle in CC, which is regulated by an 
increase in cytosolic Ca+2, are illustrated.  
4. Emergent mechanisms associated with ED 
Various aspects of neurotransmission, impulse propagation, and intracellular transduction 
of signals in penile smooth muscle remain to be elucidated. Nevertheless, the information 
about mechanisms involved in erection is quickly increasing and details regarding new 
pathways are constantly being added. The renin-angiotensin system (RAS), TNF-, MAP 
Kinases and arginase II are some of the new insights in this field.  
4.1 Renin-angiotensin system 
In the past decade, it has become apparent that the renin-angiotesin system (RAS) is 
involved in the regulation of ED. There is evidence that the local RAS exists within the CC 40 
and that several active peptides, particularly angiotensin II (Ang II), may be involved in the 
erectile mechanism. Ang II is the main effector of RAS that regulates important physiologic 
functions. The conventional idea of RAS as a systemic system has been extended recently. 
Many organs and tissues have components of RAS, working in a paracrine manner 41. Tissue 
RAS synthesizes Ang II locally and is modulated independently of systemic RAS. It has 
been demonstrated that Ang II activates the RhoA/Rho-kinase pathway via AT1 receptor, 
which is dominantly expressed in the smooth muscle and endothelial cells of the blood 
vessel wall, leading to the inhibition of myosin light chain phosphatase (MLCP) 42-43. 
Another significant function of AT1 is to activate nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, increasing reactive oxygen species (ROS) production. ROS 
rapidly react with NO, reducing its bioavailability, and also stimulate RhoA/Rho-kinase 
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activity44-45. Additionally, both Ang II 46 and AT1 47 were detected in endothelial and smooth 
muscle cells from CC, and comparing the different stages of penile flaccidity, tumescence, 
rigidity, and detumescence, Ang II levels were significantly higher during detumescence 47. 
Human CC produces and secretes physiological amounts of Ang II, as much as 200-fold 
greater than that in plasma46. Furthermore, in vivo experiments demonstrated that injection 
of Ang II into the CC terminated spontaneous erections observed in anesthetized dogs46. 
Chronic infusion of exogenous Ang II for 4 weeks induced ED in Sprague-Dawley rats 48. It 
seems that RAS is crucial in ED 49.  
Reinforcing the association of RAS and ED, agiotensin-converting enzyme (ACE) has been 
found in the endothelial cells of dog CC 50, and ACE mRNA expression is up-regulated in a rat 
model of arteriogenic ED, although it is expressed at very low levels in the penis of control 
rat51. Results from human CC smooth muscle showed that Ang II and NO interact to modulate 
penile function, since an AT1 antagonist potentiated sodium nitroprusside (a NO donor) and 
electrical field stimulation mediated CC relaxation. Also, the authors suggested that Ang II 
response involves the production of superoxide and the development of oxidative stress 52. 
Taken together, evidence from many studies suggests that the main function of the RAS 
system is Ang II-mediated contraction, contributing to maintenance of the penis in a flaccid 
state. However, the RAS system consists of two major arms: a vasoconstrictor/proliferative 
arm in which the major mediator is Ang II acting on AT1 receptors, and a 
vasodilator/antiproliferative arm in which the main effector is Ang-(1-7) acting via G protein-
coupled recetors Mas 53. The Ang-(1-7)-Mas axis may play an important role in penile erection. 
This receptor has been observed in rat CC, and it has been demonstrated that Ang-(1-7) acts as 
a mediator of penile erection by activation of Mas and subsequent NO release. Additionally, in 
the absence of Mas erectile function was severely compromised 54.  
4.2 TNF-  
The emerging role for tumor necrosis factor-alpha (TNF-) in ED has been discussed. It is a 
pro-inflammatory cytokine originally defined by its antitumoral activity and is involved in 
many cardiovascular diseases (CVD), including heart-failure and atherosclerosis55-56. In 
these diseases, TNF- plasma levels are significantly increased and the vascular 
endothelium is the major target for the actions of TNF-. In vivo administration of this 
cytokine induces impairment of endothelium-dependent relaxation in a diversity of vascular 
beds and decreases the release of NO 57. Endothelium dysfunction is a key event in the 
pathophysiology of ED and, importantly, endothelium dysfunction is impaired in the 
presence of increased oxidative stress and inflammatory conditions55. A low-grade 
inflammatory process is associated with several CVD, and accordingly, cytokines levels, 
including TNF-, are increased in response to inflammation and contribute to the changes in 
vascular reactivity observed in these conditions58-59. TNF- has been described as an 
important contributor to many cardiovascular disorders55. Patients with ED present 
increased expression and elevated plasma levels of inflammatory markers and mediators 
among them TNF-60, which have been also observed in patients with hypertension. An 
emerging basic science and clinical data base provides a strong argument for endothelial 
and smooth muscle dysfunction as a central etiologic factor in systemic and peripheral 
vascular diseases, such as ED. It has been raising the idea of ED as an early sign of CVD 61. 
Once CDV appears right after ED and after the levels of TNF- start to increase 62-63, seems 
 
Mechanisms in Erectile Function and Dysfunction: An Overview 
 
11 
that this cytokine may represent not only a common point between ED and CVD, but its 
increasing levels associated with ED may be a predictor of cardiovascular events64.  
TNF- has been associated with Rho-kinase signaling in endothelial cells. This cytokine not 
only induces inflammatory gene transcription, but also activation of RhoA and Rho-kinase65. 
In addition, TNF- leads to increased Ca+2 sensitivity via activation of the RhoA/ROCK 
pathway, a mechanism that may contribute not only to TNF--induced airway 
hyperresponsiveness and hyperreactivity 66-67. It was recently demonstrated that TNF- KO 
mice shown increased number of spontaneous erections, also these animals have enhanced 
nNOS expression in CC tissue68 , which suggests that TNF- down regulates nNOS 
expression in this tissue 68. In another work, the same authors showed that TNF--infused 
mice displays decreased NANC-dependent relaxation and increased symphathetic-
mediated concentrations in vivo, which would contribute to penile detumecesce to occur 69. 
Enhanced direct adrenergic responses were also observed in CC tissue from these animals, 
and it was suggested that downregulation of eNOS and nNOS may be the mechanism 
underlying the functional modifications in CC strips from TNF- infused mice 69. 
Endothelin-1 not only induces vasoconstriction, but it also stimulates the expression of 
adhesion molecules and activates transcriptional factors responsible for the coordinated 
increase in the expression of many cytokines and enzymes, which can in turn lead to the 
production of inflammatory mediators 70. Additionally, RAS system and Ang II, the main 
known mediator of RAS, induces vascular injury through many mechanisms, including 
vasoconstriction, oxidative stress and inflammation. Both peptides have been shown to 
increase TNF- levels and this pro-inflammatory cytokine also positively regulates release 
of these vasoactive peptides71-72. Finally, sexual performance has been negatively associated 
with circulating levels of endothelial inflammatory parameters 73. Further studies are 
necessary to better clarify the role of TNF- in ED and its mechanism in CC dysfunction. 
The positive point is that now we have access to target anti-TNF-a therapy.  
4.3 Arginase  
The involvement of arginase in ED has been evident in recent years. Arginase catalyses the 
conversion of L-arginine to ornithine plus urea. Arginase exists in two isoforms, the hepatic 
type, arginase I and the extrahepatic type, arginase II 74. Both isoforms are expressed in 
human CC tissue 75, but it seems that arginase II is the predominant isoform involved in ED 
mainly when this condition is associated with age and diabetes 76-77. In mammalian cells, L-
arginine is used as a substrate by both NOS and arginase. NO is derived from L-arginine by 
nitric oxide synthase (NOS) and both endothelial (eNOS) and neuronal (nNOS) isoforms of 
the CC serve as sources to generate essential levels of NO. NO production depends on NOS 
activity and NOS protein expression. On the other hand, NO production absolutely depends 
on the availability of L-arginine to NOS, since NOS shares L-arginine as a common substrate 
with arginase 78. Considering this, L-arginine catabolism via the arginase pathway can act as 
an endogenous negative control system to regulate overall NO production. ED mechanisms 
involve oxidative stress and vascular inflammation 79, both of which have been associated 
with enhanced arginase activity and expression in the vasculature 77. Recently, it has been 
demonstrated that diabetes-induced ED involves elevated arginase activity and expression 
80. Also, previous studies suggest that arginase activity in the CC is increased by 
hyperglycemia and aging 81.  
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Aging-associated ED involves abnormalities at multiple levels of the NO/cGMP signaling in 
the penis. These include reduced NANC nerve fibers in CC, decreased constitutive NOS 
activity, impaired endothelium-dependent smooth muscle relaxation and reduced NO 
bioavailability 82-83. It has been observed that dietary L-arginine supplementation as well as 
acute infusion of L-arginine results in improved NO release and increased endothelium-
dependent vasodilatation in the penis 84. The basis by which L-arginine supplementation can 
improve the endothelial function and NO release is questionable. Studies have been shown 
that eNOS expression is upregulated with advanced age in the penis and in peripheral 
vasculature. However, eNOS activity is reduced such that, for any given concentration of L-
arginine, vascular production of NO is reduced 85-86. Nowadays, we have evidence of a 
biological role of arginase in regulating erectile function in the aged penile vascular bed at 
both the molecular and functional level. It has been demonstrated that penile endothelial 
cells isolated from the aged mouse penis overexpressed arginase and, as a result, decreased 
eNOS activity and impaired vascular function. Moreover, inhibition of arginase via an 
adeno-associated virus (AVV) gene transfer of anti-arginase in this tissue increases penile 
eNOS activity and cGMP levels, thus restoring endothelial-derived NO vasodilatation and  
erectile function 79, speculating that an antisence for arginase may represent a novel 
molecular therapeutic target for the treatment of age-associated vasculogenic ED. Regarding  
diabetes- associated ED, reduced nitrergic and endothelial dependent smooth muscle 
relaxation, as well as arginase activation and diminished NO production are involved 87-88. 
In addition, it has been well documented that a major causative factor contributing to ED in 
diabetic patients is the reduction in the amount of NO synthesis in CC. Recently, it was 
demonstrated that arginase II deletion prevents diabetes-impairment in CC relaxation 80. 
Since a specific arginase inhitor is not available, in this study they used diabetic arginase II 
knockout mice. These animals did not exhibit increased arginase activity and expression, as 
well as decreased nNOS and phospho-eNOS (at Ser-1177 and Thr-495) levels. Arginase has 
been involved in sexual disorders not only in men, but also in women. Administration of 
arginase inhibitors in vitro and  in vivo enhances  engorgement in male and female genitalia 
89. There is no doubt that arginase is involved in ED. However, more complete 
understanding about the exact mechanism leading to disruption of erectile dynamic by 
arginase is necessary, as well as further research.  
4.4 MAP-Kinases 
Mitogen-activated protein kinases (MAPK) are a group of serine/threonine protein kinases 
which play an important role in cellular process, such as proliferation, stress response 
apoptosis and immune defense 90. The extracellular-signal-regulated kinase 1/2 (ERK1/2), 
p38 MAPK and the JUN N-terminal kinase (JNK) are the three most defined MAPK 
pathways 91. Not long ago, evidence of involvement of ERK1/2 and p38 MAPK in the ED 
began. It seems that these MAPKs are indirectly associated with NOS regulation, which 
affects NO avaibility. It has been observed that ERK plays a key role in eNOS regulation 92. 
In addition, phosphorylation of eNOS catalysed by ERK can lead to enzyme inhibition, and 
it was shown that in vivo phosphorylation of eNOS by ERK is associated with a reduction in 
enzyme activity. ERK inhibits eNOS by phosphorylating the enzyme in endothelial cells 92. 
ERK has been involved in various pathological conditions; one major mechanism involved 
in the regulation of inflammatory processes is the activation of ERK 93. Regarding cavernosal 
tissue, an inhibitory influence on activity of eNOS by ERK has been described in humans 94. 
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The first study showing a link between ERK1/2 and the CC was published in 2002 and the 
authors demonstrated that this kinase is present and active in human CC. Also, they found 
that the endothelial expression of ERK was more pronounced than muscular expression, 
and tissue from patients with ED showed a higher expression of the active ERK 94. ERK can 
be triggered by cellular stresses such as oxidative stress and hyperglycemia, which play an 
important role in the development of diabetic complications 95, a disease associated with ED. 
Recently, it was demonstrated that ERK inhibition decreases arginase activity and improves 
CC relaxation in streptozotocin (STZ)-induced diabetic mice (Nunes, 2011). Hyperglycemia 
in STZ-induced diabetic mice stimulates adipogenic induction of lipid accumulation and  
 
Fig. 5. Emergent pathways involved in ED. The influence of renin-angiotensin system (RAS), 
TNF-, ERK and P38 MAPK, and Arginase II in ED are illustrated. Tissue RAS synthesizes 
Ang II locally, which acts via two different receptors: AT-1, leading to activation of RHO-
kinase and consequently MLPC inhibition, contributing to penile flaccid, or Ang-1-7 Mass 
axis G-protein coupled receptor evoking NO release and facilitating CC relaxation. 
Additionally, Ang II can activates p38, which is involved in NOS regulation. TNF- 
promotes downregulation of eNOS and nNOS, contributing to ED. In addition, TNF- may 
lead to increased Ca+2 sensitivity, via activation of the RhoA/ROCK pathway, (???) in the 
penis. Since arginase and eNOS share L-arginine as a common substrate, increased arginase 
activity can limit NO availability, making the erectile function difficulty. ERK and p38 
MAPKs are indirectly associated with NOS regulation, which affects NO avaibility. 
Inhibitors for ERK and p38 in CC tissue resulted in decreased arginase activity, suggesting 
an association between these kinases and arginase. However, this mechanism in ED still 
needs be clarified.  
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involves ERK signaling pathway 96. Also,  neuropathy is a common complication of long-
term diabetes 97. Accordingly, the recent study showed that diabetes increased expression of 
activated ERK and arginase activity in CC and this effect was blocked by acute treatment 
with PD98059 (an ERK inhibitor). Also, the impaired cavernosal relaxation from STZ-
diabetic mice was attenuated by treatment with an ERK inhibitor, observed in nitrergic and 
endothelium-dependent relaxation responses. The authors suggested that ERK inhibition 
prevents the elevation of penile arginase activity and protects against ED caused by diabetes 
98. However, the mechanism involving ERK and arginase in ED is unclear and needs to be 
better understood.  
There are a few studies associating ERK and P38 MAPK with ED. RhoA/Rho-kinase has 
been indicated as an upstream regulator of MAPK family members such as p38 MAPK 99. 
Increased p38 MAPK in response to stress stimuli, including hyperglycemia, contributes to 
diabetic somatic neuropathy 100. The first study connecting ED and p38 demonstrated that 
inhibition of p38 MAPK corrects nitrergic neurovascular function in diabetic mice CC 101. It 
has been described that Ang II markedly activates p38 MAPK 102-103 and inhibition of p38 
MAPK attenuates organ damage and improves vascular function in cardiovascular diseases 
104-105. Recently, it was demonstrated that p38 MAPK increases arginase activity and 
contributes to endothelial dysfunction in CC 106. This study showed that acute treatment 
with p38 inhibitor prevents increased arginase activity and expression of phosphorylated 
p38 MAPK levels in CC from mice treated with Ang II. Also, decreased eNOS 
phosphorylation at Ser-1177 due to Ang II treatment, was prevented. 106. Although further 
research is needed to better clarify the exact role of these kinases in ED, new insights 
pointed to these pathways as a new therapeutic target worthy of consideration for clinical 
trials.  
5. Endothelial dysfunction in vasculogenic ED 
A number of both clinical and preclinical studies on hypercholesterolemia, hypertension, 
diabetes, and aging have demonstrated endothelial dysfunction to be a critical factor in the 
development of vasculogenic ED 107. Since the erectile function is a mechanism which 
requires a sensitive balance between the vasodilators and vasoconstrictors agents, any 
modification or impairment in endothelial function contributes to ED. Nowadays, because a 
systemic endothelial may functionally manifest itself early in the penile endothelium, the 
possibility arises that ED may be an early indicator of cardiovascular diseases 61, 108-110. In 
addition, since the penis is a rich vascularized organ, penile erection is, in large part, a 
vascular event. The endothelium, which is a layer of epithelial cells that lines structures of 
the cardiovascular system, is pivotal to the regulation of vasomotor tone. Impaired 
vasodilatation is closely linked with endothelial dysfunction, and endothelial cells are the 
primary source of NO, which is a crucial vasodilatory neurotransmitter involved in the 
regulation of vascular wall function, specifically in the penis 19. At the cellular level, 
endothelial dysfunction results in impaired release of NO. Oxidative stress, which is directly 
toxic to the endothelium and also interferes with NO signaling, is a strong factor responsible 
for the endothelial dysfunction in ED. In addition, free radical damage and impaired 
function, as well as NO availability, also results in increased adhesion and aggregation of 
platelets and neutrophils, and the release of vasoconstrictor substances 111-112. Since the penis 
is a vascular organ, it may be very sensitive to changes in oxidative stress and systemic 
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levels of NO for many reasons. The small diameter of the cavernosal arteries and the 
eminent amount of endothelium and smooth muscle (per gram of tissue compared to  
other organs) may make the penile vascular bed a sensitive indicator of systemic vascular 
disease 61.  
Oxidative stress has been implicated in endothelial damage or destruction of NO 113 as 
previously mentioned. It occurs when cells are exposed to excessive levels of reactive oxygen 
species (ROS) as a result of an imbalance between pro-oxidants and the protective mechanisms 
conferred by antioxidants 114. ROS is a superoxide (O2-) which interacts with NO reducing NO 
bioavailability and resulting peroxynitrite (ONOO-) formation. It has been demonstrated that 
the blockade of NOS increased basal superoxide production in penile arteries, suggesting that 
the release of ROS is modulated by its interaction with endogenous endothelial-derived NO, 
probably by producing peroxynitrite that reduces the bioavailability of both radicals 115. In 
addition, peroxynitrite and superoxide have been reported to increase the incidence of 
apoptosis in the endothelium of cavernosal smooth muscle, resulting in denudation of 
endothelium and further reduction of available NO 116. NOS, enzyme responsible for NO 
generation, uses l-arginine as a substrate and promotes its oxidation with NADPH and O2 
consumption to yield citrulline and NO. NADPH oxidase is a big source of superoxide radicals 
and many authors have reported that up regulation of this enzyme is associated with an 
increased risk of vascular diseases 117. Also, superoxide anions plays a role in natural aging 
process and the prevalence and severity of ED increase with age.  
Another mechanism associated endothelial damage and ED is the recently indentified 
advanced glycation end products (AGEs). It is believed that when AGEs are increased, NO 
cannot interact with GS, resulting in decreased CGMP levels and ultimately functional ED. 
Recently, it has been demonstrated that inhibitors of AGE formation can prevent formation 
of a range of complications in experimental diabetic animals, including ED 118-119. AGEs are 
elevated in diabetic human penile tissue and it has been localized to the collagen of the 
penile tunica and corpus cavernosum 120. Furthermore, AGEs and their receptors have been 
described to elevate the activity of endothelin-1, a vasoconstrictor, in rat corpus cavernosum 
121, and AGEs production is associated with increased superoxide anion. O-linked N-
acetylglucosamine (O-GlcNAc) is the major AGE product implicated in cavernosal 
dysfunction in diabetic patients. It has been reported a significant increase in the O-GlcNAc 
modification of eNOS and reduced phosphorylation of eNOS at baseline and following 
electrical stimulation in cavernosal tissue from diabetic rats compared with the controls 122. 
Finally, increased AGEs has been reported in penile tissue from aged man 123.  
Although the vascular endothelium is capable of self-repairing in general, any disruption in 
the penile endothelium balance may affect the dynamic of erectile function since the intact 
endothelium is critical to normal erection. Increase production of ROS has been associated 
with decreased normal erectile response, mainly because the reduction in NO avaibility, 
which is also observed due to endothelium damage 113. Consequently, ED can be the result 
of any number of structural or functional abnormalities in the penile vascular bed. 
Accordingly, ED may result from occlusion of the cavernosal arteries by atherosclerosis 
(structural vascular ED), impairment of endothelial dependent and/or independent smooth 
muscle relaxation (functional vascular ED), or a combination of these factors. Thus, it seems 
that endothelial dysfunction is sometimes a primary factor involved in ED even though 
reduced NO from NANC nerves has a significant contribution in ED.  
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The molecular and clinical understanding of ED continues to gain ground at a particularly 
fast rate. Significant scientific advances during the last 2 decades have increased our 
knowledge regarding physiology and pathophysiology of penile erection. Different parts of 
the pathways involving ED have been studied intensely and the investigations of new 
components in this mechanism are emerging. The main target in the mechanism associated 
with ED is still NO, and the deep understanding of NO/cGMP signaling has supported, not 
only the molecular understanding of the tumescence, but also added significantly in the 
treatment of the ED, including the possibility of stem cell use and gene therapy. Also, the 
new components found to be involved in ED may be a potential target for development of 
novel drugs. However, the erectile mechanism is not completely elucidated and despite the 
efficacy of current therapies, current knowledge remains insufficient to address a growing 
patient population who do not respond to conventional treatment.  
7. References 
[1] Lue TF. Erectile dysfunction. N Engl J Med. 2000;342: 1802-13. 
[2] Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction 
between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84: 50-6. 
[3] Hafez ES, Hafez SD. Erectile dysfunction: anatomical parameters, etiology, diagnosis, 
and therapy. Arch Androl. 2005;51: 15-31. 
[4] Lue TF, Tanagho EA. Physiology of erection and pharmacological management of 
impotence. J Urol. 1987;137: 829-36. 
[5] Mersdorf A, Goldsmith PC, Diederichs W, et al. Ultrastructural changes in impotent 
penile tissue: a comparison of 65 patients. J Urol. 1991;145: 749-58. 
[6] Andersson KE, Holmquist F. Regulation of tone in penile cavernous smooth muscle. 
Established concepts and new findings. World J Urol. 1994;12: 249-61. 
[7] Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic 
GMP formation upon electrical field stimulation cause relaxation of corpus 
cavernosum smooth muscle. Biochem Biophys Res Commun. 1990;170: 843-50. 
[8] Andersson KE. Mechanisms of Penile Erection and Basis for Pharmacological Treatment 
of Erectile Dysfunction. Pharmacol Rev. 2011. 
[9] Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75: 191-236. 
[10] Nehra A, Azadzoi KM, Moreland RB, et al. Cavernosal expandability is an erectile 
tissue mechanical property which predicts trabecular histology in an animal model 
of vasculogenic erectile dysfunction. J Urol. 1998;159: 2229-36. 
[11] Yiee JH, Baskin LS. Penile embryology and anatomy. ScientificWorldJournal. 2010;10: 
1174-9. 
[12] Manabe K, Heaton JP, Morales A, Kumon H, Adams MA. Pre-penile arteries are 
dominant in the regulation of penile vascular resistance in the rat. Int J Impot Res. 
2000;12: 183-9. 
[13] Moscovici J, Galinier P, Hammoudi S, Lefebvre D, Juricic M, Vaysse P. Contribution to 
the study of the venous vasculature of the penis. Surg Radiol Anat. 1999;21: 193-9. 
[14] Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile 
dysfunction. Urol Clin North Am. 2005;32: 379-95, v. 
[15] Fazio L, Brock G. Erectile dysfunction: management update. CMAJ. 2004;170: 1429-37. 
 
Mechanisms in Erectile Function and Dysfunction: An Overview 
 
17 
[16] Gratzke C, Angulo J, Chitaley K, et al. Anatomy, physiology, and pathophysiology of 
erectile dysfunction. J Sex Med. 2010;7: 445-75. 
[17] Sattar AA, Salpigides G, Vanderhaeghen JJ, Schulman CC, Wespes E. Cavernous oxygen 
tension and smooth muscle fibers: relation and function. J Urol. 1995;154: 1736-9. 
[18] Leite R, Giachini FR, Carneiro FS, Nunes KP, Tostes RC, Webb RC. Targets for the 
treatment of erectile dysfunction: is NO/cGMP still the answer? Recent Pat 
Cardiovasc Drug Discov. 2007;2: 119-32. 
[19] Toda N, Ayajiki K, Okamura T. Nitric oxide and penile erectile function. Pharmacol 
Ther. 2005;106: 233-66. 
[20] Steers WD, McConnell J, Benson GS. Anatomical localization and some 
pharmacological effects of vasoactive intestinal polypeptide in human and monkey 
corpus cavernosum. J Urol. 1984;132: 1048-53. 
[21] Ignarro LJ. Nitric oxide. A novel signal transduction mechanism for transcellular 
communication. Hypertension. 1990;16: 477-83. 
[22] Burnett AL, Tillman SL, Chang TS, et al. Immunohistochemical localization of nitric 
oxide synthase in the autonomic innervation of the human penis. J Urol. 1993;150: 
73-6. 
[23] Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring 
enzyme. Proc Natl Acad Sci U S A. 1990;87: 682-5. 
[24] Alexandre B, Lemaire A, Desvaux P, Amar E. Intracavernous injections of 
prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life 
on long-term treatment. J Sex Med. 2007;4: 426-31. 
[25] Saenz de Tejada I, Angulo J, Cellek S, et al. Physiology of erectile function. J Sex Med. 
2004;1: 254-65. 
[26] Albersen M, Mwamukonda KB, Shindel AW, Lue TF. Evaluation and treatment of 
erectile dysfunction. Med Clin North Am. 2011;95: 201-12. 
[27] Hurt KJ, Musicki B, Palese MA, et al. Akt-dependent phosphorylation of endothelial 
nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci U S A. 2002;99: 
4061-6. 
[28] Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53: 417-50. 
[29] Granchi S, Vannelli GB, Vignozzi L, et al. Expression and regulation of endothelin-1 
and its receptors in human penile smooth muscle cells. Mol Hum Reprod. 2002;8: 
1053-64. 
[30] Wingard CJ, Husain S, Williams J, James S. RhoA-Rho kinase mediates synergistic ET-1 
and phenylephrine contraction of rat corpus cavernosum. Am J Physiol Regul 
Integr Comp Physiol. 2003;285: R1145-52. 
[31] Ari G, Vardi Y, Hoffman A, Finberg JP. Possible role for endothelins in penile erection. 
Eur J Pharmacol. 1996;307: 69-74. 
[32] Hirano K. Current topics in the regulatory mechanism underlying the Ca2+ 
sensitization of the contractile apparatus in vascular smooth muscle. J Pharmacol 
Sci. 2007;104: 109-15. 
[33] Andersson KE. Erectile physiological and pathophysiological pathways involved in 
erectile dysfunction. J Urol. 2003;170: S6-13; discussion S13-4. 
[34] Jin L, Burnett AL. RhoA/Rho-kinase in erectile tissue: mechanisms of disease and 
therapeutic insights. Clin Sci (Lond). 2006;110: 153-65. 
[35] Chitaley K, Wingard CJ, Clinton Webb R, et al. Antagonism of Rho-kinase stimulates 
rat penile erection via a nitric oxide-independent pathway. Nat Med. 2001;7: 119-22. 
 




The molecular and clinical understanding of ED continues to gain ground at a particularly 
fast rate. Significant scientific advances during the last 2 decades have increased our 
knowledge regarding physiology and pathophysiology of penile erection. Different parts of 
the pathways involving ED have been studied intensely and the investigations of new 
components in this mechanism are emerging. The main target in the mechanism associated 
with ED is still NO, and the deep understanding of NO/cGMP signaling has supported, not 
only the molecular understanding of the tumescence, but also added significantly in the 
treatment of the ED, including the possibility of stem cell use and gene therapy. Also, the 
new components found to be involved in ED may be a potential target for development of 
novel drugs. However, the erectile mechanism is not completely elucidated and despite the 
efficacy of current therapies, current knowledge remains insufficient to address a growing 
patient population who do not respond to conventional treatment.  
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The prevalence of ED in men between 40 and 70 years old is approximately 50%. 
(Massachusetts Male Aging Study). There are many ED etiological factors, such as 
psychological, vascular, neurological and hormonal disorders. (Tomada, 2010; Kavoussi, 
2007; Glina 2002). 
In accordance with the International Society of Impotence Research, ED may be classified 
into three subtypes: organic (that includes iatrogenic, neurogenic, vasculogenic and 
hormonal), psychogenic and mixed erectile dysfunction. A thorough investigation ought to 
be performed by a multidisciplinary team in order to avoiding misdiagnosis. (Kavoussi, 
2007) 
The basic assessment is suggested by ED guidelines: detailed anamnesis and physical 
examination, fast serum glucose, total cholesterol and fractions, triglycerides and 
testosterone level. Long history of diabetes, alcohol abuse and spinal cord injuries suggest 
neurological ethiology. (Kavoussi; Tanagho & McAninch, 2007). 
Patients without contra-indications must be recommended to use 5 phosphodiesterase 
(PDE5) inhibitors after first visit. Vascular integrity may be tested by PDE5  inhibitors 
response and good drug response usually mean vascular integrity. (Tanagho & McAninch, 
2007; Glina, 2002) 
Recent studies have demonstrated the association between ED and cardiovascular diseases 
Zambon, 2010; Bal, 2007. Ultrasensible C Reactive Protein (CRP) is an early marker of 
cardiovascular risk, and patients with ED have higher levels of CRP. Risk factors such as 
hypertension, smoking, obesity, diabetes mellitus, metabolic syndrome and sedentary 
lifestyle are pretty common in patients with coronary disease and ED (Zambon, 2010; Bal, 
2007).   
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  Diabetes Mellitus
  Pelvic irradiation
  Pelvic surgery
  Cavernosal
  Neurogenic
  Central 
  Parkinson disease
  Encephalitis
  Vascular Stroke
  Brain Tumor
  Multiple Sclerosis 
  Alzheimer 
  Spinal cord injury
  Disc herniation
  Peripheral
  Pelvic surgery
  Retroperitoneal surgery






  Diabetes Mellitus
  Dyslipidemia
  Thyroid hormones
  Adrenal hormones
  Estradiol changes
  Anatomic
  Peyronie disease
  Penile fracture
Table 1. ED organic causes 
2.1 Anatomic factors 
The most frequent physiopathology of these dysfunctions is low abnormal drainage, or 
severe alterations of penile geometry. Peyronie's disease, priapism and penile trauma are 
some examples of anatomic etiological factors. Physical examination can confirm penile 
shaft fibrosis, and Doppler ultrasound can identify the fibrosis with good sensitivity and 
specificity (Navarro, 2010; Persu, 2009).  
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2.2 Endocrinological factors 
The endocrine disorders are directly or indirectly related with erection mechanism. 
Endocrine disorders can be associated or worsen the pre-existing ED. Among the etiological 
factors we can point out diabetes mellitus, obesity, hypogonadism, adrenals and thyroid 
dysfunction and Hyperprolactinemia. (Tanagho & McAninch, 2007; Kavoussi; Jabaloyas, 
2010; Persu, 2009) 
2.2.1 Diabetes mellitus 
Diabetes Mellitus (DM) is one of the most frequent etiologies of ED. Patients with higher 
levels of glucose and glycated hemoglobin has higher risk of ED. The prevalence of ED in 
men with DM ranges from 10 to 90%. Risk factors for the emergence of ED in diabetic 
patients are: disease time, age, sedentary lifestyle and glycemic control. (Jabolayas, 2010) 
Regarding PDE 5 inhibitors response, diabetic patients have lower response than normal 
patients. Furthermore, it is directly related to disease severity. Vascular and autonomic 
neuropathies are the main etiological alterations observed in diabetic patients. The main 
pathophysiological mechanisms proposed for ED in diabetic patients include the release of 
free radicals, increased endothelin receptor B, impaired nitric oxide synthesis and up-
regulated RhoA/Rho-kinase pathway. (Jabolayas, 2010; Thorve, 2011; Moore, 2006) 
2.2.2 Hypogonadism 
Low testosterone level can decrease the libido, the morning erections and penile tumescence. It 
can also increase the risk of depression and psychiatric disorders. Furthermore, hypogonadic 
patients with ED have higher risk of early osteoporosis. (Tanagho & McAninch, 2007) 
Studies have shown that hypogonadic men present high risk of metabolic syndrome and 
DM. The symptoms which are related to hypogonadism are common to many others 
diseases. It is advisable at least 2 consecutive dosages of total testosterone in the period 
between 7 and 11 a.m. The institution of compulsory treatment should be based on clinical 
and total dosage of testosterone. Moreover, hypogonadic patients may clinically present 
primary or secondary infertility. Thyroid, pituitary and adrenal disorders are less common 
etiologies, and in specific situations, alterations must be taken into account. (Traish, 2009) 
2.2.3 Hyperprolactinemia 
Hyperprolactinemia may be associated with reduced libido. The prevalence of 
hyperprolactinemia in men with ED varies between 2 and 13%. Prolactin above 35 ng/mL 
are associated with ED and decreased libido. (Jabolayas, 2010) 
The mechanism by which elevated prolactin leads to ED, is not fully understood. This 
change is attributed to the reduction of testosterone and alterations in the pulsatile release of 
LH. There are several causes for elevated prolactin, for instance pituitary adenoma (most 
common cause), drugs (especially antipsychotics), chronic renal failure and herpes zoster. 
(Jabaloyas, 2010) 
Guidelines recommended prolactin dosage when testosterone levels are low. The gold 
standard exam to evaluate pituitary adenoma is the magnetic ressonance imaging. (Tanagho 
& McAninch, 2007) 
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2.2.4 Changes in thyroid hormones 
Changes in thyroid hormones are also associated with changes in libido, erectile function 
and ejaculation. The prevalence of thyroid diseases is variable and normalization of 
hormone levels can restore an adequate erection when the ethiology is the thyroid 
dysfunction .The hypothyroidism can decrease levels of free testosterone and SHBG, and 
hyperthyroidism appears to be strictly related to changes in libido. (Jabolayas, 2010; Cauni, 
2009). 
2.2.5 Dyslipidemia 
Dyslipidemia is a risk factor for ED, and some patients are diagnosed during the ED 
investigation. The change in lipid metabolism is associated with endothelial dysfunction 
and abnormal relaxation of smooth muscle. (Vrentzos, 2007; Jabaloyas, 2010) 
Hypercholesterolemia, high level of LDL and low HDL increase the risk of atherosclerosis, 
which may change the penile blood flow. Besides, hypercholesterolemia increases the pro-
inflammatory markers and endothelial dysfunction. (Vrentzos, 2007; Bal, 2007) 
Studies demonstrated a positive correlation between cardiovascular risks, 
hypercholesterolemia and erectile dysfunction (Zambon, 2010; Koenig, 2004) have 
demonstrated that men with ED had higher levels of C-reactive protein, which is an early 
marker of endothelial dysfunction and cardiovascular diseases. (Zambon, 2010; Koenig, 2004) 
2.2.6 Changes of adrenal hormones 
The role of adrenal hormones and their changes are not well established in the etiology of 
ED. Studies have correlated the low levels of dehydroepiandrosterone with ED. 
Androstenedione can be converted into testosterone and supplementation of this hormone 
may improve erectile function. Nevertheless, there is no justification dosage of adrenal 
hormones in the initial investigation of ED. In specific cases, the dosage of hormones 
produced in the adrenal, for example, cortisol, aldosterone, androstenedione, 
dehydroepiandrosterone, among others, is recommended. (Jabolayas 2010) 
2.2.7 Changes in estradiol 
The increased production of estradiol in men can be associated with ED. Elevated estrogen 
levels decrease the production of testosterone by inhibiting the LH production. The chronic 
liver disease may be related with the hyperestrogenism. Another uncommon etiology of 
hyperestrogenism is the endocrinologic neoplasms. (Jabolayas, 2010) 
2.3 Vascular factors 
The vascular dysfunctions are common in men with ED. Commonly, the vasoreactivity is 
reduced, and consequently low penile blood flow, hypoxia and fibrosis are the final results. 
These changes decrease the penile shaft stiffness over the time. (Tomada, 2010; Cauni, 2009; 
Odriozola, 2010) 
ED seems to be an early marker of endothelial dysfunction, which can changes the 
vasoreactive substances production, such as nitric oxide and endothelin (Odriozola, 2010; 
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2.2 Endocrinological factors 
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Hannan, 2010). Local growth factors seem also to be involved in the pathophysiology. 
Therefore, there is a reduced response to vasodilating substances and an increased 
sensitivity to vasoconstrictor agents. (Odriozola, 2010; Hannan, 2010) 
Penile vascular abnormalities are strictly linked to cardiovascular risk factors such as 
hypertension, smoking, dyslipidemia, and DM among others. Diffuse and bilateral lesions 
in internal pudendal arteries, penile and cavernous as well are common in patients with 
atherosclerosis. (Odriozola, 2010, Hannan, 2010) 
The evaluation of penile vascular function can be performed using Doppler ultrasound, 
magnetic resonance image or angiography, however, the real significance of these tests 
remains unclear.  
2.4 Neurologic factors  
The prevalence of ED as a consequence of neurological diseases ranges from 10 to 19%. In 
these cases, ED is moderate or severe, with poor response to oral therapy. (Cauni, 2009; 
Antuna, 2008) 
The neurogenic etiology can be central or peripheral. Central disorders can be exemplified 
by Parkinson's disease, brain tumor, encephalitis, cerebral strokes, cranial trauma, epilepsy 
and multiple sclerosis. In the other hand, DM, spinal cord injury, and surgical trauma of the 
erector nerves during radical prostatectomy, polyneuropathy metabolic, toxic or congenital 
conditions among others, can be cited as peripheral neurogenic disorders. (Cauni, 2009; 
Antuna, 2008) 
The basic neurological assessment  must be performed in all patients with ED. Guidelines 
recommended the spinal cord reflexes evaluation, for example bulbocavernosum reflex, and 
sensitivity level. (Kavoussi, 2007) 
2.4.1 Dysfunctional system 
Multiple sclerosis is characterized by multiple areas of demyelization of the central nervous 
system. The prevalence of ED in men with multiple sclerosis is approximately 60%. 
Generally, multiple sclerosis is a progressive disease, with periods of acute crisis and 
remission. In the initial profiles, ED is mild; however, with the evolution of the disease, it 
becomes severe and unresponsive to conservative therapy. (Antuna, 2008) 
Parkinson's disease is a neurodegenerative disease characterized by progressive decrease of 
gray matter's dopaminergic neurons. This process can achieve the mesolimbic and 
mesocortical regions and areas of the autonomic nervous system. Drug therapy with PDE-5 
inhibitors can produce satisfactory results, but a careful analysis of these patients should be 
performed in order to improve the results and patient satisfaction. (Antuna, 2008) 
In patients with epilepsy, the prevalence of ED is variable and the ethiology is multifactorial. 
ED secondary to cerebral strokes depends on many factors such as age, location and extent 
of stroke. Furthermore, co-morbidities and co-related diseases can worsen the ED prognosis. 
In general, traumas also can be associated with ED. Many patients develop psychogenic 
disorders, which may raise the ED incidence. (Antuna, 2008) 
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2.4.2 Spinal cord injuries 
The spinal cord trauma is usually associated with automobilistic crashes. Generally, this 
kind of trauma affects the younger population who are economically active and the initial 
care of these patients should be performed by a multidisciplinary team, to avoid late sequel. 
(Kavoussi, 2007) 
After the trauma, there is a phase of spinal shock, which has a variable duration, what 
occurs is a reflex abolition below the affected area. Over the time with spinal shock recovery, 
patients may have reflex erections. (Kavoussi, 2007) 
The post spinal cord trauma depends on the level, extent and severity of trauma. In general, 
ED tends to be moderate to severe, and semen quality in these patients most frequently is 
poor. The use of medications can provide satisfactory results in some patients. A second 
option is the intracavernosal injections and penile prosthesis, which can be performed when 
other options did not have a good result. (Antuna, 2008) 
In conclusion, the treatment of patients with spinal cord trauma should be individualized 
and carried out by a multidisciplinary team. (Antuna, 2008) 
2.4.3 Peripheral dysfunction 
The peripheral neuropathy may be related with many differents etiologies. The clinical 
manifestation is quite variable and the correct diagnosis must be made as always as possible 
to avoid unsuccessful treatment. ED is a symptom of this syndrome. In Brazil, in addition to 
DM, there is an increasing incidence of alcoholic polyneuropathy, due to the excessive 
consumption of alcoholic beverages. In this case, ED occurs late and is often irreversible. 
(Antuna, 2008; Abdo, 2006) 
2.5 Pelvic surgery 
Excluding skin cancer, prostate cancer is more common in men after age 60. Radical 
retropubic prostatectomy is the gold standard treatment of prostate cancer. The prostate-
specific antigen (PSA) screening programs improve the early detection of this disease. 
(Zippe, 2006) 
ED is a major surgical post-operative complication after pelvic surgery. The prevalence of 
ED after radical retropubic prostatectomy is approximately 50%, but depends on factors 
such as age, tumor stage, surgical technique, associated comorbidities, among others. The 
manipulation of the periprostatic nerve plexus can cause a transient neurological injury 
(neuropraxia) or permanent (neurovascular bundle injury). These lesions can induce 
hypoxia and collagen deposition in the corpus cavernosum. (Zippe, 2006; Gallina, 2010) 
The vessel damage during surgery such as in the accessory pudendal arteries may cause a 
vascular insufficiency, by changing the irrigation of the erectile tissue. Furthermore, ligation 
of anomalous pudendal artery branches or venous plexus can induce the formation of 
fibrosis in the corpus cavernosum. (Zippe, 2006; Gallina, 2010) 
ED can also occur after surgery to remove colon cancer, which is the most common cancers 
of the distal colon and at the junction between the rectum and sigmoid.  Thus, the ED 
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incidence in patients undergoing colorectal cancer surgery varies between 10-60%. This 
incidence increases when there is need for neoadjuvant or radiotherapy adjuvant. A 
permanent colostomy also increases the rate of dysfunction to leading to alteration in body 
image. (Zippe, 2006; Gallina, 2010) 
2.6 Cardiovascular risk factors  
ED may be related to cardiovascular risk and may precede a cardiovascular event in 3-5 
years. Studies have shown that ED is an early marker of endothelial dysfunction and 
atherosclerotic disease (Bryan, 2011; Blumentals, 2004).  
The prevalence of ED in men with cardiovascular disease varies between 44 and 75%. 
(Muller & Mulhall, 2006). There is a strong correlation between cardiovascular disease and 
ED, since the risk factors are the same, such as hypertension, dyslipidemia, obesity, 
smoking, DM and sedentary lifestyle (Kupelian, 2006; Bal, 2007; Feldman, 2000; Derby, 2000)  
The endothelium and the cavernous nerves are two sources of nitric oxide. Nitric oxide acts 
on smooth muscle relaxation during erection. The production and release of this substance 
depends on the integrity of endothelium. A nitric oxide response in men with ED is lower 
than in men with a preserved erection (Muller & Mulhall, 2006; Giugliano, 2004). 
Endothelial dysfunction is an early stage of vascular damage. Cardiovascular risk factors 
can cause endothelial damage leading to an impaired nitric oxide release, atherosclerosis 
and vascular stenosis. Endothelial dysfunction seems to play an important role in the 
development of both ED and cardiovascular diseases. Organic erectile dysfunction in a 
majority of men is due to the vascular diseases. (Muller & Mulhall, 2006).  
Obesity is a multifactorial disease with high prevalence worldwide. Genetic, environmental 
and behavioral factors were identified as etiological factors.  The incidence of obesity in men 
with ED is 30% higher than men without ED, (Muller & Mulhall, 2006). It is usually 
associated with other diseases such as, dyslipidemia, diabetes mellitus and hypertension.. In 
obese ones there is a peripheral resistance to insulin and a consequent hyperinsulinemia. 
Patients with higher body mass index are at greater risk of ED, even at the prospect of 
weight loss. Clinical factors like waist-hip ratio, body mass index and resting heart rate are 
significantly higher in patients with ED (Muller & Mulhall, 2006; Zambon, 2010). 
Regarding hypertension, it has been demonstrated that the chronic changes in blood 
pressure, altering the flow of small vessels and penile vessels, which are associated with the 
development of the atherosclerotic disease can cause severe ED. A number of anti-
hypertensive medications, such as beta-blocking drugs may have ED as a side effect (Muller 
& Mulhall, 2006).  
Smoking as above mentioned is a risk factor for ED. It changes the mechanism of penile 
erection because it affects the smooth muscle relaxation. The prevalence among men with 
ED is 27.3% vs. 12.5% among men without ED. Not only the smoker, but passive exposure 
to cigarette smoke has a higher incidence of erectile dysfunction.Therefore, smoking 
increase the ED grade. (Feldman, 2000; Zambon, 2010; Muller & Mulhall, 2006). 
Metabolic syndrome is also a significant risk factor in patients aged 40 to 49. In elderly men, 
this effect of metabolic syndrome on erectile function was not prominent, probably because 
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aging itself is a risk factor for erectile dysfunction. (Bal, 2007) ED may provide a warning 
sign and an opportunity for early intervention among men who had previously been 
considered to have lower risk of metabolic syndrome and cardiovascular disease (Kupelian, 
2006; Muller & Mulhall, 2006; Zambon, 2010). 
Preventive actions such as regular diet, physical activity, and hypertension and diabetes 
controls can decrease these risks and improve erectile function (Kratsky, 2009; Derby, 2000). 
 
Fig. 2. Metabolic syndrome 
2.7 Chronic renal failure 
ED has a high incidence in patients with chronic renal failure (20-50%) and those underwent 
to renal transplantation. There is a positive relationship between the severities of both 
diseases. The cause of ED in these patients is multifactorial, including endothelial 
dysfunction, comorbidities, chronic hyperuricemia and psychogenic factors. Kidney 
transplantation can improve erectile function, due to the improvement of uremic 
neuropathy and anemia. (Phé 2008; Cauni, 2009).  
2.8 Drug induced ED 
Drug use may be responsible for up to 25% of all cases of ED. Among the medications that 
can induce it, we can highlight the drugs which affect the cardiovascular and autonomic 
nervous systems. Cauni, 2009).  
Several studies have shown that intravitreal drugs such as bevacizumab (antivascular 
endothelial growth factor) can lead to a transient ED. The mechanism is not well established, 
but it is postulated that the systemic drug absorption may lead to an interaction with nitric 
oxide in the corpus cavernosum (Yohendran & Chauhan, 2010). . Moreover, injection trauma 
can be associated with psychological effect, leading to temporary loss of erection. 
(Yohendran & Chauhan, 2010). 
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Retroviral and chemothrapeutic agents
Histamine H2 receptor antagonist
Fenitoin 
Antimuscarinic
Table 2. Drugs induced ED 
2.9 Psychogenic 
In the past, psychogenic cause was considered the most important etiologic factor of ED, 
however, currently organic factors account for 60-90% of this condition. (Cauni 2009) 
The pathogenesis of psychogenic ED is not well established. Many etiological factors have been 










Table 3. Psycogenic ED causes 
Performance anxiety related to several different causes ends up being the most common 
cause. Other causes are: an inappropriate sex education, traumatic childhood sexual 
experiences, a troubled marriage or relationship, stressful situations or psychiatric 
disorders. (Monseny, 2010) 
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Usually, psychogenic ED has short duration. Most commonly, patients have satisfactory 
erection in specific situations. (Abdo, 2006) Socioeconomic factors such as low income and 
poor educational background also have been associated withED. (Abdo, 2006). 
3. Conclusions 
ED has a high prevalence in men over than 50 years. The incidence increase with aging and 
its ethiology appears to be multifactorial. The anamnesis and detailed physical evaluation 
ought to be performed in order to detect the main etiological factors. The best approach to 
obtain better results is to identify the main etiology. A multidisciplinary evaluation should 
be recommended for all patients.  
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Usually, psychogenic ED has short duration. Most commonly, patients have satisfactory 
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1. Introduction 
Erectile dysfunction (ED) affects the quality of life (QoL) of millions of people worldwide 
(Rosen et al., 2004; Aytac et al., 1999; National Institutes of Health Consensus 
Development Panel on Impotence, 1993). Nowadays, QoL measurements have become an 
important health status indicator in determining the general health of a person. ED affects 
a man’s self-esteem, relationships with sexual partners, family, friends and colleagues and 
overall QoL. 
The impact of ED on QoL has been becoming very important in the management of ED. QoL 
is used to assess the overall well-being of a person. Most of the medical treatments for ED 
now are focussing on improving QoL of patients (Althof, 2002). 
2. What is quality of life/ health-related quality of life 
2.1 Quality of life 
QoL is defined as the perception of a person’s life in the cultural and value systems in which 
he or she lives in regards to his or her goals, expectations and standards. QoL is affected by 
a person physical health, psychological state, level of independence, social relationships, 
environment and spiritual/religion/personal beliefs (WHOQOL, 1997). 
QoL is a construct that encompasses physical function, psychological function, somatic 
sensation, social interaction, occupational and financial  (Schipper et al., 1996). QoL is a good 
indicator of functional status and well-being of a person who undergone treatment for 
medical conditions (Stewart et al., 1989). QoL is becoming important in the evaluation of 
treatment and assessment of medical conditions (Wagner et al., 2000). 
The overall QoL encompasses disease free, physical, emotional and social well-being (Tsai et 
al., 2008).  QoL is one’s ability to enjoy normal life activities. Some medical treatments can 
impair one’s QoL while there are treatments can improve it. 
The main goal of health care is to maintain or improve the QoL of people. Apart from health 
status, factors such as religion, environment, financial etc are important determinants of a 
person's QoL (Chen et al., 2005; WHOQOL, 1997). 
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2.2 Health-Related Quality of Life  
Health-Related Quality of Life (HRQoL) is widely used among health care/medical 
professionals and is an important measure to assess a person’s well-being (Wilson and 
Cleary, 1995). HRQoL includes the physical, functional, psychological, emotional, social 
function, mental and overall well-being of an individual (Fallowfield, 2009). 
ED can affect both men and women, as they may suffer due to ED.  Men will also suffer if 
their female partners have sexual dysfunction. These problems need to be look into as an 
overall health issue (Wagner et al., 2000). 
3. ED and QOL 
ED is associated with many psychosocial problems such as decreased QoL, low self-esteem, 
depression, anxiety, relationship problems, and marital tension (Althof, 2002; Litwin et al., 
1998; Shabsigh et al., 1998). According to many studies, it is undeniable that ED has a strong 
impact on QoL (Tsai, 2008; Althof, 2002; Litwin et al., 1998). 
There are many studies showing ED has an effect on QoL of men with this condition (Rosen 
et al., 2004; Althof 2002). Satisfaction in sexual life has been shown to affect overall 
satisfaction in life (Fugl-Meyer et al., 1997). Studies have shown that QoL parameters, 
especially social relationship and psychological well-being is affected by ED (Tsai et al., 
2008; Litwin et al., 1998). Men with ED suffer deterioration in emotional well-being as noted 
in some studies (Litwin et al., 1998; Rosen, 1998). 
One HRQOL study showed that ED is associated with physical function and emotional 
function (Litwin et al., 1998). This study also found that emotional domains are more 
affected than physical domains in patients with ED. 
The majority of studies showed that men who suffer ED will have poor QoL especially in 
physical, mental and social domains (Sanchez-Cruz et al., 2003). Laumann et al. 1999 found 
there is an association between ED with health status and emotional function /problems / 
satisfaction, stress, deterioration of general health and physical satisfaction.  
3.1 Young and old men 
Younger males show lower social function as compared to older men and significant 
differences were observed between non-ED and ED subjects in young age group (Sanchez-
Cruz et al., 2003). For example, it was found that men with ED tend to have lower QoL 
especially among young men compared to men without ED. One of the reasons is probably 
older men reported more sexual satisfaction than younger men as reported in one study 
(Gralla et al., 2008). 
3.2 Sexual activity and QoL 
Satisfaction in sexual activity is important in achieving good QoL. Sexual activity has been 
found to contribute to the overall QoL (Robinson & Molzahn, 2007). The psychological and 
social well-being of a man will be affected if he lacks sexual activity. However, there are 
some men who consider ED as a part of the aging process (Martin-Diaz et al., 2006). 
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3.3 ED with co-morbid condition and QoL  
It is difficult to assess the real effect of ED on QoL because ED could be due to psychological 
or other medical conditions. It was also found that men with ED with co-morbid medical 
condition such as hypertension or diabetes mellitus have lower QoL (Rosen et al., 2004). 
Men with both comorbid medical condition and ED were found to have poorer QoL as they 
are more distress and less satisfied with their sexual life (Berardis et al., 2002). It is noted 
that a man’s age is associated with QoL as suggested by Guest & Gupta, (2002). The QoL of 
men with ED who are younger than 65 years was found to be poorer (Guest & Gupta, 2002) 
compared to men of similar age who do not suffer ED (Kind, 1999). Those men younger 
than 45 years old were found to have poorer QoL compared to those aged 74 years or older. 
The deterioration of QoL in the younger age group was noted due to deterioration of erectile 
function (Feldman et al., 1994). The QoL in the older group was much better because they 
focus less attention or less emphasize on sexual activity (Guest & Gupta, 2002). Men from all 
age groups who had co-morbid illnesses were found to have poorer QoL as compared to 
those without co-morbid illnesses. ED has been shown to have contributed to the 
deterioration of emotional well being and relationship but improved after treatment (Paige 
et al., 2001). Some men with ED tend to worry about their sexual performance thus this may 
lead to premature ejaculation (Williams et al., 1984).  
3.4 ED and relationship with partner 
ED can lead to the breakdown of relationships due to conflicts with their partners and this 
affects their general health and QoL (Guest & Gupta, 2002). Study has shown that 
approximately 12%-28% of men with ED believed ED is one of the main causes that affect 
their relationships (Guest & Gupta, 2002). 
Men with ED who are single were found to be unable to develop a new relationship, thus, 
this affects their QoL (Guest & Gupta, 2002). This suggests ED may hinder them from 
forming a new relationship or may deteriorate their current relationship which may lead to 
separation. 
However, sometimes relationships can be improved through other ways other than having 
sexual intercourse such as focusing family activities or having relaxation. Pharmacological 
intervention has shown to improve men’s QoL e.g sildenafil citrate and transurethral 
alprostadil (Quirk et al., 1998; William et al., 1998; Kaiser et al., 1997). 
3.5 Quality of life following treatment of ED 
Several studies showed sexual function improves the QoL in both men and their partners 
following treatment (Rosen et al., 2004; Shabsigh et al., 2001). It has been shown that the 
mood, overall sexual function, satisfaction in relationships and their overall QoL improves 
after treatment of ED (Rosen at al., 2004). 
The level of sexual life satisfaction which was noted to be low prior to treatment for ED, 
were significantly improved after treatment (Fugl-Meyer et al., 1997). Men with ED and 
depression, their QoL were also improved after undergoing treatment for depression 
(Muller & Benkert, 2001). 
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Anxiety is a feeling of worry, fear, nervousness and apprehension exhibited by 
psychological, and physiological state such as emotional, cognitive and behavioral 
symptoms. Anxiety due to daily activities may lead to distress and deterioration of normal 
activity (Corretti & Baldi, 2007). 
Anxiety disorders include panic disorder (PD), specific and social phobia, obsessive-
compulsive disorder (OCD), post-traumatic stress disorder (PTSD), acute stress disorder 
(ASD), and generalized anxiety disorder (GAD) (Corretti and Baldi, 2007). 
The relationship between anxiety and sexual function is complex. However, anxiety and ED 
can have a two-way or bilateral relationship. Anxiety can cause sexual dysfunction and 
sexual dysfunction can cause anxiety. Sexual dysfunction and anxiety are not causally 
related. They may express differently but the symptoms may derive from one common 
source (Corretti and Baldi, 2007). 
Anxiety contributes to the development of problems associated with ED. Psychological 
impact from ED can lead to uneasiness, distance and conflicts (Hedon, 2003). This will lead 
to low sexual contact, less time together and lack of communication between partners which 
can lead to deterioration of relationship (Hedon, 2003). 
The prevalence of anxiety disorder were noted to be varies from 1.7% - 37% in men with ED 
(Mallis et al., 2005; Farre et al., 2004; Lee et al., 2000).  Some studies showed there were some 
relationships or association between anxiety and ED (Corona et al., 2006; Sugimori et al., 
2005). 
4.1 ED and performance anxiety 
If a man suffers some degree of ED, he may feel worried of the condition and this may lead 
to performance anxiety. Performance anxiety will affect men such as embarrassment if they 
are unable to perform, achieve erection or unable to satisfy their partners. They will feel 
disappointed and guilty, thus, this will affect their QoL.  
When a person suffers from anxiety disorder, it is important to investigate his/her sexual 
life and vice-versa. Studies have shown that anxiety plays a major role in the development 
of ED.  
There are many factors which can lead to anxiety and to ED. For example, job related stress 
and family problems (divorce, conflicts) which can increase anxiety thus leading to ED 
(Hedon, 2003). 
Anxiety can impair sexual arousal/desire via increased sympathetic tone which leads to 
weak erection (Graziottin, 2000; Maggi et al., 2000; Kaplan, 1988). Anxiety can also impact 
orgasm where it can lead to premature ejaculation (PE) (Dunn et al., 1999; Zilbergeld, 1999; 
Hawton & Catalan, 1986). Anxiety can affect the ejaculation control through sympathetic 
hyperactivity (Williams, 1984; Wolpe, 1982). 
Men who are anxious during sexual intercourse are found to be worried about their sexual 
performance and this affects their sexual satisfaction (Kaplan, 1989; Kaplan, 1974). There are 
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other studies which support these findings (Corona at al., 2006; Corretti et al., 2006; Tignol et 
al., 2006). 
5. Depression 
Depression can lead to feelings of fatigue, worthlessness, suicidal thoughts, agitation, 
weight loss or weight gain. It can caused by grief, family and social isolation, physical, 
genetics, biological, psychological factors. All these contribute to the deterioration of QoL. 
The person may not sleep well and/or eating well and may resort to smoking, alcohol or 
drugs to overcome the depression. 
Many studies have showed an association between ED and depression regardless of 
sociodemographic or co-morbidities (Shabsigh et al, 2006; Moreira et al., 2001; Araujo et al., 
1998; Feldman et al., 1994). In a study by Araujo et al., 1999, subjects who were depressed 
were found to have a 1.82 times higher chance of getting ED compared with patients 
without depression. Another study showed men with ED were 2.6 times more likely to have 
depressive symptoms as compared to men suffering from benign prostatic hyperplasia 
(BPH) alone (Shabsigh et al., 1998). 
Depression most of the time are due to the loss of mood/interest in daily activities. ED can 
affect the mood, family or partner relationships thus affecting QoL (Rosen et al., 2004). 
Depression and ED is a two-way or bilateral relationship (Shabsigh et al., 2001; Araujo et al., 
1998; Smith, 1998). ED has aetiology in affective components which were described in many 
studies (Smith, 1998; Barlow, 1986; Hengeveld, 1983; Jacobs et al., 1983). It was noted that 
depression may cause or exacerbate ED and that ED may cause depression. Until today, no 
one knows which one comes first. Patients presenting with ED should be screened for 
depression while patients with depression will need to be screeened for ED (Araujo et al., 
1998). One study by Nicolosi et al., 2004, found a relationship between ED, depression, 
sexual activity and sexual satisfaction. 
ED associated with depression has been observed in many studies (Araujo et al., 1998). Men 
with ED tend to feel embarrassed, frustrated and sad. This will affect his self-esteem thus 
lead to depression. Men often associate their ability to perform sex with their manhood and 
self-esteem. When they are unable to perform, they will feel disappointed and this will lead 
to depression. If the condition is not treated, ED may affect his relationship with his 
partners, friends and family. If the men treated for depression, it may become worse as 
medication may have side effects on erection (Bartlik et al., 1999).  
Depression is found to affect sexual performance as indicated in the Massachusetts Male 
Aging Study (MMAS)(Araujo et al., 1998). The findings of this study showed that those who 
are depressed are more likely to suffer moderate and severe ED (Araujo et al., 1998). This 
study also shows that the cognitive and behavioral factors may also contribute to sexual 
performance. Another study showed patients who were depressed are twice likely as the 
general population to have sexual dysfunctions (Angst, 1998).  
Depressed men can be too critical of themselves. This will lead to performance anxiety and 
thus will hinder their ability to achieve an erection.  Depression also can affect sexual drive 
(Heiman & Rowland, 1983; Bartlik et al., 1999) and sexual drive is important for helping 
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men to achieve an erection. Men with low sexual drive (libido) tend to have difficulties in 
achieving erection. 
Depression is found to be associated with neurophysiological disturbances which can affect 
the autonomic nervous system. Due to this, the parasympathetic nervous system unable to 
assist the relaxation of the penile smooth muscle tissue which require for erection (Saenz de 
Tejada I, 1985).  Men with severe depression can develop a reversible loss of nocturnal 
penile tumescence (Roose et al., 1982). Studies have shown depression can deteriorate the 
erectile function but improved following treatment with antidepressants (Nofzinger et al., 
1993).  
It was found that men with the severe depression had higher chance of getting moderate 
and severe ED (Melman & Gingell, 1999). The relationship between depression and ED is 
affected by the low frequency of sexual intercourse and poor sex life. 
ED is one of the symptoms of depressive disorder which associated with deterioration or 
loss of sexual drive, erectile function, and sexual activity (Seidman et al., 2001). This 
condition will get worse if the person is on medications such as antidepressants which can 
cause ejaculation, erection, orgasm and libido problems (Nurnberg et al., 2001; Seidman & 
Roose, 2000; Rosen et al., 1999). 
5.1 Depression, ED and treatment 
Depression with ED or vice versa is treatable. With proper counseling, men will be able to 
overcome the depression and cope with ED as there are many treatment options available 
for ED. 
The inability to achieve and maintain sexual performance often causes other problems apart 
from problems related to sexual activity. It is important for a man to seek help if he is 
experiencing depression or ED or both.  
Studies have shown that treatment is successful in improving the QoL in men with ED co-
morbid with depression.  
6. Marital problem 
Many men with ED will stay silent and not like to talk about their problems to others. Men 
with ED tend to think they are failures and thinking their partner is not happy. These men 
will find excuses to avoid having sex or having intimate relationships. 
Some will find excuses or changing their topics of conversation to avoid talking about sex. 
When men start to withdraw themselves from their partners and others, they will be 
thinking of their ED problem.  Thus, this may affect their daily activities and general health. 
When a man is unable to perform sexual intercourse or unable to satisfy his partner’s sexual 
needs, he may feel useless, embarrassed and guilty. Thus, he may find difficult to 
communicate with his partner about ED. ED affects a man's life and marriage and it was 
noted that ED contributed to one in five failed marriages (Wespes et al., 2002). 
ED affects men psychologically. Because of miscommunication and misunderstanding, the 
partner may abandon him. Men tend to blame their partner for leaving them due to ED. 
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Men are found to be sensitive in their relationships. Any withdrawals from the relationship 
due to ED may affect their overall general health and well-being (National Institutes of 
Health Consensus Development Panel on Impotence, 1993). The relationship between sexual 
and marital problems was more obvious in men compared to women as shown in one study 
(Rust et al., 1988). 
From the partner point of view, the partner will feel unattractive, lonely, depressed and 
unwanted. The partner may think that their partner is having an affair. This becomes worse 
when men do not communicate with their partner regarding their ED.  Many men refuse to 
seek medical advice due to apprehension. Apart from that there are also misunderstanding 
and poor communications which may lead to the relationship breakdown with their 
partners. 
The prevalence of sexual dysfunction was noted higher in women especially when their 
partner suffering from ED. Women who have been sexually active before will suffer some 
sexual dysfunction. The severity of ED can influence their partners’ sexual satisfaction and 
frequency of orgasm (Fisher et al., 2005). Women suffer deterioration of sexual desire, 
unable to achieve orgasm and dissatisfied with their sexual life when their partner suffering 
from ED. However, this improved after their partners’ undergone treatment. One study has 
shown women whose partners who were on pharmacological therapy (e.g. PDE5 inhibitors) 
had more satisfying sexual satisfaction than those whose partners did not use 
pharmacological therapy (Fisher et al., 2005). 
7. Summary 
Although ED is not a life-threatening condition, it has an effect on not only the QoL of men but 
that of their sexual partners as well. The effect of ED on QoL is hard to determine because the 
dysfunction can be due to the psychological problem. However, ED can cause anxiety, 
sadness, depression, low self-confidence, low self-esteem, marital tension, deteriorating 
relationships, guilt, anger, frustration etc. All these will lead to deterioration of QoL. 
It is important for men to discuss their anxiety regarding their ED with their partners. It will 
help them to reduce their fears while their partner will be able to help them to cope. Men 
should realize that they are not alone in ED. There are many avenues where they can seek 
help where they are many qualified ED medical professionals who can provide counseling 
and also there are treatments and guidelines available in the management of male sexual 
dysfunction (Wespes et al., 2009).  Men should communicate with their partners because 
they need moral support to overcome their ED problem. When it comes to HRQoL for men, 
it is vital to assess their erectile function. 
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Erectile dysfunction (ED) is defined as the persistent inability to maintain or achieve a penile 
erection sufficient for satisfactory sexual performance (1-2). ED is a very common condition 
in middle-aged men (3). According to the National Institute of Health (NIH) this 
physiological disorder affects 30 million men in the United States (US) (2). The outlook for 
2025 is scary because this number is  expected to grow to approximately 322 million (4). 
Although ED is directly associated with aging (5), its etiology is considered multifactorial. 
Both conditions, ED and aging, share a variety of risk factors such as atherosclerosis, 
sedentary lifestyle, abnormal lipids, diabetes, smoking, metabolic syndrome and 
hypertension (2, 6-7). In addition, ED is considered an important marker of cardiovascular 
disease (CVD) (8). Studies over the last decade suggest vascular changes as a common factor 
between ED and CVD (1, 7, 9). Also, the most important vascular alteration mentioned in 
these pathologies cited above is endothelial dysfunction. According to several authors, 
endothelial and smooth muscle dysfunction are crucial factors involved in systemic and 
peripheral vascular diseases, especially ED (10). In this chapter we will discuss the 
association between the main CVD and ED. 
2. ED and atherosclerosis 
Atherosclerosis begins with oxidation of Low Density Lipoproteins (LDL) particles in the 
arterial wall (11). Oxidatively modified LDL (oxLDL) damages the endothelial layer in the 
artery (8, 11), and then the elasticity of the arteries deteriorates. Impaired arterial elasticity 
and increased levels of circulating oxLDL, as well as elevated fibrinogen and resting heart 
rate associated with subclinical atherosclerosis have increased CVD risk (12-17).  
The decrease and/or loss of elasticity impair the blood flow because the cholesterol  
builds up in the blood vessel walls and forms plaque. When plaque becomes very advanced, 
it can completely stop blood from passing through the wall, characterizing a heart  
attack (18). 
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association between the main CVD and ED. 
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Atherosclerosis begins with oxidation of Low Density Lipoproteins (LDL) particles in the 
arterial wall (11). Oxidatively modified LDL (oxLDL) damages the endothelial layer in the 
artery (8, 11), and then the elasticity of the arteries deteriorates. Impaired arterial elasticity 
and increased levels of circulating oxLDL, as well as elevated fibrinogen and resting heart 
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Diseases due to atherosclerosis are common and are becoming a growing health problem in 
industrialized and developing countries, evoking a huge impact on quality of life and life 
expectancy (2, 19). Atherosclerosis affects not only the blood vessels supplying the heart 
(coronary arteries), but also blood vessels throughout the entire body. In addition, various 
alterations disturbing normal body function can occur when atherosclerosis develops 
leading to more complex pathologies such as angina, heart attacks, strokes,  and ED (18). 
The artery size hypothesis is a pathophysiologic mechanism proposed in recent years to 
explain the relationship between ED and coronary artery diseases (CAD) (20). It is based on 
the fact that atherosclerosis, a systemic disorder, should theoretically affect all major 
vascular beds at the same time and extent. However, symptoms at different points in the 
system rarely become evident at the same time. This is probably the result of larger vessels 
being able to better tolerate equivalent amount of plaque compared with smaller ones. The 
diameter of these vessels confirms this idea: penile artery has an arterial diameter of 1-2 
millimeters (mm), coronary artery is 3-4 mm, internal carotid artery is 5-7 mm and femoral 
artery is 6-8 mm. Results from patients with 50% obstruction in the penile artery with no 
coronary circulation critically affected could be explained because larger systemic arteries 
would be impacted later than the smaller penile artery. Thus, it suggests a mechanism for 
the absence of concomitant CAD in early stage ED (20-21).  
 The initial step in the development of atherosclerosis is endothelial dysfunction. Since the 
normal penile erection requires an intact endothelium, it has been proposed that patients 
with ED show a higher probability of developing atherosclerosis (2, 19). Regarding penile 
erection, nitric oxide (NO) plays an important role in physiological conditions. The sexual 
stimulus makes the parasympathetic nerves in the penis produce NO, triggering a cascade 
of events that culminate with increased dilatation of the corpora cavernosum sinusoids to 
induce penile erection. Many other agents are involved in this process that requires a perfect 
balance between vasodilators and vasoconstrictors. Thus, the physiological complexity 
makes it difficult to identify the etiology of ED. As a result, this condition is considered 
multifactorial and includes arterial, neurogenic, hormonal, cavernosal, iatrogenic, and 
psychogenic causes. However, it is now accepted that organic ED, in a substantial majority 
of men, is due to underlying vascular causes (22-23). Endothelial dysfunction is thought to 
be the main etiologic factor in systemic and peripheral vascular diseases, including ED (24). 
It has been associated with impaired vasodilatation, preceding the development of 
atherosclerotic lesions through the impaired release of NO, which is modulated by 
parasympathetic nonadrenergic, noncholinergic nerves (NANC) and by vascular 
endothelial cells (7). Moreover NO production is also influenced by oxidative stress, which 
is deleterious to the endothelium.  
Reactive oxygen species (ROS) are very important in the pathophysiology of vascular 
disease, especially atherosclerosis. Under normal physiological conditions, ROS destruction 
by antioxidant enzymes is sufficient to maintain a controlled activation of signaling 
cascades. In contrast, in vascular diseases, the production of ROS in excess of endogenous 
antioxidant capacity leads to oxidative stress, which in turn results in abnormal 
physiological responses. Interaction between ROS and NO is implicated in many vascular 
diseases such as atherogenesis and play an important role in ED (25). One of the most 
detrimental ROS is superoxide (O2-.), which interacts with NO decreasing NO bioavailability 
and resulting in formation of peroxynitrite (ONOO-). All types of vascular cells produce O2- 
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and H2O2, two of the most significant ROS in the vessel wall. H2O2 can also be metabolized by 
myeloperoxidase, a heme enzyme produced by macrophages that converts H2O2 into reactive 
nitrogen and reactive chlorine. These reactive species can attack both LDL and HDL, 
enhancing cholesterol intake, reducing cholesterol efflux and contributing to plaque formation 
(26). In pathological situations homeostasis disruption by oxidative stress contributes to 
activation of proinflamatory, profibrotic and mitogenic signaling pathways leading to 
oxidative damage in the vasculature which in turn results in increased vasoreactivity, 
endothelial dysfunction, vascular remodeling, reduced vascular compliance and elevated 
blood pressure (BP)(26-28). All these factors also contribute to an increased adhesion and 
aggregation of platelets and neutrophils, and release of vasoconstrictor substances (29-30). 
3. Stroke and ED 
Stroke is a neuroendovascular event resulting in death of brain cells due to an ischemic 
lesion. According to the World Health Organization (WHO), stroke can be classified based 
on the size and site of lesion and its clinical consequences. Most cases of subarachnoid 
hemorrhage, intracranial hemorrhage and cerebral infarction are examples of stroke (31-33). 
Cerebrovascular diseases are the third leading cause of death in the United States, affecting 
5.5 million people a year. When  analyzing diseases that cause long-term  consequences , the 
frequency of stroke is  largest compared with others  (34). Stroke has been responsible for 50 
million deaths worldwide. In adults, cerebrovascular disease is the most frequent pathology 
that induces  severe damage  (35). It is predicted that over the next 20 years, stroke will rise 
from 7th in the DALY league table to 4th, principally influenced by the aging of populations 
especially in less economically developed countries (31, 36).  
It has been hypothesized that ED represents “the tip of the iceberg” of a systemic vascular 
disorder. Thus, ED would potentially precede  larger damage in the body, working as a 
sentinel event  (5). Additionally, ED could be an indicator of potentially life-threatening 
coronary heart disease (CHD), hypertension, hyperlipidemia and stroke (37-42), which are 
diseases that have been the cause  of morbidity and mortality among adults in industrialized 
societies (43). 
In most studies about stroke, only the cognitive and emotional ability of the patient after the 
stroke has been discussed. (34) . However, the sexual function of these men has recently 
been investigated deeper. Since 1998 Koperlainen et al,  showed that stroke patients and 
their wives have some level of dissatisfaction with sexual function (44). Also, ED in stroke 
patients has been  linked with psychological causes  (45). In this case, it has been speculated 
that impairment of cerebral erectile control functions, physical limitations after the stroke, 
and emotional changes, generate psychogenic and neurogenic ED (34, 46). Studies compared 
unilateral stroke patients compared with those showing stroke lesions in the right cerebral 
hemisphere. The results reported that both patients experienced ejaculation disorders 
besides a significant decrease in sexual desire and intercourse frequency (34, 47).  
Until recently, it was believed that ED was a health problem in patients after stroke. 
However, increasing evidence supports an idea that men with ED have more comorbidities 
than men who do not. More importantly, men with ED were more likely to have strokes 
than those without. In the others words, ED has been cited as a strong indicator of stroke, as 
well as a clinical marker for cerebrovascular diseases (22, 48-49). Ponholzer et al , reported 
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that 2,561 men with moderate to severe ED had an increased risk of stroke over 10 years 
(24.7% and 43.6%) (50). Furthermore, it has been suggested that ED is an independent risk 
factor for stroke. In this study,  1,209 men from the Massachusetts Male Aging Study were 
evaluated over  a 15 year period and it was reported that  those men who have had ED were 
approximately three times more likely to have a stroke  if compared to those without ED (5).  
The penile arteries have a smaller diameter than internal carotid, coronary and others major 
arteries. Thus lumen obstruction may lead to the development of ED prior to cardiac signs or 
stroke (22). Corroborating with this idea Lojanapiwat et al performed studies showing that 
patients who developed ED had endothelial dysfunction prior to the clinical symptoms. Also 
laboratory results for this patients indicated  cardiovascular risks (51). In addition, Vicenzini et 
al suggested that cerebrovascular reactivity was reduced in patients with ED without other 
signs of clinical atherosclerosis (52). Finally Chung et al, suggested that men with ED have a 
significant increased risk for stroke 5 years after ED symptoms first began (22). 
4. Hypertension and ED 
Arterial hypertension is a systemic disorder characterized by altered regulation of 
cardiovascular hemodynamic, including arterial vascular resistance and cardiac index, 
leading to an increase in arterial blood pressure (53). It is accompanied by proliferation, 
migration of VSMCs, and varying levels of inflammation of the arterial wall, processes that 
together constitute vascular remodeling (54). Hypertension is associated with increased 
vasoconstrictor and reduced vasodilator responses (55-57). The pathological changes 
resulting from altered vascular function include injury to the brain, kidney and heart (55). 
Several studies have established a clinical correlation between incidence of hypertension 
and ED (58). According to Buccchardt et al, 30% of hypertensive patients have ED and the 
severity of this sexual disorder is directly proportional to the severity of hypertension. 
Nowadays, this fact has been well accepted because both pathologies are an unbalance 
between endogenous contractile and relaxing substances. In addition, since both are 
pathological vascular disorders, it is supposed that ED in hypertensive patients is highly 
prevalent and more severe than in the other people (3). 
Deficiency of NO has been hypothesized to be a major cause of ED in patients with 
hypertension. Another substance that is important in hypertension and ED is endothelin 
(ET-1). ET-1 is considered a physiological antagonist of NO. ET-1 induces vasoconstriction 
and activates transcriptional factors that coordinate an increase of cytokines and enzymes, 
thus enhancing inflammation, oxidative stress and tissue damage. All these factors are very 
important in hypertension associated vascular dysfunction  (59). Several studies have 
underlined the potential importance of ET-1 in the modulation of corpus cavernosum (CC) 
smooth muscle tone (60), since these cells can synthesize  ET-1. The fetal human and adult 
penile cells, and several animal species, also express endothelin converting enzyme 1, the 
endothelin recepotors A (ETA) and B (ETB) subtypes (61-63). Furthermore, Melegy et al 
showed that ET-1 levels were significantly greater in patients with ED than the normal 
group (64). 
Even though NO is well known as the major vasodilator involved in ED, other mediators 
are also involved. Activation of B1 or B2 kinin receptors by bradykinin (BK) induce NO 
and/or prostacyclin release from endothelial cells (65-66). Teixeira et al reported the 
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existence of functional B2 kinin receptors in human erectile tissues and demonstrated that 
activation of it resulted in NO release. These findings were supported by results from 
Becker et al. They demonstrated that BK is able to promote relaxation in CC. This effect 
appear to involve more cAMP than cGMP (67). However, both cGMP and cAMP are 
associated with relaxation in systemic or penile vessel circulation.  
O-GlcNAcylation is an important regulatory mechanism that also modulates stress 
responses in the cardiovascular system and may have significant influence on vascular 
blood pressure (68). Glucosamine (GlcN) is an amino sugar that can stimulate O-linked-N-
acetylglucosamine (O-GlcNAc) modification of proteins by increasing flux through the 
hexosamine biosynthesis pathway, thus increasing production of UDP-GlcNAc. UDP-
GlcNAc is a substrate for O-GlcNAc transferase (OGT), which catalyzes the O-linked 
addition of GlcNAc to serine and threonine residues of nucleocytoplasmic proteins in higher 
eukaryotes (68). GlcN has anti-inflammatory effects in a variety of inflammatory models and 
cell types. Recently, it has been demonstrated that systemic treatment with glucosamine and 
PUGNAc, which increases O-GlcNAc modification of proteins by inhibiting O-GlcNAcase, 
can inhibit acute inflammatory and neointimal responses to endoluminal arterial injury in 
rat’s carotid artery (69). ET-1-induced changes in vascular contractile responses are 
mediated by O-GlcNAc modification of proteins. Aortas from Doca-salt rats, which exhibit 
ET-1 augment, displayed increased contractions to phenylephrine and enhanced levels of O-
GlcNAC proteins. Treatment of Doca-salt rats with an endothelin A antagonist abrogated 
augmented vascular levels of O-GlcNAc and prevented the increase in phenylephrine 
vasoconstriction, suggesting that ET-1 indeed augments O-GlcNAc levels and this 
modification contributes to the vascular changes induced by this peptide (70). On the other 
hand, O-GlcNAcylation is also involved in ED. A new line of investigation has pointed to 
the significance of hyperglycemia-induced O-GlcNAc associated with modification of eNOS, 
as well as inactivation of the enzyme. It has been demonstrated that O-GlcNAc inactives 
eNOS in diabetes-associated ED (71). However, the exact mechanism through O-
GlcNAcylation is correlated with hypertension or ED is still not well understood. In the last 
decade, another mechanism involved in the regulation of ED has been the renin-angiotensin 
system (RAS). Evidence has shown that there is a RAS inside of the corpus cavenosum. 
According Becker et al human CC is able to produce and secrete physiologically relevant 
amounts of angiotensin II (Ang II) (67). Ang II is the main active metabolite of the renin-
angiotensin cascade. The most important physiologic effect of Angio II is induction of 
vascular smooth muscle contraction. This action contributes to the maintenance of systemic 
blood pressure through various mechanisms in the cardiovascular and renal systems. Ang II 
is also an important modulator of erectile function (72). Reinforcing the association of RAS 
and ED, angiotensin-converting enzyme (ACE) has been found in the endothelial cells of 
dog CC (73), and ACE mRNA expression is up-regulated in a rat model of arteriogenic ED, 
although it is expressed at very low levels in the penis of control rats (74). 
Arginase pathway has been cited as another mechanism that may be involved in both, 
hypertension and ED. Growing evidence suggests that arginage misregulation plays a key 
role in the pathophysiology of essential hypertension and that the involvement of arginase 
in ED has been apparent in recent years. Arginase exists in two isoforms, the hepatic type, 
arginase I and the extrahepatic type, arginase II (75). Both isoforms are expressed in human 
CC tissue (76). Surprisingly, the role of arginase in hypertension is poorly documented. 
Augmented arginase activity (AA)/expression were reported in different vascular beds in 
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models of essential or secondary hypertension (77-78). Recent studies reported that arginase 
inhibitor improved aortic endothelial function via a NO-dependent mechanism in pre-
hypertensive or young adult SHR, and also prevented the development of hypertension (79-80).  
During hypertension or ED, elevated levels of arginase can compete with NOS for available 
L-arginine, reducing NO and increasing superoxide production via NOS uncoupling (81). 
Considering this, arginase pathway can regulate overall NO production. Additionally, 
elevated superoxide combines with NO to form peroxynitrite further reducing NO, and also 
oxidative species increase arginase activity (82). ED mechanisms involve oxidative stress 
and vascular inflammation (83), both of which have been associated with enhanced arginase 
activity and expression in the vasculature (84). Furthermore, up-regulated arginase is 
mechanistically linked to the pathogenesis of vascular dysfunction with hypertension 
through increases in the polyamine and proline precursor L-ornithine, which contributes to 
VSM cell proliferation and intimal thickening (81, 85). There is  evidence of a biological role 
of arginase in regulating erectile function in the aged penile vascular bed, at both the 
molecular and functional level  (83). Also, endothelial arginase II has been proposed as a 
novel target for the treatment of atherosclerosis (80). Taking into account that in 
pathological conditions arginase can influence NO avaibility and consequently disrupt the 
perfect balance necessary to keep the VSM tone, arginase can be considered involved in both 
hypertension and ED. However, a more complete understanding about the exact mechanism 
leading to disruption of vascular dynamics by arginase in ED and hypertension is needed.  
Regarding hypertension and ED, another important factor is the unwanted side effects from 
anti-hypertensive drugs. The treatment for hypertension can be associated with ED because 
some medicines affect erectile function, for example, diuretics. Several studies suggest that 
about 10% to 20% of patients taking thiazide  can  have ED (86), as well as  patients that use 
an aldosterone antagonist (87). Fortunately, the effect of diuretics on ED is completely 
reversible after cessation of administration. β-adrenergic receptor blockers have also been 
suggested by several studies to be associated with ED,  specially propranolol (88). However, 
the new generation of β-blockers appears to have less effect on erectile function, such as 
nebivolol. This drug  enhances erectile response and reverses ED in diabetic rats, as well as 
potentiates  NO/cGMP-mediated relaxation of human penile  tissues (89). Interestingly, 
angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) 
appear to favorably affect sexual function (90). Patients treated with captopril showed 
improved  sexual function by 40% to 80% compared to non-treated patients (91). The same 
has been observed for hypertensive patients treated with valsartan; reduced ED and 
improved orgasmic function and sexual satisfaction (92). Also, it was found that losartan 
helps preserve erectile function in male rats after bilateral cavernous nerve injury by 
counter-acting fibrotic activator factors (93). However, recent study showed no change in 
ED progression in humans with ACEI or angioten-receptor blocker (ARB)   therapy (94).  
Regarding the -adrenoceptor agents to treat hypertension, has been showed that direct 
cavernosal injection of -antagonists cause erection in both, experimental and humans, 
although this effect is not observed with -selective drugs. Notably, it has been observed 
that patients treated with -blockers of the adrenergic receptors exhibited improvement of 
their sexual activity. On the other hand, especial attention is necessary for hypertensive 
patients treated with vasodilators such as α-blockers because if those patients have ED, they 
should not take PDE5 inhibitors, otherwise, combining these drugs will result in 
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hypotension. The treatment with calcium channel blockers, which dilate arteries by 
reducing calcium influx into cells also efectively lower blood pressure. The currently 
available ones inhibit L-type channels in humans and seem to have a neutral effect on 
erection (95). Possibly this is because this channel is linked with nNOS activation from 
cholinergic nerve endings into the penis, which is important for NO release and 
consequently erection. However, although this channel is inhibited, nNOS from nitrergic 
nerves will be activated, allowing the erectile process to begin.  Finally, direct vasodilators 
such as hydralazine and minoxidil have rarely been reported to cause ED. 
5. Heart failure and ED 
Heart failure (HF) is a syndrome manifesting as the inability of the heart to fill with or eject 
blood due to structural or functional cardiac conditions (96). Some authors believe that HF 
can be considered as the last stage of heart disease and a significant cause of mortality and 
morbidity worldwide (97). According to the American Heart Association (AHA), HF is a 
condition that affects nearly 5.7 million Americans of all ages (98). Nevertheless, in the last 
decade improvement in survival of myocardial infarction and HF has been observed, 
concurrent with consequences from these diseases. It is believed that the prevalence of these 
diseases will continue to increase in the population, with an estimated number of more than 
10 million patients by the year 2037. Coronary artery disease, with or without myocardial 
infarctions, with a subsequent development of ischemic cardiomyopathy or loss of 
contractile proteins, remains the major cause of chronic HF progression, especially among 
the elderly population (99). Looking at chronic heart failure (CHF) the numbers are equally 
alarming. The AHA has estimated more than 4.9 million people in the US have CHF (98). As 
this pathophysiology progresses, patients experience an increase in fatigue, shortness of 
breath, palpitations, or angina, decreasing their quality of life and potentially interfering 
with their sexual  performance (90).  
While HF per se can have many effects on a patient’s lifestyle, ED can further aggravate 
these effects and contribute to poor quality of life and depression. Studies showed the 
prevalence of ED is around  67% in men 65  or  older,  and 68% in men older than 79 (100). 
The prevalence of ED in patients with HF appears to be significantly higher. Baraghoush et 
al, found a prevalence of 84% general sexual dysfunction in the male population with an 
average of 59 years of age and chronic compensated HF (99, 101).  
It is common sense that the physiology behind an erection is a primarily vascular 
phenomenon. In patients with HF, several factors that come into play at the microvascular 
level, such as reduced arterial compliance, endothelial dysfunction, and generalized focal 
atherosclerosis (99). There are few theories that explain the mechanism of endothelial 
dysfunction in patients with HF. Impaired relaxation mediated by L-arginine-NO was found 
in smooth muscle cells (SMC) and in the penis from animals and humans with atherosclerotic 
coronary arteries (102). However, systemic endothelium-dependent vasodilatation has been 
shown to decrease ED in men with and without clinical CVD (103). In addition, decreased NO 
production via  downregulation of endothelial NO synthase (eNOS) and cyclooxygenase 
(COX) was observed after the onset of pacing-induced HF in dogs (104). Rho-kinase signaling 
is very important in erectile function because in the absence of arousal, the penis remains in 
the non-erect state by cavernosal vasoconstriction induced mainly by norepinephrine and 
endothelin 1 (ET-1), which are Rho-kinase mediated responses. Thus, its upregulation leads to 
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models of essential or secondary hypertension (77-78). Recent studies reported that arginase 
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ED (105). Also, this pathway is involved in the regulation of myofibrillar Ca+2 sensitivity in 
cardiac muscle and contributes to irreversible myocardial damage. Rho-kinase is involved also 
in the pathogenesis of cardiovascular remodeling and its inhibition plays a significant role in 
treatment of the failing heart by limiting infarct size, which is the major contributor to the 
development of heart failure. The cardioprotective effect of Rho-kinase inhibition involves 
PI3K/AKT and NOS activation. However, Rho-kinase inhibitor compounds need to be 
evaluated for their efficacy during varying index ischemia periods, a wide dose range, and in 
vivo animal models mimicking the clinical setting more closely (105).   
Becker et al reported that patients with HF have vasomodulators, systemic levels unbalanced  
and this change can  lead to increased SMC tone and vasoconstriction in the penile vessels 
through a variety of mechanisms (106). According to Pedersen et al, the ET-1, RhoA/Rho-
kinase and ROS are not the only mechanism that can be modified, vasopressin also is elevated 
in patients with HF (107). Compared to patients with CHF, the situation is very similar. In 2005 
Rastogi et al suggested that multiple factors may be involved in the onset of ED in patients 
with CHF. These patients have arterial compliance abnormalities and often atherosclerosis, 
which reduce blood flow into the CC (108). In addition, endothelial dysfunction decreased the 
production or increases the breakdown of NO. Other vasoconstrictors are also increased in 
patients with CHF and can be interfering with their ability to achieve and maintain an erection 
(109). Finally, several medicines commonly used to treat HF have been shown to either cause 
or worsen ED (99). Digoxin for example, is a drug that can cause ED even though the 
mechanism by which this happen is not really clear, but it has been speculated that this drug 
creates a sexual hormonal unbalance (110) and the inhibition of cavernosal sodium/ 
potassium-adenosine triphosphate activity, consequently impairing NO relaxation (111).  
 
Table 1. Relationship between the first report of ED and subsequent cardiovascular 
disease. Incident ED was statistically significant associated with subsequent angina, 
myocardial infarction and stroke (red circles). Also, number of patients who showed ED 
prior the cardiovascular event was extremely higher compared to those who shoed ED after 
cardiovascular event (red circle). Men with incident ED had a significantly increased risk of 
myocardial infarctation or angina relative to men without a report of ED. Adapted from 
Thompson et al, 2005 (112).   
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6. The link between ED and CVD 
An emerging basic science and clinical database provides a strong argument for endothelial 
and smooth muscle dysfunction as a central etiologic factor in systemic and peripheral 
diseases, including ED (113). The endothelium is the single layer of cells that line the 
luminal surface of blood vessels. It is far more than just a structural lining; it has a range of 
important physiological functions. It acts as a direct interface between the components of 
circulating blood and local tissue, and regulates numerous local blood vessel functions, 
including vascular tone, cell adhesiveness, coagulation, inflammation and permeability. The 
endothelium produces and responds to several potent, locally and active mediators. The 
most important of these is NO, which is a nonadrenergic-noncholinergic (NANC) 
vasodilator neurotransmitter involved in the regulation of vascular wall function (113). This 
highly reactive gas  presents potent anti-atherogenic properties, in addition to inhibiting 
platelet aggregation and regulating vascular tone (114). Moreover, in the atherosclerosis 
installation process there are leucocytes adhesion and inflammatory agents that contribute 
to plaque instability and rupture, and this event can be inhibited by NO.  
The vasodilatation induced by NO is initiated with the synthesis from L-arginine by nitric 
oxide synthases (NOS) (115). Physiological amounts of NO can be produced by endothelium 
(eNOS) or neuronal (nNOS) enzymes and both are involved in penile erection. Down 
regulation of eNOS in pathological conditions results in reduced bioavailability of NO and 
consequently endothelial dysfunction (8). Inhibition of nNOs attenuated erectile responses 
(116). Erectile function was also found to be preserved in mice lacking eNOS. However, 
incracavernosal pressure during erection was significantly decrease in eNOS-deficient mice 
and over all, NOS activity was only 60% of the activity observed in wild type mice. Thus, 
physiologic penile erection is mediated by both nNOS and eNOS (7, 117).  
NO activates a soluble guanylyl cyclase that forms cyclic guanosine monophosphate 
(cGMP) (118) in vascular smooth muscle cells, resulting in penile relaxation (8, 23). Reports 
of ED in cGMP-dependent kinase-I (cGKI)-deficient mice suggest that cGMP is indeed the 
main second messenger in ED (119). These findings are supported by clinical data showing 
that phosphodiesterase type 5 inhibitor (PDE5, e.g. sildenafil) prevents the degradation of 
cGMP (120). In cGKI-deficient mice cAMP-mediated pathway cannot compensate deficient 
cGMP-dependent signaling in vivo (119). However, in humans prostaglandin E1 and its 
derivative alprostadil, which induce relaxation predominantly via cAMP pathway, were 
found to be highly effective in the treatment of ED (121-122).  
Dysfunction of the endothelium may be interpreted as homeostasis disturbance due to 
breakdown. Also, endothelial dysfunction  can be caused by vascular insults, such as 
diabetes, smoking, hyperlipidemia and hypertension (123). At the cellular level, endothelial 
dysfunction outcomes in impaired release of NO, which may be considered a key 
pathomechanism in both endothelial (124-125) and erectile dysfunction (115, 126). Oxidative 
stress, which is directly toxic to the endothelium and also interferes with the NO pathway, is 
a causal factor in clinically evident occlusive CVD and vascular damage associated with 
preclinical disease. Free radical damage, impaired function and availability of NO can also 
result in increased adhesion, aggregation of platelets and neutrophils, besides the release of 
vasoconstrictor substances (29-30, 113). In addition NOS depends on tetrahydrobiopterin as 
a co-factor. Endothelial dysfunction associated with tetrahydrobiopterin depletion could be 
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reversed by supplementation of this substance (127-129). Indeed the treatment with 
tetrahydrobiopterin increased NOS activity by 30% in rabbit CC (130). 
Over the past years studies have showed that many men will realize the onset of ED occurs 
before they are diagnosed with CVD. The anatomic structure of the penis and the 
physiology of getting and maintaining an erection provide clues as to the reason the penile 
vascular bed has some unique properties that facilitate early detection of systemic vascular 
disease (113). Nowadays, it is well known that ED can result from any number of structural 
or functional abnormalities in the penile vascular bed. For instance, ED may be a 
consequence of the cavernosal arteries oclusion by atherosclerosis, impairment of 
endothelial-dependent and/or independent smooth muscle relaxation, or a combination of 
these two factors. It is believed that ED caused by functional vascular factors occurs early 
and is likely associated with oxidative stress and decreased NO availability. Initially these 
factors result in poor relaxation of penile endothelium and in smooth muscle that presents 
clinically as ED, with difficulty to maintain a firm erection. This early clinical symptom 
probably occurs before the development of structural, occlusive penile arterial disease and 
may be among the earliest signs of systemic CVD. Thus, it has been accepted that 
endothelial dysfunction is the etiologic connection between ED and systemic cardiovascular 
diseases (9, 30).  
Corroborating this idea, Lojanapiwat et al examined 41 ED patients and 30 age-matched 
normal control, subjects were investigated for cardiovascular risks and endothelial function. 
Changes in brachial arterial diameter after its occlusion were compared between the groups. 
Results did not show differences in baseline characteristics for cardiovascular risks and lipid 
levels. However, a significant difference regarding endothelial dysfunction in ED patients 
without clinical cardiovascular risks versus control patients was observed. They concluded 
that patients who developed ED showed endothelial dysfunction and cardiovascular risk 
markers prior to the clinical symptoms. In addition, a study evaluating systemic vascular 
structure and function in 30 patients with ED and 27 age-matched normal controls, 
investigated whether patients with vascular ED and no other clinical CVD have structural 
and functional abnormalities of other vascular beds. Systemic endothelial function using 
flow mediated brachial artery vasodilatation showed that men with ED exhibited 
significantly lower brachial artery flow-mediated, vascular defect in endothelium-
dependent and independent vasodilatation, which happen before the development of 
structural or functional systemic vascular disease, when compared to controls. According to 
the authors these data suggest the presence of  peripheral vascular abnormality in the NO 
pathway (131). In another study, biochemical markers of endothelial cell activation were 
used to compare 45 men with ED and no clinical CVD with 25 age-matched healthy. The 
results showed that the carotid intima-media thickness (IMT) was similar between the 
groups. However, soluble P-selectin (intracellular adhesion molecule-1) and endothelin-1 
levels were significantly higher in  men with ED and no CVD (132).  
Alterations in the several signalling pathways, mainly in Rho-kinase signaling, are common 
in ED as well as CDV, contributing to a further increase in endothelial dysfunction. Rho-
kinase, is involved in the sequence of events that stimulates vascular smooth muscle 
contraction, stress fiber formation, cell migration, and, indirectly, blood pressure regulation. 
In this way, RhoA/Rho-kinase activation has significant effects on various cardiovascular 
diseases, such as arterial hypertension (133), atherosclerosis (134), heart attack (135), stroke 
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(136), coronary vasospasm (137), myocardial hypertrophy (138), myocardial ischemia-
reperfusion injury (139), vascular remodeling (140) and ED. Since the main function of Rho-
kinase is the regulation of smooth muscle tone (141), the upregulation of the Rho-kinase 
pathway increases cavernosal smooth muscle contraction, leading to ED (142-143). 
Furthermore, studies indicate that Rho-kinase isoforms are activated in patients with a 
cardiovascular disorder or associated risk factors (144-145). Also, RhoA mRNA expression 
and activity is increased in aortas from aged rats, suggesting a role of RhoA in the 
development of age-related cardiovascular disease (146).  
7. Conclusion 
Although the link between ED and CVD has been previously documented, convincing 
evidence of the direction and magnitude of the effect has not been available. However, 
several studies support the idea that ED precedes overt structural occlusion of larger blood 
vessels, and ED is often an early manifestation of systemic vascular disease. The evaluation 
of ED in the medical history as an early symptom of endothelial dysfunction and 
atherosclerosis may be a predictor of future cardiovascular events, including death. This 
might be relevant to identifying patients with a particularly high risk of experiencing 
cardiovascular events even though is not clear yet what kind evaluation or parameters 
should be prompted in ED condition. 
 
Fig. 1. Endothelial dysfunction is a common situation in both CVD and ED. Generally ED 
is caused by unbalance between vasoconstrictors (Ang II, ET-1, Rho-kinase, arginase) and 
vasodilators (NO) endogenous agents. Endothelial dysfunction leads to ED development 
and later to onset of CVD.  
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pathway (131). In another study, biochemical markers of endothelial cell activation were 
used to compare 45 men with ED and no clinical CVD with 25 age-matched healthy. The 
results showed that the carotid intima-media thickness (IMT) was similar between the 
groups. However, soluble P-selectin (intracellular adhesion molecule-1) and endothelin-1 
levels were significantly higher in  men with ED and no CVD (132).  
Alterations in the several signalling pathways, mainly in Rho-kinase signaling, are common 
in ED as well as CDV, contributing to a further increase in endothelial dysfunction. Rho-
kinase, is involved in the sequence of events that stimulates vascular smooth muscle 
contraction, stress fiber formation, cell migration, and, indirectly, blood pressure regulation. 
In this way, RhoA/Rho-kinase activation has significant effects on various cardiovascular 
diseases, such as arterial hypertension (133), atherosclerosis (134), heart attack (135), stroke 
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(136), coronary vasospasm (137), myocardial hypertrophy (138), myocardial ischemia-
reperfusion injury (139), vascular remodeling (140) and ED. Since the main function of Rho-
kinase is the regulation of smooth muscle tone (141), the upregulation of the Rho-kinase 
pathway increases cavernosal smooth muscle contraction, leading to ED (142-143). 
Furthermore, studies indicate that Rho-kinase isoforms are activated in patients with a 
cardiovascular disorder or associated risk factors (144-145). Also, RhoA mRNA expression 
and activity is increased in aortas from aged rats, suggesting a role of RhoA in the 
development of age-related cardiovascular disease (146).  
7. Conclusion 
Although the link between ED and CVD has been previously documented, convincing 
evidence of the direction and magnitude of the effect has not been available. However, 
several studies support the idea that ED precedes overt structural occlusion of larger blood 
vessels, and ED is often an early manifestation of systemic vascular disease. The evaluation 
of ED in the medical history as an early symptom of endothelial dysfunction and 
atherosclerosis may be a predictor of future cardiovascular events, including death. This 
might be relevant to identifying patients with a particularly high risk of experiencing 
cardiovascular events even though is not clear yet what kind evaluation or parameters 
should be prompted in ED condition. 
 
Fig. 1. Endothelial dysfunction is a common situation in both CVD and ED. Generally ED 
is caused by unbalance between vasoconstrictors (Ang II, ET-1, Rho-kinase, arginase) and 
vasodilators (NO) endogenous agents. Endothelial dysfunction leads to ED development 
and later to onset of CVD.  
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1. Introduction 
Erectile dysfunction (ED) is defined as the persistent or repeated inability to achieve and/or 
maintain an adequate erection to accomplish a complete and satisfactory sexual activity. The 
term ED defines more accurately the nature of such dysfunction than the term impotence 
(National Institutes of Health (NIH) Consensus Conference, 1993; World Health 
Organization (WHO), 2000). ED manifests itself in the general population of adult males and 
increases with age. But it is more pronounced in individuals who suffer from diabetes, 
cardiovascular and metabolic problems. ED is one of the chronic complications of diabetes 
mellitus (DM), so the prevalence rate is very high in this group of men, and is one of the 
medical affectations with greatest impact on the quality of life of these patients. Because of 
the characteristic physiopathological alterations of DM, the damage caused mainly to the 
nervous and circulatory system favors the increased prevalence of ED (Kadioglu et al., 1994; 
Romero et al., 1997). In this chapter we discuss some aspects related to the epidemiology of 
ED and its prevalence in DM subjects, as well as the physiopathological mechanisms 
involved in this condition.  
2. Epidemiology of ED 
2.1 Epidemiology of ED in the general population 
It has been estimated that ED affects around 100-150 million men worldwide and it is 
expected an increase of 322 million by 2025 (Bloomgarden et al., 1998; Laumann et al., 1999); 
being DM one of the main causes. It is important to note that ED is also reflected in 
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Erectile dysfunction (ED) is defined as the persistent or repeated inability to achieve and/or 
maintain an adequate erection to accomplish a complete and satisfactory sexual activity. The 
term ED defines more accurately the nature of such dysfunction than the term impotence 
(National Institutes of Health (NIH) Consensus Conference, 1993; World Health 
Organization (WHO), 2000). ED manifests itself in the general population of adult males and 
increases with age. But it is more pronounced in individuals who suffer from diabetes, 
cardiovascular and metabolic problems. ED is one of the chronic complications of diabetes 
mellitus (DM), so the prevalence rate is very high in this group of men, and is one of the 
medical affectations with greatest impact on the quality of life of these patients. Because of 
the characteristic physiopathological alterations of DM, the damage caused mainly to the 
nervous and circulatory system favors the increased prevalence of ED (Kadioglu et al., 1994; 
Romero et al., 1997). In this chapter we discuss some aspects related to the epidemiology of 
ED and its prevalence in DM subjects, as well as the physiopathological mechanisms 
involved in this condition.  
2. Epidemiology of ED 
2.1 Epidemiology of ED in the general population 
It has been estimated that ED affects around 100-150 million men worldwide and it is 
expected an increase of 322 million by 2025 (Bloomgarden et al., 1998; Laumann et al., 1999); 
being DM one of the main causes. It is important to note that ED is also reflected in 
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conditions that frequently coexist with DM, such as hypertension and cardiovascular 
disease (Benet & Melman, 1995). Epidemiological studies clearly show the high prevalence 
of this pathology. According with a number of studies, variables such as and the 
methodology employed, the estimated prevalence of ED varies from 19% to 75%. The data 
also showed that in addition to age, as an important factor, others such as lifestyle, food and 
tobacco consumption are highly associated to ED. It is estimated that the prevalence of ED 
varies according to the age of the population from 39% at the age of 40 years to 75% in men 
aged 80 years (Morley, 1986). In the Massachusetts Male Aging Study (MMAS), it was noted 
that the prevalence rate of ED of any grade was 52% (17% classified as a minimum, 25% 
moderate, and 10% severe) (Feldman et al., 1994). In another study performed in Spain 
known as EDEM [by its Spanish acronym: Epidemiología de la Disfunción Eréctil 
Masculina, (The Epidemiology of Male ED)], it was noted that the 19% of men between 25 
and 70 years old have some degree of ED (16% classified as minimum, 2% moderate, 1% 
severe). This prevalence increases with age (8.6% in males aged from 25 to 39 years, 13.7% 
aged 40-49 years, 24.5% between 50 and 59 years, and 49% in people aged from 60 to 70 
years) (Martin-Morales et al., 2001). Further information can be found in the work carried 
out by Kubin et al., in which they describe other several studies about the incidence of ED 
made around the world (Kubin et al., 2003). 
2.2 Prevalence of ED in the diabetic population 
Prevalence of ED is significantly higher in DM when compared to that found in the general 
population. The ED is associated with an increase in age (Fedele et al., 2001; McCulloch et al, 
1980; Roth et al., 2003), poor metabolic control (Roth et al., 2003), time of evolution of DM 
(Klein, 1996; Roth, 2003), smoking (Bortolotti  et al, 2001), consumption of alcoholic 
beverages, neurological damage (Lundberg et al., 2001), depression (Fedele et al., 2000), use 
of some drugs (Kleinman et al., 2000) and microvascular complications (Romeo et al., 2000) 
among other factors. Diabetic patients, with an inadequate control of their glycemic status, 
chronically suffer from neurological and vascular damages of penile smooth muscle, 
disruptions of endothelial function, a sustained increase in oxidative stress, formation of 
advanced glycation end-products, among others, all closely related to the physiology of 
erection. All these aspects are reviewed in detail in later sections of this chapter. 
Epidemiological data show that the population of men with DM is more likely to develop ED. 
Data reported about ED in this population show a prevalence rate ranging from 35% to 78% 
depending on the age and general metabolic state of patients analyzed. In a study performed 
in 541 DM men aged 20-59 years, a prevalence rate of 35% of ED, and mainly attributed to 
microangiopathy; however, as mentioned before other factors such as age, type of treatment: 
oral hypoglycemic agents or insulin, the presence of retinopathy, symptomatic peripheral 
neuropathy, and symptomatic autonomic neuropathy (McCulloch et al., 1980) are also highly 
associated. Other studies report higher prevalence rates of 78%, of which 6% are mild, 36% 
moderate, and 36% severe. In this same study, it was found that the patients with non-insulin 
dependent diabetes that suffered of ED, had associated higher cardiovascular risks compared 
with the diabetic patients who did not have ED. Likewise, it was observed that the increase in 
cardiovascular risk factors is closely related to the severity of ED in diabetic patients (Meena et 
al., 2009). These elements suggest that ED is a common problem in diabetic patients and is a 
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direct consequence of an inadequate control of metabolic state in general and particularly of 
the glycemic state. ED has a multifactorial etiology but an appropriate diabetic patient's 
metabolic control is the best way to prevent this chronic complication of DM. 
2.3 Prevalence of ED among patients with type-1 and type-2 DM 
It is unclear whether erectile disorder is more common among men with non-insulin 
dependent diabetes (type-2, T2DM, late onset) or those with insulin-dependent diabetes 
(type-1, T1DM, early onset). Only a few studies include a prevalence of erectile disorder by 
diabetic type. In this regarding, one study reported that men with elevated body mass index 
(BMI) and T1DM showed a significantly higher risk of ED than men with elevated BMI and 
T2DM. The same study also showed that the age-adjusted prevalence of ED was higher in 
men with T1DM (51%) than with T2DM (37%) (Fedele et al., 2000). But Miccoli et al., found 
that 40% and 52% of insulin-dependent and non-insulin dependent DM participants 
respectively had impotence (Miccoli et al., 1987). Fedele et al., in 2001 also reported that the 
incidence of ED in Italian men with diabetes was higher in T2DM than in T1DM (74 versus 
45 cases per 1,000 person-years) (Fedele et al., 2001). 
3. Basic mechanism of penile erection 
Stimuli that can lead to penile erection include tactile stimuli to the penis and genitalia which 
will produce a reflex erection, while erotic stimuli, whether visual, auditory, olfactory or 
imaginative also produce penile erection by a mechanism which involves the paraventricular 
nucleus and medial preoptic area of the hypothalamus. A third mechanism is involved in the 
production of nocturnal erections that occur in all men during REM sleep (Eardley, 2002). The 
degree of contraction of the corpus cavernosum smooth muscle and the functional state of the 
penis is determined by the balance between proerectile and antierectile mechanisms that 
operate physiologically in the penis. Vasoconstriction maintains the penis in the flaccid state.  
Erectile function is dependent on relaxation of the cavernous smooth muscle, and its 
mechanism of action is mediated by Nitric Oxide (NO). NO synthesized from L-arginine is the 
key mediator of endothelium-dependent smooth muscle relaxation, and likewise it is the key 
mediator of penile erection. After any stimulation, NO is released from non-adrenergic non-
cholinergic (NANC) nerves through activation of neuronal nitric oxide synthase (nNOS). 
Binding of NO to soluble guanylate cyclase increases cyclic guanosine monophosphate 
(cGMP) levels and cGMP-dependent protein kinase-1 (PKG-1) activity, leading to smooth 
muscle cell relaxation and cavernosal dilation. Subsequent hemodynamic changes such as 
increased arteriolar shear flow stimulate the phosphatidylinositol-3-kinase/protein kinase B 
(Akt) pathway leading to activation of endothelial nitric oxide synthase (eNOS) in penile 
endothelium and further NO release. Occlusion of venous outflow is also required for 
sinusoidal filling and the maintenance of high intracavernosal pressure and erection. This 
veno-occlusion is achieved by the compression of the emissary veins that lie between the 
tunica albuginea and the expanding sinusoidal tissue (Hidalgo-Tamola & Chitaley, 2009).  
Since erection is a complex process that involves the participation of vascular, endocrine, 
cellular and neuronal mechanisms; reason why any damage at these levels, favors the 
partial or total loss of erection. These damages are not only structural but also functionally.  
The figure 1 describes the main physiological mechanisms that regulate the erectile function, 
and the morpho-physiological organizations that might suffer damages during DM.  
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direct consequence of an inadequate control of metabolic state in general and particularly of 
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(Akt) pathway leading to activation of endothelial nitric oxide synthase (eNOS) in penile 
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Fig. 1. Schematic representation of central and intracavernosal mechanisms involved in the 
control of erection. External visual, gustative, auditory, imaginative and tactile are 
transmitted to the rhinencephalon, the limbic cortex and thalamic nuclei, and are integrated 
into the hypothalamic medial preoptic area (M-POA) where they stimulate supraspinal 
erections (psychogenic erection). Up box: serotonin (5HT), corticotrophin-releasing-hormone 
(CRH) and β-endorphin (βEP) exert inhibitory effects, while gonadotrophin-releasing-
hormone (GnRH), dopamine (DA) and oxytocin (OX) are the main stimulators of 
psychogenic erections. Hypothalamic projections (possibly oxytocinergic) to the spinal cord 
control thoracolumbar sympathetic (T11-L2) and sacral parasympathetic stimulation from 
(S2 to S4) fibers which inhibit and stimulate the erection, respectively. Direct genital stimuli 
initiate a local neural loop leading to parasympathetic stimulation from S2 to S4 and 
reflexogenic erection. Down box: intracavernosal mechanisms of erection involve 
cholinergic, adrenergic, and non-adrenergic non-cholinergic (NANC) nervous fibers. The 
main stimulators of smooth muscle cell contraction (detumescence) are norepinephrine (NE) 
and endothelin-1 (ET1), while acetylcholine (ACH) and nitric oxide (NO) are the main 
mediators of smooth muscle cell relaxation and erection via reduction of intracelular 
calcium (Ca+2) content. Blood oxygen tension (pO2) in the sinusoids inversely regulates 
smooth muscle cell transforming growth factor-β (TGFB) expression and collagen 
accumulation in the pericellular spaces. Modified from Fabbri et al., 1997.  
 
Erectile Dysfunction: A Chronic Complication of the Diabetes Mellitus 
 
73 
4. Animal models of diabetes employed in the study of ED 
In recent years, our understanding of human sexual function and dysfunctions has grown. 
Sexual responses are complex; therefore, different in vivo models exist, focused on the 
neurobiology, psychophysiology and different functional components of male sexual 
responses.  When trying to understand how these preclinical models translate to humans, it 
should also be borne in mind that the primary purpose of sexual activity in animals is 
reproduction, while in humans it is predominantly recreational. The fact that animal sexual 
behaviors are highly stereotyped and species specific, it makes difficult to translate results in 
animal studies to humans (McMurray et al., 2006). 
Erectile function monitoring intracavernosal pressure (ICP) is the most common method to 
preclinical monitoring the quality of an erectile response. ICP has been monitored in both 
conscious and anaesthetised animal models. The development of electronic data capture 
systems now allows various aspects of the ICP response to be measured. The typically 
measured endpoints include basal, peak, and plateau ICP, erection and detumesence time, 
duration of response, area under the ICP time response curve and the number of erections 
observed in a given time period. The aim is to use these end points to quantify the different 
phases and quality of the ICP response and the effect of the actions of drugs upon them 
(McMurray et al., 2006). 
Despite this knowledge, clinical and epidemiological studies seldom separate type-1 
(T1DM) and type-2 (T2DM) DM; however, this section will briefly highlight some of the 
T2DM animal models and animal models of DM induced by chemical treatments (T1DM) 
used to study the ED.  
4.1 Rat models of T2DM 
The obese diabetic Zucker rat (OZR) is a model for T2DM with glucose intolerance and an 
autosomal recessive mutation in the leptin gene. It develops hyperinsulinemia, insulin 
resistance, and hyperlipidemia at an early age with progression to proteinuria and 
glomerular injury (Kasiske et al., 1992). Similar characteristics exist between the OZR and 
patients with T2DM including obesity, hypertension, and impaired vasodilation. The 
BBZ/WOR rat is a cross between the BB/WOR rat a model for autoimmune diabetes and a 
Zucker rat. Obese BBZ/WOR rats develop insulin resistance, and hyperglycemia with 
higher mean serum glucose levels compared with lean T2DM rats (Vernet et al., 1995). 
Otsuka Long-Evans Tokushima Fatty (OLETF) rats develop spontaneous diabetes by 
selective breeding. Male rats exhibit late onset hyperglycemia, hypercholesterolemia, and 
mild obesity. In this model, pancreatic islet cells changes mirror those seen in humans with 
T2DM (Kawano et al., 1992). 
4.2 Mouse models of T2DM 
Recently, mouse models of T2DM have been utilized to study ED. The high-fat diet fed 
mouse model was used as an ED experimental model (Xie et al., 2007). C57BL6 mice were 
fed a high-fat, high-simple carbohydrate, and low-fiber diet for 22 weeks, and developed 
obesity with a mean body weight of 39 g, and developed diabetes with a mean fasting 
serum glucose of 223.6 mg/dL. An additional mouse model of T2DM is the db/db mouse 
(Sharma et al., 2003). The db/db mouse has a mutation in the leptin receptor, and develops 
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spontaneous obesity, hyperglycemia, hyperphagia, hyperinsulinemia, and diabetic 
neuropathy, occurring from 10 days to 8 weeks of age.  
4.3 Rabbit and rat models of T1DM induced by chemical treatment 
The models of Alloxan-induced in rabbit (Chang et al., 2003; Vignozzi et al., 2007) and 
Streptozotocin-induced in rat (Vignozzi et al., 2007) of T1DM have been also used to study 
the ED.  
Other animal models of T2DM and insulin resistance exist but have not been used to date to 
study mechanisms of ED during diabetes (Hidalgo-Tamola & Chitaley, 2009).  
Findings gained from the study of some of these animal models have shed light on 
mechanisms underlying the cause of ED during DM. These factors include impaired 
vasodilatory signaling, cavernosal hypercontractility, and veno-occlusion, among others.  
Although hyperglycemia is a common defining feature both: type-1 and type-2 DM, many 
unique characteristics distinguish these conditions, including insulin and lipid levels, 
obesity status, and inflammatory agent profiles. In the laboratory, the presence of ED has 
been established in animal models of both type-1 and type-2 DM. Impaired cavernosal 
vasodilation has been established in type-1 diabetic rodents. This dysfunction appears to be 
mediated by a severe defect in non-adrenergic-non-cholinergic nerve signaling, as well as 
impairment in penile endothelial function. In contrast, type-2 diabetic animals appear to 
have minimal impairment in parasympathetic-mediated dilatory function, but do have 
evidence of endothelial dysfunction. Type-2 diabetic models also exhibit a significant and 
striking increase in cavernosal contractile sensitivity, and a significant veno-occlusive 
disorder, neither of which is consistently reported in type-1 diabetic animals. With the 
distinct mechanisms underlying the ED phenotype in animal models of type-1 and type-2 
diabetes, tailoring therapeutic treatments for diabetic-ED to the specific mechanisms 
underlying this disease complication may be warranted. Further examination of 
mechanisms underlying ED in DM patients may thus lead to significant changes in the way 
urologists diagnose, code, and treat diabetic-ED (Chitaley, 2009). 
5. Mechanisms proposed to explain the ED in DM 
From a historical perspective, theories pertaining to the pathophysiology of ED have 
changed as time has gone by. In the 1960´s, the prevailing wisdom was that most ED had a 
psychogenic origin, and it was only in the second half of the 20th century, as we have 
gained increasing knowledge of the physiology of normal erectile function, that we have 
begun to understand the importance of vascular, endocrine, cellular and neural mechanisms 
in the development of ED (Eardley, 2002). 
There are several ways of classifying the erectile dysfunction causes, for example as organic, 
psychogenic or mixed organic and psychogenic, with organic erectile dysfunction being the 
most common form (Maas et al., 2002). However, take into account the way in which disease 
can interfere with erection, the classification can be: psychogenic, vascular, neural, cellular, 
endocrine, and iatrogenic (Eardley, 2002). As was showed above by epidemiological studies 
(Feldman et al., 1994; Saigal et al., 2006), the risk of erectile dysfunction increases with 
diabetes and it is in relation with several pathogenic mechanisms in diabetes disease 
involved in precipitating and maintaining the ED. 
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As it is showed in the figure 2, the physiopathology of ED in DM is multifactorial and in the 
following section, we address some of these pathophysiological mechanisms being so far 
taken into account to explain the development of ED in DM. 
 
Fig. 2. Mechanisms of diabetes-associated erectile dysfunction.  
5.1 Endothelial dysfunction 
Several clinical and laboratory studies demonstrate that endothelial dysfunction is an 
important mechanism for the development of ED associated with T2DM. ED is usually 
described as a decrease in the bioavailability of NO, as a result of decreased expression 
and/or activity of eNOS, including increased removal of NO. Damage to the endothelium-
dependent vasoreactivity has been demonstrated in various animal models of T2DM. 
Myograph in vitro studies in mice fed with a high fat diet, db/db diabetic mice and obese 
Zucker rats have shown that the ability of muscle relaxation of the cavernous tissue 
decreases even when stimulated with acetylcholine (Luttrell et al., 2008; Wingard et al., 2007; 
Xie et al., 2007). Jesmin et al., observed a decrease of the immunofluorescent staining of 
eNOS and the expression of this enzyme in the penile tissue of Long-Evans Tokushima 
Otsuka obese rats, with respect to controls (Jesmin et al., 2003). The decrease in eNOS 
mRNA expression suggests that reduced expression of eNOS is initiated at the gene 
transcription level. The alteration in the eNOS activation is another mechanism that 
contributes to decreased bioavailability of NO. eNOS activation occurs through 
phosphorylation of serine-177 residue by serine/threonine protein kinase Akt. In turn, the 
Akt-dependent pathway regulates the phosphorylation of eNOS mediated by the vascular 
endothelial growth factor (VEGF). The effects of VEGF include proliferation, migration, 
angiogenesis, and antiapoptosis in endothelial cells. VEGF increased the phosphorylation 
and expression of antiapoptotic proteins, mediated by eNOS. It is considered that in the ED, 
vascular repair mechanisms mediated by VEGF are damaged, probably because the 
expression of the VEGF and its receptors are altered in the cavernous endothelium, 
conditioning its angiogenic functions (Costa & Vendeira, 2007). In addition to the decreased 
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eNOS activity, the increased removal of NO by free radicals and oxidative agents has been 
shown to be important in the cavernous endothelial dysfunction in diabetes-associated ED 
models (Hidalgo-Tamola & Chitaley, 2009). Endothelins (ET) are potent vasoconstrictor 
peptides that stimulate the contraction of trabecular smooth muscle of the corpus 
cavernosum. No one knows the exact involvement of ET on the pathogenesis of ED. High 
levels of ET-1 observed in diabetic patients could be enough to cause ED, although this does 
not happen. However, the high intracellular calcium concentration resulting from this 
condition modulates gene expression sufficiently to cause the proliferation of smooth 
muscle. Alternatively, alterations in ET receptor sensitivity in conditions such as diabetes 
and hypertension can enhance the processes of vasoconstriction. It is possible that the ET 
system may be relevant in ED, but under certain conditions where there is global 
endothelial dysfunction, such as diabetes and systemic sclerosis, the use of ET antagonists in 
these patients could be beneficial (Ritchie & Sullivan, 2010).  
5.1.1 Failure of the signaling mechanism of vasodilation 
Maintenance of cavernosal vasodilation has been hypothesized to occur through the 
activation of eNOS in endothelial cells, presumably in response to shear stress. Data from 
animal models of T2DM support the findings of impaired vasodilation in T2DM humans. 
Accompanying the impaired vasodilatory response, total penile NOS activity was found to 
be decreased in the BBZ/WOR rat model (Vernet et al., 1995). Similar result was showed by 
an age-matched case controlled study of 30 patients with T2DM and ED, where was found 
impaired the cavernosal vasodilation (De Angelis et al., 2001).  
Vascular disease is probably the most common cause of ED, and of all the vascular causes, 
the commonest is atherosclerosis; however, DM joined with other risk factors, namely 
smoking, hypertension and hyperlipidaemia are also indirectly associated with the 
development of ED (Fig.3). A reduced arterial inflow leads to relative hypoxia within the 
penis with subsequent cellular effects. The crucial cellular mediator appears to be TGF-β1, 
which is increased in hypoxia and induces trophic changes in the cavernosal smooth muscle, 
and failure of the venous-occlusive mechanism (Feldman et al., 1994; Johannes et al., 2000).   
 
Fig. 3. Schematic representation of the relationship between the DM and other risks factors, 
with the development of vascular damages that favor the ED in the diabetic patient. 
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On the other hand, DM can injure cells and cause ED in a direct way. Diabetes damage the 
endothelium impairs the vascular response of the penis to neural stimuli. The structural 
changes in the endothelium that are produced by diabetes are accompanied by functional 
changes that result in impaired smooth muscle relaxation (Cartledge et al., 2001a; Saenz de 
Tejada et al., 1989). In the figure 4, it is possible observe the alteration of penile vascular 
endothelium of the rabbit with DM.  
 
Fig. 4. Electron micrographs of normal penile vascular endothelium (a) and the effect of 
diabetes in the rabbit (b). Note the ragged appearance of the endothelium and the 
deposition of red (rb) and white (wb) blood cells in diabetes. (Micrographs published by the 
Dr. Ian Eardley in Pathophysiology of erectile dysfunction. (2002). British Journal of Diabetes 
and Vascular Disease, Vol. 2, No. 4, pp. 272-6, ISSN 1474-6514, by courtesy of Sullivan, M. 
5.1.2 Venous-occlusive dysfunction 
In ED, venous-occlusive dysfunction or venous leakage, involves the premature escape of 
blood inside the corpuses cavernous by incompetence of their drainage system and 
subsequent inability to reach the intracavernous pressure necessary to provide an effective 
stiffness. By Doppler studies and Pharmacocavernosometry, it has been observed that a high 
percentage of patients with T2DM present venous leak (Colakoglu et al., 1999; Metro & 
Broderick, 1999). Evidence from animal studies has demonstrated the importance of venous-
occlusive dysfunction in the development of ED in T2DM. It is considered that the alteration 
in the process of veno-occlusion may be caused by changes in the structure of the penis, the 
cells and/or the content of the extracellular matrix. In this regard, the expression of VEGF 
has broad implications in the structure of the penis, resulting in changes in the rate of 
apoptosis. The decrease in VEGF expression correlates with elevated levels of pro-apoptotic 
proteins such as Bcl-2, so it is suggested that the decrease of VEGF in penile tissue in T2DM 
increases apoptosis and loss of erectile cells. In other studies with animal models of T2DM, 
there has been observed an alteration in the expression of collagen and the rate of smooth 
muscle/collagen in cavernous tissue. Likewise, decreased elastin has been found in the 
corpus cavernosum, specifically, decreased expression of tropoelastin mRNA, precursor 
protein of elastin and fibrillin-1. Structural alterations in the tunica albuginea caused by 
T2DM, could affect the compliance of the corpus cavernosum, required for veno-occlusion 
and intracavernous pressure maintenance (Hidalgo-Tamola & Chitaley, 2009). 
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Fig. 3. Schematic representation of the relationship between the DM and other risks factors, 
with the development of vascular damages that favor the ED in the diabetic patient. 
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On the other hand, DM can injure cells and cause ED in a direct way. Diabetes damage the 
endothelium impairs the vascular response of the penis to neural stimuli. The structural 
changes in the endothelium that are produced by diabetes are accompanied by functional 
changes that result in impaired smooth muscle relaxation (Cartledge et al., 2001a; Saenz de 
Tejada et al., 1989). In the figure 4, it is possible observe the alteration of penile vascular 
endothelium of the rabbit with DM.  
 
Fig. 4. Electron micrographs of normal penile vascular endothelium (a) and the effect of 
diabetes in the rabbit (b). Note the ragged appearance of the endothelium and the 
deposition of red (rb) and white (wb) blood cells in diabetes. (Micrographs published by the 
Dr. Ian Eardley in Pathophysiology of erectile dysfunction. (2002). British Journal of Diabetes 
and Vascular Disease, Vol. 2, No. 4, pp. 272-6, ISSN 1474-6514, by courtesy of Sullivan, M. 
5.1.2 Venous-occlusive dysfunction 
In ED, venous-occlusive dysfunction or venous leakage, involves the premature escape of 
blood inside the corpuses cavernous by incompetence of their drainage system and 
subsequent inability to reach the intracavernous pressure necessary to provide an effective 
stiffness. By Doppler studies and Pharmacocavernosometry, it has been observed that a high 
percentage of patients with T2DM present venous leak (Colakoglu et al., 1999; Metro & 
Broderick, 1999). Evidence from animal studies has demonstrated the importance of venous-
occlusive dysfunction in the development of ED in T2DM. It is considered that the alteration 
in the process of veno-occlusion may be caused by changes in the structure of the penis, the 
cells and/or the content of the extracellular matrix. In this regard, the expression of VEGF 
has broad implications in the structure of the penis, resulting in changes in the rate of 
apoptosis. The decrease in VEGF expression correlates with elevated levels of pro-apoptotic 
proteins such as Bcl-2, so it is suggested that the decrease of VEGF in penile tissue in T2DM 
increases apoptosis and loss of erectile cells. In other studies with animal models of T2DM, 
there has been observed an alteration in the expression of collagen and the rate of smooth 
muscle/collagen in cavernous tissue. Likewise, decreased elastin has been found in the 
corpus cavernosum, specifically, decreased expression of tropoelastin mRNA, precursor 
protein of elastin and fibrillin-1. Structural alterations in the tunica albuginea caused by 
T2DM, could affect the compliance of the corpus cavernosum, required for veno-occlusion 
and intracavernous pressure maintenance (Hidalgo-Tamola & Chitaley, 2009). 
 
Erectile Dysfunction – Disease-Associated Mechanisms and Novel Insights into Therapy 
 
78
5.1.3 Diabetic micro and macro angiopathy 
Clinical and biochemical evidence support the participation of the microangiopathic 
complications of diabetes in the pathogenesis of ED. Multiple studies have shown that 
chronic hyperglycemia (which is the main determinant of the microangiopathic 
complications) is a strong risk factor for ED. Diabetes duration and other microvascular 
complications (i.e. retinopathy, neuropathy and nephropathy) are predictors of the 
occurrence of ED (Bhasin et al., 2007). 
Somatic and autonomic nerve dysfunction is present in a large percentage of individuals 
with diabetes-associated ED (Chitaley et al., 2009). Its presence is demonstrated by the 
existence of both, longer latencies in the evoked potentials of pudendal nerves and 
abnormal bulbar urethral and urethroanal reflexes. Diabetes causes degeneration of the 
nitrergic nerves, which participates in the nitric oxide-dependent cavernosal smooth muscle 
relaxation. A central neuropathic mechanism has been postulated by several authors 
(Costabile, 2003). 
Some of the biochemical mechanisms that induce endothelial dysfunction and decreased 
generation of nitric oxide participate also in the pathogenesis of diabetic neuropathy (Gur et 
al., 2009). An example is the oxidative stress. Superoxide radicals are present in high amount 
in cavernosal tissues.  Superoxide anion reacts with nitric oxide to form peroxynitrite 
resulting in decreased nitric oxide bioavailability (Boulton et al., 2004). In addition 
peroxynitrite is a highly toxic compound for vascular cells and neurons. It causes 
mitochondrial dysfunction, oxidative DNA damage and apoptosis. Other examples are the 
activation of protein kinase C and the presence of advance glycation end-products (AGEs). 
1,2-Diacylglycerol (DAG), a metabolite responsible of lipotoxicity in obesity and T2DM, 
activates protein kinase C (in particular the  isoform (PKC-). These enzymes participate in 
multiple biological networks. This enzyme is activated also by free radicals.  Experimental 
data suggest that activated PKC- plays a major role in the hyperglycemia-related tissular 
damage; one of the possible explanations is the induction of the nuclear kappa B pathway.  
It is also involved in the carvernosal corpus smooth muscle contraction. On the other hand, 
chronic hyperglycemia causes the formation of AGEs which induces tissue damage by 
modifying molecules, activating inflammation and stimulating the synthesis of growth 
factors. AGEs modify cytoskeletal and myelin structure (England & Asbury, 2004). These 
changes correlate with a reduction in myelinated fiber density in peripheral nerves. Also, 
AGEs quench endothelium derived nitric oxide. As result, AGEs decreases smooth muscle 
relaxation and impairs erectile function (Thorve et al., 2011). 
The macrovascular complications during the DM contribute to the development of ED (Chai 
et al., 2009).  Vascular atherosclerotic disease of penile arteries is present in 70-80% of cases 
with ED. Occlusion of the cavernosal arteries could be a contributing factor in the long term. 
However, recent studies have shown that structural arterial changes in the penile vascular 
bed could exist even in cases with ED free of coronary heart disease.  
5.2 Diabetic neuropathy 
Neuropathy is a common complication of diabetes, in which there is nerve damage as a 
result of hyperglycemia. The damage involves both somatic and autonomic nerves. 
Autonomic nerves of the parasympathetic division stimulate relaxation of the muscles in the 
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penis; with the resulting erection, those of the sympathetic division are responsible for the 
contraction of muscles in the penis and thus maintain penile flaccidity. Although the 
mechanisms by which it occurs are not completely clear, it is known that nerve fibers are 
structurally modified by the effect of substances derived from the metabolism of excess 
glucose, which determines the loss of myelin. The loss of myelin promotes delayed nerve 
transmission, both reception of motor commands and other. Likewise, it is considered that 
the damage is caused in turn by the injury of blood vessels supplying the nerves. 
Neuropathy is another important mechanism responsible for diabetes-associated ED 
(Costabile, 2003). Diabetes is notorious for its microvascular complications, particularly 
autonomic neuropathy and peripheral neuropathy (Agarwal et al., 2003). It has been noted 
that patients with diabetic and neuropathic ED have similar frequencies of somatic and 
autonomic nervous system neuropathies, suggesting that neuropathy contributes 
significantly to the diabetes-associated ED. A recent study showed the connection between 
diabetic and neuropathic ED, demonstrating the presence of apoptotic pathways in the 
cavernous nerves in both disease processes (Mc Vary et al., 2006). The underlying cause of 
ED, which is the result of diabetic neuropathy, might be linked to selective nitrergic 
degeneration, which has been observed in the diabetic rat penis. This selective 
neurodegeneration seems to result in decreased nNOS activity and decreased NO 
production, which leads to damage nitrergic relaxation of corpus cavernosum in diabetic 
patients (Cellek et al., 1999). Additionally, NO could participate in the selective nitrergic 
degeneration through the formation of oxygen free radicals. It has been suggested that 
oxidative damage secondary to the production of peroxynitrite derived from NO may 
contribute to neurodegeneration (Cartledge et al., 2001a; Cellek et al., 1999). Several studies 
have shown that inhibition of NO synthase and NO production; prevent nitrergic 
degeneration, suggesting that this is a NO dependent process (Cellek et al., 1999). 
5.2.1 Failure of the mechanism of nitric oxide synthesis in the nervous system non-
adrenergic non-cholinergic 
DM is one of the major risk factors to develop ED. Hyperglycemia is considered the cause of 
many vascular complications and metabolic alterations associated with both T1DM and 
T2DM. Diabetes-associated ED has been attributed to a reduction in the number of NOS-
containing nerves, the impairment of NOS activity, and both neurogenic- and endothelium-
mediated smooth muscle relaxation, and also to downregulation of the mediators 
downstream from NO, such as cGMP and PKG-1, in the corpus cavernosum (Musicki & 
Burnett, 2006).  
In the cell, NO synthases have to compete, with other enzymes with activity of arginases, for 
the substrate L-arginine. Inhibition of arginase activity by 2(S)-amino-6-boronohexonic acid 
(ABH) has been shown to cause significant enhancement of non-adrenergic, non-cholinergic 
nerve-mediated relaxation of penile corpus cavernosum smooth muscle, suggesting that 
arginase inhibition sustains L-arginine concentrations for be used in the NO synthesis (Cox 
et al., 1999). Moreover, another study demonstrated that diabetic corpus cavernosum from 
humans with ED had higher levels of arginase II protein, gene expression and enzyme 
activity than normal human cavernosal tissue. The impaired ability of diabetic tissue to 
synthesize NO was reversed by the selective inhibition of arginase activity by ABH. 
Increased expression of arginase II in diabetic cavernosal tissue may therefore contribute to 
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the diabetes-associated ED (Bivalacqua et al., 2001). Another explanation for decreased 
eNOS activity in the diabetic penis can be due to a reduced penile L-arginine content. Oral 
administration of L-arginine to diabetic rabbits increases endothelium-dependent relaxation 
of cavernosal tissue by improving the NO biosynthesis (Yildirim et al., 1999). 
5.3 Oxidative stress 
Oxidative stress occurs when there is an imbalance between pro-oxidants and the ability of 
the antioxidants to scavenge excess reactive oxygen species. However, its role in ED has not 
been investigated comprehensively but, significant associations between the production of 
reactive oxygen species and ED have been showed, especially in diabetic animal models. 
NO is a highly reactive free radical that undergoes nonenzymatic reaction with 
oxyhemoglobin or that reacts with free radicals, such as superoxide anion, to form 
peroxynitrite (Beckman & Koppenol, 1996). This observation first highlighted the 
importance of oxidative stress in ED. 
Reactive oxygen species (ROS) are formed during regular metabolism due to the univalent 
reduction of oxygen molecule. Superoxide (O2-) is the most important among the ROS. 
Hydrogen peroxide (H2O2), hypochlorous acid (HOCL), and peroxynitrite (OONO-) are 
other important free radicals implicated in the pathophysiological mechanism of vascular 
disease. The vascular endothelium is the major source for these free radicals (Beckman & 
Koppenol, 1996). Superoxide dismutase (SOD) is an important enzyme that removes the 
superoxide radicals from the human body. There are 3 types of SOD isoenzymes: cytosolic, 
mitochondrial, and extracellular. Extracellular SOD reportedly plays a critical role in 
maintaining the redox state of vascular interstitium and thereby prevents the 
pathophysiological effects of superoxide in the vasculature. 
The interaction between NO and reactive oxygen species (ROS) is one of the important 
mechanisms implicated in the pathophysiological process of ED. NO interacts with 
superoxide to form peroxynitrite, which has been reported to play a central role in 
atherogenesis. Peroxynitrite reacts with the tyrosyl residue of proteins, which inactivates 
superoxide dismutase and leads to decreased removal of superoxide. This further increases 
the formation of peroxynitrite and reduces the available NO concentration. Peroxynitrite 
causes smooth-muscle relaxation but is less potent than NO. Also, peroxynitrite and 
superoxide have been reported to increase the incidence of apoptosis in the endothelium. 
This leads to denudation of endothelium and further reduction of available NO (Agarwal et 
al., 2006). On the other hands a reduced NO concentration aggravates the adhesion of 
platelets to the endothelium, and the co-adhesion of neutrophils to platelets as well as the 
endothelium through the expression of adhesion molecules, releasing large amounts of 
superoxide which reduces more the available NO by the formation of peroxynitrite, 
countering erectile drive as well as promoting further more adhesion of platelets and 
neutrophils. Under this condition, is favored the releasing of substances (thromboxane A2 
and serotonin) that cause vasoconstriction (Jeremy et al., 2000), taking place a vicious circle 
that generates the vasculopathic erectile dysfunction.  
Another mechanism has been implicated in diabetes-associated ED is the activation of 
protein kinase C, this is an enzyme that modulates several cellular events, and increased 
levels of this enzyme are associated with increased production of ROS and reduced levels of 
NO, which can be prevented by administration of antioxidants (Ganz & Seftel, 2000). 
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The studies demonstrate that oxidative stress has a vital role in the development of diabetes-
associated ED. Hyperglycemia is an important mediator of increased production of ROS 
leading to impaired endothelial function and structural impairment in the diabetic corpus 
cavernosum. The corpus cavernosum of diabetic rats and diabetic men with ED exhibits 
increased lipid peroxidation, upregulation of superoxide anion, and decreased antioxidants 
levels, suggestive of oxidative stress (Bivalacqua et al., 2005).  
5.4 Involvement of advanced glycation end-products 
The proposed mechanisms for ED in DM patients include: damage in the synthesis of NO, 
reduction  in the activity of PKG-1, increased endothelin and endothelin B (ETB) receptor 
binding sites; ultrastructural changes in the endothelium, upregulation of the RhoA/Rho-
kinase pathway, neuropathy, increased levels of oxygen free radicals and elevated 
concentration of advanced glycation end-products (AGEs) (Jiaan et al., 1995; Moore & 
Wang, 2006; Sullivan et al., 1997; Thorve et al., 2011). 
Hyperglycemia in DM leads to AGEs, which are derived from non-enzymatic glycosylation 
reactions, actually known as glycation. Glucose reacts with amino groups, producing what 
is known as a Schiff base. Schiff base is modified to form more stable Amadori products. 
Some of these Amadori products undergo irreversible chemical changes and become AGEs 
(Brownlee et al., 1988; Cárdenas-León et al., 2009; Cartledge et al., 2001b) (Fig. 5). The action 
of AGEs is mostly via cell surface receptors, such as the receptor for AGEs (RAGE), 
P60/OST48 protein (R-1), 80KH phosphoprotein (R-2) and galectin-3 (R-3), scavenger 
receptor II, lactoferrin-like polypeptide, and CD-36 (Basta et al., 2004).  Some of the receptors 
are likely to contribute to clearance of AGEs, whereas others may mediate many of the 
adverse effects, such as quenching of NO, impairment of extracellular matrix and tissue 
remodeling, modification of circulating proteins, and receptor-mediated production of ROS. 
AGEs can also form covalent bonds with collagen vascular, leading to thickening of blood 
vessels, decreased elasticity, endothelial dysfunction and atherosclerosis (Bucala et al., 1991; 
Singh et al., 2001). AGEs are accumulated during aging (Jiaan et al., 1995) and diabetes. They 
are formed abundantly when glucose remains high for prolonged periods (Bucala et al., 
1991; Seftel et al., 1997). AGEs have been found elevated in the corpus cavernosum and tunica 
albuginea of the penis of diabetics rats and humans (Cartledge et al., 2001b; Cirino et al., 2006; 
Jiaan et al., 1995; Seftel et al., 1997). It is thought that AGEs may contribute to diabetes-
associated ED, generating oxygen free radicals, which induce cell damage by oxidative 
processes and also remove NO, culminating with the decrease of cGMP and affecting the 
cavernous smooth muscle relaxation (Bivalacqua et al., 2005; Cartledge et al., 2001b). AGEs 
may take effect at the molecular level on different channels and receptors in cavernous smooth 
muscle cells, particularly on potassium channels, which facilitate the release of intracellular 
calcium and subsequent cavernous smooth muscle relaxation. Damage to the potassium 
channels could lead to lost of the relaxation capacity of the cavernous smooth muscle and to 
early onset of diabetes-associated ED (Cartledge et al., 2001b; Costabile, 2003). Also, AGEs are 
considered to be related to ED during diabetes by increasing the expression of mediators of 
vascular damage such as VEGF and ET-1, which have mitogenic and vasoconstrictor activities 
(Morano, 2003). Several studies have shown damage to smooth muscle relaxation in the corpus 
cavernosum and penile ED in diabetic rat in the presence of AGEs (Cartledge et al., 2001b; 
Usta et al., 2003). Also, it has been observed that under conditions of diabetes, the combined 
effect of AGEs and their receptor (RAGE), may increase the activity of ET-1 in the cavernous 
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muscle cells, particularly on potassium channels, which facilitate the release of intracellular 
calcium and subsequent cavernous smooth muscle relaxation. Damage to the potassium 
channels could lead to lost of the relaxation capacity of the cavernous smooth muscle and to 
early onset of diabetes-associated ED (Cartledge et al., 2001b; Costabile, 2003). Also, AGEs are 
considered to be related to ED during diabetes by increasing the expression of mediators of 
vascular damage such as VEGF and ET-1, which have mitogenic and vasoconstrictor activities 
(Morano, 2003). Several studies have shown damage to smooth muscle relaxation in the corpus 
cavernosum and penile ED in diabetic rat in the presence of AGEs (Cartledge et al., 2001b; 
Usta et al., 2003). Also, it has been observed that under conditions of diabetes, the combined 
effect of AGEs and their receptor (RAGE), may increase the activity of ET-1 in the cavernous 
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tissue and thus promote the development of diabetes-associated ED (Chen et al., 2008). The 
involvement of AGEs in diabetes-associated ED has been demonstrated by using 
aminoguanidine, an inhibitor of AGEs formation (Usta et al., 2004) and ALT-711, a compound 
that breaks down formed AGEs (Usta et al., 2006), and observing improvement in 
endothelium-dependent cavernosal smooth muscle relaxation in vitro (Cellek et al., 2004) and 
erectile responses in vivo (Usta et al., 2003).  
 
Fig. 5. Schematic representation: mechanisms of main Advanced Glycation End-products 
(AGEs) formation. CML: Carboxymethyl lysine; CEL: Carboxyethyl lysine.  
5.5 Hyper-contractility of the cavernous body 
ED is more common in diabetic patients. Hyperglycemia among others, leads to an altered 
vasodilator neural impulse, causing smooth muscle hyperkinesis and altered veno-occlusion 
process (Hidalgo-Tamola & Chitaley, 2009). Hypercontractility of corpus cavernosum may 
occur as a result of heightened sympathetic nervous system activity and/or increase in 
signaling to smooth muscle. The role of hyperkinesis of smooth muscle cells during T2DM-
associated ED is difficult to discern from clinical studies, since most of them combine 
patients with T1DM and T2DM in the same group of evaluation. However, several animal 
studies suggest the importance of hyperkinesis in T2DM-associated ED.  
Hyperinsulinemia and insulin resistance are associated with overactive sympathetic 
nervous system, which increases smooth muscle tone and keeps the penis in flaccid state. 
Currently it is unclear whether the increase in contractility is only due to sympathetic 
overactivity or the gloom of the signaling pathways in smooth muscle play a predominant 
role (Carneiro, 2008). The results obtained by using diabetic obese Zucker rats as an 
experimental model, suggest that increased smooth muscle tone is mediated by protein 
kinase C and RhoA/Rho-kinase pathway (Wingard et al., 2007). During normal erection, 
this pathway is inhibited by NO (Mills, 2002), but during diabetes the RhoA/Rho-kinase 
pathway activity is elevated and suppresses eNOS gene expression and enzyme activity in 
the penis (Bivalacqua et al., 2004). It has been reported that corpus cavernosal tissue, 
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obtained from alloxan-induced diabetic rabbits, exhibits increased RhoA and Rho-kinase ß 
expression (Chang et al., 2003). It is considered that other modulators of tone of smooth 
muscle cells might be involved in T2DM-associated ED. In addition to the altered 
vasodilator stimuli and increased contractility of the corpus cavernosum, which limit the 
flow of blood into the penis, the inability to limit the outflow of blood due to a disorder of 
veno-occlusion, may also be a factor in T2DM-associated ED. ED during diabetes is 
associated among others with decreased PKG-1. In smooth muscle a major target of the 
PKG-1 are the calcium-sensitive potassium channels (BKCa), the overactivation of which 
hyperpolarizes smooth muscle cells, causing relaxation. But during diabetes the activity of 
PKG-1 and therefore the activity of the BKCa are low and the relaxation mechanism is 
affected. It has been observed that the elimination of BKCa channels in an experimental 
model causes hypercontractility of the smooth muscle and ED (Werner et al., 2008). 
5.5.1 Relationship between glycaemia, dyslipidemia, hypertension and its medical 
treatment with ED in DM patients 
The hyperglycemia and dyslipidemia associated to DM favors the mechanisms of oxidative 
stress, endothelial damage and the development of atherosclerosis (Li, et al., 2011; Kumar, et 
al., 2010) leading to hypertension as consequence of endothelial dysfunction and loss of 
vascular relaxation.  Due to these considerations, it is extremely important the metabolic 
control of DM subjects to avoid the appearance of ED. 
Weight loss is the prime objective of therapy. Several studies in which intensive lifestyle 
programs or bariatric surgery were implemented to lose weight have shown that erectile 
function improves in direct proportion with the difference in body weight. The potential 
mechanisms include improved endothelial function and nitric oxide bioavailability, 
decreased inflammation, increased testosterone plasma levels, and improved mood and self-
esteem. In addition, weight loss is the cornerstone for the treatment of hyperglycemia, 
hypertriglyceridemia, arterial hypertension and hypoalphalipoproteinemia (Khatana et al., 
2008). Patients should be encouraged to quit smoking, to reduce their alcohol intake and to 
give up recreational drugs. Prescription drugs and over the-counter medications should be 
checked for possible contributors to ED. Relationship counseling and a psychiatric 
medication is useful to treat anxiety and depression. 
An association exists between glycemic control and ED in men with diabetes. Hermans et 
al., analyzed 221 consecutive male outpatients with T2DM in whom ED was assessed using 
the International Index of Erectile Function (IIEF-5) questionnaire (Hermans et al., 2009). 
Patients with ED (n=83) were compared with an age-matched controls (n=51).  Patients with 
poor control have increased risk for ED compared to patients with good control. Body 
weight and adiposity are significantly associated with ED. Obesity is associated with an 
odds ratio of 1.5 to 3 for having ED. Other measures of adiposity, including the waist-to-hip 
ratio and abdominal circumference, are also independently associated with ED. A sedentary 
life style increases the risk, independently of its effect on body mass index. Arterial 
hypertension and abnormal plasma lipid level, common co-morbidities of T2DM, are 
associated with ED. Both are linked with endothelial dysfunction, reduced nitric oxide 
synthesis and increased free radicals synthesis. 
Several authors have proposed that treatment of hyperglycemia and cardiovascular risk 
factors should be part of the treatment of ED. Although this proposal is clinically sound, no 
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major randomized controlled studies are available to support it. Only the EDIC trial 
(Epidemiology of Diabetes Intervention and Complications study) have partially evaluated it. 
The EDIC study is an extension of the DDCT trial, a landmark study that demonstrated that 
the correction of hyperglycemia reduces the incidence of microvascular complications. A 
substudy of the EDIC trial (Uro-EDIC) was designed to evaluate the impact of the correction of 
hyperglycemia on the incidence of urologic complications. ED was assessed using the IEFF 
questionnaire. The effect of treatment was evaluated separately in cases (n=280) with or 
without (n=291) microvascular complications. No difference was observed in the incidence of 
ED between men randomized to intensive vs. conventional therapy (OR 1.24, 95% CI 0.68- 
2.28) in cases free of microvascular complications at the beginning of the study. In contrast, 
intensive therapy resulted in a smaller incidence of ED among men with microvascular 
complications (OR 0.33, 95% CI 0.18-0.60).  Regrettably, ED was not included among the study 
outcomes of the main trials that have evaluated the effect of intensive treatment of 
hyperglycemia (i.e. ACCORD trial) in men with T2DM. Future studies including validated ED 
measurements, adequate sample size and important potential confounders are needed to 
measure the benefit of intensive glycemic control in men with poorly controlled diabetes. 
5.6 Androgen loss systemic effects 
The erectile response in mammals is regulated by androgens; in particular it has been 
confirmed that testosterone is an important regulator of the erectile function (Yassin & Saad, 
2008). Is known that 6-12% of men between 40 and 69 years old suffer from hypogonadism. 
In adult men the disease is manifested by erectile dysfunction, among others. Male 
hypogonadism, which is also called testosterone deficiency syndrome, is characterized by 
failure of testicular testosterone production and is especially common in men with T2DM, 
affecting one third of them. Testosterone acts on the penile tissues involved in the 
mechanism of erection, so deficiency of this hormone, impairs erectile capacity. The 
pathophysiological mechanisms of low circulating testosterone concentrations are unknown, 
but it has been suggested that obesity associated with T2DM, helps to reduce testosterone 
levels by increasing the conversion of testosterone to estradiol in adipose tissue. The 
increase in the concentration of estradiol leads in turn to a suppression of hipothalamic 
gonadotrophin releasing hormone (GnRH), which is evidenced by a reduced secretion of 
pituitary gonadrotropins (luteinizing hormone, LH and follicle stimulating hormone, FSH), 
which reduces in turn the secretion of testosterone by the Leydig cells and spermatogenesis 
in the seminiferous tubules, thus manifesting as hypogonadism. This may explain the 
inverse relationship between BMI and plasma concentrations of testosterone (Dhindsa et al., 
2004; Grossmann et al., 2008; Kapoor et al., 2007; Rhoden et al., 2005; Traish et al., 2009). 
Male hypogonadism is associated with increased adipose tissue. In men with more than 
160% of ideal body weight, concentrations of plasma testosterone and sex hormone-binding 
globulin (SHBG) are usually low while estrogen levels, from the conversion of adrenal 
androgens in adipose tissue, increase. In men with morbid obesity weighing more than 
200% over the ideal weight, free testosterone may decrease. The concentrations of free 
testosterone and SHBG show an inverse relationship with waist circumference (WC) (Osuna 
et al., 2006; Pasquali et al., 1997; Svartberg, 2007). With the increase in adipose tissue also 
increases the production of leptin; favors the insulin resistance and therefore the appearance 
of hyperinsulinemia. Under these conditions, both leptin and insulin act on Leydig cells and 
inhibit testosterone synthesis (Pitteloud et al., 2005; Soderberg et al., 2001) (Fig. 6). 
 




Fig. 6. Relationship between obesity, androgen deficiency (hypogonadism), metabolic 
syndrome and ED. The increase in adipose tissue and its accumulation in abdominal region, 
increases the production of adipokines and free fatty acids, this in turn, generates insulin 
resistance and hyperinsulinemia. The excess of insulin reduces the hepatic synthesis of 
SHBG and IGFBP-1 with the consequent increase of free IGF-1. The high concentrations of 
IGF-I and insulin act synergically on the testis and the adrenals glands, reducing the 
androgens secretion. In the testis, moreover, because of the limited effect that the reduced 
LH concentration exerts on the synthesis of testosterone, the effect is more marked. 
Probably, the increase in aromatization of androgens by adipose tissue, contributes to the 
hypoandrogenemia, together with the low levels of FSH which limit the spermatic 
development, lead to ED and the hypogonadotropic hypogonadism condition, which is an 
infertility factor. 
Androgen deficiency contributes to pathologies associated with the metabolic syndrome, 
such as obesity, T2DM, hypertension and hyperlipidemia, which affect the endothelium, 
resulting in multiple vascular diseases, including ED, representing the latter, an infertility 
factor (Akishita et al., 2007; Traish et al., 2009; Tripathy et al., 2003) (Fig. 6). Also, several 
studies have shown that low testosterone levels predict development of T2DM in men 
(Tomar et al., 2006). There is evidence that the treatment with testosterone to DM animal 
models improves erectile function by influencing the NO/cGMP/PDE5 pathway (Vignozzi 
et al., 2005). Testosterone supplementation to diabetic animals also down regulates 
RhoA/Rho-kinase signaling (Vignozzi et al., 2007) improving also erectile function. The use 
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of PDE 5 inhibitors like Sildenafil (Viagra), Tadalafil (Cialis) and Vardenafil (Levitra) for ED 
treatment has allowed a better management of this condition (Yassin & Saad, 2008). In 
particular, combined therapy of testosterone and sildenafil, improves erectile function in 
patients with T2DM (Hidalgo-Tamola & Chitaley, 2009). 
5.7 Other causes of ED in diabetes 
5.7.1 Viral and Bacterial pathogens 
A role for viral and bacterial pathogens in the development of atherosclerosis has been 
suggested by multiple studies. Most evidence for this infection theory comes from 
seroepidemiological and experimental studies with cytomegalovirus (CMV) and Chlamydia 
pneumonia (CP), which are intracellular pathogens and can directly infect vascular wall cells, 
including endothelial cells and smooth muscle cells. Although still under debate, there appears 
to be an association of CMV and CP with the presence or development of atherosclerotic 
vascular disease in diabetes. Direct infection of endothelial cells leads to pro-coagulant activity 
and a local vascular pro-inflammatory response. Although the exact pathogenesis of ED in 
men with DM is still unclear, endothelial dysfunction plays a pivotal role and some studies 
suggested an association between ED and CMV and/or CP seropositivity in men with 
diabetes. Also, levels of the inflammatory markers as C-reactive protein and fibrinogen were 
elevated in patients with diabetes-associated ED (Blans et al., 2006).  
5.7.2 Drugs used in the diabetic patient 
A large number of drugs used in the managing of the DM patients may impair sexual 
function, either by an effect upon erectile and ejaculatory function or sex drive. Some of 
them are used as part of the diabetes treatment or others associated conditions like 
hypertension, anxiety and depression. The use of these drugs very rarely produces ED by 
themselves. Side effects usually appear adjunct to another pathophysiological mechanism 
(Eardley, 2002; Elías-Calles & Licea, 2003) (Table 1). 
 
Type of drug: Secondary sexual effect: 
  
Antihypertensive (Diuretics):  
Spironolactone Diminution of the libido, ED 
Thiazide Diminution of the libido, ED 
  
Agents of central action:  
Methyldopa                                                           Diminution of the libido, ED 
Clonidine                                                                ED 
Reserpine Diminution of the libido, ED and depression 
  
Alpha-adrenergic blocking agents:  
Prazosin Retrograde ejaculation 
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Type of drug: Secondary sexual effect: 
Terazosin Retrograde ejaculation 
  
Beta-adrenergic blocking agents:  
Propranolol Diminution of the libido, ED 
Metoprolol Diminution of the libido, ED 
  
Alpha and Beta Blocking Agents:  
Labetalol Inhibition of the ejaculation 
  
Blocking of the sympathetic ganglia:  
Guanethidine ED, Retrograde ejaculation 
  
Inhibitor of the angiotensin-converting 
enzyme: 
 
Lisinopril ED in 1% of the cases 
  
Psychiatric drugs (Tricyclic Antidepressants):   
Amitriptyline ED, Inhibition of the ejaculation 
Amoxapine Diminution of the libido, ED 
Desipramine Inhibition of the ejaculation 
Imipramine Inhibition of the ejaculation 
Maprotiline Inhibition of the ejaculation 
Nortriptyline Inhibition of the ejaculation 
Protriptyline ED, Inhibition of the ejaculation 
  
Atypical agent:  
Trazodone Priapism 
  
Inhibitors of Monoamine oxidase:  
Isocarboxazid Inhibition of the ejaculation 
Phenelzine ED, Inhibition of the ejaculation 
  
Antipsychotic:  
Thioridazine Diminution of the libido, Inhibition of the ejaculation 
Chlorpromazine Inhibition of the ejaculation 
Mesoridazine Diminution of the libido, Inhibition of the ejaculation 
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Type of drug: Secondary sexual effect: 
Fluphenazine Diminution of the libido, Inhibition of the ejaculation 
  
Serotonin reuptake inhibitor:  
Fluoxetine Anorgasmia 
Trifluoperazine Inhibition of the ejaculation 
Chlorprothixene Inhibition of the ejaculation 
Haloperidol  Inhibition of the ejaculation 
  
Anti-mania:  
Lithium carbonate Possible ED 
  
Anti-ulcer:  
Cimetidine Diminution of the libido, ED, Gynecomastia 
Table 1. Drugs used in the managing of the metabolic and psychological state of the diabetic 
patients with potential capacity to induce sexual dysfunctions including ED. 
6. Conclusions 
DM is one of the more important risk factors to the development ED. The uncontrolled 
metabolic state (characterized by hyperglycaemia, dyslipidemia, insulin resistance, 
hyperinsulinemia) induce oxidative stress, failure in the signaling mechanism of 
vasodilation, venous-occlusive dysfunction, atherosclerosis, angiopathy, neuropathy, 
alterations of the NO-mediated pathways, the formation of advanced glycation end-
products, hypercontractility of the cavernous body, overweight and androgen loss systemic 
effects, and ED as consequence. 
Although hyperglycemia is a common defining feature in type-1 and type-2 DM, many 
unique characteristics distinguish these diseases, including insulin and lipid levels, obesity 
status, and inflammatory agent profiles. Impaired cavernosal vasodilation has been 
established in T1DM rodents. This dysfunction appears to be mediated by a severe defect in 
non-adrenergic-non-cholinergic nerve signaling, as well as impairment in penile endothelial 
function. In contrast, T2DM animals appear to have minimal impairment in 
parasympathetic-mediated dilatory function, but do have evidence of endothelial 
dysfunction. T2DM models also exhibit a significant and striking increase in cavernosal 
contractile sensitivity, and a significant veno-occlusive disorder, neither of which is 
consistently reported in T1DM animals. With the distinct mechanisms underlying the ED 
phenotype in animal models of type-1 and type-2 DM, the therapeutic treatments for 
diabetes-associated ED most be adjustment to the specific mechanisms underlying this 
disease complication. Further examination of mechanisms underlying ED in DM patients 
may thus lead to significant changes in the way urologists diagnose, code, and treat 
diabetes-associated ED. An adequate metabolic and psychological control is the more 
effective way to avoid the ED in DM; for these reasons it is of extreme importance the 
opportune and specialized medical intervention and support. 
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1. Introduction 
Interest in the definition and management of premature ejaculation (PE) has been increasing 
significantly among all healthcare professionals and its clinical perceptions continue to 
evolve in recent years. Accumulating evidence suggests that it is considered to be the most 
common male sexual disorder (Metz & Pryor, 2000). Obtaining a universally accepted 
definition for PE has been problematic. Nevertheless, all definitions to date have repeatedly 
included two basic components which are the inability to control or delay ejaculation, and 
the resultant distress to one or both partners. Based on these components, the currently 
accepted definitions have been reported by a number of authorities which are authority-
based rather than evidence-based (Table 1). In addition, PE can be divided into primary, that 
begins when the patient becomes sexually active, and secondary, which by definition is 
acquired later in life (Godpodinoff, 1989). Further subdivisions include global PE presenting 
in all circumstances, versus situational PE which occurs only with certain partners and 
situations (Donatucci, 2006). Intravaginal ejaculatory latency time (IELT) refers to the time 
between vaginal penetration and ejaculation, usually measured with a stopwatch or simply 
estimated in retrospect (Payne & Sadovsky, 2007). There has been no widely accepted 
standard for ‘normal’ IELT. In 2005, Patrick et al. found on a large community-based 
population of men and their partners that the median IELT, recorded using a partner-held 
stopwatch, was 7.3 min for men without PE, whereas men with PE had a median IELT of 1.8 
min (Patrick et al., 2005). A multinational population survey of IELT by Waldinger et al. 
showed that 90% of 110 men with self-reported lifelong PE had an IELT of less than 60 
seconds (Waldinger et al., 2005). IELT of less than 2 minutes is generally accepted as 
defining PE (Waldinger et al, 1998). A small percentage of men will ejaculate even before 
penetration. Others have advocated not to define the disorder with a specific time duration 
and instead suggested that a diagnosis is made when the man ejaculates too early for female 
partner satisfaction in greater than one-half of encounters (Masters & Johnson, 1970).  
 
World Health Organization (WHO), 1994 (Lue & Broderick, 2007):  
Inability to delay ejaculation sufficiently to enjoy lovemaking manifests as either of the 
following: occurrence of ejaculation before or very soon after the beginning of intercourse 
(if a time limit is required: before or within 15 seconds of the beginning of intercourse); 
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seconds (Waldinger et al., 2005). IELT of less than 2 minutes is generally accepted as 
defining PE (Waldinger et al, 1998). A small percentage of men will ejaculate even before 
penetration. Others have advocated not to define the disorder with a specific time duration 
and instead suggested that a diagnosis is made when the man ejaculates too early for female 
partner satisfaction in greater than one-half of encounters (Masters & Johnson, 1970).  
 
World Health Organization (WHO), 1994 (Lue & Broderick, 2007):  
Inability to delay ejaculation sufficiently to enjoy lovemaking manifests as either of the 
following: occurrence of ejaculation before or very soon after the beginning of intercourse 
(if a time limit is required: before or within 15 seconds of the beginning of intercourse); 
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occurrence of ejaculation in the absence of sufficient erection to make intercourse 
possible. The problem is not the result of prolonged absence from sexual activity. 
American Psychiatric Association, the diagnostic and statistical manual of mental 
disorders-fourth edition (DSM-IV), 2000 (American Psychiatric Association, 2000):  
A. Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or 
shortly after penetration and before the person wishes it. The clinician must take into 
account factors that affect duration of the excitement phase, such as age, novelty of the 
sexual partner or situation, and recent frequency of sexual activity. 
B. The disturbance causes marked distress or interpersonal difficulty. 
C. The premature ejaculation is not due exclusively to the direct effects of a substance (eg, 
withdrawal from opioids). 
Specify type: 
Lifelong vs acquired 
Specify type: 
Generalized vs situational 
European Urology Association (EUA), 2001(Colpi et al., 2001):  
The inability to control ejaculation for a “sufficient” length of time before vaginal 
penetration. It does not involve any impairment of fertility, when intravaginal ejaculation 
occurs. 
Second International Consultation on Sexual Dysfunctions (ICSD), 2003 (World Health 
Organization [WHO], 2004): 
Ejaculation with minimal stimulation and earlier than desired, before or soon after 
penetration, which causes bother or distress and over which the sufferer has little or no 
voluntary control. 
American Urological Association (AUA), 2004 (Montague et al., 2004): 
Ejaculation that occurs sooner than desired, either before or shortly after penetration, 
causing distress to either one or both partners. 
International Society for Sexual Medicine (ISSM), 2007 (International Society for Sexual 
Medicine [ISSM], 2007):  
A male sexual dysfunction characterized by ejaculation which always or nearly always 
occurs prior to or within about one minute of vaginal penetration, and the inability to delay 
ejaculation on all or nearly all vaginal penetrations, and negative personal consequences, 
such as distress, bother, frustration and/or the avoidance of sexual intimacy. 
 
Table 1. Definitions of PE 
 




PE is considered as a culture-dependent symptom which is self-identified, self-reported, and 
self rated with respect to severity, a fact that has influenced the reported prevalence in the 
literature. Laumann et al. performed analysis of the National Health and Social Life Survey 
(NHSLS) which was a probability-based household survey in 1992 that included 1,410 men 
aged 18 to 59 years (Laumann et al., 1999b). The authors found that approximately 30% of 
surveyed men reported what they described as “climaxing too soon.” Interestingly, the 
analysis showed that the likelihood of PE was not affected by age, marital status, or 
race/ethnicity. Similarly, analysis the Global Study of Sexual Attitudes and Behaviours 
(GSSAB), an international survey of various aspects of sex and relationships among adults 
aged 40-80 y, was carried out to estimate the prevalence and correlates of sexual problems in 
13,618 men from 29 countries representing seven geographic regions (Laumann et al., 2005). 
The majority of the prevalence rates reported in these seven regions were very similar to the 
one reported by the NHSLS, with four of the seven regions reporting prevalence rates from 
27.4 to 30.5%.  One exception was the Middle East region, in which the rate was 12.4%, 
however lack of sampling standardization from country to country could have led to such a 
result. In a more recent data by Porst et al. (Porst et al., 2007), the PE Prevalence and 
Attitudes (PEPA) internet-based survey of 12,133 men aged 18–70 in Germany, Italy, and the 
United States reported a prevalence of 22.7%. PE prevalence as reported by female partners 
has also been examined. In a preliminary report of a survey undertaken on 129 women 
presenting to a community practice, 23.2% of women reported that their partner had PE 
(defined as ejaculating before she desired at least half of the time they had sex) (Rosenberg 
et al., 2006). 
Some have argued that despite the relatively high reported prevalence rates of PE, men do 
not frequently offer it as a medical complaint, raising the distinct possibility that the 
problem may be more prevalent than currently estimated(Grenier & Byers, 1995; Spector & 
Carey, 1990). In addition, most physicians do not inquire about the condition which support 
the above argument (Payne & Sadovsky, 2007). Underreporting of PE can be attributable to 
a number of patient or physician related factors (Table 2).  
 
Patient factors Physician factors 
 Embarrassment/Stigma 
 Loss of self-esteem 
 Belief that the condition is psychological 
 Belief that the condition is transient 
 Perception of no medical treatment exists 
 Lack of routine screening 
 Lack of knowledge with the condition 
 Lack of comfort discussing sexual issues 
 Lack of expertise 
 Consideration of PE as quality of life 
(QoL) not medical issue 
 Low prioritization of the condition by 
the medical system 
 Time constraints 
 Lack of training/motivation 
 lack of effective treatment options 
Table 2. Factors affecting PE reporting (McMahon, 2005; Moreira et al., 2005; Payne & 
Sadovsky, 2007; Shabsigh, 2006; Symonds et al., 2003) 
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3. Risk factors 
PE by its nature is dependent on subjective description as reported by patients or their 
partners. The condition has significant heterogeneity with regards to classification and 
etiology. Several investigators have attempted to pin point specific risk factors or risk 
association pertaining to PE. Some of these factors show persistent association or co-
existence whereas others show modest or conflicting one calling for further well designed 
studies to determine the impact of these factors on PE. Suggested risk factors for PE are 
shown in Table 3. 
 
 Erectile dysfunction (ED) (Corona et al., 2004; Laumann et al., 1999b) 
 Hypoactive sexual desire (Rowland et al., 2010) 
 Low libido (Payne & Sadovsky, 2007) 
 Youth (Carson & Gunn, 2006) 
 Limited sexual experience (American Psychiatric Association, 2000) 
 Low frequency of sexual intercourse (Grenier & Byers, 2001; Laumann et al., 2005) 
 Longer period of sexual abstinence (Jannini & Lenzi, 2005) 
 Poor overall health and/or a simultaneous urological condition (Carson & Gunn, 
2006; Screponi et al., 2001) 
 Type II diabetes mellitus, especially with poor metabolic control (El-Sakka, 2003) 
 Emotional disturbances and stress (Laumann et al., 1994; Laumann et al., 1999b) 
 Generalized clinical anxiety (Dunn et al., 1999) 
 Anxiety over sexual encounters (Dunn et al., 1998) 
 Familial/genetic predisposition (Waldinger et al., 1997) 
 Previous traumatic sexual experiences (Laumann et al., 1999b) 
 Any same sex activity ever 
 Partner had an abortion ever 
 Sexually touched before puberty 
 Sexually harassed ever 
 Ethnic group (hispanic/black > white) (Carson & Gunn, 2006; Laumann et al., 1999b) 
 Low education status (Laumann et al., 2005) 
 Financial problems (Nicolosi et al., 2004) 
 Hidden female partner arousal difficulties (Levine, 1975) 
 Substance abuse (Payne & Sadovsky, 2007) 
Table 3. PE risk factors 
4. Physiology of ejaculation and pathophysiology of PE 
The normal male sexual response results from a complex integrated neurophysiologic 
pathway with four components: excitement, plateau, ejaculation and orgasm followed by 
resolution (McMahon & Samali, 1999). Normal antegrade ejaculation involves the processes 
of emission and expulsion of semen, which are coordinated by a network of afferent and 
efferent neural pathways (Coolen et al., 2004; Waldinger, 2002). Three distinct physiological 
phases of the ejaculatory process have been described including emission, ejaculation, and 
orgasm. During emission, the smooth muscles in the prostate, seminal vesicles, and vas 
deferens undergo rhythmic contractions that result in seminal fluid being deposited into the 
 
Premature Ejaculation Re-Visited: Definition and Contemporary Management Approaches 
 
101 
posterior urethra. At the same time, the bladder neck contracts to prevent retrograde flow of 
seminal fluid into the bladder (Bohlen et al., 2000). The ejaculation phase involves relaxation 
of the external urinary sphincter and pulsatile contractions of the bulbocavernosus and 
pelvic floor muscles. Ejaculatory inevitability occurs in response to distention of the 
posterior urethra. Orgasm, which is the centrally experienced conclusion of sexual 
excitation, may or may not follow the ejaculatory phase (Donatucci, 2006).   
In case of PE, there appears to be a blunting of the normal curve of ejaculatory response, 
characterized by a steep excitement phase with a shortened plateau phase followed by 
ejaculation/orgasm and a rapid resolution phase (Payne & Sadovsky, 2007). Historically, 
attempts to explain the etiology of PE have included a diverse range of psychological and 
biological factors. Psychological factors include anxiety, an unpleasant introductory or early 
sexual experience, infrequent sexual intercourse, poor ejaculatory control techniques, and 
evolutionary as well as psychodynamic factors (Sadeghi-Nejad & Watson, 2008). On the 
other hand, biological factors include penile hypersensitivity, hyperexcitable ejaculatory 
reflex, hyperarousability, endocrinopathy, genetic predisposition, and 5 hydroxytryptamine 
(5-HT)-receptor dysfunction (Donatucci, 2006). Increasing interest is focused on 
neurobiological explanations, such as hyposensitivity of 5-hydroxytryptamine 2C (5-HT2c) 
receptors or hypersensitivity of 5-HT1a receptors (Diaz & Close, 2010). It has been suggested 
that the ejaculatory threshold for men with low 5-HT levels and/or 5-HT 2C receptor 
hyposensitivity may be genetically ‘set’ at a lower point, resulting in a more rapid 
ejaculation (Abdel-Hamid et al., 2009). On the contrary, men with a very high set point may 
experience delayed or absent ejaculation despite prolonged sexual stimulation and despite 
achieving a full erection (Abdel-Hamid et al., 2009). Injection of a selective serotonin 
reuptake inhibitor (SSRI) into rat hypothalamus has been shown to delay ejaculation, 
whereas administration of a selective serotonin receptor agonist has been shown to cause PE 
in the rat (Ahlenius et al., 1981). This idea is supported in humans by the successful use of 
SSRIs, which increase 5-HT levels, in patients with PE (Diaz & Close, 2010). It has been 
postulated that men with PE have a hyperexcitable ejaculatory reflex that prevents them 
from controlling ejaculation (Donatucci, 2006).  
5. Evaluation 
It is universally accepted that a validated instrument to diagnose PE does not exist as yet. In 
its absence, when men present with PE, a thorough sexual history is of paramount 
importance to the evaluation. In 2004, the American Urological Association (AUA) 
Guideline on the Pharmacologic Management of Premature Ejaculation recommends that 
the diagnosis of PE be based solely upon information gathered through the taking of a 
sexual history (Montague et al., 2004). Nevertheless, discussion about one’s private sexual 
life is usually not easy for anybody and even more difficult for a person who feels 
stigmatized for having a sexual-related problem. This embarrassment, especially in case of a 
male patient interacting with a female healthcare provider, is likely to prevent an open and 
a frank discussion about sexual problems. The evaluation of the problem should be 
grounded in recognition that the patient is placing great trust in his physician to treat his 
problem with respect and sensitivity. A skilled interviewer can help the patient clearly 
describe his true concerns. This should be carried out in a manner that avoids invasion of 
privacy, embarrassment, stigmatizing, and guilt. Patients are usually relieved when the 
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In case of PE, there appears to be a blunting of the normal curve of ejaculatory response, 
characterized by a steep excitement phase with a shortened plateau phase followed by 
ejaculation/orgasm and a rapid resolution phase (Payne & Sadovsky, 2007). Historically, 
attempts to explain the etiology of PE have included a diverse range of psychological and 
biological factors. Psychological factors include anxiety, an unpleasant introductory or early 
sexual experience, infrequent sexual intercourse, poor ejaculatory control techniques, and 
evolutionary as well as psychodynamic factors (Sadeghi-Nejad & Watson, 2008). On the 
other hand, biological factors include penile hypersensitivity, hyperexcitable ejaculatory 
reflex, hyperarousability, endocrinopathy, genetic predisposition, and 5 hydroxytryptamine 
(5-HT)-receptor dysfunction (Donatucci, 2006). Increasing interest is focused on 
neurobiological explanations, such as hyposensitivity of 5-hydroxytryptamine 2C (5-HT2c) 
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stigmatized for having a sexual-related problem. This embarrassment, especially in case of a 
male patient interacting with a female healthcare provider, is likely to prevent an open and 
a frank discussion about sexual problems. The evaluation of the problem should be 
grounded in recognition that the patient is placing great trust in his physician to treat his 
problem with respect and sensitivity. A skilled interviewer can help the patient clearly 
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healthcare provider acts on subtle cues that give permission for the patient to discuss the 
issue. Active listening and a compassionate acceptance of the patient are key components to 
melt the ice and of allow the patient to discuss a sensitive issue such as PE. Including the 
partner in the discussion is often helpful, but this should be at the patient’s discretion. If the 
patient does not offer it as a complaint, it is useful to perform the sexual history in the 
context of the review of symptoms, often during discussion of urinary tract symptoms or 
with the behavioural/relationship questions that are appropriate in the social history. 
Four key factors need to be considered when making the diagnosis of PE, three of which are 
subjective, in essence that they are self-reported, and one factor is objective. The former 
include poor control over ejaculation, dissatisfaction with intercourse by the patient or 
partner, and perceived distress about the condition by the patient or partner. Indeed not all 
of these factors need to be present to identify PE (Diaz & Close, 2010). The latter is decreased 
IELT. IELT has been assessed by patient and partner recall, and by stopwatch evaluation. 
There appears to be considerable overlap in times between PE and non-PE groups, 
suggesting that, until better normative values are available, the diagnosis cannot be made on 
an individual’s IELT alone. Waldinger suggested that in daily clinical practice, diagnosis PE 
is not difficult, and thus, evaluation with questionnaires or the use of a stopwatch is not 
required (Waldinger, 2007). Nevertheless, the importance of history taking cannot be 
overlooked and the above factors should be enquired about.  
Establishing an accurate sexual and psychosocial history is critical in identifying the etiology 
of PE and establishing an effective treatment regimen. There are several key areas that 
should be addressed when taking the history of a patient with possible PE and these areas 
has summarized by the AUA Guideline on the Pharmacologic Management of PE (Table 4). 
 
 Frequency and duration of PE 
 Proportion of sexual attempts with PE 
 Relationship to specific partners 
 Frequency and nature of sexual activity 
 Aggravating or alleviating factors 
 Impact of PE on sexual activity 
 Effect on relationships and QoL 
 Relationship to drug use/abuse 
 Other considerations 
 Lifelong vs. acquired 
 Situational vs. universal/global 
 Because of psychological or combined psychological/biological factors 
 Any links to ED?
AUA: American Urological Association; PE: premature ejaculation; QoL: quality of life; ED: erectile 
dysfunction. 
Table 4. AUA Guideline: sexual history for PE (Montague et al., 2004) 
Examples of direct questions that clinicians can ask initially to assist in the process of 
diagnosing PE have been suggested by Laumann et al. (Laumann et al., 2005): 
1. How well are you enjoying your sex life? 
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2. Do you ejaculate too soon or earlier than desired? If so, can you estimate the amount of 
time before you ejaculate? 
3. Do you feel you have control over the timing of your ejaculation? 
4. Does ejaculating early bother/distress you and/ or your partner? 
Since a full sexual history may be difficult to incorporate into the timeframe of a typical 
office visit, the development of brief screening tools to assist in diagnosis and minimize 
patient and provider embarrassment is warranted (Althof, 2006). Questionnaires in 
development include the 36-item Premature Ejaculation Questionnaire, the 10-item Index of 
Premature Ejaculation (IPE), the 10-item Chinese IPE, and the 2-part question used by 
Rowland et al. (Althof, 2004, 2006; Rowland et al., 2004).  
A comprehensive urological and medical history is equally important in evaluating PE 
patients because of the established relationship between some medical conditions, such as 
diabetes and other neuropathies, with ejaculatory dysfunction (El-Sakka, 2003). A medical 
history should include thorough information regarding current medications that might 
influence sexual functioning (Perelman et al., 2004). Physical examination should include a 
complete general examination and a genital examination. The examiner should look for 
signs of underlying chronic disease, endocrine dysfunction, and neurological impairment. 
Infection in the urethra, prostate, or epididymis should also be ruled out. There is no 
laboratory test currently available to assist clinicians with the diagnosis of PE. In fact, 
Laboratory evaluation is rarely necessary in men with lifelong PE, unless there are 
complicating factors or concerning physical examination findings (Laumann et al., 2005). 
The physician should always bear in mind that a mixture of decreased libido and 
ejaculatory problems, or a mixture of ED and PE, is possible. Acquired PE, especially if 
secondary to ED, may need additional laboratory work, specifically focused on relevant risk 
factors such as vascular disease, obesity, diabetes, and depression (Palmer & Stuckey, 2008). 
6. Treatment 
The ultimate aim of PE treatment is to increase the overall sexual satisfaction and 
relationship satisfaction. The goal is to increase ejaculatory latency. It should be emphasized 
that PE is not a life-threatening condition and that the primary target outcome for PE 
treatment is patient and partner satisfaction. In general, treatment options include 
psychological, behavioral, and attempts to alter the sensory input or retard the ejaculatory 
reflex through pharmacologic means. It is important to review all available treatment 
options with the patient and preferably with his partner. The risks, benefits and success of 
each strategy should be delineated clearly. Each treatment modality can be used 
individually or in combination with others. Therapeutic options should suit both partners 
and be appropriate to their habit in planning and frequency of their sexual activities. 
Arranging follow-up at appropriate intervals to judge treatment efficacy and progress is 
needed.   
6.1 Patient self-help measures 
Some patients may attempt self-help measures before seeking medical attention. Self-help 
approaches are usually gained through personal experience, bibliotherapy (books), or online 
research. The effectiveness of such remedies is not known and rarely long-lasting. Some of 
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approaches are usually gained through personal experience, bibliotherapy (books), or online 
research. The effectiveness of such remedies is not known and rarely long-lasting. Some of 
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the common measures include using distracting thoughts as well as engaging in short 
foreplay, gentle thrusting, interrupting thrusting and withdrawing for a few moments 
(Hartmann et al., 2005; Riley & Segraves, 2006). In other instance, young men with a short 
refractory period can often experience a second and more controlled ejaculation during a 
subsequent episode of lovemaking (McMahon, 2005). Some men masturbate before sexual 
intercourse to desensitize the penis and delay subsequent ejaculations. Other remedies 
include taking alcohol, using thick condoms or multiple condoms, and applying an over-
the-counter purchased anaesthetic preparation to the penis (Riley & Segraves, 2006). Many 
of these tactics, although creative, curtail the pleasures of lovemaking and are unsuccessful 
for delaying ejaculatory latency (Althof, 2006). 
6.2 Psychological treatment 
PE exerts a signicant psychological burden on men and their partners (Rowland et al., 
2001). These men tend to have mental preoccupation with their condition, show general 
negative affect associated with sexual situations, more intense feelings of 
embarrassment/guilt, worry/tension and fear of failure (Hartmann et al., 2005). 
Psychosexual therapy is best used to help the patient cope with the stress and relationship 
problems that develop secondary to sexual dysfunction (Palmer & Stuckey, 2008). It 
promotes open discussion between sexual partners, education about the condition, and 
expression of physical and emotional concerns (Althof, 2006). Counselling may be useful in 
conjunction with other treatments if it is considered to be helpful in improving self-esteem, 
but is rarely effective in treating the cause of lifelong PE. It is more likely to be successful in 
patients with acquired PE, especially those with situational PE. 
Cognitive strategies that are relevant to treatment include the man’s increased attention to 
his somatic sensations so he might better monitor his level of physical arousal, and the use 
of sensate focus, which in turn permit enjoyment of physical sensations without necessarily 
generating sexual arousal (Carey, 1998). In another word, the treating physician should 
teach his PE patient to recognize the signs of increased sexual arousal and then teaching him 
how to keep his level of sexual excitement below the level of intensity that elicits the 
ejaculatory reflex. Preliminary studies indicate that this approach is superior to a waiting list 
control (de Carufel & Trudel, 2006). These techniques also deemphasize the focus on 
intercourse and orgasm within the sexual relationship and can help to decrease the man’s 
performance anxiety, which, because it presumably operates through sympathetic 
pathways, may serve to prime the ejaculatory response prematurely (Rowland & Rose, 
2008).  
6.3 Behavioral techniques 
Behavioural techniques were once the mainstay of treatment of PE. The cornerstones of 
behavioral treatment are the ‘stop-start’ manoeuvre and its modification, the ‘squeeze 
technique’. Both methods are based on the theory that PE occurs because the man fails to 
pay sufficient attention to pre-orgasmic levels of sexual tension (Masters & Johnson, 1970; 
Semans, 1956). In addition, the procedures may act to attenuate stimulus–response 
connections by gradually exposing the patient to progressively more intense and more 
prolonged stimulation but maintaining the intensity and duration of the stimulus just below 
the threshold for triggering the response (Guthrie, 1952).  
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In 1956, Semans described one of the earliest behavioral interventions, namely the “stop –start 
technique” (Semans, 1956). This method involves the partner stimulating the man’s penis until 
he has the sensation of almost climaxing, at which time stimulation is ceased until this feeling 
abates. This cycle is repeated until the ejaculation can be controlled voluntarily. Eventually, the 
length of time before each stop gets gradually longer. Once the couple feels comfortable with 
vaginal penetration, they may be instructed to engage in “quiet vagina,” in which the female 
partner temporarily stops moving during intercourse when the man indicates that he is 
approaching ejaculation, resuming once he says that he has regained control (Payne & 
Sadovsky, 2007). A similar technique was proposed by sex therapists Masters and Johnson in 
1970 (Masters & Johnson, 1970). Their technique differed from the previous in that the partner 
squeezes the frenulum of the penis after cessation of the stimulus, resulting in a partial loss of 
erection. The female partner resumes sexual stimulation after at least 30 seconds have passed. 
However, many practitioners and patients report that this technique is unpractical.  
Unfortunately most men do not show any lasting improvement using either of these 
techniques (De Amicis et al., 1985). Hawton et al. reported that 75% of men with PE who 
initially responded to behavioral therapy showed no long lasting improvement after 3 years 
of follow-up (Hawton et al., 1986). The ICSD noted that psychological and/or behavioral 
therapies, have been at least moderately successful in alleviating PE for some men (Sharlip, 
2006). Based on their Guidelines, these approaches have no adverse effects, are specic to 
the problem, and encourage open communication between men and their partners. 
However, they lack immediacy and can require a substantial investment of time and money. 
Generally, the best results have been seen in men who are motivated, are hopeful, and are in 
a stable monogamous relationship with a cooperative partner (Althof, 2005). The popularity 
of these practices is declining because of their lack of reproducible success and their 
intrusiveness in normal sexual activity. 
Other behavioral measures that have been described including encouraging couples to carry 
out attempts with the partner superior or lateral positions, as these typically provide men 
with a greater sense of ejaculatory control (Rowland & Rose, 2008). Other suggestions 
include moving the pelvis in a circular motion, slowing down during intercourse, breathing 
deeply, and practicing shallower penile penetration (Rowland & Cooper, 2005).  
6.4 Pharmacologic interventions 
6.4.1 Locally acting topical therapy 
The oldest form of therapy for PE is the use of local anesthetic agents as described by 
Schapiro in 1943 (Schapiro, 1943). Topical anesthetics are available in cream, ointment, spray 
formulations and the rational for their application is based on the theory that men with PE 
are hypersensitive to penile stimulation. Some of these formulations have been shown to 
improve IELT compared with baseline (Busato & Galindo, 2004; Dinsmore et al., 2007). The 
advantages of topical therapies are that they can be applied as needed and systemic side 
effects are likely to be minimal. However, there are several drawbacks that make them a less 
than ideal therapeutic option. They are associated with inconvenience of use, messiness and 
interference with spontaneity (as the agents have to be applied and wiped off at specific 
times before sexual contact). Like all topical medications, there is always a risk of local 
burning, irritation, or allergic reaction. Signicant penile hypoesthesia may occur which in 
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turn can lead to excessive loss of pleasurable sensation and in some instances prevent the 
patient from achieving an orgasm (McMahon & Samali, 1999). Some reports indicated that 
the use of local anesthetics can induce mild erectile dysfunction and lowering of sexual 
arousal (Slob et al., 2000). One of the most feared drawbacks is the potential for transvaginal 
absorption of the agents used, which could induce vaginal numbness and even female 
anorgasmia (Morales et al., 2007). However, this can be prevented with condom use. As a 
general rule, reliable controlled studies have been lacking in this area. 
6.4.2 Lidocaine–prilocaine cream 
The eutectic mixture of local anesthetic (EMLA™; AstraZeneca, London, UK) is a local 
anesthetic cream that contains 2.5% of both lidocaine and prilocaine for topical application. 
This mixture has a 16ºC melting point and thus can be formulated into preparations without 
the use of a non-aqueous solvent (Gurkan et al., 2008). The cream is applied thinly to the 
glans penis and distal shaft and covered by a condom for 20-30 minutes. If the condom is 
removed for intercourse, residual cream should be washed off. The high water content of 
this mixture enables it to penetrate the intact skin of the penis (Atikeleret al., 2002). The 
AUA 2004 guideline document described the lidocaine–prilocaine cream to be effective in 
treating PE when applied 20–30 min before intercourse (Montague et al., 2004).  
Nevertheless, trials using this topically in men with PE are scant. Busato and Galindo 
performed a double-blind, randomized, placebo-controlled study to determine the efficacy 
of EMLA cream in treating PE (Busato & Galindo, 2004). The study included 42 men divided 
in two groups; group A used a lidocaine-prilocaine solution and group B used an inert 
cream. There was a significant increase in the mean IELT, from 1.49 to 8.45 min (P < 0.001) in 
group A but not in group B following 2 months use. Although 42 patients were initially 
recruited, only 29 completed the study; however, none of the drop-outs were due to adverse 
effects. Adverse events were reported in five (17%) patients in the treatment group. In 
another study, Atikeler et al. randomized 40 patients into four groups, each comprising 10 
patients to assess the efficacy and optimum usage of EMLA cream in managing PE (Atikeler 
et al., 2002). Patients in group 1 applied lidocaine-prilocaine cream 5% for 20 min, the 
patients in group 2 applied it for 30 min, and the patients in group 3 applied the cream for 
45 min before sexual contact, with all patients covering the penis with a condom. Patients in 
the fourth group applied a base cream to act as placebo. In the placebo group, there was no 
change in their pre-ejaculation period. In group 1, the pre-ejaculation period increased to 
6.71 +/- 2.54 min without any adverse effects. In group 2, the pre-ejaculation period 
increased in four patients up to 8.70 +/- 1.70 min, however six patients in this group and all 
patients in group 3 had erection loss because of numbness.  
6.4.3 Lidocaine–prilocaine spray (PSD502) 
Topical eutectic mixture for premature ejaculation (TEMPE Plethora Solutions PLC, London, 
UK) is a formulation of lignocaine and prilocaine in a metered dose aerosol-delivery system. 
Each spray delivers 7.5 mg of lidocaine and 2.5 mg of prilocaine. It is designed to optimize 
tissue penetration such that the onset of effect is more rapid than with the cream formulations 
and a condom is not required (Gurkan et al., 2008). The spray does not penetrate keratinized 
epithelium, and so only anesthetizes the glans; however there still appears to be some risk of 
hypoesthesia associated with its use (Dinsmore et al., 2007). It has an oily texture that enhances 
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adherence to the penile surface and is easily washed off with water (Henry et al., 2008). 
TEMPE has been examined in a pilot study (N = 14) , a placebo-controlled phase II study (N = 
55) (48), and in two large, placebo-controlled phase III trials, all of which have shown 
statistically and clinically significant prolongation of IELT compared with placebo (Carson & 
Wyllie, 2010; Dinsmore et al., 2007; Dinsmore & Wyllie, 2009; Henry & Morales, 2003).  
6.4.4 Lignocaine spray 
The active ingredient within this spray is the local anesthetic lignocaine (9.6%). It is 
marketed as Stud 100 or Premjact and applied to the glans penis in 3-6 sprays, 5-15 minutes 
before sexual intercourse. In theory, this agent works in the same way as other topical 
anesthetic agents. Although it has been available for more than 25 years and can often be 
bought over the counter without a prescription, there has been a paucity of data from 
clinical trials to support its use in the management of PE. 
6.4.5 Dyclonine/alprostadil cream 
A preparation which combines dyclonine, a local anesthetic usually used in the field of 
dentistry, with the vasodilator alprostadil has been described in the management of PE by 
one pilot study published as an abstract (Gittleman et al., 2005). The cream is applied to the 
tip of the penis in the region of the meatus 5–20 min before intercourse. The study claims 
some positive results, however the data is limited and further studies are needed before any 
conclusion can be drawn.  
6.4.6 Severance-secret (SS) cream 
SS-cream (Cheil Jedan Corporation, Seoul, Korea), developed at the Yong-Dong Severance 
Hospital in Korea, is made with extracts from nine herbal products including Korean ginseng, 
bufonoid venom and cinnamon. Some of these products have local anaesthetic as well as 
vasoactive properties (Morales et al., 2007). It is thought to also act through desensitization , 
although its exact mechanism is unclear. The cream is applied topically to the glans penis 1 
hour prior to intercourse and washed off immediately before coitus begins. It is marked with 
its unpleasant smell and colour, which makes it unacceptable to many patients. It is available 
for use only in Korea in which all studies conducted on its efficacy were published there by the 
same group. Within these clinical trials, SS cream resulted in significant increases in IELT and 
satisfaction with sexual intercourse in comparison with placebo (Choi et al., 1999, 2000). 
Because of its unpleasant odour, the original SS-cream was unlikely to be of interest outside of 
South Korea (Powell & Wyllie, 2009). To compensate for the unpleasant smell and color, a 
reformulation was designed by the producers that contain only couple of the main ingredients 
present in the original cream. However, only animal data is available for this new formulation 
that claims higher efficacy than the original formulation (Tian et al., 2004).  
6.5 Systemic therapy 
6.5.1 Phosphodiesterase Type 5 (PDE5) Inhibitors 
It has been estimated that at least 30% of PE men have concomitant ED (Laumann et 
al.,1999a). Whether the man with ED ejaculates early during intercourse before his erection 
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fails, or whether the man with PE develops secondary ED due to anxiety regarding his PE is 
unknown. An alternative view held by other investigators suggests that PE and ED share a 
vicious circle, in which the level of excitation is instinctively reduced by a man with PE 
trying to control his ejaculation (thus leading to ED), and on the other hand, a man suffering 
from ED will try to increase his excitation to achieve an erection, thus leading to a rapid 
ejaculation (Jannini et al., 2005). Whatever the cause of PE co-existing with ED, the 
ssuccessful use of PDE-5 inhibitors in this subgroup of patients has raised the question of 
whether PDE-5 inhibitors can be efficacious in the treatment of primary PE. It has been 
proposed that the use of a PDE5 inhibitor may increase the level of nitric oxide centrally 
(reducing sympathetic drive) and peripherally (leading to smooth muscle dilatation of the 
vas deferens and seminal vesicles, opposing sympathetic vasoconstriction), thus leading to 
prolongation of IELT in men with PE (Palmer & Stuckey, 2008). Despite this theory, it is 
deemed unlikely that PDE-5 inhibitors have a signicant role in the treatment of primary 
PE. This argument is supported by McMahon et al. who reviewed all reports on the use 
PDE-5 inhibitors for PE that were published between 2001 and 2006 (McMahon et al., 2006). 
The authors analysed 14 studies that reported on sildenafil, vardenafil and tadalafil. They 
concluded that PDE-5 inhibitors were not effective in the management of men with lifelong 
PE and normal erectile function.  However, Sadeghi-Nejad and Watson suggested that PDE-
5 inhibitors may exert a secondary beneficial effect for patients with PE since they (i) allow 
for a sustained penile erection, even after ejaculation; (ii) facilitate a second coitus after the 
initial ejaculation, which is likely to be less prone to PE; and/or (iii) help the patient to 
overcome performance anxiety, that often exacerbates PE (Sadeghi-Nejad & Watson, 2008).  
6.5.2-adrenoceptor antagonist 
Ejaculation is peripherally controlled by the sympathetic nervous system, and therefore 
blocking the sympathetic system by  α1-blockers may theoretically delay ejaculation. This 
hypothesis has been supported by a rat model demonstrating a decreased vasal and seminal 
vesicle pressure in response to hypogastric nerve stimulation (S.W. Kim et al., 2004). 
Clinically, terazosin and alfuzosin have been investigated in men with PE. Cavallini showed 
that both terazosin 5 mg/d and alfuzosin 6 mg/d proved effective in approximately 50% of 
the cases in a  placebo-controlled study in 91 men with PE (Cavallini, 1995). Similarly but 
more recently, Basar et al. demonstrated that daily use of terazosin 5 to 10 mg showed a 
clinically signicant improvement during a short-term follow up in another placebo-
controlled study in 90 men with PE and urinary tract symptoms without chronic prostatitis 
and benign prostatic hyperplasia (Basar et al., 2005). It should be pointed out that the 
methodology of both studies has been rather weak making their validity under question and 
calling for additional well-designed controlled studies. Despite these limitations, α-blockers 
use in the PE patient with concomitant lower urinary track symptoms may be of benefit 
(Basar et al., 2005). 
6.5.3 Tramadol 
Tramadol is a centrally acting synthetic on-demand analgesic that has been on the market 
for a number of years. It has two distinct mechanisms of action: it exerts an effect on the 
opioid receptor, but also inhibits noradrenaline and serotonin reuptake (Frink et al., 
1996). It is available in generic form in most countries and has been used in an on-demand 
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fashion (off-label and empirically) to treat PE. The exact mechanism by which it delays 
ejaculation is not well understood, however it is thought to be related to its action on the 
opioid receptor, which may reduce sensitivity, in addition to the inhibition of serotonin 
reuptake, which may delay ejaculation (Linton & Wylie, 2010). It has a short half-life and 
acceptable safety profile.  Since its is rapidly absorbed and eliminated, it makes it desirable 
for an as needed dosing regimen (Eradiri et al., 2006). 
Salem et al. conducted a single-blind, placebo-controlled, crossover, stopwatch monitored 
two-period study on 60 patients with lifelong PE utilizing 25 mg of tramadol (Salem et al., 
2008). The treatment group experienced a 6.3 fold increase in IELT compared to a 1.7 fold 
increase in the placebo group. Patients uniformly reported satisfaction with their resulting 
control over ejaculation. Mild side effects were reported in eight patients (13.3%), consisting 
of mild dyspepsia and somnolence. In another study, Safarinejad and Hosseini performed a 
double-blind, placebo-controlled, fixed-dose, randomized study to evaluate the efficacy and 
safety of tramadol (Safarinejad & Hosseini, 2006). They randomly assigned 64 potent men 
with PE to receive 50 mg tramadol or placebo and showed an increase in IELT from 19 
seconds to over 4 minutes in the tramadol arm. The most common adverse events were 
nausea (15.6%), vomiting (6.2%), and dizziness (6.2%), but they were reported to be mild. A 
large phase III trials is in progress in Europe and other trials are anticipated (Hellstrom, 
2011). Although tramadol is reported to have a decreased risk of dependence compared to 
traditional opioids, its use as an on-demand treatment for PE is still limited by the potential 
risk of addiction (Cossmann et al.,1997). In community settings, dependence does occur, 
albeit minimal (McDiarmid et al., 2005).  
6.5.4 Clomipramine 
Clomipramine is a tricyclic antidepressant used in the treatment of obsessive compulsive 
disorders. It inhibits the reuptake of noradrenaline and 5-HT by adrenergic and 5-HT 
neurones (Gur et al., 1999). In 1973, Eaton published his novel report on the efficacy of 
clomipramine to manage PE marking the beginning of a new era in the approach to treating 
this condition and several  subsequent publications have confirmed its effectiveness (Eaton, 
1973). It has been studied both as a daily dose and as an on-demand medication.  
On-demand use of 20 to 40 mg clomipramine can effectively delay ejaculation if taken 3 to 5 
hours prior to intercourse (Haensel et al., 1996; Segraves et al., 1993). Waldinger et al. 
showed a 4-fold increase in the IELT with on demand 25 mg of clomipramine (Waldinger et 
al., 2004a). The on demand dosing appears to be associated with high incidence of side 
effects with nausea being the most common, which is experienced on the day of sexual 
intercourse and the day after (Waldinger et al., 2004a). Rowland et al. indicated that patients 
with initial ejaculatory latencies over 60 seconds, self-reported sexual satisfaction of 5 or 
higher (on a seven-point scale) and ejaculation frequency of twice or more per week were 
more likely to benefit from on-demand 25 mg clomipramine therapy (Rowland et al., 2004). 
In the 1970s to the 1990s, various studies demonstrated clomipramine  efficacy in delaying 
ejaculation in daily rather low dosages of 10 to 30 mg (Assalian, 1988). For instance, in a 
randomized, placebo-controlled crossover trial in 36 men with PE, Kim an Seo were able to 
show that continuous dosing with clomipramine significantly lengthened the IELT 
compared with placebo ( P 0.01), as measured by stopwatch assessment (S. C. Kim & Seo, 
1998). In addition, a meta-analysis evaluating the systemic treatments for PE by Waldinger 
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fails, or whether the man with PE develops secondary ED due to anxiety regarding his PE is 
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et al found clomipramine to be efficacious, particularly continuous dosing (Waldinger et al., 
2004b). The results also showed it to be comparable to the commonly used selective 
serotonin re-uptake inhibitors (SSRIs) in its effects. Small studies showed that after daily 
treatment with clomipramine, men with PE reported improved relationship and emotional 
satisfaction, men and their partners reported increased sexual satisfaction, and the partners 
reported an increased ability to achieve coital orgasm (Althof et al., 1995). Rowland et al. 
examined the role of daily treatment with clomipramine in 4 men with PE when the as 
required regimen was ineffective (Rowland et al., 2001). They recommended a two-tiered 
approach, initially using a single dose of up to 25 mg, taken from 4 to 24 hours prior to 
intercourse. If on-demand treatment proved unsatisfactory, a daily, long-term dose of 10–30 
mg was instated. The study concluded that men with PE who do not respond to 
clomipramine 'as required' are probably not insensitive to pharmacological treatment, but 
may simply require higher doses or a different regimen. All four subjects improved when 
taking daily clomipramine at varying doses. 
Use of clomipramine in men with PE might be limited by its associated adverse events. 
Common side effects include dry mouth, fatigue, nausea, and dizziness (Haensel et al., 
1996). Although these side effects may abate over time, stopping the medication is also 
associated with a loss of efficacy (Althof et al., 1995). The study by Kim and Seo showed that 
on continuous dosing, the adverse event profile of clomipramine was found to be 
significantly worse than with SSRI treatment (S. C. Kim & Seo, 1998). Furthermore, 
Waldinger et al. reported that the use of an on-demand regimen to reduce exposure to 
clomipramine did not eliminate potentially annoying nonsexual side-effects, including 
sleepiness, yawning and nausea, which were significantly worse on the day of dosing and 
the subsequent day with clomipramine than with SSRI therapy (Waldinger et al., 2004a). 
Other possible side effects involved with the usage of clomipramine include an increased 
risk of suicide, especially when initiated in men under the age of 24 (U S Food and Drug 
Administration [FDA], 2007) and an adverse effect on sperm function when used at higher 
doses (75 mg for more than 3 months) (Maier & Koinig, 1994). It may impede both sperm 
motility and vasal/epididymal contractility by blocking calcium channel mechanisms 
(Mousavizadeh et al., 2002). This potential consequence of long-term, high dose usage 
should be kept in mind when choosing  PE therapy for men who may be contemplating 
fatherhood in the future (Sadeghi-Nejad & Watson, 2008).  
6.5.5 Selective serotonin reuptake inhibitors 
Although none of the selective serotonin reuptake inhibitors (SSRIs) are approved by 
regulatory bodies for the management of PE, their common “side effect” of delaying 
ejaculation in 30%–50% of otherwise healthy depressed patients has made them the 
preferred “off-label” treatment option for PE (Balon, 2006). Indicated primarily in the 
treatment of depression, SSRIs can increase the level of serotonin in the brain, inhibiting the 
ejaculatory reflex centre, and can prolong IELT for several minutes (Hellstrom, 2006). The 
extent of this delay varies widely depending upon the type, dose, and frequency of SSRI 
administration and the genetically determined ejaculatory threshold set point (Sadeghi-
Nejad & Watson, 2008). The effect of this class of medication is not restricted to PE patients 
since its use by otherwise healthy subjects can also significantly delay ejaculation (Wang et 
al., 2007). Dosing levels of SSRIs are generally lower for PE than for depression, and various 
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dosing regimens have been tested (including continuous, daily or situational). Indeed, this is 
the most common class of medications used to treat PE nowadays.  
Currently four SSRIs are commonly in use in the treatment of PE including fluoxetine, 
paroxetine, sertraline and citalopram. Paroxetine has been found to have substantially 
greater efficacy, increasing IELT approximately 8.8-fold above the baseline, followed by 
sertraline and fluoxetine (Waldinger et al., 2003, 2004). Among the SSRIs, fluvoxamine and 
venlafaxine have been shown to be ineffective (Kilic et al., 2005; Waldinger et al., 2002). 
Daily treatment with paroxetine 10–40 mg, sertraline 50–200 mg, uoxetine 20–40 mg, and 
citalopram 20–40 mg is usually effective in delaying ejaculation (Rowland et al., 2010). The 
desired ejaculation delay usually occurs within 5–10 days of starting treatment, however the 
full therapeutic effect may require 2–3 weeks of treatment and is usually sustained during 
long-term use (McMahon, 2002). The first publication about the delaying effect of paroxetine 
was published in 1994 and since then multiple placebo-controlled randomized studies have 
confirmed the effectiveness of each of the aforementioned SSRIs in treating PE (Biri et al., 
1998; Gurkan et al., 2008; Kara et al., 1996; S. C. Kim & Seo, 1998; Waldinger et al., 1998). The 
argument for daily dosing comes from the fact that the pharmacokinetic profile of 
conventional antidepressants should be optimized for the treatment of depression which 
requires their continuous presence in the bloodstream to achieve the maximum effect 
(Althof, 2006b). Side effects are usually minor, starting in the first week after intake and 
gradually disappearing within 2–3 weeks of starting the course of treatment which include 
fatigue, yawning, mild nausea, loose stools and perspiration (McMahon, 2005). Diminished 
libido and mild erectile dysfunction are reported infrequently (Waldinger, 2007), especially 
in the absence of concomitant depression (Montejo et al., 2001). Rare side effects that have 
been reported include bleeding (Halperin & Reber, 2007), weight gain related type II 
diabetes mellitus (Raeder et al., 2006), bone mineral density loss with prolonged treatment 
(Haney et al., 2007), and priapism (Dent et al., 2002), however, these events were reported in 
patients suffering from depression. The use of SSRIs, especially in young depressed patients, 
is reported to increase impulsive actions and suicide Rate (Cohen, 2007). There is also the 
potential for the development of a serious drug interaction that can lead to ‘serotoninergic 
syndrome’ which manifests as headache, nausea, sweating and dizziness in mild cases, and 
in hyperthermia, rigidity and delirium in severe cases (Sharlip, 2006). Symptoms can occur 
following abrupt cessation or reduction of SSRI therapy beginbeginning from 24 to 72 hours 
after discontinuance and may last more than a week (Linton & Wylie, 2010). This is thought 
to be more prevalent with the SSRIs that have shorter half lives (Hellstrom, 2009). Based on 
this, it is generally recommended that SSRIs should not be stopped suddenly but reduced 
over several weeks (Sadeghi-Nejad & Watson, 2008). Several physicians may consider the 
reported side effects hard to ‘justify’ for the treatment of PE, in which the primary outcome 
is patient satisfaction. However, the AUA has suggested that the level of side effects is 
acceptable for the benefit derived in the patient with PE, and the type and rate of occurrence 
of these effects also appears to be acceptable to most patients (Montague et al., 2004). 
The side effect profile of the SSRIs taken on a chronic daily basis has led to the suggestion 
that an “on demand” SSRI may be useful for PE. This is supported by the fact that men may 
be reluctant to receive an antidepressant to treat a condition other than depression and use it 
chronically, having known that sexual activity does not generally occur on a daily basis 
(Althof, 2006b). On-demand administration of paroxetine, sertraline, and uoxetine 4–6 
hours before intercourse is modestly efcacious and well tolerated but is associated with 
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substantially less ejaculatory delay than daily treatment (S. W. Kim & Paick, 1999; McMahon 
& Touma, 1999; M. D. Waldinger et al., 2004a). McMahon and Touma performed a 
comparison of 20 mg paroxetine PRN 3 to 4 hours prior to intercourse vs 20 mg paroxetine 
daily for 4 weeks, followed by PRN paroxetine in those who responded to daily paroxetine 
(McMahon & Touma, 1999). The authors showed that the schedule of daily dosing followed 
by PRN dosing was significantly superior to the PRN only schedule. However, sexual side 
effects were observed in the daily paroxetine group and the initial benefits that they 
experienced were not sustained with time in men with primary PE (11 of 16 failures).  In the 
PRN only group 15 of 19 men with primary PE failed to respond. Publications focusing on 
on-demand use of SSRIs for PE continue to be limited and the data available is difficult to 
compare as it is heterogeneous in terms of medications used, study design and outcome 
reporting. Paroxetine appears to be the most effective medication again (Gurkan et al., 2008).  
Dapoxetine is the first compound specifically developed for the treatment of PE. It is a novel 
fast-acting SSRI that exerts its effects through the inhibition of the serotonin reuptake 
transporter (Hellstrom, 2009). Because of its short acting property,  it probably better suited as 
an “on-demand” treatment for PE. In fact, it has received regulatory approval as an on-
demand treatment for PE in several parts of the world (McMahon et al., 2010). In contrast to 
conventional SSRIs, maximum plasma concentrations are achieved 1.01 h after a 30-mg oral 
dose, initial half-life is 1.42 h and 24 h after administration, plasma concentrations decrease to 
less than 5% of peak levels (Dresser et al., 2006). Pryor et al. published an integrated analysis of 
two double-blind, randomised controlled trials to determine the efficacy and tolerability of 
dapoxetine in the treatment of PE (Pryor et al., 2006). Men with moderate-to-severe premature 
ejaculation took placebo (n=870), 30 mg dapoxetine (874), or 60 mg dapoxetine (870) on-
demand (as needed, 1-3 h before anticipated sexual activity). The primary endpoint was IELT 
measured by stopwatch. At the completion of the study, 672, 676, and 610 patients completed 
in the placebo, 30 mg dapoxetine, and 60 mg dapoxetine groups, respectively. Dapoxetine 
significantly prolonged IELT (p<0.0001, all doses vs placebo). Mean IELT at baseline was 0.90 
minute, 0.92 minute, and 0.91 minute, and at study endpoint (week 12 or final visit) was 1.75 
(2.21) minutes for placebo, 2.78 (3.48) minutes for 30 mg dapoxetine, and 3.32 (3.68) minutes 
for 60 mg dapoxetine. Both dapoxetine doses were effective on the first dose. Common 
adverse events (30 mg and 60 mg dapoxetine, respectively) were nausea (8.7%, 20.1%), 
diarrhoea (3.9%, 6.8%), headache (5.9%, 6.8%), and dizziness (3.0%, 6.2%). More recently, 
Buvat et al. published results from phase III trial from 22 countries, evaluating dapoxetine 30 
mg and 60 mg versus placebo (Buvat et al., 2009). The trial showed that IELT was significantly 
increased with dapoxetine. At the end of 24 weeks the IELT had increased from 0.9 minutes to 
1.9 minutes, 3.1 minutes, 3.5 minutes with placebo, dapoxetine 30 mg and 60 mg. All patients 
reported outcome measures were significantly improved with dapoxetine versus placebo. The 
drug was submitted for FDA approval in 2004, however in October 2005, the company 
developing the drug received a “not approvable” letter from the FDA ("Dapoxetine: LY 
210448," 2005; Press release, 2005).The questions raised by the FDA letter were not disclosed, 
however dapoxetine’s developer mentioned that it plans to address the questions and 
continue the drug’s global development program (Press release, 2005).  
6.6 Combination therapy 
While the choice of PE treatment is essentially between behavioural and pharmacological 
approaches, physicians should recognize that combination treatment is an option,  
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especially for patients with severe PE or those refractory to mono-therapy. In a study by 
Atan et al., oral fluoxetine 20 mg/day, when reinforced by the topical application of 
lidocaine ointment, showed a “cure” or an improvement in 83.3% of men with PE, 
compared with 72% of those treated with uoxetine alone (given as 20 mg/day then 
increased to 40 mg/day) (Atan et al., 2000). Chen et al. examined the efficacy of sildenafil as 
adjuvant therapy to paroxetine in alleviating PE (Chen et al., 2003). They found that 
sildenal combined with paroxetine was effective in 97% of patients, compared to an 
improvement for only 47% using paroxetine alone. In addition, the best results obtained in 
this study were observed when sildenal was combined with SSRIs as well as implementing 
behavioral counseling. In another study, Salonia et al. have shown in a prospective open-
label study that paroxetine combined with sildenafil provided significantly better results in 
terms of ejaculatory latency time and intercourse satisfaction versus paroxetine alone in 
potent patients with PE, albeit with a mild increase in drug related side effects (Salonia et al., 
2002). Perelman and Althof independently described combination therapy as a “concurrent 
or stepwise integration of psychological and medical interventions”(Althof, 2006a; 
Perelman, 2006). Patients with severe PE need more than pharmacotherapy to overcome 
obstacles to effective sexual activity and require targeted psychoeducational interventions 
termed “coaching” (S. Althof, 2006a). Steggall et al. speculated that a combination approach 
may offer both an improvement in ejaculatory delay, but also facilitate engagement with 
behavioural therapies (Steggall et al., 2008). In a small-scale study, the authors randomised 
participants with PE either to paroxetine 20 mg daily or to a lidocaine-based spray 
(Premjact) for 2 months followed immediately by a standardized behavioral therapy 
programme for a further 2 months. Of the 60 men who consented to participate in this trial, 
44 completed the pharmacologic phase and 22 completed both phases of the program. It was 
found that both paroxetine and premjact Spray provided a statistically significant delay in 
ejaculation (as measured by stopwatch); which was partially maintained during the 
behavioral program. However, the improvement induced by medications could only be 
continued through sex therapy in those men reporting acquired PE; the men with lifelong 
PE returned to baseline. It was concluded that for acquired PE, combination therapy may 
offer advantages through an initial stabilizing effect on the couple with subsequent 
increased acceptance of and adherence to behavioral therapy. There is growing evidence 
that combination therapy using new pharmaceuticals and psychotherapy will become the 
treatment of choice (Perelman, 2006). 
6.7 Emerging and experimental treatment options for PE 
It has been demonstrated that desensitisation of the 5-HT 1A receptor during chronic 
administration of SSRIs [e.g., combination of robalzotan (NAD-299) with fluoxetine and 
citalopram (Williamson et al., 2003) and combination of WAY-100635 with citalopram (de 
Jong et al., 2005) and paroxetine (Looney et al., 2005) induces prolonged delay in ejaculation 
in the rat. However, when used alone they had no effect on ejaculation. Although this novel 
pharmacological combination is promising, further clinical research is warranted to evaluate 
the efficacy and potential adverse effects of this combination. A new avenue being explored  
in the pharmacological treatment of PE is the use of oxytocin compounds as potential 
therapeutic agents (Giuliano, 2007), based on immunohistochemical studies that have 
demonstrated local synthesis of oxytocin and its synthesis-associated protein, neurophysin I, 
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in the epithelial cells of the epididymis (Filippi et al., 2005). Dietary deciencies, such as low 
magnesium intake, may prove to play a limited role as well (Aloosh et al., 2006). Although 
its role in the management of ED is well established, the use of vasoactive intracavernosal 
injection (ICI) pharmacotherapy for the treatment of PE is not supported by a large body of 
peer-reviewed literature, and is not commonly used in clinical practice. ICI has been used as 
a strategy in certain cases to allow men with PE to maintain their erections and continue 
satisfactory sexual intercourse despite rapid ejaculation (Fein, 1990).  
Non-pharmacological approaches are also being explored. Optale et al. showed that 
immersive virtual reality can speed up the therapeutic psychodynamic process, wherein the 
patient wears a helmet with miniature television screen and earphones to discuss and 
summarize his thoughts (Optale et al., 2004). Wise and Watson suggested a novel device based 
on the penile hypersensitivity hypothesis (Jan Wise & Watson, 2000). This experimental device 
is a “desensitizing band” which, when worn during masturbation, does not constrict blood 
flow and helps the PE sufferer gain control over ejaculation. Unfortunately, the device is  
hardly available for patient use for economic reasons of viability of sales (Linton & Wylie, 
2010). Basal et al. described the application of pulsed radio frequency neuromodulation to treat 
PE by the desensitization of the dorsal penile nerves (Basal et al., 2010). This was a small pilot 
study consisting of 15 patients and showed a significant increase in the IELT compared to 
baseline. After the procedure, there were no reported problems with pain, penile hypoesthesia, 
or ED. Nevertheless, sham-controlled studies with larger numbers of patients are needed. 
Recently, Sunay et al. performed a randomized, placebo-controlled trial to determine if 
acupuncture is an effective measure to manage PE (Sunay et al., 2011). Ninety PE patients were 
randomly assigned into paroxetine 20mg/day, acupuncture or sham-acupuncture (placebo) 
which was treated twice a week for 4 weeks. The acupuncture points were selected and 
performed by an experienced acupuncturist according to the publication World Health 
Organization Standard Acupuncture Point Locations in the Western Pacic Region. Significant 
differences were found between IELTs of the paroxetine and placebo groups (p=0.001) and the 
acupuncture and placebo groups (p=0.001) after treatment. Increases of IELTs with paroxetine, 
acupuncture, and placebo acupuncture were 82.7, 65.7, and 33.1 , respectively. The study is  
criticized for obvious lack of follow up. 
Some authors have reported the use of surgically induced penile hypoanesthesia as a mean 
to manage PE. A surgical approach consisting of a dorsal neurectomy with or without 
glandular augmentation using hyaluronic acid gel has been reported (J.J. Kim et al., 2004). 
Although there are reported positive results with significantly increased IELT, the two 
groups that underwent dorsal neurectomy or dorsal neurectomy and glandular 
augmentation, both had significant side effects, including penile numbness, paresthesia and 
pain. The group that underwent hyaluronic acid augmentation alone reported no adverse 
side effects. Five years study on the glans augmentation arm of the trial and the hyaluronic 
acid implants were well maintained, showing long-term efficacy (Kwak et al., 2008). The 
role of surgery in the management of PE remains unclear, and thus further trials are needed 
before its role can be established. 
6.8 Treatment recommendation 
Since the frequency of sexual intercourse is very variable, and spontaneity in sexual 
intercourse is usually an important factor, an ideal drug for treating PE would be a discrete 
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and ‘on-demand’ therapy with a predictable therapeutic effect within a few minutes of 
administration so that it could be taken once sexual foreplay has commenced (Riley & 
Segraves, 2006). It should have a low incidence of side-effects and have no unwanted effects 
on the partner (Hellstrom, 2006). Unfortunately, such drug is not currently available. In 
addition, no drug exists yet that was able to obtain FDA approval as specific treatment for 
PE. Until such a day is seen, the off-label application of different pharmacotherapy 
continues to be practiced.  
Based on the above mentioned limitations, several authorities have attempted to produce 
guidelines and algorithms on the management of PE. These guidelines include but are not 
limited to those published by the American Urological Association (AUA) (Montague et al., 
2004), the European Association for Urology (EAU) (Colpi et al., 2004) and the International 
Consultation on Sexual Dysfunctions (ICSD) (McMahon et al., 2004). These guidelines share 
common directions and similarities. For example, in terms of treatment modalities, the AUA 
committee suggested that although oral antidepressants and topical anaesthetic agents are 
not approved by the FDA for PE, they have been shown to delay ejaculation in men with PE 
and have a low side effect profile when used at the lower doses commonly used for the 
treatment of PE (Montague et al., 2004). The commonly used agents in the management of 
PE as published by the AUA guidelines are shown in Table 5. Additionally, it was suggested 
that medication could be used to restore confidence together with behavioral treatment, 
where available, to help men learn to overcome PE on their own (Althof, 2006b; Perelman, 
2006). This strategy has become an important part of many of the currently published 
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7. Concluding message 
PE is one of the most common male sexual disorders that can have a significant impact on 
the quality of life of couples. It is a complex disease process that requires clear definition to 
facilitate research and treatment. It remains substantially under-diagnosed and under-
treated, since it is not very well understood by healthcare providers. It is a self reported 
disorder and one in which the diagnosis is mainly based on history. A sexual history should 
include all three aspects of PE, namely short IELT, lack of control and distress for both 
partners. Among the many neurotransmitter systems involved in ejaculatory modulation, 
central 5-HT has been implicated as a key mediator of ejaculatory control and thus a 
therapeutic target. Both behavioral and pharmacological options are available to manage PE. 
Behavioral techniques and psychotherapy can be cumbersome and expensive, with limited 
long-term efficacy, and therefore are used to complement pharmacotherapy. Currently 
available pharmaceutical therapy involves the off-label use of SSRIs, Clomipramine, 
tramadol,  PDE-5 inhibitors, as well as topical anaesthetics, each of which have shown 
varying degrees of efficacy and tolerability. These pharmacotherapies are far from ideal. 
Their clinical utility is limited by several factors, including a high incidence of adverse 
events. Each treatment option should be discussed with the PE patient including dosing, the 
anticipated success rate and possible side effects such that the patient participates in the 
decision making. Therapy should be tailored for each patient as one treatment does not fit 
all, as well as preference varies between men. Therapy for PE will continue to develop as the 
understanding of ejaculation expands and current agents in development may eventually 
come closer to an ideal and specific therapy for PE.  
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1. Introduction 
In the U.S. there are over 300,000 people who suffer from spinal cord injuries. This incident 
increases every year by 10,000 to 12,000 new patients (Harrop et al., 2006). In Canada, about 
36,000 people live with spinal cord injuries, while 55% of them, are people in the 
reproductive phase of their life, aged 16-30 years, and the ratio of men to women is 
calculated to 4 /1(Mittmann et al., 2005). For several years there was a myth in societies that 
people with paraplegia or quadriplegia have no sexuality, do not have erectile function and 
that they are infertile. In fact, sexual expression is a component of personality and it is 
independent to the erectile function or fertility status. In handicaps lack of sexual interest is 
associated with social withdrawal and inability to recover while sexual alertness is 
associated with faster and better recovery. The degree of sexual rehabilitation is directly 
related to physical rehabilitation, social integration and quality of life (Biering-Sorensen & 
Sonksen, 2001; Fisher et al., 2002). Last years the medical community emphasizes on quality 
of life and sexuality of people with spinal cord injuries. It is shown that the 66% of patients 
with spinal cord injuries consider their erection sufficient for sexual activity. The incidence 
of injury on the person's sexual function depends on the location and the extent of the 
damage. After Spinal Cord Lesions (SCL), both men and women are reporting decreased 
desire and low frequency of sexual activity (Deforge et al., 2006).  
2. Pathophysiology of Erectile Dysfunction (ED) after SCL 
Erection is a neurovascular phenomenon which takes place under neuro-hormonal control. 
Sensory data from the eyes and skin are relayed to certain areas within the hypothalamus 
where appropriate signals are relayed to the penis. The upper centers which regulate the 
erectile function in the brain are located at the cortex and the hypothalamus, as mentioned 
above. The main involved nuclei are: paraventicular nucleus, medial preoptic area, 
paragigantocellular nucleus, and locus coeruleus. The lower centers are located in the spinal 
cord. These centers are two: the psychogenic, sympathetic erection center which is located at 
the Th11-12 until L2-3 level of spinal cord and the reflexogenic, parasympathetic erection 
center which is located at the S2-4 level of spinal cord. The sympathetic erection center is 
purely autonomous, contains fibers with evoked and others with inhibitory action and 
travels with the inferior hypogastric plexus. The parasympathetic erection center contains 
also somatic fibers. The afferent fibers are coming from the pudendal nerve and the dorsal 
penile nerve, while the efferent fibers involve in the formation of the cavernous nerves and 
the inferior hypogastric and sacral plexus. Sympathetic innervation provides inhibitory 
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pathways whereas parasympathetic and somatic innervations are crucial for erection. The 
two centers of the spinal cord are under the control of the brain (Saenz de Tejada et al., 
2005). 
Erection can be distinguished to reflective and psychogenic according to the origin of its 
induction and the erection center which is mainly involved. Reflective erection is the 
outcome of somatoaesthetic stimulation and may be independent of sexual arousal. This 
erection takes place through the reflexogenic, parasympathetic erection center. Psychogenic 
erection, which predominates in humans, is the result of sexual desire caused by images, 
fantasies and thoughts related to previous sexual experiences. The psychogenic, sympathetic 
erection center is mainly responsible for this kind of erection. The erectile function in 
patients with SCL depends on the location of the injury and the extent of the lesion. In 
patients with upper cord lesions, reflexogenic erections are preserved in 95% of them, while 
in patients with complete lower cord damages this rate is only 25%. The quality of erection 
is better as higher the lesion is located (Eardley & Kirby, 1991). Derry et al., in their study are 
reporting that 25% of men with SCL regain their erectile function one month after injury, 
when 60% and 80% regain their erections in a period of six months and one year 
respectively after injury (Derry et al., 2002). The preservation of the sacral parasympathetic 
neurons leads to the maintenance of reflexogenic erection. In case of sacral injury 
thoracolumbar pathway may take over through synaptic connections. In general, men with 
cervical and thoracic lesions regain their erections sooner and better than men with lumbar 
lesions (Courtois et al., 1993). 
Reflexive erections, which require the integrity of parasympathetic erectile center (S2-4), 
have been observed in people with SCL. These arise after irritation of the skin or mucosa 
below the level of the lesion. Manipulations such as rubbing of the thighs or nipples, 
squeezing of the glans, suprapubic percussion, irritation of the anal region, proved to be 
more effective than masturbation or any other stimulation of the genitalia (Saenz de Tejada 
et al., 2005; Derry et al., 2002). Lesions higher to Th11 level are combined with erection of 
both corpora cavernosum and corpus spongiosum, while lesions below this level exclude 
the participation in the erection of the corpus spongiosum (Biering-Sorensen & Sonksen, 
2001). This erection is usually sufficient for penetration, but it has short duration. The 
reflexive erections maintain in 95% of patients with total damage over the sacral center, 
while in lower level lesions this percentage is up to 25%. The training for the challenge of 
this reflex is part of the sexual rehabilitation. 
Psychogenic erections have been observed in 60% of patients with intact sympathetic 
erectile center (Th11-L2) and lesion below the L2 level. Psychogenic erections, as mentioned 
above, are independent from direct physical stimulation and are the result of visual or 
acoustic stimuli, dreams, fantasies or memories. These erections are usually with low quality 
and short duration. Objectively, it is more of a swelling of the penis rather than a hard 
erection, rarely allowing penetration (Derry et al., 2002; Courtois et al., 1999; Smith & 
Bodner, 1993; Chapelle et al., 1980). 
Mixed erection occurs when the SCL is between the two centers. These erections onset after 
a psychic stimulus and maintain or even are enhanced by a physical stimulus, or they are 
prolonged reflecting erections which are enhanced by a strong sexual desire. 
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Nocturnal erections have been also recorded in men with SCL. These erections usually take 
place during the REM phase of the sleep. The comparison between the erections of 
quadriplegic and paraplegic patients showed that quadriplegic men had better erections 
(regarding hardness and duration) than paraplegic patients. Additionally, thoracic spinal 
lesion was associated with poor nocturnal erections comparing with cervical spinal injuries 
(Suh et al., 2003). 
Patients with lesions above the Th6 level often present the phenomenon of autonomous 
dysreflexia, which involves reflecting increased sympathetic tone at the level below the 
lesion. This increased sympathetic response causes vasoconstriction and hypertension. At 
the levels higher to the spinal lesion, vasodilatation takes place and causes flashing and 
headache. The more serious symptom is the parasympathetic activation which decreases the 
heart rate. This situation with excessive hypertension and bradycardia is dangerous for the 
patient and it was found that sexual arousal may trigger dysreflexia. In these cases sexual 
activity must be avoided (Rossier et al., 1971; Frankel & Mathias, 1980). 
3. Diagnostic approach to patients with SCL 
3.1 Sexual history 
Sexual history is the first step in the evaluation of patients with ED. Our purpose is to assess 
the pre-injury and the post-traumatic sexual function and to identify the ED. The absence or 
presence of erections, under what circumstances they took place, the number and the 
frequency of them, the quality of erections (regarding hardness and duration) compared 
with the erectile function before injury and the frequency of sexual intercourse, are some of 
the questions which have to be answered. Additionally, a good history will assess the 
mental and psychological status of individuals whereas ED with psychogenic origin 
described in 10% of men with SCL (Monga et al., 1999; Tay et al., 1996). 
3.2 Physical examination and laboratory tests 
Physical examination reveals clinical signs which contribute to the diagnostic approach of 
ED. During the examination of the external genitalia, neurological examination should also 
be included. Our aim is to identify the level of lesion, according the sacral and the thoracic-
lumbar origin of the neurosis of external genital organs. Assess of the sensation of the 
genitalia, the perineum and the perianal region as well, is essential for the evaluation of 
parasympathetic erectile center, as the somatic-sensation of these areas reflects to the S2-4 
level of the spinal cord. By evaluating the reflex of the cremaster muscle, we can assess the 
S1-2 reflex arc. By evaluating the reflexes of rectus muscles, we can assess the Th9-12 reflex 
arcs and the bulbocavernous reflex is suitable to investigate the integrity of S2-4 reflex arc 
(Vodusek, 2003). Additionally, tendon reflexes of the lower limbs can evaluate the lumbar 
region of spinal cord. 
Apart from control of reflexes, the use of specific neurological tests has been reported in the 
literature. The measurement of latency time of the bulbocavernous reflex by placing 
electrodes on the penis and the bulbocavernosal muscles and the measurement of 
somatosensory cortical evoked potentials by placing electrodes on the scalp, may give an 
accurate assessment of the nervous lesions (Bird & Hanno, 1998). 
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3.3 Nocturnal Penile Tumescence and Rigidity (NPTR) 
The recording of nocturnal erections in normal subjects is a method for the differential 
diagnosis of psychogenic from organic erectile dysfunction. The recording of these erections, 
usually during REM phases of sleep, is made by the Rigiscan (Fig. 1). Rigiscan uses two 
inflatable rings which are adapted at the base and at the tip of the penile shaft. These rings  
work as sensors for the increase in the diameter (tumescence) and the hardness during 
erection. The duration and the quality of these erections represent the erectile capacity of the 
patient. The findings must be confirmed for at least two nights. 
 
Fig. 1. Rigiscan device uses two inflatable rings which act as transducers in order to study 
the tumescence and the rigidity during erectile episodes. 
Rigiscan studies have shown that the onset of erection does not appear to require intact 
pathways from the brain towards the spinal cord, while nocturnal erections were observed 
in men with complete SCL (Suh et al., 2003). Rigiscan studies showed that men with SCL do 
suffer from psychogenic ED at a rate of up to 10% (Tay  et al,. 1996). 
3.4 Dynamic Doppler Ultrasound Evaluation 
Dynamic Color Doppler ultrasound tomography is a method which can evaluate the 
vascular potential of the corpora cavernosa and can assess the hemodynamic of the penis. 
After the administration of vasoactive drugs (intracavernousal injection of alprostadil 10μg), 
blood flow is studied by measuring the peak-systolic and the end-diastolic velocity (Fig.2). 
According to these findings, vascular etiology (low arterial inflow or venous escape 
syndrome), of erectile dysfunction can be identified. 
In cases of neurogenic ED, ultrasound findings are usually normal, as the majority of these 
patients, is young with no vascular pathology. If a reduced blood supply of the cavernous 
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artery is present, probably this occurs due to concomitant vascular inefficiency (Kim et al., 
2006). Normal reply to vasoactive drugs is described in 80% of patients with SCL, while 
there are some other studies which record high rates of vascular lesions in these patients 
(Robinson et al., 1987). 
 
Fig. 2. Color Doppler ultrasound, 10 minutes after intracavernousal injection of 10 μg 
alprostadil. Due to high End-Diastolic Velocity (EDV) this is an image of venous escape 
syndrome. 
4. ED treatment in men with SCL 
The treatment of ED in paraplegic or quadriplegic patients follows the therapeutic strategy 
of any other case of organic ED. According to that, we can apply stepped treatment of 1st, 2nd 
and 3rd line. The 1st line of treatment includes oral inhibitors of phosphodiesterase type 5 
(PDE-5) and vacuum devices. In the 2nd line of treatment there are penile injections and 
transurethral application of vasoactive substances. Finally, in the 3rd line of treatment option 
there is the implantation of penile prosthesis (Ramos & Samso, 2004). Patients should be 
informed about all the treatment options from the beginning of the therapy, although the 
treatment is applied step by step. This is very important for neurogenic patients in order to 
be optimistic for the outcome of the treatment. General considerations regarding blood 
pressure, lipid profile, hormonal status, diabetes mellitus and stop smoking are necessary to 
all patients with ED. On the other hand, most of the patients with SCL are young men with 
excellent sexual function before injury and the etiology of their ED is mostly neurogenic. In 
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these patients psychogenic component is present sometimes and other organic causes, 
vascular inefficiency for example, occur rarely. 
4.1 First line treatment 
4.1.1 Oral treatment 
Since sildenafil gained the approval of use, it has proved its efficiency against ED, of any 
organic reason. The efficacy and its safety have been demonstrated in studies in patients 
with SCL. In bibliography there are two relevant, randomized, prospective, multicenter 
placebo controlled studies. Giuliano et al. studied 178 patients with SCL and indicated 76% 
efficacy of sildenafil compared with 4% of placebo (Giuliano et al., 1999). In another similar 
study by Maytom et al. (with only 27 patients) it was referred efficacy in sildenafil 65% vs. 
8% in placebo (Maytom et al., 1999). In the same study the overall satisfaction with their 
sexual activity reported in 75% in the sildenafil group compared with 7% in the placebo 
group. In a meta-analysis of eight other studies it was indicated the overall effectiveness of 
sildenafil in 80% of these patients (Deforge et al., 2006). Derry et al. reviewing the literature 
indicates that the proportion of patients with SCL showing improvement in their erectile 
function reaches 94%. The majority of them (72%) indicate successful sexual intercourse, as 
well. Response rates were generally higher in patients with partial section of the spinal cord 
(incomplete lesions). However, a significant proportion of patients with complete cross-
section, regardless of the location of the lesion, benefited from the administration of 
sildenafil (Derry et al., 2002; Sanchez Ramos et al., 2001). The existing literature, thus, 
demonstrates high efficacy and safety of oral treatment with sildenafil in patients with ED 
after SCL. 
There are at least two studies in the literature supporting the efficacy of vardenafil in the 
treatment of ED for patients with SCL. Giuliano et al. in a multicenter, double-blind and 
placebo controlled study, with duration of 12 weeks, which included 418 patients, reported 
erections, sufficient for penetration in 76% of patients in the vardenafil group, compared 
with 41% of patients in the placebo treatment group (Giuliano et al., 2006). In the same 
study, 59% of the vardenafil group indicated satisfactory duration of erection, compared to 
22% of the placebo group. Another open label study, without control, dealing with 
vardenafil administration in SCL patients, based on 38 patients, indicated achievement of 
erection, efficient for penetration in 83% of patients and duration of erection satisfactory for 
88% of those (Kimoto et al., 2006). 
Regarding tadalafil, there is a comparative study by Del Popolo et al. between sildenafil and 
tadalafil in patients with ED and SCL (Del Popolo et al., 2004). This was a randomized, 
blind; cross-over study with 15 patients in each arm and duration of 12 weeks. The study 
indicated that tadalafil allowed to the majority of patients to achieve a satisfactory erection 
for up to 24 hours after the administration of the drug, but this was due to pharmacokinetic 
of tadalafil. Additionally, an improvement of sexual satisfaction of both patients and their 
sexual partners has been recorded in both groups (sildenafil and tadalafil). In another 
multicenter, randomized, placebo-controlled study by Giuliano et al. was reported statistical 
significant improvement, to the tadalafil group, at the erectile function domain of the IIFF 
questionnaire and at the questions 2 and 3 of the Sexual Encounter Profile (SEP) which 
 
Erectile Dysfunction in Paraplegic Males 
 
133 
regards the achievement of sufficient erection and satisfactory intercourse (Giuliano et al., 
2007). These findings were confirmed by another study by Lombardi et al., that reported 
improvement at the IIFF score and at the ability to achieve an efficient erection (SEP 2) and a 
satisfactory intercourse (SEP 3), in patients with SCL after the appropriate dose of tadalafil 
(Lombardi et al., 2008). 
There is a comparative study of all PDE-5 inhibitors in patients with SCL which was 
published in 2007 (Soler et al., 2007). The study consisted of three groups of patients, 
according the PDE-5 inhibitor which was used. In the group of sildenafil there were 120 
patients, in the group of vardenafil there were 66 patients and in the group of tadalafil there 
were 54 patients. Initially all patients received the lower dose of each drug and there was 
dose up regulation until the efficacy was sufficient. The overall efficacy was similar for all 
the drugs (85% for sildenafil, 74% for vardenafil and 72% for tadalafil). The duration of 
erections was also similar for all (26 - 34 minutes).  The higher dose of the drug required in 
45% in the group of sildenafil, compared with over 70% of the patients in the other two 
groups. In another meta-analysis of 18 studies, regarding PDE-5 inhibitors in men with SCL 
was reported statistical significant improvement of erectile function compared to placebo in 
11 studies (Lombardi et al., 2009). The overall amount of patients was 705 in sildenafil, 305 
in vardenafil and 224 in tadalafil. Only 15 patients stopped treatment due to adverse events. 
This meta-analysis came to the conclusion that the relatively small amount of patients and 
the different methodology of the studies do not allow reliable comparisons between the 
drugs. On the other hand, there is enough data in the literature supporting that PDE-5 
inhibitors are safe and effective treatment option for the ED of men with SCL. 
4.1.2 Vacuum devise 
The use of vacuum device is an alternative treatment option for the ED of people with SCL, 
with satisfactory efficacy (Zasler & Katz, 1989; Heller et al., 1992). The vacuum device is a 
cylinder with an open edge. The penis is placed through the open edge inside the device 
and by pumping; vacuum is created inside the cylinder. The negative pressure forces the 
blood to fill the corpora cavernousa, causing erection. After erection a ring which is placed 
tight around the base of the penis is necessary for the maintenance of the erection (Fig. 3). 
Efficacy and complications of these devices were studied in 20 patients and their partners 
(Denil et al., 1996). After 3 months of use, 93% of men and 83% of women reported erections 
sufficient for vaginal penetration which lasted for about 18 minutes. After 6 months, 
however, only 41% of men and 45% of women were satisfied with the use of vacuum device. 
The most unpleasant fact was the early loss of the rigidity of the erection. Overall, 60% of 
men and 42% of women reported improvement in their sexual lives by using the vacuum 
device. Finally, adverse effects such as bruising or swelling and even gangrene of the penis 
have been recorded (Rivas & Chancellor, 1994). The higher complication rate of vacuum 
device in men with SCL has to do with the absence of sensation in the area, so a very tight 
ring remaining for a long time can cause tissue ischemia and necrosis without any pain or 
disturbance. The appropriate advice for the people using the device is to be careful with the 
overall use and to avoid the very high negative pressure and the long-lasting strangle of the 
penile shaft. 
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Fig. 3. The vacuum device is a cylinder with an open edge. The penis is placed through the 
open edge inside the device and by pumping; vacuum is created inside the cylinder. 
4.2 Second line treatment 
4.2.1 Intracavernousal injections of vasoactive substances 
Men with ED after SCL respond very well to intracavernousal injections of vasoactive 
substances (Hirsch et al., 1994; Deforge et al 2006). This happens, because most of these 
people are young, with small likelihood of an additional vascular disease. The technique is 
simple and relatively painless. The high effectiveness of the injections in combination with 
the absence of sensation at the penis makes this choice friendlier to paraplegics. The 
injection takes place between the 1st and 3rd or between the 9th and 11th hours of the penile 
shaft (Fig. 4). A gentle massage of the area helps the drug to be absorbed. The erection 
begins five to ten minutes later and it is independent from any sexual arousal. 
Most studies report high rates, which reach 95% response to vaso-active substances such as 
papaverine and alprostadil (Lebib Ben Achour et al., 2001; Dietzen & Lloyd, 1992). Side 
effects and complications described in the literature are: priapism, skin bruises and 
cavernosal fibrosis. Papaverine is responsible for higher rates of priapism and fibrosis than 
alprostadil. Patients with SCL develop priapism more often, maybe due to excessive release   
 







Fig. 4. The injection takes place between the 1st and 3rd or between the 9th and 11th hours of 
the penile shaft, after penile stretching. 
of neurotransmitters which promote erection or due to sympathetic hypertonia. For these 
reasons in the beginning of the treatment lower doses of vasoactive drugs are used and the 
dose is entitled for each patient. In a meta-analysis of other studies, there was an overall rate 
of men with satisfactory erections reaching the 90% of the users of intracavernousal 
injections (DeForge et al., 2006). In another study there was a comparison between the use of 
vacuum device and the administration of injections of papaverine (Chancellor et al., 1994). 
Eighteen men with SCL participated in this study, which was cross-over designed. After 
both treatment options, half of the patients chose injections and half of them chose vacuum 
device. 
4.2.2 Urethral administration of vasoactive substances 
The communication between the corpora cavernosa and the corpus spongiosum was the 
base for the intra-urethral application of vasoactive drugs. Alprostadil (PGE1) has been used 
for this purpose. The way of action is the same to intracavernousal injections, without 
needles and punctures. There is an applicator which places the drug into the urethra (Fig. 5). 
The overall efficacy rate is reported at 65.9% of 995 men with ED (Padma-Nathan et al., 
1997). 
In patients with SCL the outcome was not as satisfactory as using intracavernousal 
injections (Bodner et al., 1999). Regarding adverse events, systemic absorption of alprostadil 
was responsible for hypotensive episodes. The use of a tight ring at the base of the penis is 
essential in order to avoid this rapid absorption and to maintain the achieved erection. 
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Fig. 5. For the intra-urethral placement of alprostadil a specific applicator is used. 
4.3 Third line treatment 
The implantation of penile prosthesis is the 3rd line treatment and represents the surgical 
option for the management of ED. The prosthesis can be malleable or hydraulic. Hydraulic 
one may consist of two or three pieces (Fig. 6). The application of penile prosthesis in men 
with SCL accompanied with a high rate of complications, as it was indicated in some older 
studies (Dietzen & Lloyd, 1992). In these series it was reported mechanical damage in 43%, 
infection in 37%, erosion in 10% and hematoma 7% of patients. An overall complication rate 
of 13.3% was also reported in another study (Kimoto & Iwatsubo, 1994). 
As the prosthesis models become more contemporary the results improve as well. In a 
relatively recent study a total number of 245 patients with SCL participated (Zermann et al., 
2006). Apart from the restoration of erectile function, penile prosthesis implantation offered 
a wide enough penis in order to achieve a better fixation of a condom catheter. Regarding 
erectile function, 82.6% of men and 67.5% of their sexual partners reported the treatment as 
successful. Complication rate was lower than in older studies. It was reported infection in 
5%, and erosion from 0 to 18% depending on the type of prosthesis (none for the three 
pieces inflatable ones and 18% for the malleable types). In a meta-analysis based on five 
previous studies where prostheses were implanted in patients with SCL, serious 
complications were reported in 10% of the cases. On the other hand, patients who 
experienced no complications were very satisfied (Deforge et al., 2006; Xuan et al., 2007). 
The higher complication rate which is reported in paraplegics, compare to ambulant, 
impotent patients probably has to do with the absence of sensation which may lead to 
excessive use of the prosthesis which is compressing the glans and the other tissues, causing 
ischemia. This is the first step for erosion. Generally speaking, a penile prosthesis improves 
the quality of life of patients with SCL significantly; however, erosion and infection are still 
remarkable problems. 
 









Fig. 6. On the left: a malleable prosthesis (one of the two cylindrical pieces); on the right: a 
three pieces inflatable prosthesis with some of additional tips. You can distinguish the 
cylinders, the pump and the reservoir.  
5. Therapeutic strategy  
The accurate diagnostic for SCL is crucial for choosing an adequate treatment. The level, the 
extension and the total or partial character of the neural damage may drive to one or other 
treatment option. Generally, patients with partial section of the spinal cord will respond 
better to oral or topical treatments. It has been also proven that oral pharmacotherapy with 
PDE-5 inhibitors is more effective if at least one of the erection centers has maintained. At 
the begging, PDE-5 inhibitors were used in patients with intact S2-4 reflex arc, which 
indicated the integrity of parasympathetic erection center. Later on, it was found that this 
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The use of vacuum device and penile injections require skill on behalf of the patients. 
Tetraplegic patients face more difficulties in the appliance of these therapies, which are 
possible only by the partner’s contribution. If the patient is a condom catheter user due to 
incontinence, penile prosthesis may offer a solution for both erectile dysfunction and 
incontinence, by supporting a better fixation of the condom catheter. 
In our center we use an algorithm for the management of ED in paraplegics. This is 
described below: If the patient has residual (spontaneous or induced by sexual arousal) 
erection, which is, in general, not sufficient for vaginal penetration, vacuum device and/or 
oral pharmacotherapy with PDE-5 inhibitors are offered. If the patient is not satisfied we 
apply intracavernousal injections of vasoactive drugs, alprostadil in most cases. At this point 
the majority of our patients is satisfied. In cases that there is fibrosis of the cavernosal tissue, 
usually after recurrent priapism episodes, penile prosthesis remains the only reliable choice 
for the management of the ED of these men. The implantation of the penile prosthesis is the 
ultimate therapeutic option with excellent results. Finally, it has to become clear to all 
patients that the above treatment options are suitable for the ED and do not solve the 
ejaculation or/and orgasm disorders they might experienced. 
The role of sexual partner is very important as the partner must be part of the therapeutic 
option. The couple has to “open its mind” regarding the sexual activity. They must 
compromise, at the beginning, and finally, regulate their sexual lives in a status that 
penetration is not the main sexual activity. 
6. Conclusion 
Men with paraplegia suffer from sexual dysfunction which impacts the quality of their life 
and affects their partners. ED, possible absence of orgasm and infertility are conditions 
related to paraplegia. Patients with SCL face neurogenic ED. Erection is a neurovascular 
phenomenon which takes place under neuro-hormonal control. Any lesion at the involved 
neural pathways is responsible for this dysfunction. On the other hand the vascular element 
of the erection is, in general, healthy. According to these principals, the treatment strategy is 
designed and applied. No therapeutic method is efficient and suitable for all patients. 
Treatment must follow the wishes, the mental level and the skills of the patient according 
the needs of the couple. 
The physicians who treat paraplegic patients must take these conditions into consideration. 
A team work by rehabilitation doctors, urologists and psychiatrics is needed for the optimal 
treatment option.Sexual rehabilitation targets in neuromodulation using voluntary release 
of a reflex erection attempting to use this erection for sexual purpose. This is possible 
through stimulation of the skin or mucosa below the level of the lesion. If a trigger point 
which promotes an erection is identified, patient has to get familiar with the onset of this 
reflex in order to use it during sexual activity. 
Treatment options like PDE-5 inhibitors, vacuum devices, intracavernousal injections or 
intra-urethral administration of vasoactive medications and penile prosthesis are in 
specialist’s armament for the treatment of erectile dysfunction in men with paraplegia.The 
oral treatment with PDE-5 inhibitors is effective in the majority of paraplegic patients. 
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Vacuum device is a reliable treatment option with some restrictions. The most effective 
conservative treatment is the intracavernousal injection of vasoactive drugs, as the erectile 
dysfunction is not caused by vascular inefficiency. Urethral application of vasoactive drugs 
is less effective and is associated with high incidence of hypotension. The implantation of 
penile prosthesis remains the most effective treatment option, which is associated with a 
relatively high rate of complications (~10%) in this population (Deforge et al., 2006). Sexual 
rehabilitation remains very important for the physical rehabilitation and the active return of 
these people to the society. 
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1. Introduction 
Erectile dysfunction (ED) is the most common sexual problem in men [1]. ED is defined as a 
difficulty in initiating or maintaining penile erection adequate for sexual activity. ED has a 
weighty effect on intimate relationships, quality of life, and overall self-esteem for men. In 
addition, ED may also be an early indication of undetected cardiovascular disease [2]. One 
of the largest current studies of ED, the Massachusetts Male Aging Study, established that 
the prevalence of ED increases with age as it affects up to half of the male population 
between 40 and 70 years old [3]. Thus, as the world’s older population increases, it is 
estimated that the prevalence of ED will double from 152 million men in 1995 to 322 million 
men in 2025, indicating a dire need to reevaluate current ED therapeutic strategies [4]. In 
most documented cases, ED may also present with comorbidities of hypertension, diabetes 
mellitus, obesity, and atherosclerosis [3].  
During the 1980s, most of the pioneering research in ED was sparked by the introduction of 
intracavernosal vasoactive drugs, which were very effective as agents inducing penile 
rigidity [5]. It was not until the late 1990’s and early 2000’s that oral phosphodiesterase-5 
inhibitors were introduced, which were truly instrumental in revolutionizing the sexual 
medicine field [6]. Today, first-line therapy for the treatment of ED consists of orally as well 
as sublingually administered drugs, while intracavernosal injection (ICI), therapy, which 
involves direct injection of vasoactive agents into cavernosal tissue, is considered only as a 
second-line therapy. This chapter will discuss current perspectives on ED’s 
pharmacotherapy and present a more in-depth review on treatments for ED, based on the 
works from Andersson, K.E. [7] and Uckert, S. [8].  
2. First-line treatment: Oral pharmacotherapy 
2.1 PDE5 inhibitors  
The family of phosphodiesterases is comprised of 11 catalytic enzymes that regulate the 
second messenger activity in cells by cleavage of the phosphodiester bond of either cyclic 
adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP), or both [9] 
PDE5 is present in high concentrations in the smooth muscle of corpora cavernosa of the 
penis and in the smooth muscle of the pudendal arteries; therefore, phosphodiesterase 5 
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inhibitors (PDE5) are the major initial line of pharmacotherapy for erectile dysfunction (ED). 
PDEs are orally active agents that are taken, on demand, prior to sexual intercourse [9]. 
PDE5 was discovered by Corbin and colleagues [3, 4]. The PDE5 enzyme is a homo-dimer 
with two identical subunits, and each subunit is 100,000 kilo Daltons. Both subunits have a 
catalytic domain and a regulatory domain; however, it is the catalytic domain that is the 
main target for PDE5 inhibitors [9]. Nevertheless, it was the discovery of nitric oxide (NO) 
and cGMP as the major effectors in penile smooth muscle relaxation that led to the 
identification of PDE5 inhibitors that can further elevate intracellular levels of cGMP [10-11]. 
Most PDE5 inhibitors have a comparable structure to sildenafil; in addition, a part of the 
molecular structure of most PDE5 inhibitors bears resemblance to the cGMP structure. This 
is of significance since PDE5 inhibitors are competitive antagonists of both cGMP and  
PDE5 [7].  
The actions of PDE5 inhibitors are often described in terms of their selectivity when 
compared to other PDE inhibitors.  The selectivity of PDE5 inhibitors is a key factor since 
studies have shown that some PDE5 inhibitors may cross-react with PDE6, (predominant 
phosphodiesterase in the retina), causing visual disturbances; for example perception of 
bluish haze and increased light sensitivity, has occurred in some patients [12-13]. 
Additionally, some PDE5 inhibitors also cross-react with PDE11; PDE11 is mainly located in 
cardiac, testicular and pituitary tissues of the heart and testes; however, the consequences of 
this cross-reaction are unknown [7]. The normal pathway for penile erection is by sexual 
stimulation, which releases NO at nerve endings in the penis whereby increasing the blood 
supply to the penis. NO, the major vasodilatory agent causes this increase in blood by 
diffusing into vascular smooth muscle cells in both the penile corpus cavernosum and the 
pudendal arteries to cause stimulation of guanylyl cyclase (GS). Elevation of cGMP in these 
cells leads to the activation of cGMP-dependent protein kinase (PKG), a lowering of 
intracellular calcium, resulting in smooth muscle relaxation. PDE5 inhibitors act by 
selectively enhancing erectile function by penetrating into smooth muscle cells and 
inhibiting PDE5, resulting in decreased breakdown of cGMP, thus PDE5 inhibitors increase 
blood flow of the smooth muscle by increasing relaxation, allowing for an erection to occur 
[9, 14]. PDE5 inhibitors are degraded in the liver, since they are not metabolized by any 
other enzymes in the smooth muscle cells of the corpus cavernosum. So, PDE5 inhibitors 
must be transported to the liver in order to be degraded. This is important to note, as it 
determines the duration of action, because the disappearance of the inhibitor from the 
plasma may indicate, but does not always prove, its clearance from the cells in which its 
effects were produced [9].   
PDE5 inhibitors are the most widely used treatment for ED and their efficacy have been 
rigorously evaluated in numerous clinical trials [8]. Subjects receiving a PDE5 inhibitor 
report erections adequate for sexual intercourse [8, 15]. However, PDE5 inhibitors seem to 
be less effective in studies where male subjects have comorbid diseases such as diabetes [16]. 
Nevertheless, PDE5 inhibitors remain the primary line of oral treatment, and the most 
common reported side effects include headaches, dyspepsia, and nasal congestion [17-19]. In 
regard to cardiovascular (CV) safety, PDE5 inhibitors have proven to be safe in patients with 
CV disease; however, due to their mechanisms of action, PDE5 inhibitors are 
contraindicated in ED patients taking nitrates due to unpredictable hypotension [8]. On the 
other hand, it should be noted that the interaction between organic nitrates and PDE5 
inhibitors varies according to the PDE5 inhibitor and the nitrate used [7]. 
 




Since the launch of sildenafil as an effective basis for the treatment of ED in 1998, similar 
agents have undergone clinical trials and have been subsequently introduced into clinical 
practice [14]. There is clear evidence that sildenafil is efficacious in the treatment of ED for 
the broad population of men [20]. As a result, sildenafil has proven effective in cases when 
ED has arisen as a consequence of comorbid diseases such as diabetes, depression, 
cardiovascular disease, hypertension and lower urinary tract infections [9].  
Sildenafil has shown efficacy when taken at doses of 25, 50, or 100 mg and has an onset of 
action usually within 25–60 minutes; however, absorption of the drug is slowed with food 
[9, 14, 21]. Minor side effects do occur with the use of sildenafil; the most reported side 
effects were headaches, flushing, indigestion, and visual changes [9, 19, 22]. Sildenafil will 
most likely continue to be the drug of choice for physicians, since there have not been any 
reports that have cast uncertainty on its safety for men with ED.  
2.1.2 Udenafil (DA-8159) 
Udenafil (DA-8159) is a PDE5 inhibitor; it is a long-acting drug with a half-time (t1/2) of 11–
13 hours, and it has a relatively fast absorption with the plasma concentration after ingestion 
reaching  its tmax, that is, its peak drug level, in 1–1.5 hours [4]. Phase II clinical trial data 
revealed that in men with mild-to-severe ED, udenafil produced a considerable 
improvement in erectile function after 12 weeks of treatment [8]. A phase III study in Korea 
evaluated the efficacy and safety of udenafil in ED patients. All responses to udenafil were 
significantly greater than the placebo (p < 0.0001) and patients receiving either udenafil 
doses of 100 mg or 200 mg were significantly (p < 0.0001) more satisfied with their sex life 
compared with men taking the placebo [4]. In animal studies, the administration of DA-8159 
(0.3 or 1 mg/kg) induced a dose-frequency dependent increase in intracavernosal pressure 
(ICP); chronic treatment with DA-8159 restored erectile responses induced by electric 
stimulation, improved endothelial function, and significantly decreased plasma levels of 
both endothelin, (a potent vasoconstrictor), and asymmetrical dimethyl arginine (ADMA), 
(an inhibitor of NO production) [8]. Udenafil has been reported to be a well tolerated, since 
most of the adverse side effects were flushing, upset stomach and headaches, which were 
generally mild to moderate [4, 8]. 
2.1.3 Avanafil 
Avanafil is a pyrimidine derivative synthesized to be a highly selective PDE5 inhibitor for 
the treatment of ED [9]. Studies have shown that up to 84% of avanafil doses resulted in 
sufficient erections for sexual activity, as compared to placebo [8]. In clinical trials, avanafil 
showed a higher selectivity, almost 120-fold, against PDE6 than both sildenafil and 
vardenafil [4]. Additionally, when compared with sildenafil, vardenafil, and tadalafil 
(described later), avanafil’s chemical structure is distinctive from the standard nucleic 
base/sugar/phosphate diester model; avanafil’s molecular structure is a nitrogen derivative 
of a pyrimidine carboxamide where the nitrogen atom of the amide substituent is bound to a 
pyrimidinylmethyl group [8]. As a result of its unique chemical structure, theoretically, 
avanafil can bind to the catalytic site of PDE5 regardless of the spatial orientation of the 
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molecule, significantly increasing the effectiveness and affinity of the inhibitor for PDE5 [8]. 
In the pharmacokinetic evaluation of this drug, studies reported rapid absorption with a 
tmax approximately 35 minutes and a short t1/2 of less than 1.5 hours without any 
unwanted accumulation of the drug [4]. Favorable data from a nitrate interaction study 
showed only a modest impact on blood pressure and heart rate [23-24].  
2.1.4 Lodenafil 
Lodenafil carbonate is a newer PDE5 inhibitor; it is a dimer formed by two lodenafil 
molecules linked by a carbonate bridge [11]. After ingestion, the carbonate bridge is broken 
delivering the active lodenafil compound [8, 25]. The effects of lodenafil have been 
extensively investigated in vitro; the drug was noted to cause concentration-dependent 
relaxation of both rabbit and human corpus cavernosum tissue by amplifying the NO-
dependent relaxation of the penile tissue in response to acetylcholine or transmural 
electrical field stimulation (EFS) [8]. In comparison lodenafil was shown to be 
approximately twofold more potent than sildenafil for inhibition of the breakdown of cGMP 
[26]. Its efficacy and safety at doses of 20 mg, 40 mg and 80 mg was also tested and shown to 
significantly improve erectile International Index of Erectile Function domain scores (IIEF 
domain scores: a widely used, multi-dimensional self-reporting instrument for the 
evaluation of male sexual function), with only mild to moderate adverse reactions such as 
headache, flushing, visual disorders, and dyspepsia [9, 26]. Lodenafil is an attractive 
pharmacotherapy agent for the treatment of ED [25-26]. 
2.1.5 Tadalafil 
Tadalafil has proven to be efficacious in a number of special populations of men in which 
ED is due to a variety of conditions including diabetes, radiation therapy for prostatic 
cancer, spinal cord injury, and lower urinary tract infection [9, 27]. When taken at doses of 
10 and 20 mg, tadalafil significantly improved erectile function and was well-tolerated, as 
the only reported side effects were headache, flushing, indigestion, nasal congestion, and 
back or girdle pain [9, 27-28]. At present there is no convincing evidence of any significant 
safety issues regarding cardiovascular contraindications with the use of tadalafil when 
taking the recommended doses of 2.5 mg and 5 mg per day [7, 28]. 
2.1.6 Vardenafil 
Vardenafil is an effective vasoactive agent for the treatment of ED in a broad population at 
doses of 10 mg and 20 mg [9, 29]. Vardenafil was even able to cause adequate erections for 
sexual activity in special populations, where ED was a result of diabetes, chemotherapy, 
depression, hypertension, and spinal cord injury [9, 29]. Vardenafil has a mechanism of 
action similar to other PDE5 inhibitors, thus its side effects are similar to those reported by 
other PDE5 inhibitors such as headache, flushing, indigestion, and nasal congestion [4, 9]. 
Overall, vardenafil remains a highly recommended vasoactive agent, since it has been 
proven beneficial for a wide variety of patients with ED, and at present, there is no 
convincing evidence of any significant safety issues, regarding cardiovascular 
contraindications, with its use [7, 9, 29].  
 




Trazodone is an “atypical” antidepressive agent and it selectively inhibits central 5-
hydroxytryptamine (5-HT) uptake by increasing the turnover of brain dopamines [30]. 
Trazodone has alpha-adrenergic blocking effects (α-AR) and, together with its meta-
chlorophenylpiperazine (m-CCP) metabolite, trazodone is known to induce erections in 
animal studies by selectively blocking the α-AR receptors and by increasing the 
spontaneous firing rate of cavernosal tissue nerves [31]. Despite its promising mode of 
actions within the cavernosum tissue, trazodone is not an effective treatment for most men 
with ED, since orally administered trazodone has been associated with high frequencies of 
priapism [32]. Furthermore, in a double-blind, placebo trial trazodone was not effective even 
at high doses of 150 to 200 mg per day [30, 33-34]. However, trazodone is still a viable option 
for men with psychogenic ED, resulting from anxiety or depression [33-34].  
2.3 Melanocortin receptor agonists (PT-141)  
PT-141 was initially produced as a tanning agent; however it was discovered, when it was 
injected subcutaneously, to initiate potent erections in men with nonorganic ED [35-36]. PT-
141 is a synthetic cyclic nonselective melanocortin receptor agonist, with a high affinity to 
MC receptors 1, 3, and 4, and it is believed to be a metabolite of melanotan-II (MT-II) [36]. 
Theoretically, MC receptor agonists may have beneficial effects in patients with ED based on 
the results from a double-blind, placebo-controlled study in which PT-141, at doses ranging 
from 4 to 20 mg, was administered to 32 healthy subjects [37]. Results from this study 
showed that PT-141 significantly increased erectile activity even without visual sexual 
stimulation, compared with placebo-treated subjects. Additionally, in a placebo-controlled 
crossover trial, men with mild to moderate ED, treated with PT-141 together with visual 
sexual stimulation, experienced a threefold increase in erectile activity when compared to 
the placebo [37]. Co-administration of PT-141 with sildenafil 25 mg significantly increased 
penile rigidity when compared with sildenafil alone [7, 37]. It was also noted that, when 
patients took the two drugs in combination, there were no significant increase in the side 
effects, compared to those experienced, when taking either sildenafil or PT-141 alone [7].  
2.4 Potassium-channel Openers  
Potassium channel openers such as pinacidil, cromakalim, lemakalim, and nicorandil have 
all been shown as efficacious in achieving erections in men with ED [7]. Potassium channel 
openers work by hyperpolarizing the cell membrane, which increases the cell membrane 
permeability to potassium ions causing relaxation and subsequent erection [7]. Presently, 
clinical experience with these potassium channel openers for treatment of ED is limited; 
therefore, potassium channel agonist drugs have not been approved in controlled clinical 
trials as an alternative treatment for men with ED [7].  
2.5 Rho-kinase inhibitors  
Smooth muscle contraction and relaxation is related to the level of free cytosolic calcium, 
which is partly regulated by the accumulation of intracellular secondary messengers such as 
inositol triphosphate (IP3) and diacylglycerol (DAG) via phospholipase C (PLC) activation 
[3]. PLC activation facilitates the release of and the increase of intracellular Ca2+ 
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concentration, resulting in calcium binding to calmodulin and subsequent activation of 
myosin light chain kinase [3]. When intracellular calcium levels decrease, RhoA, a small 
monomeric G protein, activates Rho-kinase; in turn, Rho-kinase phosphorylates and 
simultaneously inhibits the regulatory subunit of myosin light chain phosphatase [3, 38-39]. 
Thus, Rho-kinase is considered essential to the cell calcium sensitization system as its 
activation creates a cascade whereby the phosphorylation of myosin light chains triggers 
cycling of myosin cross-bridges along actin filaments, generating a contractile force that is 
maintained, unless inhibited, within the corpus cavernosum tissue [38]. It was first shown 
by Chitaley, K., et al. that Rho-kinase contributes to smooth muscle tone in the corpus 
cavernosum [40]. Injection of the Rho-kinase inhibitor Y-27632 into cavernosal sinuses 
increased intracavernosal pressure within minutes in a dose-dependent manner, without 
significantly decreasing systemic blood pressure [40]. Furthermore, the increase in 
intracavernosal pressure with Rho-inhibition was independent of the relaxing effects of N.O. 
and of guanylate cyclase, indicating that the Rho-kinase pathway may be an alternative 
therapeutic target for treating ED [38, 40]. In animal studies the Rho-kinase inhibitor fasudil, 
was effective against vasculogenic ED, in addition it was capable of reducing levels of pelvic 
atherosclerosis [41]. In a recent study involving diabetic-associated ED in rats, it was shown 
that chronic administration of fasudil was more effective, than other popular ED treatments, 
at reversing the damaging biochemical changes invoked by high insulin levels [42]. 
Human clinical trials have recently reported that low-dose atorvastatin (Lipitor), (a drug 
which works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue, that plays 
a key role in production of cholesterol in the body), normalizes the diabetic response to 
sildenafil in streptozotocin (STZ) treated diabetic rats [43]. This result suggests that statins 
may also have inhibitory actions in the RhoA/Rho-kinase mechanism [42-43].  
2.6 Alternative treatments for ED 
2.6.1 HERBAL treatment for ED (Yohimbine)  
Though herbal medicines are not a prescribed option of choice for patients in the United 
States, in other parts of the world like Asia, Africa and the Middle East, it is a widely used 
form of therapy for men with ED [44]. However, although there are a myriad of herbal 
treatments that are very appealing for patients with ED, caution must be warranted, since 
some herbal medicines may cause deleterious drug interactions, especially in men with 
comorbid diseases such as CV and diabetes. On the other hand, the herbal or traditional 
therapeutic approach may be more culturally acceptable with some patients, who may 
prefer this holistic option because of religious, social, monetary or other personal 
preferences. As a result, there is a growing interest among the population for alternative 
holistic treatment options, which has increased demand for such therapies in the United 
States [44]. Though there are many herbal remedies available at present for ED, this review 
will focus on the efficacy of yohimbine.   
Yohimbine is an alkaloid derived from the African yohimbe tree (Pausinystalia yohimbe) [44]. 
Yohimbine has been well characterized as an alpha-2 adrenergic receptor (α2-AR) antagonist 
[44]. It specifically inhibits the pre-synaptic α-2 adrenergic receptors in the brain; as a result 
there is a reduction of sympathetic tone since the brain and spinal cord noradrenaline levels 
are diminished [45]. The plasma half-life of yohimbine was found to be 0.6 hours, whereas 
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the plasma noradrenergic effects of the drug lasted for more than 12 hours [46]. 
Theoretically, yohimbine should be a very effective treatment for ED; nevertheless, in 
several controlled trials on patients with different types of ED, yohimbine only produced 
modest effects [7]. However, a comprehensive systematic review demonstrated the 
advantage of yohimbine over a placebo in the treatment of ED [44, 47]. In combination with 
other drugs, oral yohimbine (15 mg daily) with trazodone (50 mg daily) was found to be a 
safe and effective treatment for psychogenic ED [44]. Despite its growing popularity, 
yohimbine is not currently recommended in most guidelines for management of ED, due to 
conflicting  clinical reports concerning its efficacy [7].        
2.6.2 Antioxidant therapy (Quercetin) 
Oxidative stress occurs when there is an imbalance between pro-oxidants and antioxidants’ 
ability to scavenge reactive oxygen species (ROS) [48]. ROS rapidly inactivate NO, thereby 
limiting its ability to relax smooth muscle [49]. Studies have also demonstrated that ROS 
have a central role in inducing apoptosis in cavernosum tissues [49-50]. Thus, there is 
overwhelming evidence implicating the role of oxidative stress in the pathophysiology of 
ED [48]. As a result, antioxidant treatment to regulate ROS is being explored as a potential 
therapeutic treatment for ED [49].  
Quercetin (pentahydroxyflavone) is the most abundant flavonoid in the human diet, and it 
is available without a prescription as a dietary supplement [51]. Flavonoids are plant phenolic 
compounds with strong antioxidant properties, and they are found in various dietary sources, 
such as tea, onion, and broccoli. Quercetin is a potent anti-oxidant, and its mechanism of action 
involves the direct scavenging of free radicals such as hydrogen peroxide and superoxide, the 
inhibition of the pro-oxidant enzyme xanthine oxidase, the inhibition of lipid peroxidation, the 
chelating of iron and the altering of the anti-oxidant defense pathways in the cell [51-52]. 
Given its beneficial effects against oxidative damage, quercetin was hypothesized to be 
effective in the treatment of ED, in particular ED as a result of diabetes mellitus [51-52]. Animal 
studies have revealed that quercetin treatment effectively improved intracavernosal pressure 
of diabetic rats by preserving superoxide dismutase (SOD) activity, (an antioxidant enzyme), 
while simultaneously increasing endothelial nitric oxide synthase (eNOS) expression. The 
results clearly demonstrate that eNOS expression and NO levels in corpus cavernosum were 
significantly increased in diabetic rats, in response to quercetin treatment [52]. Though these 
studies show a promising potential for quercetin, more investigations are needed to establish 
its efficacy in human penile tissue.   
3. Second-line treatment: Intracavernosal pharmacotherapy 
Intracavernosal injection (ICI) is a second-line therapy that is mainly considered for patients 
who fail to respond to first-line therapy or those who cannot use the least invasive forms of 
currently available pharmacotherapy [53]. The ideal candidates for ICI therapy are those 
who use nitrates or could potentially use nitrates, have neural injury from pelvic surgery, 
trauma, diabetic patients, and patients who desire rapid onset of erection, greater rigidity 
and or duration of erection [54]. Contraindications for ICI therapy include patients with a 
history of priapism with vasoactive drug use, and those with severe penile fibrosis with the 
use of monoamine oxidase inhibitors (MAOIs); in addition, a nonresponse to ICI occurs 
mostly as a result of an inadequate dose, misdirected injection into the subcutaneous or  
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Fig. 1. SOD in the Pathophysiology of Erectile Dysfunction: During oxidative stress, SOD 
expression decreases causing an increase in superoxide (O2-). As O2- rises within the cell, NO 
production is attenuated leading to ED. 
trabecular regions of the penis, leakage of vasoactive agent prior to ICI and insufficient 
sexual stimulation, or premature ejaculation [54]. 
Following an ICI and sexual stimulation, penile rigidity is achieved usually within 5–10 
minutes, as a rapid increase in cavernosal artery blood flow leads to compression of 
subtunical venules located between the smooth muscle of the corpora cavernosa and the inner 
tunica albuginea (3). With venous outflow blocked, intracavernosal pressures can be greater 
than 100 mmHg. Vasoconstriction and the loss of penile rigidity occur as a result of an 
increase in sympathetic tone coincident with ejaculation (3). For ICI therapy, the most 
commonly prescribed vasoactive agents are prostaglandin E-1 (PGE-1), phentolamine, and 
papaverine (1, 3). However, with advances in medical research, other effective treatments 
are currently available, such as vasoactive intestinal polypeptide, calcitonin gene-related 
peptide, and guanylate cyclase activators.  
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3.1 Papaverine  
Papaverine was discovered by Merck in 1848, it is an opium alkaloid originating from the 
poppy Papaver somniferum. In the treatment of ED, intracavernosal papaverine injection was 
the first pharmacological agent proven to be a clinically effective therapy for ED (1). 
Papaverine induces relaxation of the corpus cavernosal smooth muscle tissue and pudendal 
artery leading to penile erection via nonspecific inhibition of phosphodiesterase, leading to 
increased intracellular levels of cGMP and cyclic adenosine monophosphate (cAMP) (1). In 
in vitro studies, papaverine was shown to increase relaxation not only in isolated corpus 
cavernosum smooth muscle strips, but also in penile arteries and penile veins; in addition, 
these studies have also shown that papaverine was able to attenuate contractions induced 
by stimulation of adrenergic nerves and exogenous noradrenaline [9]. Papaverine may also 
regulate corpus cavernosum smooth muscle tone via a cAMP independent pathway by the 
inhibition of voltage-dependent L-type calcium channels [9, 55]. 
Although papaverine is an effective and inexpensive treatment for ED, compiled reports 
have implicated the use of papaverine with an increased rate of priapism and fibrosis [20, 
56-57]. Penile pain is also very common following administration of papaverine [57-58]. 
Papaverine may cause other side effects such as flushing, sweating, upset stomach, loss of 
appetite, diarrhea, constipation, and irregular heartbeat [9, 59]  
3.2 Alpha-adrenoreceptor antagonist (Phentolamine) 
Although the beneficial vasoactive effects of phentolamine were discovered in the 1970s, the 
current clinical use of this drug is limited to use as a component of other vasoactive drug 
combinations [20, 60]. In the penile corpus cavernosum, there are at least three important 
alpha-adrenoreceptor iso-forms: 1A, 1B, and 1D. All three subtypes have been detected 
and the 1A and 1D proteins have been identified as the predominant subtypes in the 
corpus cavernosa [61-62]. However, the distinction and role of each individual receptor 
subtype to cell signaling pathways in erectile function remains mostly undetermined [63]. 
Alpha-1 and 2-adrenoreceptors are classified as G-protein coupled receptors which initiate 
several complex downstream processes [61]. It has been suggested that alpha 1 receptors 
preserve the penile contractile tone by increasing intracellular calcium levels followed by 
extracellular calcium influx [61]. It should also be noted that the -adrenergic receptor 
system plays a critical role in the modulation of penile flaccidity (8). Contraction induced by 
post-junctional 2-receptors is caused by increased intracellular calcium but also involves 
the recruitment of ion channels, activation of phosphodiesterases and attenuation of 
adenylate cyclase activity [60, 64]. 
Phentolamine mesylate produces an -adrenergic blockade; it is a nonselective -
adrenoreceptor antagonist with a similar affinity for 1 and 2-adrenoreceptors; it also has 
direct, positive inotropic and chronotropic effects on cardiac muscle, as well as vasodilator 
effects on vascular smooth muscle [20]. Although ICI of phentolamine increases corporal 
blood flow, a concurrent increase in noradrenaline prevents sinusoidal relaxation [65]. 
Studies have also shown that phentolamine induces the relaxation of corpus cavernosum 
erectile tissue independently of 1 and 2-adrenoreceptors blockades, via a noradrenergic, 
endothelium-mediated mechanism suggesting NO synthase activation (68, 77).  
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3.3 Prostaglandin E1  
Prostaglandins were first characterized by Bergstrom, S., Bengt, S. and Vane, J. however, it 
was not until 1986 that the vasoactive effects of prostaglandin E1s (PGE-1) were described 
for intracavernosal use by Ishii, N. and Adaikan, PG. [20]. In 1996, PGE-1 became the first 
FDA-approved vasoactive intracavernosal drug for the treatment of ED, and its efficacy has 
been confirmed in three multi-centered, randomized prospective clinical trials with a six-
month open-label extension [66]. Since then, a vast body of knowledge has described the 
efficacy and mechanism of this drug. Presently, PGE-1 is one of the most popular vasoactive 
agents for ICI therapy [67]. 
PGE-1 induces relaxation of human corpus cavernosum smooth muscle by regulating 
adenylate cyclase activity, upregulating the production of cAMP in the penis via activation 
of EP prostaglandin receptors, and subsequently leading to a decrease in intracellular 
calcium concentration, resulting in cavernosal smooth muscle relaxation [9, 20, 68-69]. PGE-
1 mediated vaso-dilation occurs via gap junctions within the penis; additionally PGE-1 
inhibits sympathetic activity by acting upon the presynaptic neurons, blocking the release of 
noradrenaline [70-72]. PGE-1 is metabolized by 15-hydroxydehydrogenase and has a blood 
plasma half-life of less than 1 minute, as liver, kidney, and penile enzymes all contribute to 
the conversion of PGE-1 to its inactive form [67]. Rates of priapism, a potentially devastating 
adverse effect, are low with the use of PGE-1, which makes it the most utilized injectable 
vasoactive agent [20]. 
3.4 Vasoactive Intestinal Polypeptide 
Vasoactive intestinal peptide (VIP) is a naturally occurring neurotransmitter and a potent 
smooth muscle relaxing agent. VIP, which was isolated from the small intestine, was also 
first described as a specific neurotransmitter for inducing penile erection in 1986 [73]. While 
VIPergic nerves are most densely concentrated in the penis around the pudendal arteries, 
preliminary intracavernosal studies using VIP produced unsatisfactory results; however, 
when VIPs were used in combination with drugs such as papaverine and phentolamine, 
adequate penile erections were observed [9, 74]. As a result, current VIP therapy for ED is 
predominantly used in combination with phentolamine mesylate [20]. 
The effects of VIP are mediated via a specific G protein-coupled receptor (GPCR) which is 
linked to adenylate cyclase [9]. VIP co-localizes with nitric oxide synthase (NOS) within the 
perivascular and trabecular nerve fibers innervating the penis, thus regulating penile blood 
flow, and smooth muscle tone in the male genitalia [75]. Most of the NO and VIPergic 
nerves are cholinergic in nature, as they contain a vesicular acetylcholine transporter [76]. 
Given that the actions of VIP have been directly linked to adenylate cyclase, VIP can elevate 
cAMP concentrations in cavernosal tissues without affecting cGMP levels [77]. VIP has 
commonly observed side effects, such as facial flushing and headaches, which are frequent 
events characteristic of most vasoactive therapies [78]. 
3.5 Linsidomine chlorhydrate 
Nitric oxide donors such as sodium nitroprusside (SNP) and linsidomine (SIN-1) can be 
used for the treatment of ED [79]. In vivo studies have shown that SNP and linsidomine 
(SIN-1) upregulates cGMP production, which increases NO release in a dose-dependent 
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manner [80]. NO release causes the relaxation of vascular smooth muscle as well as 
cavernosum smooth muscle. Even though SIN-1 has a short half-life of only 1–2 min, there is 
a potential to cause systemic hypotension with use of this drug [81-82]. SNP and SIN-1 have 
positive hemodynamic effects promoting erectile function and show long-term promise as 




Fig. 2. Pharmacotherapy treatments for ED: Cavernosal nerves contribute to smooth muscle 
relaxation by releasing Acetylcholine (Ach). Trazadone increases cavernosal nerve firing, 
which increases Ach release, which stimulates eNOS, causing the release of NO. ROS causes 
eNOS uncoupling, which reduces its activity, however Quercetin has potent antioxidant 
effects and effectively reduces ROS generation. Once NO is released, it activates sGC, 
increasing the cGMP levels. SIN-1 and PDE5 inhibitors, such as sildenafil, also elevates 
cGMP levels resulting in the activation of PKG. On the other hand, PGE-1 and Papaverine 
elevates cAMP, causing the activation of PKA. PKG and PKA activation causes a cell 
signaling cascade which hyperpolarizes the cell membrane. Nicorandil also has similar 
hyperpolarizing effects by opening the potassium channels. Overall activation of PKG and 
PKA reduces intracellular calcium levels, resulting in increased activity of myosin-light 
chain phosphatase resulting in smooth muscle relaxation and subsequent erection. Fasudil 
also increases myosin-light chain phosphatase leading to smooth muscle relaxation by 
inhibition of Rho-kinase. Erections are also caused by neural stimulation, through the 
release of neuronal NO.  
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3.6 Calcitonin Gene-Related Peptide 
Calcitonin-gene-related peptide (CGRP) causes an increase in penile arterial inflow, 
cavernosal smooth muscle relaxation and cavernosal outflow occlusion [84]. As a potent 
vasodilator, CGRP has also been shown to induce dose-related increases in penile blood 
flow with CGRP-specific receptor agonists [84-85]. For the treatment of ED, CGRP is usually 
co-administered with PGE-1, and this combined therapy has been proven successful in 
improving erectile function [86]. 
3.7 Guanylate Cyclase activator 
Soluble guanylate cyclase (sGC) activators have been shown to increase intracavernosal 
pressure in corpus cavernosum tissue (23-24). BAY41-2272 is a sGC activator that has been 
shown to relax the human corpus cavernosum with or without the presence of NO (16). The 
sGC enzyme converts GTP to cGMP, which is activated when NO is released from erectile-
autonomic nerves, resulting in smooth muscle relaxation. In the penis, cGMP is a down-
stream cell-signal messenger that relaxes cavernosal smooth muscle, causing adequate blood 
flow for penile erection (23).  
4. Conclusion 
ED will continue to be a problem affecting many individuals. Though there are advances in 
the treatment of ED, there is still a need for more effective therapy for men with complex ED 
caused by comorbid diseases such as diabetes. In addition, there are an increasing number 
of patients with cardiovascular disease for whom first-line and second-line 
pharmacotherapy are contra-indicated. For first-line therapy, the major drawback is severe 
hypotension and bothersome side effects including headaches, dizziness, vision and hearing 
changes, which sometimes occur during sexual activity. For second-line therapy, even 
though it is an effective alternative for men who cannot tolerate or respond to first-line 
therapy, the chief drawback of such an approach is a high attrition rate. However, although 
this chapter did not focus on the option of combination therapy, (the combined used of 
various oral vasoactive drugs and or intracavernosal therapies), this form of therapy is 
becoming an increasingly popular option for patients and may represent the most 
promising alternative for men with complex ED. At present it is very common, especially for 
second-line ED treatment algorithms to include combination therapy. Therefore, as we 
move ahead into the future, we can better understand and provide more appealing options 
for the management of ED, through continued combined efforts of researchers and 
clinicians.  
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1. Introduction 
Erectile dysfunction (ED) is defined as the consistent or recurrent inability of a man to attain 
and/or maintain penile erection sufficient for sexual activity. According to current 
guidelines, a 3-month symptom duration is accepted to establish the diagnosis except for 
some cases of trauma or surgically induced ED (Lewis R 2010).  ED affects physical and 
psychosocial health and has a significant impact on the quality of life (QoL) of sufferers and 
their partners and families. Epidemiologic studies for ED estimate the prevalence of ED 
ranging between 20-30 % among men aged between 40-80 years (Laumannn et al 2005, 
Lewis R 2010). These differences in reported incidences are probably due to variations in the 
methodology and the age and socioeconomic status of the study populations. 
ED is a disorder in which subjective perception of patients is very important, therefore, the 
aim of the treatment should not only be organ focused but also be patient-outcome oriented. 
Patient satisfaction with sexual intercourse, their overall sex lives and ED treatments may 
represent reliable predictors of key patient-related treatment outcomes, in addition to 
pharmacological efficacy and safety (Carson C, et al. 2004) 
The basic diagnostic work-up for patients who presented with ED should include a 
thorough medical and psychosexual history to identify common causes and risk factors of 
ED and assess psychological status of patients by using validated instruments 
(Hatzimouratidis K, et al. 2010). A focused physical examination should be the next step to 
evaluate possible penile deformities, prostatic diseases, signs of hypogonadism, 
cardiovascular and neurological status of the patients. Evaluation of serum glucose, lipid 
and testosterone levels is also an essential part of the initial evaluation of ED patients.  
Patients suffering from ED should be treated with a structured strategy which may be 
influenced by efficacy, safety, invasiveness, cost effectivity and satisfaction of both the 
patient and his partner. These parameters should also be considered for the selection of the 
treatment option for each particular patient and his partner.    
Although newer medical treatment alternatives such as PDE-5 inhibitors, vacuum erection 
devices and intracavernosal applications are considered first and second lines of ED 
therapy, respectively; surgical treatment, especially penile prosthesis implantation, is the 
standard of care in cases of medication-resistant ED. Surgical treatment options in order to 
correct ED are divided into three categories. These categories are: 
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1. Penile prosthesis implantation 
2. Penile revascularization 
3. Surgery for corporal veno-occlusive dysfunction 
2. Penile prosthesis implantation 
From the historical point of view, the wooden sticks that were either placed under the skin 
of the penis or into the urethra are known as the earliest implanted materials designed to 
improve erectile function (Henry GD, 2009). With increased knowledge of human anatomy, 
autologous materials were started to be implanted. The first real attempt to create an 
internal penile support and provide penile rigidity was described in 1936 by Bogoras who 
used a piece of cartilage as a penile stiffener in a total phallic reconstruction (Bogoras 1936). 
This is followed by Beheri who first documented successful intracavernosal placement of 
polyethylene rods in 700 patients in 1966 (Beheri 1966). The successful implantation of a new 
semirigid silicone cylinder that fulfills the whole corpora was described in 1973 which lead 
to the development of new implants that are currently used(Scott 1973). 
2.1 Indications of surgery 
There are many types of penile prosthesis designs that are currently available for 
implantation, but it should be kept in mind that not all patients with ED are candidates for 
penile prosthesis implantation. Implantation of penile prosthesis is indicated for the 
treatment of organic ED in men who fail or reject more conservative measures, such as oral 
PDE5 inhibitors, vacuum erection devices (VED), urethral alprostadil suppositories, and 
intracavernosal injection therapy. Additionally, implants are appropriate when medical 
therapy is contraindicated, cause severe side effects, vacuum erection therapy has proven 
unsatisfactory or unacceptable, and/or in men with end organ failure (e.g. diabetes 
mellitus), severe structural abnormalities (e.g. Peyronie’s disease), cavernosal fibrosis (e.g. 
after prolonged priapism or infection). Patients who experience ED after radical 
prostatectomy or pelvic organ transplantation may also serve as the candidates for penile 
prosthesis implantation. Careful counseling before penile implant procedures will reduce 
the probability of problems that may result in postoperative dissatisfaction. The type of the 
prosthesis for each particular patient should be selected according to the patients’ needs and 
expectations (Carson CC 2005). Patients at younger age with normal manual dexterity or 
who wear firm clothing often choose a three-piece inflatable penile prosthesis because 
appearance in the flaccid position is better than other designs (Hellstrom WG, et al. 2010). In 
addition, inflatable penile prosthesis should be the preferred option in patients with 
Peyronie’s disease, history of previous implantation procedures or neurological disorders 
where considering interior tissue pressures are declined between uses and the risk of 
extrusion is diminished (Zermann DH, 2006).  For some patients such as paraplegics, 
malleable prostheses can be chosen since inflatable ones have much higher malfunction 
rates. Malleable penile prosthesis can be better served in those patients who lack adequate 
manual dexterity, or those with significant obesity (Hellstrom WG, et al. 2010). 
2.2 Types of implants  
There are three classes of penile implants including hydraulic, semi-rigid and soft silicone. 
The hydraulic implants consist of two types, the three-piece inflatable and the two-piece 
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inflatable. The only two-piece device currently available is AMS Ambicor(Fig.1). When this 
nondistensible device is deflated, the cylinders collapse and the penis, unlike that with a 
malleable prosthesis, is not rigid. When the scrotal pump is cycled, a small volume of fluid 
is transferred from the rear tips of the cylinders into the distal nondistensible chambers 
filling and then pressurizing them. Different from 3-piece inflatable prosthesis, Ambicor 
does not increase in size with inflation. Flaccidity and erection are more compromised with 
this model when compared with 3-piece device due to low, restricted reservoir volume. Also 
the device is not available with antibiotic impregnated forms as of yet, but has an acceptable 
short-term mechanical reliability (Levine LA 2001).  
 
Fig. 1. AMS Ambicor two-piece inflatable penile prosthesis 
The ideal penile prosthesis would produce flaccidity and erection that mimics natural 
condition. Three-piece inflatable prostheses provide these conditions by transferring fluid 
into and out of cylinders. These devices consist of a pair of cylinders, reservoir and a pump. 
AMS and Coloplast are the two main companies that manufacture 3-piece inflatable 
prostheses. Coloplast manufactures the Titan Inflatable Penile Prosthesis (Fig. 2) and the Titan 
Narrowbase Inflatable Penile Prosthesis. The Narrowbase implant is developed for patients 
with small penises or for cases in which dilation is limited because of scarring from corporal 
fibrosis or previous surgery. All of these cylinders expand in girth, but not in length. AMS 
manufactures the AMS 700 CX Inflatable Penile Prosthesis (Fig. 3), the AMS 700 LGX Inflatable 
Penile Prosthesis, and the AMS 700 CXR Inflatable Penile Prosthesis. The CXR device, like the 
Titan Narrow-base prosthesis, has smaller diameter cylinders and is used in revision cases and 
less commonly in men with small penises.  
Apart from other devices, AMS LGX cylinder has a unique property that it expands both in 
girth and length (Fig 4). The CX and CXR have a unidirectional weave that allows only girth 
expansion, whereas the LGX has a bidirectional weave permitting expansion both in length 
and girth. In patients with organic ED and penile deformity or curvature, girth only 
expanding devices may provide better cosmetic outcome. In men with small penises or men 
with scarring due to ischemic priapism or previous penile surgery where corporeal dilation 
is limited, smaller diameter CXR cylinders often serve as a better alternative. 
Infections are known to be the most significant and unwanted complications in IPP surgery, 
especially for revision/replacement, which may develop due to decreased host resistance,  
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inflatable. The only two-piece device currently available is AMS Ambicor(Fig.1). When this 
nondistensible device is deflated, the cylinders collapse and the penis, unlike that with a 
malleable prosthesis, is not rigid. When the scrotal pump is cycled, a small volume of fluid 
is transferred from the rear tips of the cylinders into the distal nondistensible chambers 
filling and then pressurizing them. Different from 3-piece inflatable prosthesis, Ambicor 
does not increase in size with inflation. Flaccidity and erection are more compromised with 
this model when compared with 3-piece device due to low, restricted reservoir volume. Also 
the device is not available with antibiotic impregnated forms as of yet, but has an acceptable 
short-term mechanical reliability (Levine LA 2001).  
 
Fig. 1. AMS Ambicor two-piece inflatable penile prosthesis 
The ideal penile prosthesis would produce flaccidity and erection that mimics natural 
condition. Three-piece inflatable prostheses provide these conditions by transferring fluid 
into and out of cylinders. These devices consist of a pair of cylinders, reservoir and a pump. 
AMS and Coloplast are the two main companies that manufacture 3-piece inflatable 
prostheses. Coloplast manufactures the Titan Inflatable Penile Prosthesis (Fig. 2) and the Titan 
Narrowbase Inflatable Penile Prosthesis. The Narrowbase implant is developed for patients 
with small penises or for cases in which dilation is limited because of scarring from corporal 
fibrosis or previous surgery. All of these cylinders expand in girth, but not in length. AMS 
manufactures the AMS 700 CX Inflatable Penile Prosthesis (Fig. 3), the AMS 700 LGX Inflatable 
Penile Prosthesis, and the AMS 700 CXR Inflatable Penile Prosthesis. The CXR device, like the 
Titan Narrow-base prosthesis, has smaller diameter cylinders and is used in revision cases and 
less commonly in men with small penises.  
Apart from other devices, AMS LGX cylinder has a unique property that it expands both in 
girth and length (Fig 4). The CX and CXR have a unidirectional weave that allows only girth 
expansion, whereas the LGX has a bidirectional weave permitting expansion both in length 
and girth. In patients with organic ED and penile deformity or curvature, girth only 
expanding devices may provide better cosmetic outcome. In men with small penises or men 
with scarring due to ischemic priapism or previous penile surgery where corporeal dilation 
is limited, smaller diameter CXR cylinders often serve as a better alternative. 
Infections are known to be the most significant and unwanted complications in IPP surgery, 
especially for revision/replacement, which may develop due to decreased host resistance,  
 




Fig. 2. Hydrophilic-coated Coloplast Titan™ threepiece prosthesis with reservoir lock-out 
valve to minimize autoinflation  
 
Fig. 3. AMS 700 CX inflatable penile prosthesis  
 
Fig. 4. AMS LGX inflatable penile prosthesis   
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impaired antibiotic penetration due to capsule formation, and decreased wound healing 
related to scarring. Most bacteria produce a mucin coat or biofilm that is the bacterial 
colonisation over the device and resistant to systemic antibiotic treatment due to decreased 
metabolic needs (Silverstein A, et al 2003). Antibiotics or the body’s defense mechanisms can 
not eradicate the bacteria inside the biofilm without removing all prosthetic components 
and irrigation of the implant spaces (Stewart et al 2001). Both manufacturers developed 
advances in the designs of prosthesis in order to decrease the incidence of infections by 
applying coatings to the prosthesis designed to retard bacterial growth. In 2001, AMS 
introduced InhibiZone™ (Fig. 5) which is a patented antibiotic surface treatment that 
impregnates minocycline and rifampin into the external silicone surfaces of all the 
components, except the RTE, giving the orange-like color.  
 
Fig. 5. AMS 700 MS™ series cylinder with Inhibizone® antibiotic surface treatment. AMS = 
American Medical Systems. 
The antibiotics reach into the implant space within 10 days. They seem effective in the 
prevention of bacterial colonization and development of biofilm layer (Nickel JC, et al.1998). 
Minocycline and rifampin may help decrease the probability of developing bacterial 
resistance by inhibition of protein synthesis and inhibition of DNA-dependent RNA 
polymerase, respectively (Darouiche RO, et al 1999). In-vitro and in-vivo studies have 
demonstrated the effectiveness of minocycline in retarding the emergence of staphylococcal 
strains that are resistant to rifampin (Raad et al 1995). Short-term follow-up for this 
prosthesis enhancement shows statistical improvement in infection reduction for first time 
implant patients by a single surgeon (Wilson SK, et al 2002). Coloplast also produced 
antibiotic-coated devices named as Titan and Titan NB. The hydrophilic coating absorbs 
much more water and the idea is the adherence of antibiotics to the surface of prosthesis 
when soaked into antibiotic solutions.  
It should be remembered that pumping systems of inflatable devices require some manual 
dexterity and patients who lack this ability may experience difficulties in order to make 
these devices work. AMS developed Momentary Squeeze Pump (MSP) that contains a much 
smaller pump with the inflation part in the most dependent site and deflation part in the 
upper portion of pump. It delivers more volume per squeeze and is easier to find deflation 
button. The main difference with the previous pump is that the MSP deflates completely 
after pressing the deflation button for a few moments. It also has a lock-out valve precluding 
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auto-inflation of the implant. Early clinical studies reported significant reduction in time 
spent instructing the patient in use of this device (Henry GD, et al 2004). 
Semi-rigid rod prostheses are constructed of two solid prostheses that are independently 
placed in each corpus cavernosum(Sadeghi-Nejad H 2007). They are divided into two types 
as the malleable and the mechanical. Coloplast’s Genesis is a malleable device that consists 
of a braided silver wire surrounded by a silicone hydrophilic coat. The AMS 650 and 600 
implants have similar construction of silicone surrounding a stainless steel woven core.  Soft 
silicone rods were originally manufactured in France by Subrini (Subrini L 1982). They are 
ideal for patients in whom the cosmetic advantages of the inflatable devices are not as 
important as the ease of use and the lower chances of mechanical failure in semirigid 
implants. Pelvic organ transplant recipients may be well served by the semirigid devices 
rather than a three-piece inflatable device due to the results of a study addressing the higher 
incidence of reservoir complications in the retroperitoneal space (Cuellar DC, 2001). The 
narrow cylinders are appropriate for thin penises and for the penises with scar tissue where 
dilation to a large caliber corporal body is not easily performed. 
Implantation of three-piece inflatable prostheses is a complex issue since they require a 
reservoir which has a large volume to be placed in the abdominal cavity. Since reservoir has 
a high capacity, complications such as stretching of pliant tunica and compression of erectile 
tissue that cause deterioration of the erectile tissue with time which are observed with the 
use of self-contained or two-piece devices with no reserve fluid volume are not seen in 
three-piece inflatable implants (Wilson SK, et al 1996). The three-piece inflatable also gives 
the best flaccidity, as all fluid can be drained out of the cylinders into the reservoir when the 
non-erect state is desired. Satisfaction rates of 70–87% are reported from patients after 
appropriate consultation. 
2.3 Patient selection 
The surgeon has three choices when selecting a prosthesis for a particular patient which 
include semirigid, two-piece inflatable, and three-piece inflatable prosthesis. Generally, the 
decision of the type of the prosthesis to be used depends on the physician’s comfort with the 
surgical approach, assessment of body habitus, penile size, previous abdominal surgery and 
manual dexterity of the patient. Recently, the 3-piece inflatable prosthesis is accepted as the 
gold standard option in industrialized countries. 
The semi-rigid rods are easy to implant and manipulate since they are bendable and can 
easily be maneuvered (Hellstrom WG et al, 2010). This kind of implants may have tendency 
to be eroded through glans because of cylinder pressure and loss of sensation in patients 
with spinal cord injury. Implantation of inflatable prostheses in this patient population can 
be recommended even if the implant is used only to make condom catheter urinary 
drainage easier (Rossier 1984). 
Two-piece inflatable devices have the advantage of avoiding intra-abdominal reservoir 
placement. They provide better functional outcomes than rod implants in terms of rigidity 
and flaccidity. 
Although three-piece inflatable devices provide the best rigidity, it should be beneficial to 
use these devices in patients with a larger penis. Similarly, patients with shorter penises 
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mostly prefer three-piece devices because of the difficulty to hide semi-rigid rods and two-
piece implants. Semi-rigid rods are generally selected in patients with limited manual 
dexterity or those who experience problems with the use of hydraulic devices. A motivated 
partner who may manipulate the device will be an exception to this issue. 
Penile prosthesis implantation restores penetrative ability, however, it has no effect on 
recovery of sexual drive, glandular sensitivity and ejaculatory functions. If the removal of 
implants occurs at a later date, the capsule remains and the empty space will partially fill 
with proliferating scar tissue which makes it difficult for the patient to respond sufficiently 
to other medical treatment alternatives. Therefore, it is important that the patient should be 
aware of his expectations about the penile prosthesis. Also, a detailed discussion between 
surgeon and patient about the outcomes and potential complications of the procedure such 
as infection which may necessiate reoperation with a rate of 1-4% and mechanical 
dysfunction should be performed (Govier et al 1998, Wilson et al 1999). 
2.4 Preoperative preparation and postoperative care 
Preoperative preparation of patient aims to reduce the risk of infection (AUA Guidelines 
2005). Lower urinary tract should be investigated before prosthetic surgery to find out some 
abnormalities such as urinary tract infection and urethral stricture. A urinalysis, 
determination of post-void residual urine, and cystoscopy in indicated cases should be 
performed in order to rule out these abnormalities. If infection is detected, it should be 
treated or the patient should be placed on prophylactic antibiotic treatment before the 
surgery. Any obstruction that may be due to prostatic hypertrophy or bladder neck 
contracture should be treated prior to prosthetic surgery. Simultaneous insertion of penile 
prosthesis and artificial urinary sphincter may be recommended in patients who suffer from 
urinary incontinence after radical prostatectomy. Although there are some studies which 
reported that a better control of blood sugar in patients with diabetes mellitus is associated 
with a lower risk of infection, larger studies detected no difference in infection rates in 
normal or elevated blood glucose level (Wilson SK, et al 1998). More recently, Mulcahy et al 
reported the results of 6071 diabetic patients who underwent penile prosthesis implantation 
with antibiotic (minocycline and rifampin) impregnated and 624 patients implanted with 
non-antibiotic impregnated implants with initial revision rates of 1.47% and 4.17%, 
respectively(Mulcahy et al 2011). At the end of 7 year-follow-up, authors found out the rate 
of infection related revisions significantly lower for antibiotic impregnated implant (1.62%) 
than for nonimpregnated implants (4.24%). It is also determined that diabetic men had a 
significantly higher rate of revisions due to infection at 7 yr (1.88%) than men without 
diabetes (1.53%). Finally, authors concluded that this long-term evidence obtained from the 
largest patient population establishes that the use of an antibiotic-impregnated IPP can 
decrease revisions due to infection and this decline may represent a significant medical 
advance in erectile restoration for diabetic patient population. There are a few measures to 
decrease the risk of infection such as showering with antibacterial soap, shaving operation 
area and use of broad-spectrum antibiotics one hour prior to surgery. Insertion of a catheter 
may facilitate urethral dissection and provide space for reservoir placement by emptying the 
bladder if a scrotal incision is carried out. The catheter may remain until the following 
morning. Some surgeons have tendency to use drains at the end of the surgery to reduce 
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edema and provide an exit for bleeding. Such a drain is removed the following morning and 
has not demonstrated an increased incidence of prosthesis infection (Wilson SK, et al 1996). 
Most patients need oral pain medication following the surgery. Heavy exercise and other 
activities which may cause displacement of the reservoir into the inguinal canal are 
proscribed for 4 weeks. Patients are instructed to use the device and return the sexual 
activity at the postoperative period of 4 to 6 weeks (Montague DK. 2011). Since initial 
inflation of the prosthesis may be difficult to perform; it will be beneficial to instruct the 
patients to inflate and deflate the device twice daily for the first month after surgery.  
2.5 Operative technique 
There are a variety of approaches for the implantation of penile prostheses described in the 
literature. These are distal penile, infrapubic and penoscrotal approaches. The distal penile 
approach is generally preferred for insertion of a semirigid or malleable penile prosthesis. 
Better visualization for the reservoir placement is the advantage of infrapubic approach. 
However, neurovascular injury which may result in decreased distal penile sensation is 
more likely due to close relationship with neurovascular bundle. Two-piece devices, due to 
the absence of a separate reservoir, are best implanted through a penoscrotal incision. 
Infrapubic approach may be preferred in patients with the history of previous abdominal 
surgeries where reservoir placement is complicated, however, penoscrotal approach 
provides ease in massive obese patients. In conclusion, the approach chosen for each 
particular patient should be based upon the type of prosthesis available, anatomy and 
surgical history of patient and preference of the surgeon. 
2.5.1 Distal penile approach 
This approach is generally accepted as the best approach for insertion of a semirigid or 
malleable penile prosthesis. It provides some advantages such as well incision healing, 
allowing corporeal dilation, and facilitation of rod placement. 
After placement of a foley catheter, a circumcoronal incision is carried out and dissection is 
performed down to the layer of Buck’s fascia with special consideration to prevent harm to 
dorsal penile nerves, which course within Buck’s fascia. After identification of Buck’s fascia, 
stay sutures are placed in the two corpora through the tunica albuginea lateral to the penile 
nerves. Dilation of corpora is performed by large scissors to establish a track in the corporal 
tissue. Dilation then follows with Hegar or Brooks dilators from 9 to 14 depending upon 
required cylinder girth. Once the corpora are measured by using a Furlow or other dilator, 
the cylinders can be placed. The corporotomy is then closed with 2-0 absorbable, synthetic 
sutures. With noninflatable cylinders, a penile block can be performed and a 
noncompression dressing is applied. 
2.5.2 Infrapubic approach 
The infrapubic approach is carried out by a horizontal or vertical incision approximately one 
finger below the symphysis pubis. After performing incision, subcutaneous tissue is 
dissected down to the rectus fascia. The rectus fascia is then incised and dissected for 
approximately 2 to 3 cm. A midline separation of the rectus muscles is achieved by sharp 
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and blunt dissection to create a pouch beneath the rectus muscles in order to insert the 
reservoir without any discomfort. Dissection is then carried out over the corpora cavernosa. 
Sharp and blunt dissection is performed on either side of the fundiform ligament, 
identifying the dorsal neurovascular bundle. At this point, it should be remembered that the 
dorsal nerves of the penis lie approximately 2 to 3 mm lateral to the deep dorsal vein. Once 
Buck’s fascia has been dissected free from the tunica albuginea, the shiny white tunica 
albuginea is fixed with longitudinal traction sutures. Then, a corporotomy incision is 
performed between the traction sutures. Following corporotomy, scissors are used to initiate 
the tunneling of the corpora cavernosa. Hegar dilators from size 9 to 14 can also be used. If 
corporeal fibrosis is encountered, Rossillo cavernotomes can be used to dilate to size 12. 
After performing dilation bilaterally, Furlow introducer can be used to measure corporal 
length by using the traction suture as the reference point.  
Proximal and distal measurements are added to give total corporal length and choose 
appropriately sized inflatable cylinders. A length slightly less than the total measurement is 
usually used to permit comfortable positioning of the cylinders. Rear tip extenders of size 
0.5, 1, 2, 3 cm, or combinations thereof are placed on the proximal cylinder end to adjust 
length. 
Following measurement, interrupted sutures can be placed for subsequent corporotomy 
closure. When the corporotomy sutures are placed, cylinders are positioned in the dilated 
corpora cavernosa using the Furlow inserting tool with distal needle to pull the cylinders 
into position. It is important to ensure that adequate positioning of proximal and distal ends 
of cylinders has been performed. The corporal incision should be placed proximal enough to 
allow easy exit of the input tube and minimize cylinder/input tube contact. Closure of the 
corpora cavernosa is carried out with traction on the cylinder placement suture to maintain 
it in a flat, nonkinking position and ensure adequate seating. Following placement of 
cylinders and closure of the corporotomy incision, cylinder inflation can be tested by 
pumping fluid to identify any abnormalities in position, curvature, or related problems. A 
finger is placed beneath Scarpa’s fascia down into the scrotum on one side to develop a sub 
dartos pouch for the pump. The pump is then positioned in the most dependent portion of 
the scrotum. The reservoir is then placed into the previously prepared area and filled with 
saline. Before connection, it is important to release pressure on the filling syringe and 
determine if any backfilling is observed. This backfilling or backpressure may predict an 
autoinflation problem in the future. Tubing connection is then carried out using quick 
connectors or suture tie plastic connectors. The tubing is tailored to eliminate excessive 
length but to allow for adequate pump positioning. Shodded clamps are used to compress 
the ends of tubes. Following tailoring, tubes are irrigated to eliminate small particles or 
blood clots. After the tubing is connected, the adequacy of the connection is tested by gently 
pulling on the connectors. All shodded clamps are removed and the device is inflated and 
deflated on multiple occasions to ensure adequate location, placement, and erection. 
After that, thorough irrigation with antibiotic solution and then closure of rectus fascia with 
interrupted sutures are carried out. The wound then is closed in the standard fashion with 
two layers of subcutaneous tissue and a subcuticular skin suture leaving the cylinders 
partially inflated for 24 hours to improve haemostasis. A dry, sterile dressing is applied and 
a foley catheter is placed at the end of the procedure. Suction drains may be used according 
to surgeon’s preference. The catheter is usually removed in the first postoperative day. The 
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surgical history of patient and preference of the surgeon. 
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dorsal penile nerves, which course within Buck’s fascia. After identification of Buck’s fascia, 
stay sutures are placed in the two corpora through the tunica albuginea lateral to the penile 
nerves. Dilation of corpora is performed by large scissors to establish a track in the corporal 
tissue. Dilation then follows with Hegar or Brooks dilators from 9 to 14 depending upon 
required cylinder girth. Once the corpora are measured by using a Furlow or other dilator, 
the cylinders can be placed. The corporotomy is then closed with 2-0 absorbable, synthetic 
sutures. With noninflatable cylinders, a penile block can be performed and a 
noncompression dressing is applied. 
2.5.2 Infrapubic approach 
The infrapubic approach is carried out by a horizontal or vertical incision approximately one 
finger below the symphysis pubis. After performing incision, subcutaneous tissue is 
dissected down to the rectus fascia. The rectus fascia is then incised and dissected for 
approximately 2 to 3 cm. A midline separation of the rectus muscles is achieved by sharp 
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and blunt dissection to create a pouch beneath the rectus muscles in order to insert the 
reservoir without any discomfort. Dissection is then carried out over the corpora cavernosa. 
Sharp and blunt dissection is performed on either side of the fundiform ligament, 
identifying the dorsal neurovascular bundle. At this point, it should be remembered that the 
dorsal nerves of the penis lie approximately 2 to 3 mm lateral to the deep dorsal vein. Once 
Buck’s fascia has been dissected free from the tunica albuginea, the shiny white tunica 
albuginea is fixed with longitudinal traction sutures. Then, a corporotomy incision is 
performed between the traction sutures. Following corporotomy, scissors are used to initiate 
the tunneling of the corpora cavernosa. Hegar dilators from size 9 to 14 can also be used. If 
corporeal fibrosis is encountered, Rossillo cavernotomes can be used to dilate to size 12. 
After performing dilation bilaterally, Furlow introducer can be used to measure corporal 
length by using the traction suture as the reference point.  
Proximal and distal measurements are added to give total corporal length and choose 
appropriately sized inflatable cylinders. A length slightly less than the total measurement is 
usually used to permit comfortable positioning of the cylinders. Rear tip extenders of size 
0.5, 1, 2, 3 cm, or combinations thereof are placed on the proximal cylinder end to adjust 
length. 
Following measurement, interrupted sutures can be placed for subsequent corporotomy 
closure. When the corporotomy sutures are placed, cylinders are positioned in the dilated 
corpora cavernosa using the Furlow inserting tool with distal needle to pull the cylinders 
into position. It is important to ensure that adequate positioning of proximal and distal ends 
of cylinders has been performed. The corporal incision should be placed proximal enough to 
allow easy exit of the input tube and minimize cylinder/input tube contact. Closure of the 
corpora cavernosa is carried out with traction on the cylinder placement suture to maintain 
it in a flat, nonkinking position and ensure adequate seating. Following placement of 
cylinders and closure of the corporotomy incision, cylinder inflation can be tested by 
pumping fluid to identify any abnormalities in position, curvature, or related problems. A 
finger is placed beneath Scarpa’s fascia down into the scrotum on one side to develop a sub 
dartos pouch for the pump. The pump is then positioned in the most dependent portion of 
the scrotum. The reservoir is then placed into the previously prepared area and filled with 
saline. Before connection, it is important to release pressure on the filling syringe and 
determine if any backfilling is observed. This backfilling or backpressure may predict an 
autoinflation problem in the future. Tubing connection is then carried out using quick 
connectors or suture tie plastic connectors. The tubing is tailored to eliminate excessive 
length but to allow for adequate pump positioning. Shodded clamps are used to compress 
the ends of tubes. Following tailoring, tubes are irrigated to eliminate small particles or 
blood clots. After the tubing is connected, the adequacy of the connection is tested by gently 
pulling on the connectors. All shodded clamps are removed and the device is inflated and 
deflated on multiple occasions to ensure adequate location, placement, and erection. 
After that, thorough irrigation with antibiotic solution and then closure of rectus fascia with 
interrupted sutures are carried out. The wound then is closed in the standard fashion with 
two layers of subcutaneous tissue and a subcuticular skin suture leaving the cylinders 
partially inflated for 24 hours to improve haemostasis. A dry, sterile dressing is applied and 
a foley catheter is placed at the end of the procedure. Suction drains may be used according 
to surgeon’s preference. The catheter is usually removed in the first postoperative day. The 
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cylinders are deflated and patient discharged after the removal of drain. At discharge, 
patients are prescribed with a one-week antibiotic regimen and instructed to start cycling 
the device. Sexual activity can usually be resumed 6 weeks postoperatively (Garaffa G, et al 
2010).  
2.5.3 Penoscrotal approach 
Three-piece inflatable penile prostheses, as well as semirigid and two-piece prostheses can 
be implanted by a transverse or vertical penoscrotal incision. This approach has distinct 
advantages in obese patients and is the most common approach for routine penile prosthesis 
implantation. Since differentiation of corpus spongiosum and corpus cavernosum is 
mandatory during dissection in this approach, initial insertion of a foley catheter is 
generally recommended. The incision is placed in the upper portion of the scrotum one 
finger below the penoscrotal junction. Once the skin incision has been carried out, dissection 
is continued lateral to the corpus spongiosum and urethra to expose the corpora cavernosa. 
Incision, dilation, and closure of the corpora cavernosa are similar to that described 
previously for the infrapubic incision, but synthetic absorbable sutures should be used with 
this approach because the suture line may be palpable postoperatively. Cylinder sizing and 
placement are as described above. Pump placement is likewise in the most dependent 
portion of the scrotum just below the dartos fascia. Dissection for reservoir placements can 
be carried out with a second separate infrapubic incision, but is more commonly performed 
through the penoscrotal incision. The scrotal skin incision is retracted to the area of the 
external inguinal ring and dissection is carried out medial to the spermatic cord. It is 
important to drain the bladder completely at this point. The transversalis fascia is then 
identified and incised sharply using large scissors pushed firmly through the medial aspect 
of the external inguinal ring. Dilation is carried out with the index finger after incision of the 
transversalis fascia. The reservoir balloon is then positioned over the index finger and 
placed in the perivesical space. Inflation of the reservoir is carried out with care that no 
backpressure is observed. Pocket enlargement should be performed to prevent autoinflation 
in case of syringe refilling. Once the reservoir is placed, inflated, and tubing connected as 
previously described, the device is tested in inflation and deflation modes. Closure is carried 
out with a subcuticular suture in the standard fashion. 
2.6 Complications of penile prosthesis implantation  
Complications of penile prosthesis can be divided into two categories as intraoperative and 
postoperative complications. Intraoperative complications include corporal cross-over and 
corporal/urethral perforation. Corporal cross-over can be subdivided into proximal and 
distal and might be encountered during corporal dilatation or cylinder placement (Garaffa 
et al 2010). This complication may be easily detected and corrected during the procedure. 
Testing for cross over is performed by side by side placement of dilators in each corpus 
cavernosum with special consideration to symmetry and proper positioning. If a crossover  
is detected, the dilator may be simply redirected with the contralateral dilator left in situ  
to prevent repeat crossover. Corporal perforation may also be recognized and easily 
repaired during the procedure, however, if urethral perforation is suspected, the procedure 
should be abandoned to allow for spontaneous recovery of the tear or a direct repair 
through a separate incision should be performed while the cylinder is in place. 
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Postoperative complications include infection, mechanical failure, auto-inflation, glans 
tumescence or coolness, reservoir displacement, cylinder erosion or extrusion and 
cavernosal fibrosis. 
The two main complications of penile prosthesis implantation are mechanical failure and 
infection. Mechanical failure of penile prosthesis can include leakage from the cylinders, 
tubing fracture, reservoir malfunction, connector disruption, tube kinking and cylinder 
aneurysm. Historically, mechanical failure rates have been known to be low with many 
studies reporting rates of failure between 5-15% (Milbank et al 2002, Deuk et al 2001, Daitch 
et al 2001). Although, mechanical failure rates are low, manufacturers provided some 
improvements in the design of prostheses to achieve more successful outcomes. Five year 
freedom from mechanical failure rates reached over 90% after these improvements. More 
recently, Dhar et al. reported the long-term results of 455 patients who underwent penile 
prosthesis implantation with AMS 700 CX and found out that the overall freedom from 
reoperation was 74.9% and from mechanical failure was 81.3% after ten years (Dhar NB, et 
al 2006).  A large-scale study performed with 2384 patients who had undergone penile 
prosthesis implantation with four different implant types reported revision-free survivals 
for all reasons to be 68.5% at 10 years and 59.7% at 15 years. For freedom from mechanical 
failure, the results were 79.4% at 10 years and 71.2% at 15 years (Wilson SK, et al. 2007). In 
another recently published, long-term study, Kim et al. reported the mechanical reliability 
results of AMS 700CX/CXM in 397 men with mean age of 63.1 years and follow-up duration 
of 113 months (Kim et al 2010). Mechanical survival rates of the prostheses were 97.6%, 
93.2% and 78.2% at 3, 5, and 10 years after implantation, respectively. It is also reported that 
the overall survival of implants were significantly lower in patients with neurogenic ED 
when compared to non-neurogenic ones which may be due to decreased glandular 
sensation and difficulty in having natural position during sexual intercourse. 
Infection is the bane of penile prosthesis surgery because, if it occurs in the space around the 
implant, total removal of all prosthetic material will be needed. Penile prosthesis 
reimplantation is more difficult due to corporal fibrosis in these patients. 
A number of measures have been taken to decrease the risk of infection in prosthesis 
implanted patients. The most popular approach to reduce the rate of infection is the 
impregnation of antibiotics to the surface of prosthetic devices. Initial research suggests 
these newer interventions decrease the rate of prosthetic infection. With antibiotic 
prophylaxis, the infection rate is 2–3% and may be further reduced by using an antibiotic 
impregnated or hydrophilic-coated implant. Recently, Carson et al. reported the results of 
the retrospective comparison of the initial revision events due to infection in patients who 
underwent antibiotic impregnated or non-impregnated implantation with a follow-up of 7.7 
years. At the end of follow-up, it is determined that initial revision rates due to infection 
were significantly lower in the impregnated group (Carson CC 2011). In another study, the 
antimicrobial activity of InhibiZone-coated IPPs produced by AMS was compared with the 
Titan hydrophilic-coated implants (produced by Coloplast) dipped in vancomycin, in both in-
vivo and in-vitro animal models (Mansouri MD, et al 2009). The antimicrobial activity of the 
two implants was also compared against a control. In-vivo zones of inhibition were compared 
for each group against methicillin-resistant Staphylococcus aureus (MRSA), methicillin-
resistant S. epidermidis (MRSE), vancomycin-resistant Enterococcus (VRE), and Escherichia 
coli. It is found that the InhibiZone-treated implants produced a larger zone of inhibition 
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previously for the infrapubic incision, but synthetic absorbable sutures should be used with 
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be carried out with a second separate infrapubic incision, but is more commonly performed 
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of the external inguinal ring. Dilation is carried out with the index finger after incision of the 
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placed in the perivesical space. Inflation of the reservoir is carried out with care that no 
backpressure is observed. Pocket enlargement should be performed to prevent autoinflation 
in case of syringe refilling. Once the reservoir is placed, inflated, and tubing connected as 
previously described, the device is tested in inflation and deflation modes. Closure is carried 
out with a subcuticular suture in the standard fashion. 
2.6 Complications of penile prosthesis implantation  
Complications of penile prosthesis can be divided into two categories as intraoperative and 
postoperative complications. Intraoperative complications include corporal cross-over and 
corporal/urethral perforation. Corporal cross-over can be subdivided into proximal and 
distal and might be encountered during corporal dilatation or cylinder placement (Garaffa 
et al 2010). This complication may be easily detected and corrected during the procedure. 
Testing for cross over is performed by side by side placement of dilators in each corpus 
cavernosum with special consideration to symmetry and proper positioning. If a crossover  
is detected, the dilator may be simply redirected with the contralateral dilator left in situ  
to prevent repeat crossover. Corporal perforation may also be recognized and easily 
repaired during the procedure, however, if urethral perforation is suspected, the procedure 
should be abandoned to allow for spontaneous recovery of the tear or a direct repair 
through a separate incision should be performed while the cylinder is in place. 
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Postoperative complications include infection, mechanical failure, auto-inflation, glans 
tumescence or coolness, reservoir displacement, cylinder erosion or extrusion and 
cavernosal fibrosis. 
The two main complications of penile prosthesis implantation are mechanical failure and 
infection. Mechanical failure of penile prosthesis can include leakage from the cylinders, 
tubing fracture, reservoir malfunction, connector disruption, tube kinking and cylinder 
aneurysm. Historically, mechanical failure rates have been known to be low with many 
studies reporting rates of failure between 5-15% (Milbank et al 2002, Deuk et al 2001, Daitch 
et al 2001). Although, mechanical failure rates are low, manufacturers provided some 
improvements in the design of prostheses to achieve more successful outcomes. Five year 
freedom from mechanical failure rates reached over 90% after these improvements. More 
recently, Dhar et al. reported the long-term results of 455 patients who underwent penile 
prosthesis implantation with AMS 700 CX and found out that the overall freedom from 
reoperation was 74.9% and from mechanical failure was 81.3% after ten years (Dhar NB, et 
al 2006).  A large-scale study performed with 2384 patients who had undergone penile 
prosthesis implantation with four different implant types reported revision-free survivals 
for all reasons to be 68.5% at 10 years and 59.7% at 15 years. For freedom from mechanical 
failure, the results were 79.4% at 10 years and 71.2% at 15 years (Wilson SK, et al. 2007). In 
another recently published, long-term study, Kim et al. reported the mechanical reliability 
results of AMS 700CX/CXM in 397 men with mean age of 63.1 years and follow-up duration 
of 113 months (Kim et al 2010). Mechanical survival rates of the prostheses were 97.6%, 
93.2% and 78.2% at 3, 5, and 10 years after implantation, respectively. It is also reported that 
the overall survival of implants were significantly lower in patients with neurogenic ED 
when compared to non-neurogenic ones which may be due to decreased glandular 
sensation and difficulty in having natural position during sexual intercourse. 
Infection is the bane of penile prosthesis surgery because, if it occurs in the space around the 
implant, total removal of all prosthetic material will be needed. Penile prosthesis 
reimplantation is more difficult due to corporal fibrosis in these patients. 
A number of measures have been taken to decrease the risk of infection in prosthesis 
implanted patients. The most popular approach to reduce the rate of infection is the 
impregnation of antibiotics to the surface of prosthetic devices. Initial research suggests 
these newer interventions decrease the rate of prosthetic infection. With antibiotic 
prophylaxis, the infection rate is 2–3% and may be further reduced by using an antibiotic 
impregnated or hydrophilic-coated implant. Recently, Carson et al. reported the results of 
the retrospective comparison of the initial revision events due to infection in patients who 
underwent antibiotic impregnated or non-impregnated implantation with a follow-up of 7.7 
years. At the end of follow-up, it is determined that initial revision rates due to infection 
were significantly lower in the impregnated group (Carson CC 2011). In another study, the 
antimicrobial activity of InhibiZone-coated IPPs produced by AMS was compared with the 
Titan hydrophilic-coated implants (produced by Coloplast) dipped in vancomycin, in both in-
vivo and in-vitro animal models (Mansouri MD, et al 2009). The antimicrobial activity of the 
two implants was also compared against a control. In-vivo zones of inhibition were compared 
for each group against methicillin-resistant Staphylococcus aureus (MRSA), methicillin-
resistant S. epidermidis (MRSE), vancomycin-resistant Enterococcus (VRE), and Escherichia 
coli. It is found that the InhibiZone-treated implants produced a larger zone of inhibition 
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against MRSA, VRE, and E. Coli when compared with the vancomycin-dipped Titan implant 
and control and zones of inhibition were equivalent for MRSE in both implants. Similar results 
were obtained in animal models. Authors concluded that InhibiZone prostheses have a 
broader spectrum in vitro and a more durable antimicrobial activity in vitro and in an animal 
model than implants dipped in vancomycin. Therefore, the use of InhibiZone implants may 
help reduce the incidence of penile implant infection.  
The use of prophylactic broad spectrum antibiotics is widespread in penile prosthetic 
surgery; however, the timing of the administration of these antibiotics varies among 
different studies. According to the guidelines “infusion of the first antimicrobial dose should 
begin within 60 minutes before surgical incision and that prophylactic antimicrobials should 
be discontinued within 24 hours after the end of surgery”. It is well-known that infection 
rates in revision penile prosthetic surgery have been higher than primary implant surgery. 
During the revision surgery, the entire device is removed and the implant spaces are 
lavaged with multiple antiseptic solutions before implantation of a new device, the infection 
rate is similar to that with first time (primary) penile prosthesis implantation (Henry GD, et 
al 2005). Mulcahy et al. reported an 82% success rate achieved by using salvage therapy 
which involves removal and reimplantation immediately following thorough irrigation of 
the corpora with a multiantibiotic solution (Mulcahy et al 1996). More recently, the success 
rate increased to 84% in 101 patients who had infected implants (Mulcahy et al 2003). The 
salvage protocol described by Mulcahy should be performed in a stepwise fashion which 
consists of the removal of all prosthetic parts and foreign material, irrigation of wound and 
all compartments with 7 antiseptic solutions, changing operative equipment such as gloves, 
drapes and implantation of new prosthesis, closing the wound primarily without any drain 
and prescribe oral antibiotics according to culture for one month. The 7 antiseptic solution 
contains kanamycin and bacitracin, half strength hydrogen peroxide, half strength povidone 
iodine, water pic pressure irrigation with 1 gm vancomycin and 80 mg gentamicin in 5 liters, 
half strength povidone iodine, half strength hydrogen peroxide, kanamycin and bacitracin.  
Autoinflation of a three-piece device may cause discomfort for the patient. In a study, the 
rate of autoinflation was reported between 3-5% (Hollenbeck BK et al 2002).  
In order to prevent auto-inflation, Mentor developed a lockout valve mechanism that is 
added to prosthetic reservoir stem. This mechanism decreased the risk of autoinflation by 
transferring the fluid from reservoir in response to negative pressure from the pump 
(Wilson SK, et al 2002). Autoinflation risk decreased to the rate of 1.3% after this 
modification. 
Coloplast developed Coloplast Titan One-Touch Release (OTR) pump to make device 
deflation easier for the patient. The new OTR pump allows cylinder deflation with one firm 
squeeze to the release pads. One firm squeeze of these pads causes the deflate valve to shift 
into the open position, providing a new pathway for fluid flow from the cylinders to the 
reservoir. In a recent study, Shaw et al assessed the functionality and surgeon experience 
with 100 consecutive patients implanted with a Titan OTR pump, compared with 100 prior 
consecutive patients implanted with a Titan Genesis pump (Shaw et al.2011). At the end of a 
mean length of follow-up of 20.8 months in the Genesis group and 8.4 months in the OTR 
group, the average number of postoperative teaching sessions needed to teach the patient 
how to operate the device was significantly lower in the OTR group (1.87 vs. 1.19). It is also 
reported that no pump malfunctions were seen in either group and the OTR pump was 
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subjectively easier for the surgeon and the patient to deflate when compared with the 
Genesis pump.  
Reservoir complications are not commonly encountered, however, they include herniation 
into inguinal canal and upper scrotum or erosion into adjacent viscera. Reservoir herniation 
is a rare complication that occurs in approximately 0.7% of three-piece inflatable prosthesis 
surgery cases (Sadeghi-Nejad et al. 2001). This complication is exclusively limited to cases 
when the penoscrotal approach is used. It may be caused by vigorous postoperative 
coughing or failure of proper initial reservoir placement under the transversalis fascia. 
Reservoir protrusion through an unrecognized existing hernia or a large tranversalis defect 
created intraoperatively are other possible contributory factors. Decreased spontaneous 
autoinflation of the cylinders in the immediate postoperative period may result in a lower 
incidence of this adverse event. Correction of this complication is by revision through an 
inguinal incision with placement of the reservoir in its proper position and repairing the 
defect (Hellstrom WG, et al.2010). 
Some patients may suffer from poor support of the glans by the tips of the prosthesis. This 
angulation of the glans penis is called as the supersonic transport (SST) deformity because of 
the similarity of its appearance to the supersonic transport of aircraft. This deformity may 
develop secondary to small-size prosthesis or incomplete distal dilation of the corpora. If the 
problem occurs during the operation, following the achievement of adequate distal dilation, 
a larger rear-tip extender may be placed to lengthen the cylinder and see whether the defect 
is corrected. If the problem is noted in the immediate postoperative period, it is wise to wait 
a few weeks and allow for complete healing and scar formation, which may result in glans 
fixation and resolution of the SST deformity (Carson C. 1999)  
Device extrusion may develop as an isolated finding or may be a sign of the device infection. 
Semirigid prosthesis are more prone to erosion, as the rate was reported as 18.1% for 
semirigid prostheses, 2.4% for self contained inflatable and 0% for 3-piece inflatable ones 
(Zermann et al 2006). Distal cylinder extrusion can be corrected by preparing a new cavity 
for the distal cylinder behind the back wall of the fibrotic sheath containing it (Mulcahy JJ. 
1999). An alternative technique is to perform distal corporoplasty using synthetic material. 
Proximal perforation of the crura during the implant procedure can be repaired by the 
constructing wind sock of vascular prosthetic material and anchoring this to the prosthesis. 
More recently, Shindel et al described a novel technique of transglanular repair of the 
impending distal erosion of penile prostheses and reported successful outcomes in 4 of 6 
patients during the follow-up (Shindel et al. 2010).   
2.7 Outcomes of penile prosthesis surgery 
Different from other treatments of ED, inflatable prostheses allow men to achieve a rigid 
erection on demand and as often as desired and also allow them to maintain the erection for 
a long period of time. Men with ED may develop performance anxiety and loss of 
confidence in their sexual capabilities, however, implantation of penile prosthesis may 
restore both erectile capacity and men’s sexual confidence and provides the best results 
among all ED treatment modalities in terms of satisfaction. 
In a study performed with 138 ED patients, the satisfaction rates were found to be 
significantly higher in patients treated with penile prosthesis implantation when compared 
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(Zermann et al 2006). Distal cylinder extrusion can be corrected by preparing a new cavity 
for the distal cylinder behind the back wall of the fibrotic sheath containing it (Mulcahy JJ. 
1999). An alternative technique is to perform distal corporoplasty using synthetic material. 
Proximal perforation of the crura during the implant procedure can be repaired by the 
constructing wind sock of vascular prosthetic material and anchoring this to the prosthesis. 
More recently, Shindel et al described a novel technique of transglanular repair of the 
impending distal erosion of penile prostheses and reported successful outcomes in 4 of 6 
patients during the follow-up (Shindel et al. 2010).   
2.7 Outcomes of penile prosthesis surgery 
Different from other treatments of ED, inflatable prostheses allow men to achieve a rigid 
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significantly higher in patients treated with penile prosthesis implantation when compared 
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with patients treated with sildenafil and intracavernous prostoglandin E1(Rajpurkar et al 
2003). There are various studies that reported high satisfaction rates for both patients and 
partners after penile prosthesis implantation for the treatment of ED. Montorsi et al reported 
the results of 200 consecutive patients who underwent prosthetic surgery with 3-piece 
inflatable implants and reported a 98% patient and 96% partner satisfaction rate. Authors 
noted that the major factors that contribute to these high satisfaction rates are the rapid 
ability of the implants to produce an erection and consistent excellent rigidity (Montorsi et 
al 2000). However, loss of penile length which is likely to occur in revision surgeries after 
infection or penile shortening in Peyronie’s disease may result in much lower satisfaction 
rates (Montorsi et al 1996).   
There are many factors that may influence the patient satisfaction, such as postoperative 
pain and edema, occurrence of postoperative complications, cosmetic outcome, functional 
integrity of the device, ability to use and partner acceptance. Apart from these factors, 
reduced sensitivity, diminished sexual drive, unnatural feeling and perception of having a 
diminished role in initiating erection by the partner may be accepted as the other reasons of 
dissatisfaction. In a study performed by Akin-Olugbade et al over 114 penile prosthesis 
recipients, all patients showed significant improvement in IIEF and EDITS scores, however, 
patients with Peyronie’s disease, body mass index over 30 and who underwent radical 
prostatectomy had lower satisfaction rates than the overall group. It should be kept in mind 
that these men have shorter penile length and failure of the implants to restore this length 
loss may contribute to increased rate of dissatisfaction (Akin-Olugbade et al 2008). High 
complication rates and unrealistic expectations are the other reasons of this low satisfaction 
rate.  
More recently, Natali et al reported the results of 200 patients who underwent penile 
prosthesis implantation with AMS 700 CX, AMS Ambicor and AMS 600-650 with a mean 
follow-up of 5 years and found out a patient satisfaction rate of 97%, 81% and 75%, 
respectively (Natali et al 2008). In the same study, partner satisfaction rate was reported as 
92%,91% and 75%, respectively. In another case series, 41 of 42(97.6%) patients reported 
successful intersourse after penile prosthesis implantation (Xuan XJ et al 2007). Paranhos et 
al reported the outcomes of 139 patients who underwent penile prosthesis implantation 
with a mean follow-up of 40 months (Paranhos et al 2010). The overall satisfaction rate was 
86.3% for patients and 83.4% for partners at the end of the follow-up. In a recently 
performed study, Bettocchi et al evaluated 80 patients who underwent prosthesis surgery 
and reported that seventy-six patients (97%) affirmed to use penile prostheses frequently. 
Fifty-four patients (69%) and 70 partners (90%) affirmed that they never had problems with 
the use of the prosthesis and they considered themselves satisfied. Outcomes of these 
studies of penile prosthesis implantation concerning patient and partner satisfaction are 
summarized in table-1. 
3. Penile arterial revascularization   
Penile microarterial bypass surgery which was first described by Michal, is considered as a 
milestone in the treatment of ED because it is accepted as the only treatment option that is 
capable of restoring normal erectile function without the need of using any external 
mechanical (vacuum erection) devices, vasoactive medications or surgical placement of  
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implant 






















2010 80 97% 90% AMS 700 CX 
Table 1. Outcomes of the penile prosthesis procedures 
penile prosthesis (Michal 1973). The objective of the surgery is to bypass arterial lesions that 
cause obstruction in the hypogastric-cavernous arterial bed (Hellstrom WJ, et al. 2010). 
Specifically, this surgery aims to increase the cavernosal arterial perfusion pressure and 
blood inflow in patients with vasculogenic ED that is developed due to pure arterial 
insufficiency. Lack of standardization in patient selection, hemodynamic evaluation and 
surgical technique as well as limited long-term outcome data using validated instruments 
have resulted in this surgery being considered by many surgeons as an experimental 
procedure. However, guidelines recommended that this type of surgery is proposed only to 
men with recently acquired ED secondary to focal arterial lesions and with the evidence of 
no existing generalized vascular disease. Additionally long operation time and the 
requirement for microsurgical expertise resulted in less frequent use of penile 
revascularization procedures. The efficacy of this surgery is still controversial and not 
evidence-based, largely because the selection criteria, outcome measurements, and 
microsurgical techniques have not been objective or standardized.  The patients who are 
candidates for MABS (microarterial by-pass surgery) should fulfill some criteria such as age 
younger than 55 years with recently acquired ED due to focal occlusive disease of the 
common penile or cavernosal arteries detected by penile Doppler ultrasound, 
cavernosometry and selective internal pudendal arteriography. The patients who have 
vascular risk factors (diabetes, hypertension, tobacco use, hypercholesterolemia), evidence 
of neurological ED (eg multiple sclerosis, pelvic surgery, lumbosacral radiculopathies etc), 
nontreated hormonal abnormalities, psychiatric disorders (severe depression, bipolar 
disease, schizophrenia), Peyronie’s disease, premature ejaculation and any evidence of 
corporo-occlusive dysfunction should not be considered as a candidate for this type of 
surgery. Young men who have sustained traumatic arterial lesions appear to have better 
outcomes compared to elderly patients. 
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Historically, Michal et al who reported the first MABS, performed a direct anastomosis 
between the inferior epigastric artery (IEA) and the corpus cavernosum (Michal I) which 
provided a sufficient flow rate and intraoperative erection. However, this procedure 
resulted in anastomotic stenosis in all patients and unsatisfactory success rates. 
Consequently, they performed the anastomosis between the IEA (end-to-side) and the 
dorsal penile artery (DPA) and achieved a success rate of 56% (Michal II)( Michal et al 1980).  
Virag et al. performed the anastomosis between the IEA to the deep dorsal vein in order to 
increase penile perfusion in a retrograde fashion and reported a 49% success rate and an 
additional 20% improvement (Virag et al 1981). Furlow et al. also performed arterialization 
procedures of the dorsal vein with ligation of the circumflex branches to avoid glanular 
hyperemia, with success rates of 62% (Furlow et al 1988). Hauri reported a complicated side-
to-side anastomosis between the dorsal artery and vein covered by a spatulated IEA that 
resulted in success rates of 80% (Hauri 1984) 
MABS techniques that are currently defined include an anastomosis between the IEA to the 
dorsal vein (arterialization) or artery (revascularization). Artery-to-vein procedures are 
easier to perform than artery-to-artery, however, the failure rates are higher due to some 
reasons such as that the dorsal vein has valves that most likely impair penile reperfusion 
and may be associated with anastomotic thrombosis. Also, the use of a valvulotome may 
improve retrograde reperfusion to the corpora, but may also cause endothelial injury, which 
may activate the intrinsic pathway of the clotting system, leading to early thrombosis and 
failures. Finally, artery-to-artery MABS eliminates the possibility of penile hyperemia. 
Munarriz et al reported the long-term results of the patients who underwent MABS and 
although not supported by their data, they favor a MABS with the anostomosis between 
IEA- and the dorsal artery(Munarriz et al 2009).  
MABS has three steps which include dorsal artery dissection, IEA harvesting, and 
microsurgical anastomosis (Munarriz et al 2004).  
1. Dorsal artery dissection is performed via a 5-cm semilunar incision 2 cm below the 
penoscrotal junction. While the penis is stretched, blunt dissection is carried out along Buck’s 
fascia towards the glans to invert the penis. The fundiform ligament is identified and 
preserved to minimize penile shortening. The selected dorsal artery is isolated and mobilized 
proximally, avoiding injury of the dorsal nerves. Temporary scrotal closure is performed.  
2. Harvesting of IEA begins with a 5-cm transverse incision between umbilicus and pubis. 
Dissection is carried down through Scarpa’s fascia, the rectus fascia is divided vertically, and 
the rectus muscle mobilized medially. The IEA is identified and mobilized from its origin at 
the level of the common external iliac artery to the umbilicus. If arterial branches are found, 
they are controlled with bipolar cautery and divided. During the mobilization of the IEA, 
papaverine is utilized to prevent vasospasm. The distal end of the IEA is clipped near the 
umbilicus and divided. Subsequently, the scrotal staples are removed and a clamp is utilized 
to transfer the IEA to the dorsal aspect of the penis through the external inguinal ring. The 
abdomen is closed in a multilayer fashion using a running technique with 0 polyglycolic acid 
suture for the rectus fascia, 2-0 for Scarpa’s, and a 4-0 monocryl for the skin. 
3. Microvascular Anastomosis: The dorsal artery is mobilized and divided in a proximal 
location on the penile shaft. The proximal end is cauterized using the bipolar cautery. 
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Aneurismal clips are placed on the dorsal artery and IEA. The adventitia of the distal end of 
the IEA and proximal dorsal artery is sharply excised with microscissors to prevent 
thrombosis of the anastomosis. A microsurgical anastomosis is performed using a simple 
interrupted technique with 10-0 Nylon stitches. The dorsal aneurismal clip is removed and 
back blood flow is observed, documenting anastomotic patency. The IEA aneurismal clip is 
removed and if there is no anastomotic leak, the penis is placed back on its normal 
anatomical position, the Dartos closed with a running 2-0 polyglycolic acid suture, and the 
skin with a 4-0 polyglycolic acid suture. Patency of the anastomosis is further confirmed by 
Doppler ultrasound. 
3.1 Complications of the penile revascularization surgery 
Penile shortening and decreased penile sensitivity may be observed in up to 25% of the 
patients after the procedure (Munarriz 2010). It is thought that penile shortening is the result 
of fibrosis/scarring of the fundiform ligament and its incidence may be minimized by the 
preservation of this ligament during the procedure. Decreased penile sensation is mostly 
seen due to a denervation injury during surgery, however, patients who underwent this 
operation may still report improvement in their orgasmic function. Glans hyperemia is 
another commonly observed complication with a rate of 13% in some series (Manning M, et 
al 1998). Other less common complications are wound infection and inguinal hernia. 
3.2 Outcomes of penile revascularization surgery 
Generally, the studies reporting the results of penile revascularization surgery are 
retrospective, had small numbers of patients, short term follow-up, variable patient selection 
criteria and type of surgery. To make a standardization and proper evaluation of these 
studies published, however, AUA guidelines recommend some inclusion criteria such as 
presence of a normal serum testosterone level, failure of pharmacologic erection test, 
abnormal nocturnal penile tumescence or penile duplex Doppler ultrasonography, 
abnormal penile arteriogram, artery to artery or artery to dorsal vein anastomosis employed 
in surgical technique, objective follow-up data reported by either duplex Doppler 
ultrasonography, penile arteriogram, or validated outcome questionnaire in the absence of 
diabetes mellitus and history of smoking. Also the follow-up period of studies to be 
included should at least have a period of 12 months. There are only four studies fulfilling 
these criteria which report variable success rates with different surgical techniques (Table-2).     
Author Type of 
surgery 







Ang (1997) Dorsal vein 6 8-37(20) 66 (4) NPT,Doppler 
De Palma 
(1995) 
Dorsal artery 11 12 to 48 60% (7) Doppler 
Grasso (1992) Dorsal artery 22 12 months for all 68 (15) 36 (8) NPT, Doppler 
Jarow (1996) Mixed  11 12 to 84 (50) 91 (10) Doppler  
Munarriz 
(2010) 
Dorsal artery 71 NA(34.5) 88.7% (63) IIEF 
Table 2. Outcomes of the penile revascularization procedures 
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Apart from these studies, Kawanishi et al. reported the results of 51 men with arteriogenic 
ED who had objective outcome data reported by color Doppler duplex studies and a longer 
follow up period (Kawenishi et al 2004). The patency of the neoarterial blood flow either by 
the Hauri or Furlow-Fischer procedure was assessed objectively by color flow duplex 
Doppler. The authors reported the objective estimated efficacy rate as 84.9 % at 3 and 65.5% 
after 5 years of follow-up. 
Although guidelines do not recommend this kind of procedures in elderly people, Kayigil et 
al reported the results of deep dorsal vein arterialization (DDVA) in 43 carefully selected 
healthy elderly patients with a mean follow-up of 22 months(Kaygil et al 2008). All patients 
underwent DDVA using the Furlow-Fisher technique. Surgical outcome was tested 
postoperatively by IIEF score. The success rate of the operation was 60.5% at the end of 
follow-up. More recently, Kaygil et al reported the long-term results (73.2 months) of 110 
men who underwent revascularization surgery and reported an overall success rate of 
72%(Kaygil et al 2011). The success rates were 81.8% at 3 months, 77.2% at 1 year, 70% at 2 
years, 66.3% at 3 years, and 63.6% at 5-year after surgery in the patients who achieved a no-
ED threshold score of more than 26 in the IIEF-15. Authors concluded that this procedure 
may serve as a better alternative to prosthesis surgery by using a physiological restoration 
mechanism further studies are needed to compare the outcomes of different treatment 
modalities.   
Recently, Babei reported a systematic review and metaanalysis to determine the results of 
patients with arteriogenic ED who underwent penile revascularization surgery. 
Characteristics of participants, study qualities, types of interventions, cure rates and adverse 
events were analyzed. Outcomes of procedures were found to be better in men younger 
than 30 years old and in men with the absence of venous leakage and history of smoking. In 
conclusion, the authors noted that inconsistent measurements of outcomes limited the 
findings, and none of the studies were randomized controlled trials. Authors also concluded 
that this kind of procedures may be beneficial in highly selected patients, however, 
randomized-controlled trials examining penile revascularization techniques are needed to 
recommend one technique over another (Babei et al 2009). 
Robot-assisted vessel harvesting for penile revascularization is a new surgical approach in 
patients who suffered pelvic crush injuries resulting in post-traumatic ED. Raynor et al. 
reported five patients that underwent penile revascularization using a modified Virag-V 
technique (Raynor et al.2010). The epigastric artery was harvested robotically and 
transposed through a 3 cm incision at the base of the penis. Microscopic revascularization 
was performed by anastomosing the epigastric artery to the deep dorsal vein. Distal dorsal 
vein ligation of the subcoronal plexus was performed to prevent glans hyperemia. The 
procedure was successful in 4 patients. Authors concluded that this procedure is an ideal 
minimally invasive complement to penile revascularization which may shorten operation 
time and offer a novel option for the use of minimally-invasive technology.  
4. Surgical treatment of Corporal Veno-Occlusive Dysfunction (CVOD) 
Cavernous veno-occlusive dysfunction is another type of ED which may result from 
congenital reasons or trauma in young men, and acquired factors such as Peyronie’s disease, 
diabetes mellitus and late onset hypogonadism in older men. 
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Pathophysiology of venogenic ED (VED) consists of formation of large venous channels 
draining the corpora cavernosa, degenerative changes to the tunica albuginea, structural 
alterations of the cavernous smooth muscle and endothelium (Ghanem et al 2008). Whatever 
the cause is, the objective of the treatment is to obstruct this leakage. It is found out that the 
deep dorsal vein is the major site of venous leakage in more than 75% of cases (Fuchs et 
al.1989).  
Surgical treatment for VED should be considered when medical treatment fails to provide 
sufficient erection. Selection criteria for surgery include the patients with erections of short 
duration or tumescence only with sexual stimulation; younger than 50 years; normal 
cavernous arterial inflow in response to an intracavernous injection agent; and who are 
more likely to have venous leakage after performing Doppler ultrasound or penile 
cavernosography in the absence of chronic systemic diseases (Manning M et al 1998). 
Surgery for penile venous leakage is not recommended in older men because penile venous 
leakage often results from atrophy of the intracorporeal muscles or the tunica albuginea 
(Lue TF 1999, Montague DK, et al 1996).  However, when venous leakage is congenital, the 
deciency is usually in the large, ectopic, supercial and deep dorsal veins or the large 
crural veins (Lue TF, 1999, Ebbehoj et al. 1979). Currently, there is no evidence from 
randomized controlled trials to recommend a standardized approach for the diagnosis and 
effective treatment of veno-occlusive ED. Since it is generally accepted that venous leakage 
is an effect rather than a cause, and newer pathophysiologic mechanisms that cause CVOD 
and therapeutic possibilities that might address these causes, are being examined. Research 
continues to detect an effective surgical treatment alternative.  
Although there is no standard evidence-based surgical option, ligation of superficial dorsal 
vein, deep dorsal vein, crural vein, crural plication/ ligation, arterialization of deep dorsal 
or cavernosal veins or extraperitoneal laparoscopic penile vein ligation are some of the 
intervention types used in CVOD surgery. 
Recently, Cayan et al reported the results of a study including 26 men with a mean age of 34, 
who underwent penile venous surgery for primary venous leakage with a mean follow-up 
of 42 months (Cayan 2008). Surgical procedure consists of resection of the superficial and 
deep dorsal veins, ligation of the cavernous vein and 2 crura proximal to the entrance of the 
cavernous artery with umbilical tapes, and preservation of the dorsal artery and nerve on 
each side. In the follow-up, erectile function improved in 19 men and remained unchanged 
in 7 men. Patient satisfaction with no additional treatment or with phosphodiesterase-5 
inhibitors was 88.4% and only 3 patients were unsatisfied with the surgery. It is concluded 
that penile venous surgery with crural ligation for venous leakage has excellent long-term 
results, high patient satisfaction rate and should be offered to young men with primary 
cavernous ED. Additionally, young patients who have normal penile arterial system and no 
risk factors such as diabetes are the best candidates for the improved postoperative 
outcome. Since the surgery of ligation or resection for venous leakage has not been very 
successful and unsatisfactory long-term results have reduced the indications for venous 
surgery, a new technique which is the embedding of dorsal vein for dorsal venous leakage is 
reported to improve the long-term outcomes (Zhang et al 2009). The procedure is performed 
through a curved incision made over the root of the penis. Following the dissection of deep 
dorsal vein, a whole thickness tunica albuginea excision of about 0.8 cm was performed and 
the dissected vein is embedded to this newly formed groove. At the end of 42 months of 
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ED who had objective outcome data reported by color Doppler duplex studies and a longer 
follow up period (Kawenishi et al 2004). The patency of the neoarterial blood flow either by 
the Hauri or Furlow-Fischer procedure was assessed objectively by color flow duplex 
Doppler. The authors reported the objective estimated efficacy rate as 84.9 % at 3 and 65.5% 
after 5 years of follow-up. 
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4. Surgical treatment of Corporal Veno-Occlusive Dysfunction (CVOD) 
Cavernous veno-occlusive dysfunction is another type of ED which may result from 
congenital reasons or trauma in young men, and acquired factors such as Peyronie’s disease, 
diabetes mellitus and late onset hypogonadism in older men. 
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deep dorsal vein is the major site of venous leakage in more than 75% of cases (Fuchs et 
al.1989).  
Surgical treatment for VED should be considered when medical treatment fails to provide 
sufficient erection. Selection criteria for surgery include the patients with erections of short 
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is an effect rather than a cause, and newer pathophysiologic mechanisms that cause CVOD 
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of 42 months (Cayan 2008). Surgical procedure consists of resection of the superficial and 
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cavernous artery with umbilical tapes, and preservation of the dorsal artery and nerve on 
each side. In the follow-up, erectile function improved in 19 men and remained unchanged 
in 7 men. Patient satisfaction with no additional treatment or with phosphodiesterase-5 
inhibitors was 88.4% and only 3 patients were unsatisfied with the surgery. It is concluded 
that penile venous surgery with crural ligation for venous leakage has excellent long-term 
results, high patient satisfaction rate and should be offered to young men with primary 
cavernous ED. Additionally, young patients who have normal penile arterial system and no 
risk factors such as diabetes are the best candidates for the improved postoperative 
outcome. Since the surgery of ligation or resection for venous leakage has not been very 
successful and unsatisfactory long-term results have reduced the indications for venous 
surgery, a new technique which is the embedding of dorsal vein for dorsal venous leakage is 
reported to improve the long-term outcomes (Zhang et al 2009). The procedure is performed 
through a curved incision made over the root of the penis. Following the dissection of deep 
dorsal vein, a whole thickness tunica albuginea excision of about 0.8 cm was performed and 
the dissected vein is embedded to this newly formed groove. At the end of 42 months of 
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average follow-up, 14 of 17 patients reported satisfactory intercourse and three had 
sufficient erection after oral treatment. Besides, it was also noted that there were significant 
improvements in terms of IIEF-5 scores and some Doppler USG parameters in all patients. 
According to these results, authors concluded that this new surgical technique is a simple 
operation which seems to provide promising results with the need of future studies in the 
treatment of penile deep dorsal venous leakage of ED.      
Possible complications that may be encountered in the post-operative period include wound 
infection, skin necrosis, glandular hyperemia or hypoesthesia, inguinal hernia, penile 
curvature, shortening or edema. 
If CVOD surgery is going to be performed, a long-term follow-up of at least 48 months is 
recommended with the use of pre and postoperative validated scales (e.g. IIEF). Post-
operative follow-up should include objective evaluation of the penile vascular and erectile 
status. Penile color duplex ultrasound after complete cavernosal smooth muscle relaxation is 
the gold standard investigation of choice for both pre-op and post-op objective assessment. 
The type of operation offered to the patient should be determined depending on the 
experience and preference of the surgeon and the basis of the site, nature, and size of the leak. 
5. Conclusion  
Penile prosthesis implantation is currently the most effective treatment option in terms of 
both patient and partner satisfaction in the management of ED. Satisfaction rates and 
prosthesis survival significantly increased with the improvements in both prosthesis design 
and surgical techniques. Among prosthesis types, inflatable 3-piece prosthesis have the best 
outcomes and recommended for younger patients with normal manual dexterity, patients 
with Peyronie’s disease, neurological disorders, patients who underwent radical 
prostatectomy and in revision procedures. Preoperative preparation and use of antibiotic 
impregnated devices during surgery are the essential points to reduce the risk of prosthesis 
infection. The ideal prosthesis aims to mimic natural erection and flaccidity as well as 
possible and research to find the ideal prosthesis still continues. Further technological 
improvements may provide additional significant increases in satisfaction and survival rates 
and decrease the number of infected implants. Penile revascularization is not a commonly 
performed procedure and its use is limited only to selected cases because of the variabilities 
in inclusion and exclusion criteria, short length of follow-up, and lack of objective follow-up 
data. However, patients who are younger than the age of 55, non-smoker, non-diabetic with 
the absence of venous leakage may have a better outcome after the procedure. Penile venous 
surgery is not a recommended surgical treatment modality due to absence of a standardized 
surgical technique and follow-up data. This operation may only be recommended for young 
patients with site-specific congenital, posttraumatic or post-inflammatory venous leaks with 
informed consent. The type of the operation for each particular patient should be decided 
according to experience of surgeon, site, size and nature of the venous leak. 
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recommended with the use of pre and postoperative validated scales (e.g. IIEF). Post-
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prostatectomy and in revision procedures. Preoperative preparation and use of antibiotic 
impregnated devices during surgery are the essential points to reduce the risk of prosthesis 
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improvements may provide additional significant increases in satisfaction and survival rates 
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the absence of venous leakage may have a better outcome after the procedure. Penile venous 
surgery is not a recommended surgical treatment modality due to absence of a standardized 
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1. Introduction 
Erectile dysfunction (ED) is a complex, multifactorial issue commonly affecting men of all 
ages. ED is currently defined as “the inability to achieve and/or maintain penile erection 
sufficient to permit satisfactory sexual intercourse”, and has been associated with such risk 
factors as hypertension, diabetes, alcoholism, smoking, and pelvic surgery [1]. This condition 
has seriously impacted the men’s quality of life. Even though nowadays there are a large 
number of options to treat ED, a considerable number of patients do not answer adequately 
the conventional therapies available. Penile erection is achieved through a neurovascular 
response exhibiting an increase in arterial inflow, relaxation of corporal smooth muscle, and 
restriction of the venous outflow. Relatively recent pharmacological advances, namely oral 
phosphodiesterase-5 (PDE5) inhibitors, have become the first line of treatment in ED. PDE5 
inhibitors allow the patient to achieve a penile erection via the effects on the nitric oxide (NO) 
signaling pathway, which is the principal mediator of corporal smooth muscle relaxation. The 
inhibition of the degradative actions of PDE5 on 3’,5’-cyclic guanosine monophosphate 
(cGMP), the second messenger molecule of NO signaling, lead to an increased bioavailability 
of NO in the corporal smooth muscle thus promoting vasodilation and penile erection. 
However, despite the widespread efficacy of these medications, there are still men for which 
oral PDE5 inhibitors are ineffective. ED in men with diabetes, for example, is typically more 
severe, exhibiting a less effective response to PDE5 inhibitors when compared to non-diabetic 
patients. The vascular injuries that accompanies diabetes is often too damaging to endothelial 
physiology to allow adequate penile erections [4] and thus complicates use of the oral 
medications as treatment for ED. Due to the vast array of potential causes of ED ranging from 
neurogenic and vasculogenic to hormonal issues, there exists a continuing need to address 
these deficiencies in patient management of ED and pursue new treatments. Two avenues 
showing a great deal of promise in ED treatment are gene therapy and stem cell therapy, both 
of which could possibly provide methods to prevent or even cure ED. This chapter will focus 
on recent studies in both gene and stem cell therapies in ED research, with the objective to 
establish that continued scientific exploration into these fields will yield clinically applicable 
approaches to combat this condition.  
2. Gene therapy and ED 
Gene therapy is the introduction of exogenous genetic material into cells that either restores 
or enhances normal cellular function that is defective, or essentially attenuates the functional 
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number of options to treat ED, a considerable number of patients do not answer adequately 
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response exhibiting an increase in arterial inflow, relaxation of corporal smooth muscle, and 
restriction of the venous outflow. Relatively recent pharmacological advances, namely oral 
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severe, exhibiting a less effective response to PDE5 inhibitors when compared to non-diabetic 
patients. The vascular injuries that accompanies diabetes is often too damaging to endothelial 
physiology to allow adequate penile erections [4] and thus complicates use of the oral 
medications as treatment for ED. Due to the vast array of potential causes of ED ranging from 
neurogenic and vasculogenic to hormonal issues, there exists a continuing need to address 
these deficiencies in patient management of ED and pursue new treatments. Two avenues 
showing a great deal of promise in ED treatment are gene therapy and stem cell therapy, both 
of which could possibly provide methods to prevent or even cure ED. This chapter will focus 
on recent studies in both gene and stem cell therapies in ED research, with the objective to 
establish that continued scientific exploration into these fields will yield clinically applicable 
approaches to combat this condition.  
2. Gene therapy and ED 
Gene therapy is the introduction of exogenous genetic material into cells that either restores 
or enhances normal cellular function that is defective, or essentially attenuates the functional 
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effects of the mutant genetic phenotypic expression. This is accomplished through the use of 
vectors, which are designed to deliver or transfect a given gene into an organism allowing 
the organism to subsequently reproduce the gene and its protein product. Many different 
types of vectors have been characterized; viral vectors such as retroviruses and 
adenoviruses, cell-based vectors such as myoblasts and endothelial cells, as well as non-viral 
vectors such as plasmid DNA and naked DNA. Viral vectors are commonly used due to 
their high cellular transfection efficiency; however they have been shown to trigger immune 
and inflammatory responses which can reduce their effects [5]. The host’s immune response 
can generate antibodies to the virus being used as vector, prompting destruction of the 
delivery system before it generates a therapeutic effect [1]. Additionally, many of the viruses 
used as vectors do not exhibit tissue specificity, contributing to issues associated with viral 
migration through the systemic circulation to other unwanted tissues or organ systems [1].  
Several molecules have been examined as potential gene therapeutic approaches for ED, 
including vascular endothelial growth factor (VEGF), NO synthase, precalcitonin gene-
related peptide, brain derived neurotrophic factor, and the calcium sensitive potassium 
(maxi-K) channel [5]. The penis is considered to be a well suited structure for gene therapy 
due to its limited blood supply, which would decrease the risks associated with non-target 
infection via the systemic circulation. Its external positioning allows for an ease of 
accessibility for genetic manipulation, and the intracellular transference of the erectile tissue 
response to the delivery by gap junctions of corporal smooth muscle further make gene 
therapy a useful approach as only a proportion of cells are required to be transfected [5]. 
The relatively low turnover rate of vascular smooth muscle cells indicates the potential for 
long term expression of introduced genes and thus would yield an improvement over the 
short term effects of current pharmacological therapies [4]. The role of NO in regulating 
corporal smooth muscle relaxation is a primary area of concern in ED, and consequently a 
great deal of the research examining potential gene therapeutic treatments focuses on ways 
to repair deficient endothelial NO production. [4] 
2.1 eNOS gene therapy 
eNOS, or nitric oxide synthase 3, is an enzyme found in endothelial cells that produces the 
NO required for relaxation of the surrounding smooth muscle. It has been shown in patients 
with ED that a lack of eNOS expression potentiates the difficulties in achieving and 
maintaining adequate penile erection through low bioavailability of NO and subsequent 
increase in vascular tone [4]. There have been several studies examining the role of eNOS 
gene therapy to treat many of the underlying vascular pathologies leading to ED. Champion 
et al. studied the effects of using adenoviral gene transfer of eNOS in an age-related rat 
model of ED. Through the increase in production of eNOS mRNA and subsequent increase 
in protein expression, it was observed that there was a notable increased erectile response to 
cavernous nerve stimulation, PDE5 inibitors, and also acetylcholine post-treatment. Within 
the aged-penis there was also an increase in the presence of cGMP noted. In diabetic rat 
models, intracavernosal pressure recorded during cavernosal nerve stimulation is markedly 
lower when compared to the control animals [1]. Bivalacqua et al. have shown that the use 
of intracavernous eNOS transfection is also a viable therapy, improving both the erectile 
response to cavernous nerve stimulation and the levels of corporal NO in diabetic rat model 
of ED. These findings were assessed in conjunction with the use of a PDE5 inhibitor in the 
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diabetic rat model, and it was observed that when combined with intracavernous eNOS 
transfection the erectile response to the pharmacologic treatment was increased along with 
levels of cGMP in the penis.  
2.2 VEGF gene therapy 
Vascular endothelial growth factor (VEGF) is a multifunctional protein and a critical 
mediator of endothelial and smooth muscle physiology. It stimulates angiogenesis and 
increases vascular permeability as well inhibits apoptosis, and as such it provides a potential 
therapeutic approach for the treatment of ED by increasing NO levels through the 
expansion of penile vasculature [1]. The increase in vasculature would bring about an 
accompanying increase in endothelial cells, thus creating an increase of NO production in 
the target organ. Both VEGF and its receptor flk-1 have been shown to be downregulated in 
certain types of ED [4], suggesting a possible pathological association. There have been 
several studies indicating the potential benefits of VEGF treatment for ED. Intracavernous 
injection of VEGF has been shown to provide a protective effect against hypercholesteremia 
in penile corporal endothelium from an atherosclerotic rabbit model of ED. This protective 
effect of VEGF has also been shown in other models of ED such as those accompanying 
diabetes or in traumatic arteriogenic ED. Additionally, endothelial hypertrophy and 
hyperplasia were observed following intracavernous VEGF protein delivery in another 
hypercholesteremic ED model [4]. It is believed that the anti-apoptotic effects of VEGF are 
associated with this hyperplasia and hypertrophy of endothelial cells, potentially by directly 
inducing anti-apoptotic pathways in the endothelium. Other potentially therapeutic effects 
of VEGF in connection with ED are an increase in the expression of eNOS and a stimulatory 
effect on eNOS phosphorylation.  
Further studies have utilized the data supporting the benefits of VEGF protein introduction 
as a foundation for designing VEGF gene therapy treatments. The goal was that introducing 
VEGF DNA would increase long-term expression of VEGF and ameliorate any deficiencies 
in protein amount, essentially acting as a curative treatment for ED [4]. In a study by Rogers 
et al., an adeno-associated virus was used to transfect VEGF DNA into a model of venogenic 
ED, with resulting active angiogenesis indicated by endothelial cell hypertrophy and 
hyperplasia. A similar study examining VEGF DNA delivery in a venogenic model of ED 
using an adenovirus was shown to increase phosphorylation of eNOS leading to a 
concurrent increase in the bioavailability of NO and recovery of erectile function [10]. VEGF 
introduction has also been examined using a combined gene therapy approach with 
angiopoetin-1, an angiogenic growth factor that promotes the creation of new blood vessels 
from pre-existing vessels. Using an adenovirus for both VEGF and angiopoetin-1 in a 
hypercholesteremic rat model of ED, it was found that the ratio of phosphorylated eNOS to 
total eNOS was markedly higher in animals receiving the gene therapy versus the control 
animals. The combined gene therapy approach was found to increase factor VIII-positive 
endothelial density with a subsequent increase in erectile response to electrical stimulation, 
suggesting the importance of functional endothelium in management of ED. 
2.3 SOD gene therapy 
Another potential target for gene therapy in ED is utilizing superoxide dismutase (SOD) to 
decrease the levels of reactive oxygen species (ROS). Reactive oxygen species have been 
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diabetic rat model, and it was observed that when combined with intracavernous eNOS 
transfection the erectile response to the pharmacologic treatment was increased along with 
levels of cGMP in the penis.  
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therapeutic approach for the treatment of ED by increasing NO levels through the 
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accompanying increase in endothelial cells, thus creating an increase of NO production in 
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injection of VEGF has been shown to provide a protective effect against hypercholesteremia 
in penile corporal endothelium from an atherosclerotic rabbit model of ED. This protective 
effect of VEGF has also been shown in other models of ED such as those accompanying 
diabetes or in traumatic arteriogenic ED. Additionally, endothelial hypertrophy and 
hyperplasia were observed following intracavernous VEGF protein delivery in another 
hypercholesteremic ED model [4]. It is believed that the anti-apoptotic effects of VEGF are 
associated with this hyperplasia and hypertrophy of endothelial cells, potentially by directly 
inducing anti-apoptotic pathways in the endothelium. Other potentially therapeutic effects 
of VEGF in connection with ED are an increase in the expression of eNOS and a stimulatory 
effect on eNOS phosphorylation.  
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in protein amount, essentially acting as a curative treatment for ED [4]. In a study by Rogers 
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ED, with resulting active angiogenesis indicated by endothelial cell hypertrophy and 
hyperplasia. A similar study examining VEGF DNA delivery in a venogenic model of ED 
using an adenovirus was shown to increase phosphorylation of eNOS leading to a 
concurrent increase in the bioavailability of NO and recovery of erectile function [10]. VEGF 
introduction has also been examined using a combined gene therapy approach with 
angiopoetin-1, an angiogenic growth factor that promotes the creation of new blood vessels 
from pre-existing vessels. Using an adenovirus for both VEGF and angiopoetin-1 in a 
hypercholesteremic rat model of ED, it was found that the ratio of phosphorylated eNOS to 
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endothelial density with a subsequent increase in erectile response to electrical stimulation, 
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2.3 SOD gene therapy 
Another potential target for gene therapy in ED is utilizing superoxide dismutase (SOD) to 
decrease the levels of reactive oxygen species (ROS). Reactive oxygen species have been 
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shown to play a critical role in endothelial cell dysfunction, primarily through the actions of 
superoxide scavenging of NO to form the toxic substance peroxynitrite [4]. Superoxide and 
peroxynitrite create a cascade of ROS formation by uncoupling eNOS within the 
endothelium, decreasing the production of NO and thus impairing erectile function. This 
creation of ROS is exacerbated by the expression of inducible nitric oxide synthase (iNOS) 
during oxidative stress conditions, leading to the production of even more ROS. 
Antioxidants are involved in attenuating the toxic effects of ROS. SOD, found in cells such 
as vascular endothelium, helps to decrease levels of superoxide by catalyzing the 
dismutation of the ROS into hydrogen peroxide and water [4].  
In a study by Bivalacqua et al., intracavernous adenoviral gene transfer of extracellular SOD 
was performed in an age-related rat model of ED in an attempt to decrease the levels of 
ROS. In the rat model there was an observed increase in superoxide production, a decrease 
in cGMP production as well as a decrease in erectile response to cavernous nerve 
stimulation. Additionally, they used nitrotyrosine staining as a measure of oxidative stress 
and found elevated levels in the aged rats. Following transfection of extracellular SOD 
DNA, there was an increase in extracellular SOD mRNA, protein, and activity levels, along 
with an increase in cGMP production. Oxidative stress was again measured using 
nitrotyrosine staining and a decrease was observed post therapeutic treatment. Erectile 
response to cavernous nerve stimulation was also restored, suggesting that the introduction 
of extracellular SOD DNA holds potential a viable gene therapy treatment to combat ED 
resulting from ROS damage to penile endothelium. It has also been shown that ROS play a 
role in diabetes-related vascular dysfunction and also ED [4], prompting studies on the 
effects of extracellular SOD gene therapy in diabetic models of ED. Extracellular SOD 
expression was notably decreased in the diabetic penis, contributing to an increase in the 
levels of ROS present. Adenoviral transfection of extracellular SOD decreased levels of 
superoxide and increased cGMP production, which together improved erectile function in 
an endothelium dependent manner. 
2.4 Anti-arginase gene therapy 
Supplementation of the amino acid L-arginine, either through the diet or direct infusion, has 
been shown to cause an increase in NO and a subsequent enhancement of endothelium-
related vasodilation in the penis [2]. L-Arginine is used as a substrate by both eNOS and 
arginase, the latter of which converts L-arginine to urea and L-ornithine. This creates a 
synergistic relationship between the two enzymes, as an increase in arginase activity leads 
to a downregulation of NO biosynthesis through competition with eNOS [2]. The enzyme 
arginase has two isoforms, arginase I and arginase II. Arginase I and II are commonly 
referred to as the hepatic type and extrahepatic type, respectively, though in a study by 
Bivalacqua et al. which showed an increase in arginase activity in human diabetic corpus 
cavernosum that both arginase isoforms were found. It was suggested that the impaired 
endothelium-derived NO bioactivity or signaling via an increased expression of arginase 
plays a role in the reduction of endothelium-dependant response in the penis of aged mice 
[2]. Utilizing adeno-associated viral gene transfer of anti-arginase, Bivalacqua et al. found 
that there was a decrease of arginase-1 protein and mRNA in the aged mouse penis 
accompanied by restoration of endothelial and erectile function in vivo [2]. The increase in 
erectile function was attributed to the increase in constitutive NOS activity and penile cGMP 
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levels, suggesting that arginase can interfere with normal erectile function by decreasing 
production of endothelium-derived eNOS in the penis. Interestingly, it has been shown that 
in the aged rat penis there is an increase in eNOS protein expression in endothelial cells due 
to a reduction in caveolin-1, a protein that regulates eNOS. This increase in eNOS protein 
expression is accompanied by a significant decrease in eNOS activity, suggesting that the 
upregulated protein is not biologically active. This is supported by the restoration of 
endothelial vascular responses as a result of increased eNOS activity following adeno-
associated viral gene transfer of anti-arginase [2]. While arginase inhibition was shown to 
improve erectile function, it was not shown to fully restore it, suggesting that there are likely 
multifactorial mechanisms of endothelial dependant erectile response impairment. Even 
still, the enhanced penile eNOS activity and cGMP levels resulting from arginase inhibition 
via anti-arginase gene therapy make it a potential molecular therapeutic treatment of age-
associated vasculogenic ED [2]. 
When considering gene therapy as a treatment for ED, there are a number of potential issues 
that need to be taken into consideration. As mentioned previously, there is the risk that viral 
vectors could enter the systemic circulation and thus cause random transgene expression in 
unwanted tissues or organs. Increasing the specificity of viral vectors, such that they could 
target appropriate cells without damaging other cells, could allow for injection systemically 
rather than intracavernously. There are several methods that have been examined by which 
to increase the specificity of the viral vectors such as transcriptional and transductional 
targeting. Transcriptional targeting works through the selection of a cell specific promoter , 
whereas transductional targeting utilizes cell specific membrane markers to induce delivery 
of the genetic material. The risk of an immune response to the commonly studied viral 
vectors is also a concern, as this could hinder use of the therapy in both, acute or repeated 
clinical treatments. To limit the possibility of an unwanted immune and inflammatory 
response, it would be beneficial to lower the necessary load of virus required to transduce 
cells in the penis. Future studies exploring gene therapy for the treatment of ED should look 
to create as normal of an erectile response as possible by maximizing the specificity of the 
treatments as well as decreasing any potential unwanted side effects.  
3. Stem cell therapy and ED 
Stem cells have become increasingly popular as a potential treatment for a wide variety of 
diseases, including ED. Stem cells are defined by the capacity to self renew and differentiate 
into one or more distinct cell types. The stem cell’s potential to differentiate can be 
extensive, being referred to as pluripotent when it can differentiate into any cell type in the 
organism. Other levels of differentiation ranging from multipotent to the more limited 
progenitor cells exist, providing numerous avenues from which potential therapies can be 
pursued. With the advent of induced pluripotential stem cells (iPS cells), scientists now have 
access to a line of pluripotent cells with which to work without many of the moral and 
ethical concerns revolving around the use of human embryonic stem cells. Adult-derived 
stem cells are also an area of current research, utilizing cell types such as mesenchymal stem 
cells and adipose-derived stem cells to replace lost or damaged cells in target tissues [2]. 
Stem cell treatment is attractive as a potential therapy for ED due to the underlying 
multifactorial pathologies responsible for the disease. The ability to replace whole cells 
could correct several of the associated specific molecular pathologies of ED with one type of 
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multifactorial pathologies responsible for the disease. The ability to replace whole cells 
could correct several of the associated specific molecular pathologies of ED with one type of 
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treatment [2]. Stem cell replacement of penile endothelial cells may allow for recovery of 
normal erectile response, as endothelial dysfunction is one of the primary causes of ED.  
3.1 MSC therapy 
One of the more commonly used adult stem cells is mesenchymal stem cells (MSCs). There 
are produced in the bone marrow, as well as certain other tissues and organs, and they 
possess the ability to differentiate into a wide variety of cell types depending on the 
biological environment [2]. They are able to be isolated and expanded ex vivo, making them 
an advantageous choice for cell therapy [3]. It has been shown previously that MSCs are 
able to differentiate into endothelial and smooth muscle cells to repair vascular injury in 
vivo, making them a viable option for the treatment of vasculogenic ED. In a study by 
Bivalacuqa et al., MSCs were used to differentiate into endothelial cells, thereby improving 
endothelium-derived NO bioavailability and thus erectile physiology. The MSCs were 
injected intracavernously with or without simultaneous eNOS gene therapy, and in both 
groups there was a marked increase in erectile response, eNOS activity, and cGMP levels. 
The MSCS were found to still be present and expressing endothelial and smooth muscle cell 
markers not present before injection twenty-one days post injection, which suggests that the 
differentiated stem cells could provide long term replacement of damaged cells. Other 
studies have also examined the combined use of MSCs and gene therapy. In a recent study 
by Qiu et al., the efficacy of MSCs both alone and in combination with VEGF gene therapy 
for the treatment of ED in a type 1 diabetic rat model was observed. The survival of 
engrafted stem cells in the target tissue is always a concern during treatments, including in 
this study following intracavernous implantation. Survival of MSCs has been shown to 
increase when coupled with VEGF treatment, as noted by the accompanying increase in pro-
survival factors phosphorylated Akt and Bcl-xL. Improved erectile function and an increase 
in the number of endothelial and smooth muscle cells were noted post injection, with the 
rats receiving the combined stem cell and VEGF gene therapy exhibiting the greatest 
increase compared to the animals treated with MSCs alone or the control group [3]. This 
suggests that the use of MSCs is a potential route for stem cell therapy of ED, especially 
when considered with concurrent gene therapeutic treatments.  
3.2 ADSC therapy 
Another type of adult stem cells that has been examined for the treatment of ED is adipose-
derived stem cells (ADSCs). They are found in fat tissue and possess the qualities of stem 
cell, namely self-renewal and differentiation into multiple cell phenotypes, as well as the 
ability to provide functional repair of damaged tissue. In terms of differentiation and 
therapeutic potential, ADSCs are similar to MSCs but are easier and safer to harvest in large 
quantities as adipose tissue is a readily available biological source. ADSCs have been shown 
to be vascular precursor stem cells, making them an appropriate choice for stem cell therapy 
of ED [24]. In a study by Bella et al., the effects of ADSCs to repopulate endothelial and 
smooth muscle cells in erectile tissue following bilateral cavernous nerve crush injury were 
examined. Using intracavernosal pressure (ICP) as a measure of erectile function, the 
animals treated with ADSCs were observed to have higher ICP response and thus a better 
recovery of erectile function when compared with the control animals. The ability of ADSCs 
to help restore erectile function in this study was suggested to result from their 
 
Gene and Stem Cell Therapy in Erectile Dysfunction 
 
191 
differentiation into local penile cell types, as well through the secretion of growth factors 
that recruited local stem cells to differentiate, promoted IGF-1 mediated local functional cell 
growth, and exhibited a neurotrophic effect to promote nerve regeneration [26].  
In another study using ADSCs, Garcia et al. tested the use of ADSCs for the treatment of ED 
in obese type 2 diabetic ZDF rats. These rats were shown previously to have an 85% 
prevalence of impotence (ICP60 cmH2O) among their population, making them an 
appropriate model to test the efficacy of ADSCs to survive in-vivo and subsequently restore 
erectile function. Three weeks after ADSCS injection into the rat penis, there was a noted 
functional improvement in erectile function when compared with untreated animals, as 
indicated by an improvement in ICP. It was determined that the effect of the treatment may 
be a result of an increase in the population of endothelial cells and a decrease in 
intracorporal tissue apoptosis among the treated rats. The survival of the ADSCs was 
assessed using BrdU labeling, which did not indicate the presence of many injected ADSCs 
after three weeks post injection. This suggests that the observed therapeutic effects likely 
result from elaboration of cytokines and growth factors from the ADSCs as opposed to 
direct differentiation in local cell types. An increase in nNOS (NOS type 1) was also seen, 
indicating that there may have been a restorative impact on nitrergic neuron axons and 
ganglia leading to improved erectile function. However, it is also possible that this increase  
 
Fig. 1. Gene and stem cell therapies for the treatment of ED. Gene therapy treatments consist 
of eNOS, VEGF, SOD, and arginase inhibitor vectors. Stem cell therapy treatments include 
adipocyte-derived stem cell (ADSCs) and mesenchymal stem cell (MSCs) introduction into 
the cavernosal tissue. A combined gene therapy and stem cell therapy approach utilizing 
MSCs and VEGF has also been studied. 
 
Erectile Dysfunction – Disease-Associated Mechanisms and Novel Insights into Therapy 
 
190 
treatment [2]. Stem cell replacement of penile endothelial cells may allow for recovery of 
normal erectile response, as endothelial dysfunction is one of the primary causes of ED.  
3.1 MSC therapy 
One of the more commonly used adult stem cells is mesenchymal stem cells (MSCs). There 
are produced in the bone marrow, as well as certain other tissues and organs, and they 
possess the ability to differentiate into a wide variety of cell types depending on the 
biological environment [2]. They are able to be isolated and expanded ex vivo, making them 
an advantageous choice for cell therapy [3]. It has been shown previously that MSCs are 
able to differentiate into endothelial and smooth muscle cells to repair vascular injury in 
vivo, making them a viable option for the treatment of vasculogenic ED. In a study by 
Bivalacuqa et al., MSCs were used to differentiate into endothelial cells, thereby improving 
endothelium-derived NO bioavailability and thus erectile physiology. The MSCs were 
injected intracavernously with or without simultaneous eNOS gene therapy, and in both 
groups there was a marked increase in erectile response, eNOS activity, and cGMP levels. 
The MSCS were found to still be present and expressing endothelial and smooth muscle cell 
markers not present before injection twenty-one days post injection, which suggests that the 
differentiated stem cells could provide long term replacement of damaged cells. Other 
studies have also examined the combined use of MSCs and gene therapy. In a recent study 
by Qiu et al., the efficacy of MSCs both alone and in combination with VEGF gene therapy 
for the treatment of ED in a type 1 diabetic rat model was observed. The survival of 
engrafted stem cells in the target tissue is always a concern during treatments, including in 
this study following intracavernous implantation. Survival of MSCs has been shown to 
increase when coupled with VEGF treatment, as noted by the accompanying increase in pro-
survival factors phosphorylated Akt and Bcl-xL. Improved erectile function and an increase 
in the number of endothelial and smooth muscle cells were noted post injection, with the 
rats receiving the combined stem cell and VEGF gene therapy exhibiting the greatest 
increase compared to the animals treated with MSCs alone or the control group [3]. This 
suggests that the use of MSCs is a potential route for stem cell therapy of ED, especially 
when considered with concurrent gene therapeutic treatments.  
3.2 ADSC therapy 
Another type of adult stem cells that has been examined for the treatment of ED is adipose-
derived stem cells (ADSCs). They are found in fat tissue and possess the qualities of stem 
cell, namely self-renewal and differentiation into multiple cell phenotypes, as well as the 
ability to provide functional repair of damaged tissue. In terms of differentiation and 
therapeutic potential, ADSCs are similar to MSCs but are easier and safer to harvest in large 
quantities as adipose tissue is a readily available biological source. ADSCs have been shown 
to be vascular precursor stem cells, making them an appropriate choice for stem cell therapy 
of ED [24]. In a study by Bella et al., the effects of ADSCs to repopulate endothelial and 
smooth muscle cells in erectile tissue following bilateral cavernous nerve crush injury were 
examined. Using intracavernosal pressure (ICP) as a measure of erectile function, the 
animals treated with ADSCs were observed to have higher ICP response and thus a better 
recovery of erectile function when compared with the control animals. The ability of ADSCs 
to help restore erectile function in this study was suggested to result from their 
 
Gene and Stem Cell Therapy in Erectile Dysfunction 
 
191 
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in nNOS was a result of increased oxygenated blood flow supplying more dorsal nerve 
nNOS following erectile function improvement. The use of ADSCs is an attractive 
therapeutic option in future studies, as the ease with which great numbers of cells can be 
harvested eliminates the need for ex vivo cell culture, thereby reducing the risk of 
contamination from a variety of organisms.   
4. Conclusion 
The advent of gene and stem cell therapy has unveiled new horizons for the future of 
medicine and clinical treatments. Among the many potential diseases able to be positively 
altered by these therapeutic treatments, ED has already been shown to be an appropriate 
pathological target. The use of gene and stem cell therapies alone or in combination with 
each other and other treatments such as pharmacological interventions holds great promise 
in the future care of patients afflicted with ED (Figure 1). 
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1. Introduction 
Cardiovascular disease (CVD) is a major factor in mortality rates around the world and 
contributes to more than one-third of deaths in the United States [1]. The distribution of 
blood volume to different parts of the human vascular system can be seen in Figure 1. CVDs 
are the world’s largest killers, claiming 17.1 million lives a year [1]. Tobacco use, an 
unhealthy diet, physical inactivity and harmful use of alcohol increase the risk of heart 
attacks and strokes [2]. Table 1 introduces the common risk factors of CVD.  In addition, 
Table 1 shows some common types of CVD risk factors. 
 
Fig. 1. Distribution of blood volume for the different parts of the human vascular system 
Source: [3] 
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Risk factor Risks can’t be changed 
Risks can be 
modified or treated 
Factors contribute 
to heart disease risk 
1 Increasing age Tobacco smoke Response to stress 
2 Gender High blood cholesterol 
Drinking alcohol 
3 Heredity high blood pressure Smoking 
4 Family history Physical inactivity  
5  Obesity  
6  Diabetes mellitus  
Table 1. Common types of CVD risk factors 
The underlying cause of CV disease is atherosclerosis, a chronic inflammatory process that 
is clinically manifested as coronary artery disease, carotid artery disease, or peripheral 
artery disease [1; 4]. The frequency and prevalence of atherosclerosis are difficult to be 
assessed exactly. It has been predicted that atherosclerosis will be the primary cause of 
death in the world by 2020 [5]. Usually, atherosclerosis is an asymptomatic condition that 
might begin from childhood, whereas symptomatic organ-specific clinical manifestations 
often do not appear until 40 years of age or older when it is most commonly diagnosed [6]. 
Atherosclerosis can be characterized as a slow disease in which the arteries become 
hardened. In other words, it is characterized by the formation of arterial lesions or plaques 
as a result of an inflammatory response to endothelial injury [7]. Atherosclerosis eventually 
leads to artery enlargement, arterial stenosis, and may ultimately produce an arterial 
rupture [8]. The more commonly used subclinical vascular markers in the clinical setting are 
carotid intima media thickness (CIMT) and plaque measured by ultrasound, coronary artery 
calcium detected by cardiac computed tomography (CT), ankle–arm index pressure (AAI) 
measured by distal pressure Doppler measurement, and aortic pulse wave velocity (PWV) 
measured from carotid and femoral pressure wave recordings with a Doppler or 
mechanographic device [9-10]. Atherosclerosis can occur because of fatty deposits on the 
inner lining of arteries, calcification of the wall of the arteries, or thickening of the muscular 
wall of the arteries from chronically elevated blood pressure [11]. Atherosclerosis does not 
usually produce any symptoms until a CVD occurs. Therefore the prediction of 
atherosclerosis might contribute a lot to disease stratification and risk prevention. Figure 3 
represents the process of developing atherosclerosis in the carotid intima-media arteries. It 
seems clearly that, inflammation affects the formation of arteries and the propagation of 
blood stream as well. Endothelial dysfunction is observed in the early stages of the 
atherogenic process, and it is initiated by injury to the arterial endothelium [1]. Such injury 
has been associated with CV risk factors including diabetes mellitus or impaired glucose 
metabolism, hypertension, cigarette smoking, dyslipidemia, obesity, and/or metabolic 
syndrome [12]. Endothelial dysfunction is the initial step of the atherosclerotic process 
involving many vascular districts, including penile and coronary circulation [13]. 
Endothelial dysfunction is associated with CVD risk factors [14-15]. Endothelial dysfunction 
has been proposed to be an early event of patho-physiologic importance in the 
atherosclerotic process [16-17] and provides an important link between diseases such as 
hypertension, chronic renal failure, or diabetes and the high risk of cardiovascular events in 
patients exhibiting these conditions [18]. 
 




Fig. 2. The process of atherosclerosis development in general. Source: [38] 
 
Fig. 3. Atherosclerosis risk at carotid intima-media arteries, Source: [39] 
Elevated blood pressure reflects the existence of atherosclerosis. There is irresistible 
evidence that high blood cholesterol increases the risk of developing atherosclerosis; but 
cholesterol is not the damaging mechanism. In fact, the risk of atherosclerosis is more 
precisely assessed by measuring the proportional association between HDL cholesterol and 
LDL cholesterol [18].  Stiffening of large arteries predicts adverse cardiovascular outcomes 
[19-21]. Until now, measurements of arterial stiffness required the use of complex 
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ultrasound equipment or explanation tonometry at the level of the peripheral arteries, with 
the subjects in the supine or sitting position [22-23]. Medically, atherosclerosis is considered 
the dominant pattern of arteriosclerosis which affects primarily the elastic and large- to 
medium-sized muscular arteries. Therefore, hypertension is an established risk factor for the 
development of atherosclerosis [24]. Atherosclerosis is the term applied to a focal condition 
of the intima of arteries associated with medial changes. In fact, atherosclerosis can involve 
many of the body’s blood vessels with a variety of presentations [25].  Pathological and 
epidemiological data confirm that atherosclerosis begins in early childhood, and advances 
seamlessly and inexorably throughout life [26]. Risk factors in childhood are similar to those 
in adults, and track between stages of life. When diagnosed, aggressive treatment should 
begin at the earliest indication, and continue for years. For those patients at intermediate 
risk according to global risk scores, C-reactive protein (CRP), coronary artery calcium 
(CAC), and carotid intima-media thickness (CIMT) are available for further stratification.  
Atherosclerotic lesions develop slowly, but continuously leading to the main causes of 
mortality in diabetic patients such as coronary arterial disease, stroke, and renal failure [27]. 
In diabetic children, the presence of subclinical atherosclerotic disease as a precursor of 
macrovascular complications has been shown in several studies [28]. Also, impaired 
endothelial function preceding atherosclerotic changes has been observed [29]. As the 
measurement of the intima-media thickness of the carotid arteries is considered a surrogate 
marker of subclinical atherosclerosis, this method has been used widely in these patients to 
asses vascular health [28]. CIMT is a noninvasive and reproducible method to detect and 
quantify subclinical atherosclerosis [30]. Autopsy studies have demonstrated a direct 
histoligical relationship between carotid and coronary atherosclerosis [31-32]. CIMT 
measurements have been used to measure differences in the progression of atherosclerosis in 
clinical trials [33]. In observational trials, increased CIMT is associated with prevalent and 
incident cardiovascular disease [34-36]. Although ultrasound measurement of CIMT has been 
recommended as a clinical screening tool, its use has been limited to research studies or 
selected institutions, in part because of labor- and time-intensive measurement protocols [37]. 
Mainly, atherosclerosis starts with oxidation of LDL particles in the arterial wall [40-41]. 
Oxidative modified LDL (oxLDL) damages the endothelium of the artery - a 
pathophysiology similar to that of vascular erectile dysfunction (ED) [41-42]. As a result, the 
elasticity of the arteries deteriorates. Impaired arterial elasticity and increased levels of 
circulating oxLDL as well as elevated fibrinogen and resting heart rate associate with 
subclinical atherosclerosis and increased risk of cardiovascular disease (CVD) events [43-48]. 
Besides similar pathophysiology, ED and CVD share same risk factors [49]. In addition, a 
high prevalence of both silent and clinical CVD has been reported among ED patients [49-
50]. ED has also been reported as an independent predictor of incident CVD [51-52]. Since 
ED often precedes CVD symptoms from other vascular beds, it is thought to be an early 
clinical manifestation of systemic atherosclerosis [49; 53]. There is increasing evidence of a 
strong link between ED and atherosclerosis [54-55]. ED and atherosclerosis share similar risk 
factors and both conditions are characterized by endothelial dysfunction and impaired nitric 
oxide bioavailability [56]. Peripheral artery disease (PAD) as similar to ED is associated with 
atherosclerotic risk factors [57]. 
With advanced age, men experience decreases in important health indicators (muscle 
amount, muscle power, physical activity, bone density, blood generation, and sexual drive) 
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[58]. Various research [57-59] on the decrease in blood testosterone with aging suggests that 
many clinical characteristics related to age, including ED, are closely related to lack of 
testosterones. Recent research results indicate that testosterone and ED are closely related to 
one other [60-61], which suggests that supplementary therapy with testosterone may be one 
useful method in the treatment of ED [62]. However, the link between ED and 
atherosclerosis is well known to doctors. Doctors thought of atherosclerosis to be the main 
cause of ED. The thought was driven from the hypothesis that small arteries will be clotted 
before the large or medium ones. Since erection depends mainly on the amount of delivered 
blood to the penis, normal arteries thought to have no problem in supporting the process of 
blood delivering. In contrast, if the arteries become stiffen due to the deposition of 
atherosclerosis (which in turn will reduce their compliance as a result of the increment in 
arteries walls resistance), the amount of delivered blood will be declined which affects the 
process of erection. Atherosclerosis as an indicator of endothelium dysfunction, thought to 
be the underlying cause of CVDs and ED. Once the arteries start losing their elastic 
properties, the atherosclerosis is proven to be existed. The development of atherosclerosis 
prevents endothelial cell from regulating blood flow. Moreover, the accumulation of 
atherosclerosis affects the propagation of blood which can be detected by the recording of 
Photoplethysmogram (PPG) signal. PPG is an optoelectronic technique that reflects blood 
volume changes in arteries [63]. It functions by illuminating the skin with a light by light-
emitting diode (LED) and recording the scattered lights by a photodetector.  
ED as a vasculogenic disorder may indicate that, blood vessels anywhere in the body are not 
in perfect health. ED still has no establish method for diagnosing subjects to be subject with 
ED or normal subject (normal erection). Therefore, linking ED to atherosclerosis is the most 
acceptable thought in this area. ED may be a sign that coronary artery disease is developing 
some risk factors. That’s why; being under-risk of atherosclerosis raises the chance of 
experiencing ED at any age. The endothelium can be damaged by high cholesterol, high 
blood pressure, smoking, or diabetes. They also cause atherosclerosis. Once damaged, the 
endothelium can't expand arteries to increase blood flow as well. Less blood flow into the 
penis means a less tumescence and consequently no satisfactory erection. In this study, a 
sample of 68 ED patients were hired to run a research that aims to investigate and evaluate 
the associations between atherosclerosis and ED. The PPG signal was used to predict the 
high-risk of atherosclerosis. Its noteworthy that, CIMT test was used to evaluate the risk of 
atherosclerosis. Since the CIMT method continues to be a measure of atherosclerosis, the 
value of 0.7 was determined as the critical point. As a result, any value below or equal to 0.7 
(CIMT=<0.7mm) represents a normal case, otherwise, it represents a case under risk. And 
since the diagnostic test is used to reveal the health status of the subject, a new index 
derived from CIMT which is called high-risk atherosclerosis (HRART) was used to 
discriminate between at-risk-of-the-disease and normal subjects based on the critical value 
of 0.7.  Statistically, HRART was taken as the dependent variable. All subjects were from 
Urology clinic at the medical center of the National University of Malaysia (PPUKM).  
Thinking of atherosclerosis as the main cause that might cause ED represents a big 
motivation for the development of a predictive model for high-risk atherosclerosis 
assessment. Once atherosclerosis has been predicted, ED can be examined and checked by 
means of atherosclerosis. The measurement of CIMT and PPG were done at the same time. 
We started our research by hypothesizing that PPG is willing to predict high-risk 
atherosclerosis by utilizing PPG’s contour analysis technique. Since PPG reflects changes in 
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blood volume, it will be affected clearly by aging and by atherosclerosis. Therefore, the aim 
was to extract some indices from PPG waveform morphology and relate these indices to 
atherosclerosis measured by CIMT test. Since the pulsatile components of PPG waveform 
are the important features due to their ability to reflect blood flow and blood volume 
changes in the arteries, we paid extra attention to PPG amplitude indices without neglecting 
PPG time indices. Atherosclerosis plays an important role in the process of blood 
propagation and blood volume changes. As we age, PPG amplitude is subject to reduction 
because of the accumulated atherosclerosis, which in turn increases the resistance of arteries 
and reduces arterial compliance. It is noteworthy that, atherosclerosis affects the elastic 
properties of the arterial wall, making it stiffen. As arteries become stiffer, blood 
propagation becomes faster and pulse amplitude becomes lower as well. In this research 12 
main indices of PPG were extracted and evaluated Table 2 demonstrates the extracted 
parameters.  
 
Index B S.E. Wald df Sig. Exp (B) 
Age .071 .028 6.198 1 .013** 1.07 
BMI -.025 .058 .179 1 .673 .976 
SP .04 .024 2.7 1 .1 1.04 
DP -.017 .034 .25 1 .614 .98 
MAP .016 .033 .23 1 .634 1.02 
PP .071 .032 4.8 1 .028** 1.07 
H -.114 .045 6.3 1 .012** .89 
PT 1.02 1.6 .4 1 .52 2.76 
MET 52.8 32.5 2.6 1 .1 8.7E+22 
ST 15.4 6 6.57 1 .01** 4732574 
DT 4.96 6 .68 1 .41 143 
PPT -14.7 6.96 4.5 1 .034** .00 
SI .04 .087 .23 1 .63 1.04 
MEV -552.3 1231 .2 1 .65 .00 
PM -1.08 10.2 .01 1 .92 .338 
DM 1.76 15.2 .013 1 .9 5.8 
RI 1.78 1.9 .88 1 .35 5.9 
b/a -5.43 1.88 8.3 1 .004** 72.6 
c/a -.073 3.75 .00 1 .98 .93 
Note: Each index was tested separately to obtain any statistically significant against the dependent 
variable. The table represents their collection.  
Table 2. Initial variables tested for model development 
Given the importance of the medical data in pathogenesis of atherosclerosis, clinical interest 
has focused on the development of markers of risk. Therefore, blood pressure (SP, DP, PP, 
and MAP) in addition to body mass index were recorded as well. Among the medical data 
measurements mentioned, PP was found to be a significant factor contributing to the 
process of atherosclerosis. PP is an independent predictor of myocardial infarction (MI) [64]. 
The progression of atherosclerosis is accompanied by an increase in PP [65].  Our results 
supported such an observations by revealing a positively association between PP and 
atherosclerosis.  
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In addition, subject’s height (H) was inversely correlated with atherosclerosis in our results. 
Height was inversely associated with risk of MI [66], and an inverse association between 
height and risk of coronary heart disease (CHD) has been reported in several analytic 
studies [67-68]. Therefore, H and PP were statistically significant in this research. Detail on 
H and PP characteristics in the follow sections.   
Basically, the first attention was to utilize PPG technique only in the assessment of high-risk 
atherosclerosis. But, as a result from the final research, PP and H were contributable to the 
risk of atherosclerosis. Which in turn resulted in a predictive model represents the 
contribution of PPG (b/a ratio), PP and H to the development of atherosclerosis. Obviously, 
it is worthy to investigate the contribution of PPG (b/a ratio) alone to atherosclerosis and 
the contribution of PP, H and PPG (b/a ratio) together. To make these investigations 
achieved, we conducted the analysis of logistic regression (Backward: LR). Logistic 
regression (LR) is used normally to model the relationship between a binary response 
variable and one or more predictor variables, which may either be discrete or continuous. 
Binary outcome data is common in medical applications. In our work, the binary response 
variable might be whether or not a patient is at risk of atherosclerosis. In multiple 
regressions, we are concerned with finding an appropriate combination of predictor 
variables to help explain the binary outcome. However, a logistic regression model was 
developed to assist in the early prediction of high-risk atherosclerosis, and to be used as an 
alternative rapid measure for screening for atherosclerosis. 
The developed model went through three main methods of logistic regression. The first 
method (ENTER: LR) was used to test the significance of each index separately against the 
dependent variable, Risk of atherosclerosis initiated from CIMT test. The second method 
(Forward: LR) was used to test the significance of the significant indices against the 
dependent variable. The final method (Backward: LR) was used to test the significance of 
the significant indices against the dependent variable as well. Both forward and backward 
methods were used for the same techniques and they were fed with the same significant 
indices; and the one with a higher performance in terms of (Nagelkerke R-square and 
likelihood ratio) was used to implement the final model.  The results revealed that some 
indices (age, PP, H, PPT, ST, and b/a) were statistically significant and that they could be 
used to initiate the model. The six chosen indices were fed to forward: LR and backward: LR 
methods. Table 3 shows the associated Nagelkerke R-square for each variable. 
 
Index  R-square Likelihood-ratio 
Age .133 87.14 
PP .11 88.4 
H .138 86.8 
PPT .094 89.3 
ST .135 87 
b/a .184 84.2 
Note: R-square represents the amount that this index contributes to the process of high-risk of 
atherosclerosis.  
Table 3. Nagelkerke R-square for the selected indices 
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However, to investigate the effects of the multiple variables together in the model, the 
forward: LR method was used first. After feeding the model with all the chosen variables, 
forward: LR responded as follows:  
 Two out of six indices remained in the model (b/a and H), therefore age, PP, PPT, and 
ST were excluded from the calculations. Table 4 illustrates the model summary of the 
forward: LR method. 
 The model revealed a value of Nagelkerke R-square (.288) and a likelihood ratio of 77.69 
 Step 2, forward: LR was chosen to represent the model based on this method. 
 
Step -2 Log likelihood Cox & Snell R Square 
Nagelkerke R 
Square 
1 84.179 .138 .184 
2 77.694 .216 .288 
Note: Step 2 is used to represent the final decision about the model 
Table 4. Model summary of forward: LR 
On the other hand, backward: LR responded better than the forward: LR method. The 
model revealed a higher Nagelkerke R-square value (.372). A summary of the model is 
shown in Table 5. After feeding the model with all chosen variables, backward: LR 
responded as follows:  
 Three out of six indices remained in the model (b/a, PP, and H); Therefore PPT, age and 
ST were excluded from the calculations. Table 5 illustrates the model summary of the 
backward: LR method. 
 The model revealed a value of Nagelkerke R-square (.372) and a likelihood ratio of 74 
 Step 4 backward: LR was chosen to represent the model based on this method. 
 
Step -2 Log likelihood Cox & Snell R Square 
Nagelkerke R 
Square 
1 71 .287 .383 
2 71 .287 .383 
3 72 .279 .372 
4 74 .258 .372 
Note: Step 4 was used to represent the final decision about the model 
Table 5. Model summary of backward: LR 
Moreover, it is helpful to demonstrate the relationship between the predicted outcome and 
certain characteristics found in observations. Table 6 represents the final characteristics of 
the developed model. 
Our chief interest was to use the logistic model to predict the outcome for a new subject. 
How good was this model for prediction? When we have a new subject, we can use the 
logistic model to predict his probability of having high-risk atherosclerosis. Let us say we 
have a black box where we input the b/a index, PP and H of a subject and the output is a 
number between 0 and 1 which denotes the probability of the subject having a high-risk of 
atherosclerosis (Figure 4). 
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       95% C.I.for 
EXP(B) 
 B S.E. Wald Df Sig. Exp(B) Lower Upper 
BA -4.758 2.020 5.55 1 .019 .009 .000 .450 
H -.123 .052 5.62 1 .018 .884 .798 .979 
PP .066 .037 3.27 1 .047 1.07 .994 1.148 
Constant 20.696 8.924 5.38 1 .020 973357650   
Note: Model’s final selected factors and their characteristics  
Table 6. The final factors included into the model and model characteristics 
 
 
Fig. 4. The logistic regression predictive model 
In the black box we have the equation for calculating the probability of having high-risk 
atherosclerosis, which is given by Y (Model’s outcome) = 20.696 – 4.758*b/a + 0.066*PP – 
0.123*H. Therefore, the probability of having high-risk atherosclerosis can be calculated as 
HRART = Exp (Y) / (1+Exp (Y)). This tells us that increasing the b/a value decreases the 
risk of atherosclerosis. Moreover, increasing PP increases the chance of being under high-
risk of atherosclerosis. Finally, increasing height decreases the risk of atherosclerosis. The 
classification table of the predictive model is shown in Table 7.  
 
Observed Predictive 
HRART Percentage correct 
No-risk High-risk 
Step 1  No-risk 24 10 70.6 
  High-risk 9 25 73.5 
 Overall percentage     72.05 
Step 2  No-risk 25 9 73.5 
  High-risk 7 27 79.4 
 Overall percentage    76.5 
Note: Classification table based on backward: LR 
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2. Agreement between the PPG and the CIMT 
We often hope to have data on, for example, atherosclerosis or arteriosclerosis where direct 
measurement without adverse effects is difficult or impossible. The true values remain 
unknown. Therefore, indirect methods are used, and a new method has to be evaluated by 
comparison with an established method rather than with the true quantity. If the new 
method agrees adequately well with the old one, the new one may be used as an alternative 
measure, or the old one may be replaced. In this work, CIMT is an established method for 
the measurement of atherosclerosis. The PPG as a new method comes into this work to 
assist or replace CIMT. And since CIMT is the used method, the convention of assisting or 
interchanging use of the two methods was employed.  
However, the Bland-Altman plot [69] is a graphical method to compare two measurement 
methods. In this graphical method the differences (or alternatively the ratios) between the 
two methods are plotted against the averages of the two methods. On the other hand [70] 
the differences can be plotted against one of the two methods, if this method is a reference 
or "gold standard" method. Horizontal lines are drawn at the mean difference, and at the 
limits of agreement, which are defined as the mean difference plus and minus 1.96 times the 
standard deviation of the differences. It is noteworthy that the agreement between the two 
methods must be done using the raw data (CIMT vs. b/a (PPG)). 
A comparison between CIMT and PPG in the measurement of high-risk atherosclerosis is 
plotted in Figure 5. PPG is a new non-invasive method. Here the mean difference is 0.05 
percentage points with a 95% confidence interval. The limits of agreement (-0.81 and 0.91) 
are small enough for us to be confident that the new method (PPG) can be used to assist 
CIMT for clinical purposes.  
 
Fig. 5. Agreement of CIMT and PPG in the measurement of risk atherosclerosis 
The plot reveals good agreement between the two methods, since the data are scattered 
around the mean. In addition, the mean value (0.05) is so close to zero that this strengthens 
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the agreement between CIMT and PPG. Such agreement raises the possibility of using PPG 
as an alternative rapid measure of high-risk atherosclerosis. 
3. Model performance  
The new proposed measure of high-risk atherosclerosis, (PPG’s b/a index), needs to be 
evaluated to be used in clinical settings. Basically, the performance of any established test or 
any newcomer test must be assessed. The diagnostic performance of a test or the accuracy of 
a test to discriminate risky cases from non risky cases is evaluated using Receiver Operating 
Characteristic (ROC) curve analysis [71-72]. ROC curves can also be used to compare the 
diagnostic performance of two or more laboratory or diagnostic tests [73]. Moreover, a 
measure of how well an index can distinguish between two diagnostic groups (risky/non 
risky) can be evaluated by the area under the ROC curve (AUC). Since the CIMT method 
continues to be a measure of atherosclerosis, the value of 0.7 was determined as the critical 
point. As a result, any value below or equal to 0.7 (CIMT=<0.7mm) represents a normal 
case, otherwise, it represents a case under risk. And since the diagnostic test is used to 
reveal the health status of the subject, a new index derived from CIMT which is called high-
risk atherosclerosis (HRART) is used to discriminate between at-risk-of-the-disease and 
normal subjects based on the critical value of 0.7.  HRART was taken as the dependent 
variable. Figure 6 demonstrates the error bar plot for b/a index based on HRART data. 
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Fig. 6. Error bar of PPG (b/a index) based on HRART 
Statistically, an ROC curve provides an objective measure of the discriminatory power of a 
screening test and also an idea of where to place the cut-off point. Therefore, a ROC test 
(HRART vs. b/a) was run to obtain the sensitivity (the true positive rate) and the 100-
specificity (the false positive rate) for different cut-off points of the PPG (b/a ratio). MedCalc 
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software (version 11.4.4) was used to obtain the ROC curve and the AUC. The ROC curve 
for (HRART vs. b/a index) is shown in Figure 7. 
 
Fig. 7. ROC curve of HRART vs. PPG (b/a index) 
As seen in Figure7, the ROC curve revealed a sensitivity of 76.5% and a specificity of 64.7% 
in the discrimination between risky and normal subjects. A sensitivity of 75% would be 
reasonable [74-76]. When the probability of disease and the sensitivity and specificity of the 
test are known, the predictive value positive (PVP) and the predictive value negative (PVN) 
can be calculated [77]. Moreover, the combination of ROC curves for all model factors can be 
obtained to reflect the relationship between each factor and the dependent variable. The 
three factors (b/a index, PP and H) contributed by some means to the process of 
atherosclerosis. Figure 8 represents the ROC curves for all the model’s factors.  
The combined ROC for the model’s factors revealed the contribution of each factor to the 
development of atherosclerosis inside our arteries. As a result of that, each factor 
contributed separately to the atherosclerosis process, and all of them together contributed 
also to the process of atherosclerosis development partially. Partially means “not making a 
full contribution,” in other words, there are some other untested factors that might be 
contributing to atherosclerosis. However, the model produced a highly satisfactory 
Nagelkerke R-square value (0.372) which makes it a good rapid measure for the prediction 
of atherosclerosis risk. The effectiveness of the diagnosis is measured by the AUC.  
 
The Assessment of Atherosclerosis in Erectile Dysfunction Subjects Using Photoplethysmography 
 
207 
















Fig. 8. The obtained ROC curves for b/a index, PP and H 
3.1 Area Under the Curve (AUC) 
The correctness of any medical test depends on how well the test separates the sample being 
tested into those with or without the disease. The area under the ROC curve (AUC) is 
frequently used as a measure for the effectiveness of diagnostic markers [78]. Moreover, 
AUC is an overall test for the performance of the test. Statistically, the area of 1 represents a 
perfect test which rarely appears in real empirical data. The analysis of our data produced 
an AUC of 0.724, which is fair enough to ensure that the test is reliable in discrimination 
between normal and risky specimens. The details of the AUC obtained can be seen in  
Table 8.  
 
Variable  b/a index 
Classification variable HRART 
Sample size 68 
Positive group: HRART = 1 34 
Negative group: HRART = 0 34 
Disease prevalence (%) 50.0 
Area under the ROC curve (AUC) 0.724 
Standard error 0.06 
95% Confidence interval 0.6 to 0.83 
Z statistic  3.5 
Significance level P (Area = 0.5) 0.0004 
Table 8. The AUC obtained and its characteristics 
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software (version 11.4.4) was used to obtain the ROC curve and the AUC. The ROC curve 
for (HRART vs. b/a index) is shown in Figure 7. 
 
Fig. 7. ROC curve of HRART vs. PPG (b/a index) 
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Basically, AUC can be interpreted as the probability that the test result from a randomly 
selected diseased subject is more indicative of disease than that from a randomly selected 
non-diseased subject. Therefore, getting a value of AUC to be 0.724 can be an indicator of 
the good performance of the developed predictive model. The interactive dot diagram 
(Figure 9) illustrates a sensitivity of 76.5% and a specificity of 64.7%. During the present 
study we defined normal subjects (without risk of atherosclerosis) who had a value of b/a 
index to be greater than 0.8. Otherwise, the subject will be diagnosed as a subject at risk of 


















Fig. 9. Interactive dot diagram of b/a index based on HRART 
In conclusion, this investigation introduced the acquired results based on our analysis. 
Moreover, a detailed discussion on the developed model and its characteristics were 
presented. The focus was completely on the association between atherosclerosis and the 
PPG signal indices. The developed model revealed a sensitivity of 76.5% and a specificity of 
64.7% which in turn suggested that it could be a rapid measure for the assessment of the 
prediction of high-risk atherosclerosis. Mainly, thinking of atherosclerosis to represent an 
important cause of ED raises the important of this developed model. As the developed 
model successes to predict high-risk atherosclerosis, it can be used to assist ED as well. 
Therefore, predicting the high-risk atherosclerosis at early stages could really improve the 
prevention of experiencing ED and improve the treatment methods. The analysis can be 
further extended to other cardiovascular risk factors such as hypertension, hyperlipidemia 
and smoking. These factors are not analyzed in this study due to limitation in the number of 
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subjects with one of the particular above mentioned risk factors. However, there is no doubt 
that the assessment of arterial stiffness and the assessment of high-risk atherosclerosis will 
make a major contribution to the improved management of cardiovascular disease in 
clinical settings and to the process of diseases prevention. 
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Erectile dysfunction is a widespread problem, affecting many men across all age 
groups and it is more than a serious quality of life problem for sexually active men. 
This book contains chapters written by widely acknowledged experts, each of which 
provides a unique synthesis of information on emergent aspects of ED. All chapters 
take into account not only the new perspectives on ED but also recent extensions of 
basic knowledge that presage directions for further research. The approach in this book 
has been to not only describe recent popular aspects of ED, such as basic mechanism 
updates, etiologic factors and pharmacotherapy, but also disease-associated ED and 
some future perspectives in this field.
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